# Bioorganic & Medicinal Chemistry Letters

A **Tetrahedron Publication**
for Rapid Dissemination of
Preliminary Communications on all aspects of
**Bioorganic Chemistry, Medicinal Chemistry,**
**Bioinorganic Chemistry** and related disciplines

Editor-in-Chief: **DALE L. BOGER**, *The Scripps Research Institute, La Jolla, CA 92037, USA*
Chairman of the Executive Board of Editors for Tetrahedron Publications: Sir Derek Barton, *Texas A&M University, USA*

**SUBJECT INDEX AND AUTHOR INDEX**
**Volume 4 (1994)**

**Pergamon**

# BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

*Editor-in-Chief:* **PROFESSOR D. L. BOGER**
*Managing Editor:* A. Crown
Department of Chemistry, The Scripps Research Institute, 10666 North Torrey Pines Road
La Jolla, California 92037, USA
Fax: (1) 619 554 6401
[Fax: (800) 410 1557 toll-free from USA and Canada]

*European Regional Editor:* **Professor L. Ghosez**, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium
Fax: (32) 10 47 41 68

*Japanese Regional Editor:* **Professor M. Shibasaki**, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo 113, Japan
Fax: (81) 3 5684 5206

## EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

*Chairman:* **Professor Sir Derek Barton, FRS,** Department of Chemistry, Texas A & M University, College Station, Texas 77843-3255, USA

**Professor J. E. Baldwin, FRS**, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

**Dr S. G. Davies**, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

**Professor S. Ito,** Faculty of Pharmaceutical Sciences, Tokushima Bunri University, Yamashiro-cho, Tokushima 770, Japan
(Associate Editor, Professor Y. Shizuri)

**Professor A. R. Katritzky, FRS,** Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

**Professor N. K. Kochetkov,** N. D. Zelinsky Institute of Organic Chemistry, Academy of Sciences, Moscow B-334, Russia

**Professor Lin Guo-Qiang,** Shanghai Institute of Organic Chemistry, Academia Sinica, Shanghai 200032, China

**Professor S. F. Martin,** Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

**Professor A. McKillop,** University of East Anglia, School of Chemical Sciences, University Plain, Norwich, NR4 7TJ, UK

**Professor W. B. Motherwell,** Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

**Professor A. Nickon,** Department of Chemistry, The Johns Hopkins University, Baltimore, MD 21218, USA

**Professor G. Ourisson,** Centre National de la Recherche Scientifique, Centre de Neurochimie, 67084 Strasbourg, Cedex, France
(Associate Editor, Professor G. Solladié)

**Professor T. Shioiri,** Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan

**Professor W. Steglich,** Institut für Organische Chemie der Universität München, Karlstr. 23, D-80333 München, Germany

**Professor H. H. Wasserman,** Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520-8107, USA

**Professor C.-H. Wong,** Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

**BOARD OF CONSULTING EDITORS**

**R. Abeles,** Waltham, MA
**P. S. Anderson,** Lansdale, PA
**M. J. Ashton,** Collegeville, PA
**J. K. Barton,** Pasadena, CA
**S. Bell,** Raritan, NJ
**S. J. Benkovic,** Pennsylvania, PA
**R. C. Breslow,** New York, NY
**T. C. Bruice,** Santa Barbara, CA
**J. P. Collman,** Stanford, CA
**P. N. Confalone,** Wilmington, DE
**E. J. Corey,** Cambridge, MA
**S. J. Danishefsky,** New York, NY
**P. B. Dervan,** Pasadena, CA
**T. W. Doyle,** Killingworth, CT
**A. Eschenmoser,** Zürich
**D. M. Floyd,** Princeton, NJ
**A. K. Ganguly,** Bloomfield, NJ
**D. Gani,** St Andrews
**H. B. Gray,** Pasadena, CA
**J. T. Groves,** Princeton, NJ
**G. L. Grunewald,** Lawrence, KS
**H.-J. Hess,** Groton, CT
**M. Hirobe,** Tokyo
**R. H. Holm,** Cambridge, MA
**D. C. Horwell,** Cambridge
**W. L. Jorgensen,** New Haven, CT
**D. D. Keith,** Nutley, NJ
**R. A. Lerner,** La Jolla, CA
**S. J. Lippard,** Cambridge, MA
**D. Mansuy,** Paris
**B. W. Metcalf,** King of Prussia, PA
**L. A. Mitscher,** Lawrence, KS
**W. H. Moos,** Emeryville, CA
**K. Mori,** Tokyo
**K. Nakanishi,** New York, NY
**K. C. Nicolaou,** La Jolla, CA
**T. Ogawa,** Saitama
**M. Ohno,** Ibaragi
**H. L. Pearce,** Indianapolis, IN
**P. Potier,** Gif-sur-Yvette
**C. D. Poulter,** Salt Lake City, UT
**A. V. Rama Rao,** Hyderabad
**J. Rebek, Jr,** Cambridge, MA
**B. Samuelsson,** Stockholm
**R. L. Schowen,** Lawrence, KS
**S. L. Schreiber,** Cambridge, MA
**P. G. Schultz,** Berkeley, CA
**A. I. Scott,** College Station, TX
**I. Shinkai,** Rahway, NJ
**T. J. Simpson,** Bristol
**J. Stubbe,** Cambridge, MA
**C. T. Walsh,** Boston, MA
**G. Whitesides,** Cambridge, MA
**R. V. Wolfenden,** Chapel Hill, NC

PUBLISHED TWICE MONTHLY

*Publishing, Subscription and Advertising Office:*
Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford, OX5 1GB, UK (Tel: (01865) 843000; Fax: (01865) 843010)

*Subscription Rates*
Annual Institutional Subscription Rates 1995: North, Central and South America, U.S.$ 984.00, Rest of World £ 660.00. Associated Personal Subscription Rates are available on request for those whose institutions are library subscribers. Sterling prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice. Subscription enquiries from customers in North America should be sent to: Elsevier Science Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA, and for the remainder of the world to: Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK.
Second Class Postage paid at Newark, NJ. Postmaster send address corrections to Elsevier Science Inc., 660 White Plains Road, Tarrytown, New York 10591-5153, USA.

Copyright © 1995 Elsevier Science Ltd

# Subject Index 1994


A

**A-81988** 5-membered ring heterocyclic analogs, angiotensin antagonists, 169
**Abasic nucleotide**
incorporation stem-loop II hammer-head ribozymes, synthesis 1-deoxy-D-ribofuranose phosphoramidite, 1715
**ABT-200** antidepressants combining α-2 antagonism with uptake inhibition, 13
**ACAT** inhibitors, chemistry, activity imidazolidinones, pyrazolones, 1095
**Acceptor analogs** inhibitors of bovine β-1,4-galactosyl transferase, 391
**Acetogenins** cytotoxic annonaceous, 2,4-*cis*- and *trans*-bulladecinones from *Annona bullata*, 473
**Acetyl migration** deacetylation peracetylated 1-methyl α,β-D-glucopyranosides by *Candida* lipase hydrolysis, 1629
**Acetyl-coenzyme A** carboxylase, indolizidinedione oxime inhibition, 1983
**Activators** protein kinase, benzofuran analog of ILV, 637
**Acyclic substrates** amide and ester, enzymes exhibiting different structural specificity, β-lactam recognition, 2291
**Acyclonucleosides** 6-fluoropurine prodrugs of acyclovir and ganciclovir, 1309
**Acyclovir** 6-fluoropurine acyclonucleoside prodrugs, 1309
**Acylation** N-debenzoyltaxol, prep N-acyl taxol analogs, 335
**Adamantane** nipecotic acid derivs, β-turn mimics, 1361
**Adducts** stable, reaction of pyruvate with 3-acetyl quinolinium and pyridinium derivs of papain, 1415
**Adenine** total substit with 7-deaza-adenine in HDV antigenomic ribozyme changes kinetics of RNA folding, 987
**Adenosines**
reaction with oxiranol carbamate, 291
receptor antagonist activity, pyrazolo[4,3-*e*]-1,2,4-triazolo-[1,5-*c*]pyrimidine and 1,2,3-triazolo[4,5-*e*]-1,2,4-triazolo-[1,5-*c*]pyrimidine, 2539
**2',5'-Adenylate** trimers carrying 3'-amino-3'-deoxyadenosine at 2'-terminus, 1047
**α-Adrenergic receptors** cloned human, efficacy of 2-amino-2-oxazolines, 2317
**Agonists**
β-adrenergic, atypical selective SR 9062A, synthesis, 1921
$H_2$-receptor histamine, amselamine, 1913
HOE140, reduced effect on endothelium-free femoral artery of sheep, 781
kappa opioid U-50,488, north-west region, SAR, 2139
ketone related benzoate 5-$HT_4$ receptor antagonist, partial high affinity, 2477
muscarinic:
1,2,5,6-tetrahydropyridine oxime ethers with electron withdrawing groups, 557
bridged 1,2,5,6-tetrahydropyridine esters and oxime ethers related to arecoline, 1185
containing 1,2,4-triazine ring as ester bioisosteres, 1411
muscarinic receptor:
functional M-1 selective, SARs alkyl substit xanomeline analogs, 2205
intermediate compd 3-lithio-quinuclidin-2-ene, 2837
nicotinic, selective central crossing blood-brain barrier, isoarecolones and arecolones, 573
receptors:
5-$HT_4$, nanomolar affinity, 1433
arylacetamido-type K opiate, EMD 61753 representative, 677
melatonin:
C-5 OM group not essential for biological activity, 1555
indole derived analogs with C-3 amidoethane side chain constrained in a ring, 1559
motilin:
acid-stable, orally active macrolide GM 611 and derivs, 1347
bioevaluation 2'- and 4''-groups of 8,9-anhydro-erythromycin 6,9-hemiacetals, 1649
**(+)-AJ76** synthesis C-5 modified derivs, increased dopamine $D_3$ receptor preference and improved pharmacokinetic properties, 689
**Alanine** peptide nucleic acid with chiral backbone, 1077
**Alcohol oxidase** from methylotrophic yeasts, 2-methyl-1-butanol oxidation, 1745
**Aldehydes** peptidyl aspartyl, evaluation as ICE inhibitors, 2359
**Alkaloids**
bioactive clausenaquinone-A from *Clausena excavata*, structure, synthesis, 2395
penazetidine A inhibitor of protein kinase C, 2447
protoberberine analogs with *in vivo* antimalarial activity, 1663
symmetrical disteroidal cephalostatin 12 and 13, isolation and structures, 1507
**Alkyl piperidines** ether derivs, sigma/5$HT_2$ anti-psychotic agents, 2347
**N-Alkylquinuclidinium substance P** non-peptide antagonists, 1153
**Amides** ester dimer library, synthesis, bioevaluation, rapid compd generation, screening, 2821
**Amination** reductive, prep enzyme labelled oligonucleotides, 1005
**Amines** 5-membered heterocyclic,

anti-rheumatoid arthritis agents, 1673
**Amino acids**
light-switchable, synthesis for inclusion conformationally mobile peptides, 2145
$P_2/P_3$ ligands for HIV-1 protease inhibitors, 1391
resolution N-protected derivs in supercritical carbon dioxide catalysed by alcalase, 625
sequences, role in triterpenoid cyclase evolution, 285
structurally new series, development of valsartan angiotensin antagonist, 29
**4''-Amino analogs** 4''-*epi* and 4''-deoxy derivs 9-deoxo-8a-aza-8a-homoerythromycin A, antibacterial activity, 1111
**Amino esters**
ribavirin, synthesis, antiviral activity, 2831
**Amino ethers**
*gem*-disubstit based substance P antagonists, 2733
Amino linkers at 5-position of 2'-deoxyuridine, post synthetic modification method for oligodeoxyribonucleosides, 361
**2-Amino-2-oxazolines**, efficacy at cloned human α-adrenergic receptors, 2317
**β-Aminoalaninamide moiety**
enzyme dependent molecular switch, mechanism enzymatic inactivation bleomycin, 705
**5-Aminocyclopentanepolyols**
N-phenyl cyclic isourea deriv, enzyme inhibition of sugar hydrolases, 2643
**2-Aminoethyl ethers** 2-benzhydryl deriv, acyclic NK-1 antagonists, 1903
**7-Aminofurochromenone**
antiplatelet, synthesis bioactivity, 2621
**Aminoheterocyclic guanidine** cell permeability of surrogates and thrombin inhibitory activity, 2165
**Aminomethylthioxanthones**
anti-solid tumor activity of WIN 33377, prep and related derivs, 609
**Aminopeptidases** leucine, overexpression allows *E. coli* proline auxotroph to grow faster on prolinamide, 2555
pseudopeptide inhibitors with Ψ[CH(CN)NH] surrogate as transition state mimic, 1491
**Aminophosphonate**
endothelin converting enzyme inhibitors, potency-enhancing and selectivity-improving phosphoramidon, 1257
**Aminophosphonic acid** inhibitors human collagenase, modification $P_1$ residue, 2833
**AMPA**
current, potentiated by cyclothiazide isomers, 1957
receptor antagonist, (1,2,3,6,7,8-hexahydro-3(hydroxy-imino)-N,N,7-trimethyl-2-oxobenzo[2,1-*b*:3,4-*c'*]dipyrrole-5-sulfonamide), 371
**Amselamine** selective histamine $H_2$-receptor agonist, 1913
**Amylase** induction barley seeds, helminthosporic acid analogs stimulation, 1847
**Anacardic acids** analogs, β-lactamase inhibition, 1423
**Analgesics** antagonist $PGE_2$, SC-51322, 509
**Analysis** electrospray ionization MS, post-synthetically modified oligodeoxynucleotides, 1869
**Angiogenic factors** synthesis 12(*R*)- and 12(*S*)-hydroxy-eicosa-5(*Z*),8(*Z*),14(*Z*)-trienoic acid and 14,15-dehydro analogs, 2689
**Angiotensin**
antagonists:
- 5-membered ring heterocyclic carboxylic acids, 169
- aryl-fused imidazole-based, 213
- $AT_1$ selective, conformationally restrained series, 93
- $AT_1/AT_2$ balanced, quinazolinone with acylsulfonamide and sulfonylcarbamate acidic functions, 81

C-linked pyrazole biaryl tetrazole, pharmacokinetics and regioselective synthesis, 151
dihydropyridine, 133
equipotent affinity for human $AT_1$ and $AT_2$ receptor subtypes, 2337
fused ring heterocycles, synthesis, evaluation, 173
imidazole, acyl sulfonamides and sulfamides as tetrazole replacements, 69
imidazo[4,5-*b*]pyridine, synthesis
imidazo[1,2-*b*]pyridazine isosteres, 219
nonpeptide related GR117289, imidazopyridinyl benzofurans, 725
tetrahydroquinoline with substit biphenyltetrazole group, 2615
tetrazole bioisosteres, 45
triazolinone non-peptide, discovery
triazolinone acylsulfonamide, 115
valsartan, orally active, developed from amino acid series, 29
binding inhibitor, L-161,638, 1479
converting enzyme:
- inhibition by 4-substit proline derivs, 2673
- inhibitors with α-hydroxyketo-methylene dipeptide isosteres, 2799
- mercaptoacetyl containing inhibitor with *in vitro* enhanced activity while retaining *in vivo* potency, 1795
- mercaptoacyl dipeptide dual inhibition by N-phosphono-methyl and N-carboxyalkyl dipeptides, 2715
- neutral endopeptidase, dual inhibition by mercaptoacyl dipeptide, SAR studies, 1783

mediated antihypertensive agents, substit lactam biphenyltetrazoles, 87
receptors:
- $AT_1$ binding affinity, substit 1,3-benzodioxole and 1,3-benzo-dithiole-2-carboxylates and tetrazole analogs, 747
- $AT_1/AT_2$, binding affinity of substit phenylthiophene benzoylsulfonamides, 189
- binding $AT_2$, inhibition by tetrahydroisoquinoline derivs, 57

receptor antagonists:
- 1H-1,2,4-triazole, C-linked analogs of SC-50560, 105
- 1H-1,2,4-triazole, N-phenyl-pyridinylmethyl and N-pyridinylphenylmethyl analogs of SC-50560, 99
- 2H-imidazol-2-one, $N^1$-sterically hindered, synthesis $^3$H-SC-54628

and -54629, 111
4H-pyrido[1,2-*a*]pyrimidin-4-one deriv, 183
6-isoxazolinyl and isoxazolidinyl substit quinazolinones, 1703
6-substit quinazolinones, 1819
6-oxo-3-pyridazinylbenzimidazoles, 1297
1,4-substit indoles, 145
4,5,6,7-tetrahydro-8-carboxymethylidene cycloheptimidazoles, 1637
$AT_1/AT_2$, imidazo[4,5-*b*]-pyridine based, 17
balanced:
4-aminomethyl- and acyliminomethylimidazoles, 2229
effect biphenyl *ortho*-substitution on $AT_1/AT_2$ affinities, 2011
effects of imidazole substit in 5-position, 2235
chiral recognition by phenoxyproline octanoamide, 51
diacidic nonpeptide, 35
dihydroimidazolone derivs, chiral effect on activity, 163
imidazoles and pyrroles bearing hydroxymethyl and carboxy substit, 177
imidazo[1,2-*b*]pyridazine isosteres of imidazo[4,5-*b*]pyridine, 219
nonpeptide:
2(1H)-pyridinone series, SAR, 121
acidic phenols, 207
annelated 2(1H)-pyridinone series, SAR, 127
conformationally restricted, 2591
DMP-581 and DMP-811, 63
imidazolinones, 1527
imidazopyridine-based, incorporating heterocyclic acid equivs, 41
properties, SAR 3-substit 2,6-dialkyl-4-(biphenylmethylaminopyridine derivs, 139
quinazolinone biphenyl acyl sulfonamides, 75
quinazolinone-2,3-dihydro-4(1H) deriv, 141
quinazolinone-2,3,6-substit derivs, 1135
quinoline-4-carboxylic acids and orally active prodrugs, 195, 201
triazolinone based with affinity for $AT_1$ and $AT_2$ subtypes, 2787
**8,9-Anhydroerythromycin A 6,9-hemi-acetals** assessment of 2' and 4'' OH groups as motilin receptor agonists, 1649
***Annona bullata*** 2,4-*cis* and *trans*-bulladecinones, cytotoxic annonaceous acetogenins, 473
**Antagonists**
$5\text{-}HT_4$ receptor:
ketone analog is high affinity partial agonist, 2477
oxazolo, oxazino and oxazepino-[3,2-*a*]indole derivs, 667
$5HT_3$, pyrazolo[1,5-*a*]pyridines and pyrazolo[1,5-*a*]pyridazines, 695
$A_{2a}$ adenosine receptor, activity of pyrazolo[4,3-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidine and 1,2,3-triazolo[4,5-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidine, 2539
α-2, combined with NE uptake inhibition, ABT-200 antidepressants, 1319
acyclic NK-1:
2-benzhydryl-2-amino ethyl ethers, 1903
replacement for benzhydryl group, 2161
analgesics $PGE_2$, SC-51322, 509
angiotensin:
$AT_1$ selective, conformationally restrained series, 93
$AT_1/AT_2$ balanced, quinazolinone with acylsulfonamide and sulfonylcarbamate acidic functions, 81
carboxylic acids, heterocyclic 5-membered ring, 169
dihydropyridine, 133
equipotent affinity for human $AT_1/AT_2$ receptor subtypes, 2337
heterocycles, fused ring, synthesis, evaluation, 173
imidazole, acyl sulfonamides and sulfamides as tetrazole replacements, 69
imidazole-based, aryl-fused, 213
nonpeptide:
related GR117289, imidazopyridinylbenzofurans, 725
triazolinone, discovery triazolinone acylsulfonamide, 115
pyrazole biaryl tetrazoles, C-linked, pharmacokinetics and regioselective synthesis, 151
tetrahydroquinoline, with substit biphenyltetrazole group, 2615
tetrazole bioisosteres, 45
valsartan developed from amino acid series, orally active, 29
angiotensin receptor:
1H-1,2,4-triazole, C-linked analogs of SC-50560, 105
1H-1,2,4-triazole, N-phenylpyridinylmethyl and N-pyridinylphenylmethyl analogs of SC-50560, 99
2H-imidazol-2-one $N^1$-sterically hindered, synthesis [$^3$H]-SC-54628 and -54629, 111
4H-pyrido[1,2-*a*]pyrimidin-4-one substit derivs, 183
6-isoxazolinyl and isoxazolidinyl substit quinazolinones, 1703
6-substit quinazolinones, 1819
4,5,6,7-tetrahydro-8-carboxymethylidene cycloheptimidazoles, 1637
$AT_1$, cyclopentane spiro-3H-dihydropyrimidinones, 157
$AT_2$, imidazo-5-acrylic acid, 23
$AT_1/AT_2$, imidazo[4,5-*b*]-based, 17
balanced:
4-aminomethyl- and acylaminomethylimidazoles, 2229
effect biphenyl *ortho*-substit on $AT_1/AT_2$ affinities, 2011
effect of imidazoles substit in 5-position, 2235
chiral recognition by phenoxyproline octanoamide, 51
dihydroimidazolone derivs, chiral effect on activity, 163
imidazoles and pyrroles bearing hydroxymethyl and carboxy substituents, 177
imidazo[1,2-*b*]pyridazine isosteres of imidazo[4,5-*b*]-pyridine, 219
imidazo[4,5-*b*]pyridine, synthesis of imidazo[1,2-*b*]pyridazine isosteres, 219
indoles, 1,4-substit, 145
isoxazolidinyl, CL332 877 and enantiomer synthesis, bioevaluation, 1709
nonpeptide:
2(1H)-pyridinones, annelated, 127

SAR, 121
6-butyl-1,2-dihydropyridin-2-ones, 3-substit, 683
2,6-dialkyl-4-(biphenylmethyl)-aminopyridine 3-substit derivs synthesis, SAR, 139
acidic phenols, 207
conformationally restricted, 2591
diacidic, 35
DMP 581 and 811, 63
imidazopyridine-based incorporating heterocyclic acid equivs, 41
quinazolinone biphenyl acyl sulfonamides, 75
quinazolinone-2,3-dihydro-4(1H)-deriv, 1141
quinazolinone-2,3,6-substit deriv, 1135
quinoline-4-carboxylic acids, 195
quinoline-4-carboxylic acid, orally active prodrugs, 201
triazolinone based with affinity for $AT_1$ and $AT_2$ subtypes, 2787
Ca, heterocyclic guanidines, 351
histamine $H_3$ receptor, unsymmetrical substit guanidines, 2907
$hNK_1$ piperidine-ether based, stereochemical requirements, 2545
$5\text{-}HT_{2a}$ 1,1-diphenyl-3-dialkyl-amino-1-silacyclopentane derivs, 415
$LTB_4$, benzenepropanoic acid with chromanone or naphthalenone moieties, 2883
$LTB_4$, synthesis, properties, 1461
morpholine based substance P, assessment 3-point binding model, 1917
muscarinic:
3-lithioquinuclidin-2-ene intermediate, 2837
activity 3-(5-alkoxy-oxazol-2-yl)-1,2,5,6-tetrahydropyridines, 1721
neurokinin NK-2 receptor, nonpeptide, GR159897 and related analogs, 1951
non-NMDA glutamate, activity 4-phosphonoalkylquinoline deriv, 2035
nonpeptide:
N-alkylquinuclidinium substance P, 1153
$NK_1$, perhydropyranopyrroles, 669
RPR 100893, synthesis prototype, triarylperhydro-isoindoles, 673
substance P, 2-aryl-1-azabicyclo-[2.2.2]octanes, 839
receptors:
$5\text{-}HT_3$, irreversible N-chloromethylquinuclidinium derivs, 945
$5\text{-}HT_3$, synthesis *endo*-3,9-diaza-bicyclo[3.3.1]nonan-7-amino derivs, 2373
$5\text{-}HT_4$, bioevaluation 2-benzyloxy substit ketones 2481
AMPA, 1,2,3,6,7,8-hexahydro 3-(hydroxyimino)-N,N,7-trimethyl-2-oxobenzo[2,1-*b*]:[3,4-*c*']-dipyrrole-5-sulfonamide, 371
channel, glycine, NMDA complex synthesis, SAR 2H-[1,2,4]-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivs, 2735
endothelin-A, BQ-123Na, large scale prep, 1613
GPIIb/IIIa, SARs double-strand RGD peptides, 1749
$LTB_4$, SC-53228 with high intrinsic potency and selectivity, 811
nonpeptide:
angiotensin, imidazolinones, 1527
fibrinogen design centrally constrained inhibitor, 1835, 1841
*ortho*-phenylphenol $LTB_4$, SAR, 795
selective, tachykinin $NK_3$, dipeptide library in drug design, 1679
tachykinin NK-2, design, synthesis prototype model, 1397
thromboxane, dual thromboxane, inhibitor, orally effective oxa-prostanoid analogs, 2073
thromboxane together with thromboxane synthase inhibitor activity, bio-evaluation thia-prostanoid analogs, 2067
xanthone dicarboxylic acid $LTB_4$, structural analogs
LY292728, spatial positioning secondary acid groups, 2077
substance P:
discovery by pharmacophore driven strategy, 1865
*gem*-disubstit amino-ether based, 2733
**Anthracene-9-carbonyl-$N_1$-spermine** stabilizes DNA more than spermine or spermidine, 2435
**(benz)Anthracycline** analog 4-demethoxydaunorubicin antitumor agent, 2781
**Anti-allergy agents** angular tricyclic ether derivs of 1,8-naphthyridin-2(1H)-one ring system, 1327
**Anti-arthritic agents**
D-penicillamine derivs, 1167
five-membered heterocyclic amines, 1673
**Antibacterials**
2-isocephems with dihydroxy-pyridone moiety at C-7, 1601
3-(N-alkylpyridinium-4'-thio)-methyl optically active derivs of 2-oxaisocephems, 1147
4''-*epi* and 4''-deoxy-4''-amino analogs derived from 9-deoxo-8a-aza-8a-homoerythromycin A, 1111
5-aryl-β,γ-butenolide derived from N-aryloxazolidinone DUP-721, 1925
2-isocephems with dihydroxy-pyridone moiety at C-7, 1601
noviosylcoumarin antibiotics with C-3' ester introduction, modification, 1623
**Antibiotics**
noviosylcoumarin with C-3' ester introduction, antibacterial activity, 1623
**Antibodies**,
$^{99m}Tc$ labelling using methylphosphonylated bifunctional cyclams as chelators, 2597
anti-B-lymphocytes, detection by piezoelectric immunosensor, 2429
catalysis automation, 297
catalytic use in organic syntheses, 297
chorismate mutase activity, mechanistic studies, 2945
**Anti-coccidial agents** synthesis 1,2,4-triazine-(2H,4H)-3,5-dione via Pd-catalysed cross-coupling, 835
**Anti-convulsants** enantioselective

synthesis PD144723, 823
**Anti-depressants** ABT-200 combining α-2 antagonism with NE uptake inhibition, 1319
**Antifungal agents**
azole, 2,2,4-trisubstit oxetanes, 1313
broad spectrum orally active azole optical isomers Sch-42538 and -45012, 2023
**Anti-HCMV activity** synthesis 9-[ethoxy(hydroxyphosphinyl)-methoxy]-guanine isostere of PMEG monoethyl ester, 2241
**Antiherpes agents**
A-ring functionalized dehydro-abietane derivs, activity, 1101
virus agent, (2'*S*)-2'-deoxy-C-methyl-5-iodouridine, 367
**Anti-histaminic properties**
5-lipoxygenase and PAF antagonists, design of pyrrolo-1,4-benzoxazine derivs as inhibitors, 2383
**Anti-HIV activity**
3',4'-di-O-(-)-camphanoyl-(+)-*cis*-khellactone and related compds, 593
cucurbitacin F derivs *Cowania mexicana*, 1323
N-(2,3-dihalogenopropyl)- and N-allyl-glycine containing pentapeptides, 2533
synthesis poly(cysteic) acid, 2245
**Anti-hyperglycaemic activity**
BRL 49653 synthesis, 1181
**Anti-hypertensive activity**
angiotensin mediated, substit lactam biphenyltetrazoles, 87
K-channel benzopyran activators related to cromakalim with heterocyclic replacements at position 4, 1285
L-162,441 and L-162,620, oral admin animals, 17
**Anti-inflammatory activity** RO 24-0553, 5-lipoxygenase inhibitor, 339
**Anti-ischemic agents** N-substit 1-(5-fluoro-2-pyrimidinyl)-piperazine derivs, 1941
**Anti-leukaemic activity**
12-hydroxydaphnetoxin derivs, 2649
**Anti-malarials** *in vivo* activity of protoberberine alkaloid analogs, 1663
**Anti-MRSA β-lactams** synthesis bioevaluation 2-(thiazol-2-ylthio)-carbapenems, 2793
**Anti-MUC1** mAbs SM3 and HMPV, reactivity of penta-O-glycosylated MUC1, 1813
**Antineoplastic activity**
12-hydroxydaphnetoxin derivs, 2649
cancer cell growth inhibitor phakellistatin 5, isolation, structure, 2091
isolation, structure of phakellistatin 6 from *Phakellia contata*, 2677
synthesis 1-(2-deoxy-2-C-fluoromethyl-β-D-arabino-furanosyl)-cytosine, 721
synthesis, activity, SAR 1-(substit benzenesulfonyl)-5-oxopyrrolidine-2-carboxylic acid hydrazides, 377
**Anti-platelet agent**
7-aminofurochromone, synthesis bioactivity, 2621
**Anti-proliferative activity**
15-oxoprostaglandins, contribution omega-chain enone group to cytotoxicity, 1739
diastereoisomerically modified dolastatin 15 analogs, 1947
haloosmocenium ions against human and murine cancer cell lines, 483
heparin-like, of sulfated tetra-saccharide, 1419
**Anti-pseudomonal activity**
2-isocephems with dihydroxy-pyridone moiety at C-7, 1601
**Anti-psychotic agents**
sigma/5HT$_2$, ether derivs of alkyl piperidines, 2347
**Antisense activity**
chimeric oligodeoxynucleotides, 1041
cholic acid conjugates of oligonucleotides, 1053
interaction of linear and folded oligonucleotides modified with sequences containing secondary structure elements, 1019
oligodeoxyribonucleotide phosphorothioates, synthesis, 2017
oligonucleotide phosphorothioates with segments of oligodeoxy-nucleotides and methyloligoribo-nucleotides, 2929
oligonucleotides, comparison of flexible and rigid backbones, 395
synthesis and introduction of 2'-O-methyl-6,3'-ethanouridine, 237
**2-5A-Antisense chimera**
resistance to metabolic deactivation via dephosphorylation, 2609
**Antitubulin activity**
aza-combretastatins, 699
**Antitumor activity**
1,3-dioxolane-2-(2-ethanamine)-2-methanamine Pt complexes, *in vitro* cytotoxicity, 911
14-β-hydroxytaxol and analogs, 1565
14-hydroxydocetaxel, 1571
3'-alkyl and 3'-alkenyldephenyl-docetaxels, 2631
4-demethoxydaunorubicin, synthesis benz[*a*]anthracycline analog, 2781
6-methyl derivs of flavone-8-acetic acid, 2313
bacteriochlorins, synthesis, 1263
clerodane diterpenoid from oleoresin of *Copaifera langsdorfii*, 2889
cyclic hexapeptides, prep [N-alkyl-Ala$^2$]RA-VII, 1633
cytotoxic agents 2-(1-cyclopenten-1-yl)-2-[2-(dimethylamino)ethyl]-5-(*E*)-benzylidene cyclopentanone hydrochlorides, 2701
distamycin A derivs, SARs, 1467
effect of propargylic substitution on aromatization and activation of enediynes, 2925
evaluation 2'-oxycarbonylpaclitaxels, 1861
isolation axinastatin 5 from *Axinella carteri*, 2935
modified enediyne chemotypes, 711
[N-alkyl-Ala$^2$]RA-VII cyclic peptides, 1633
relationship of monogalactosyl diacylglycerols, 1619
stabilization DNA topoisomerase II cleavable complex by mitonafide analogs, 1643
unsat epoxy-C-glycosides with DNA cleavage properties, 421
vinyl sulfone based, pharmacological evaluation, 1585

WIN 33377, prep and related derivs, 609
**Antiviral activity**
2'-deoxy- and 2',3'-dideoxy-nucleosides, stereoselective syntheses, 861
3-substit imidazo[1,2-*a*]pyridines, 1937
6'-C-methyl-3-deazaneplanocin A's, 6'*R*-config essential, 605
[(2'*S*,3'*S*)-bis(hydroxy-methyl)azetidin-1-yl]pyrimidine-nucleosides, oxetanocin-A analogs, 2083
alkylphosphonic acid derivs of oxetanocin-A, 1991
amino esters of ribavirin, 2831
HIV protease inhibitor containing heterocyclic $P_1$'-$P_2$' amide bond isostere, 2441
difluorostatone type bearing (*R*)-valinol derivs as C-termini, 1213
hypericin, role of oxygen in photo production, 1339
**Anxiolytic activity** (±)1-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, $GABA_A$ modulator, 279
**Apoptosis** fragmentation, duocarmycin induction endonucleolytic DNA, 631
**Arabinonucleic acid** synthesis, 1909
**Arachidonic acid** analogs, synthesis and bioevaluation, 247
**Arecolines**
related to bridged 1,2,5,6-tetrahydropyridine esters and oxime ethers, muscarinic agonists, 1185
selective central nicotinic agonists crossing blood-brain barrier, 573
**Argatroban** analogs, synthesis thrombin inhibitory activity and cell permeability of amino-heterocyclic guanidine surrogates, 2165
**Aromatization** activation of bicyclo[7.1.0]ene-diynes, effect of propargylic substitution, 2925
**Artemisinin** related trioxanes, anti-viral activity HIV-1, 931
**Artery** endothelium-free of sheep, reduced agonist effect of HOE140, 781
**Arylamine-DNA** adduct formation, mechanism, 2323
**Ascomycin**
C31-O-desmethyl deriv, immuno-suppressive macrolide, related alkyl ether deriv of FK-506, 927
related alkyl ether analogs of FK-506, 921
**Assays** C-7 modified taxol derivs, synthesis, SARs and bio-evaluation, 2223
**Asymmetric syntheses** *cis*-and *trans*-γ-lactones useful in HIV-1 protease inhibitor synthesis, 903
enantiomerically pure 4'-fluoroalkyl-2',3'-dideoxy nucleosides, 1577
**$AT_1$/$AT_2$** affinities, effect of biphenyl *ortho*-substit balanced angiotensin receptor antagonists, 2011
receptors, human subtypes, angiotensin antagonists with equipotent affinity, 2337
triazolinone based angiotensin receptor antagonists, 2787
**$AT_2$** selective quinazolinone angiotensin binding inhibitor, L-161,638, 1479
**ATP binding** DnaA protein, 3-acetoxy-2,2'-bi-1H-indol inhibitors, 1771
**Autacoids** angiogenic factors and synthesis 12(*R*)- and 12(*S*)-hydroxyeicosa-5(*Z*),8(*Z*),14(*Z*)-trienoic acid and 14,15-dehydro analogs, 2689
**Automation** antibody catalysis, 297
*Axinella carteri*, isolation axinastatin 5, inhibition of cancer cell growth, 2935
**Axinastatin 5** cyclo-octapeptide, inhibition of cancer cell growth isolation from *Axinella carteri*, 2935
**Aza analogs** staurosporine and K 252a as PKC inhibitors, 495
**Aza-combretastatins** synthesis, antitubulin activity, 699
**Azabenzene** moiety, protected amino acid, synthesis for inclusion conformationally mobile peptides, 2145
**1-Azabicyclo[2.2.2]-octanes** 2-aryl deriv, substance P nonpeptide antagonists, 839
**3-Azagranatanes** 5-$HT_3$ receptor antagonist, synthesis, 2373
**Azetidin-2-ones** 4-allyl, optically active, access to carbacephams, 2841
**Azoles**
antifungal agents, 2,2,4-trisubstit oxetanes, 1313
optical isomers, broad spectrum orally active antifungal agents, 2023
**AZT** diaryl phosphate derivs as pro-drugs, reduced cytotoxicity compared to parent nucleoside, 427

**B**

**Baccatin**
C-9 carbonyl modified, conversion to taxol and taxotere analogs, 1831
synthesis 19-hydroxy docetaxel, 233
**Backbone modification** antisense oligonucleotides, 395
**Bacteriochlorins** antitumor activity, synthesis, 1263
**Barley seeds** helminthosporic acid analog amylase induction, 1847
**Benzazepinone** based mercaptoacetyls, dual inhibition against ACE and NEP, 1795
**Benzenepropanoic acids** with chromanone or naphthalenone moieties, orally active $LTB_4$ antagonists, 2883
**Benzhydryl group** replacement acyclic NK-1 antagonists, 2161
**Benzimidazoles** (6-oxo-3-pyridazinyl), angiotensin receptor antagonists, 1297
**Benzisothiazolone** selective mechanism-based inhibitors of human leukocyte elastase, 1801
**Benzoate analogs** symmetrical 3,5-disubstit, EPSPS inhibitors, 2605
**Benzodiazepine nucleus**
5,7-diphenylhexahydroazepine-2-one alternative for CCK-B receptor ligands, 2877
**1,3-Benzodithiole-2-carboxylates** and tetrazole analogs, binding affinity angiotensin $AT_1$ receptors, 747

**Benzofurans**
analog of ILV, protein kinase activator, 637
dihydro-deriv analogs of 5-carboxamidotryptamine, serotonergic activity, 1207
**Benzolactams** conformation, activity, chiral requirements for tumor promoters, 491
**Benzopyran-4-(N-cyano)carboxamidine**
substituent effects K-channel openers, selective activity for guinea pig trachealis, 1995
**Benzopyrans**
2-fluoromethyl deriv, $K^+$ channel openers, vasorelaxants, 2893
4-carbothioamide deriv, K channel opener, comparative molecular field analysis, 2903
K-channel activators related to cromakalim with heterocyclic replacements at position 4, 1205
N-imino-2-(benzopyran-4-yl) pyridine $K^+$ channel openers, vasorelaxants, 2899
**Benzoquinone** structure maesaquinone isoated from *Maesa lanceolata*, 1131
**Benzothiepin** derivs, orally active inhibitors of 5-lipoxygenase, 549
**Benzoxepin** derivs, orally active inhibitors of 5-lipoxygenase, 549
**Bicyclic β-lactams** hybrid, bioevaluation 1-substit-7-(1-hydroxyethyl)carbacephems, 2279
**Bilanes** hydroxymethyl analogs, substrates/inhibitors activities of uroporphyrinogen III synthase, 1105
**Bile** intercalator steroids, potential DNA binding compds, 1253
**Binding**
affinity:
angiotensin $AT_1$ receptor, substit 1,3-benzodioxole and 1,3-benzodithiole-2-carboxylates and tetrazole analogs, 747
changes in PK-C for 3-O-acyl-2-deoxy-L-ribonolactones with different acyl chains, 355
2 cocaine analogs modified at N, 303
PK-C of 2-deoxy-L-ribonolactones produced by isosteric groups, conformationally restrained DAG analogs, 1369
substit phenylthiophene benzoylsulfonamides to angiotensin $AT_1$ and $AT_2$ receptors, 189
DNA ability:
anthracene-9-carbonyl-$N^1$-spermine probed by LD, CD absorption and molecular modelling comparison spermine and spermidine, 2435
non-diynene class of dynemicins and aza-anthraquinones, 2377
phosphonate analogs 1,3-bisphosphoglyceric acid to yeast phosphoglycerate kinase, 2567
PK-C affinity of δ-lactone effect side chain orientation conformationally restrained diacylglycerol analogs, 2405
properties, 6-amino-2'-O-methylcytidine incorporated in oligonucleotides, 1025
receptor of HO-DPAT isomers, stereoselective synthesis, 2589
selective, dicationic 2,4-diarylpyrimidines, 2913
σ competitive site, spatial relationship with allosteric or lipophilic phenytoin, 2185
taxol analogs to microtubules, analysis, comparative molecular field derived model, 2211
**Bioisosteres** tetrazole, development in angiotensin antagonists, 45
**Biological activity**
14-hydroxydocetaxel, 1571
1α,25-dihydroxy-vitamin $D_3$ hybrid analogs, structural changes at both A-ring and C, D-ring side-chain, 2919
2'- and 4''-OH groups 8,9-anhydroerythromycin A 6,9-hemiacetals, motilin II receptor agonists, 1649
2-isocephems with dihydroxy-pyridone moiety at C-7, 1601
3'-furyl and 3'-pyridyl substit taxanes, 1381
3'-phenyl taxol analogs, 2331
human tumor cell lines, 1571
indole derived melatonin analogs with restricted conformations of C-3 amidoethane side chain, 1559
melatonin, 5-OMe group not essential, 1555
photoaffinity labelled N-(4-azidobenzoyl)-N-debenzoyltaxol and 7-(4-azido-2,3,5,6-tetra-fluorobenzoyl)-taxol, 487
structural modification taxol analogs, 1531
trisubstit indanes, design dipeptide helical mimetics, 2825
**Biotin** phosphoramidites, synthesis for solid phase biotinylation of oligonucleotides, 1761
**Biotinylation** solid phase of oligo-nucleotides, synthesis biotin phosphoramidites, 1761
**Biphenyltetrazolo-lactams**
angiotensin mediated antihypertensive agents, 87
**1,3-Bis(1H-pyrazol-1-yl)propane unit** included in diester crowns, lipase catalysed regioselective synthesis, 2523
**Bis-lactol** chiral synthesis 12(*R*), 20- and 12(*S*),20- DIHETE, 2113
**Bisbenzimidazoles** Hoechst 33342 related, SAR topoisomerase I poisons, 2871
**Bisindolylmaleimide**, inhibitors protein kinase C, Ro 32-0557 conformationally restricted tertiary amine side chain, 1303
**Bis(*p*-nitrophenyl)-phosphate** hydrolysis via Ni complex of pyrazine-2,5-dicarboxylate, 1889
**1,3-Bisphosphoglyceric acid** phosphonate analogs, synthesis and binding to yeast phosphoglycerate kinase, 2567
**Bleomycin** mechanism enzymatic inactivation, β-aminoalaninamide moiety enzyme-dependent molecular switch, 705
**Blood**
brain distribution of solutes, physicochemical analysis of governing factors, 2511
brain penetration, 5-hydroxytryptamine derivs, 1485
**BMY-14802** anti-ischemic activity of structural permutations, 1941
**BMY-40481** synthesis water-soluble etoposide prodrug, 2567
**BOC-CCK-4** derived oxopiperazines, prep CCK receptor

ligands, 867
**Bone-seeking** estrogen, synthesis β-estradiol-3-benzoate-17-succinyl-12A-tetracycline, 1375
**Boronic acid** RTEM β-lactamase inhibition, 1229
**BPMP** prodrug, RTEM β-lactamase inactivation, 1225
**BQ123Na** representative $ET_A$-selective antagonist, large scale prep, 1613
**Bradykinin** guanidinobenzoyl-[$Hyp^3$, $Thi^5$, D-$Tic^7$, $Oic^8$] deriv, reduced agonist effect on endothelium-free femoral artery of sheep, 781
**Brain**
blood distribution of solutes, physicochemical analysis of governing factors, 2511
blood penetration, 5-hydroxytryptamine derivs, 1485
**BRL 49653** antihyperglycaemic agent, synthesis, 1181
**Benzodiazepine nucleus**
5,7-diphenylhexahydroazepine-2-one alternative for CCK-B receptor ligands, 2877
**Brominated 1-phenyl-2-pyridylethenes** protein-tyrosine kinase inhibitors, 1729
**BSO** γ-glutamylcysteine synthetase inhibitors, ability to deplete glutathione and alter drug metabolizing enzymes, 935
**Bulladecinones**, from *Annona bullata*, cytotoxic annonaceous acetogenins, 473
**β,γ-Butenolide** replaced oxazolidinone ring of DUP 721, antibacterial activity, 1925

C

**Calcineurin**
FK506/FKBP12 complex affinity, non macrocyclic FK506 deriv study, 1581
inhibitors based on structure and SAR FK506, 2501
tight-binding pocket for cyclosporin A side-chain residue, 267
**Calcitriol** analogs with structural changes at both A-ring and C, D-ring side-chain, 2919
**Calcium**
antagonists heterocyclic guanidines, 351
$Ca^{2+}$-ATPase inhibitory activity of thapsigargin locked analog, 657
channel:
L-type, reduced activity via modification N-atom quinuclidines framework, 1903
L-type peptide mimetic, CD, 817
receptors, pyrrolo[2,1-*c*][1,4]-benzothiazin-1-ones and pyrrolo[2,1-*d*][1,5]benzothiazepin-10-one derivs, 1235
sialyl Lewis X complex, electrospray mass spectrometry, 2863
*Calophyllum teysmannii* inhibitory activity of coumarins from latex, 1961
**Camptothecins**
derivs, inhibitory evaluation flexible analogs topoisomerase, 2753
water-soluble 7-(acylhydrazono)-formyl derivs, DNA topoisomerase inhibitors, 579
**Cancer**
cell growth inhibitor phakellistatin 5, isolation, structure of antineoplastic agent, 2091
chemo-preventive/therapeutic agents, N-linked analogs of retinoid O-glucuronides, 2117
human and murine cell lines, antiproliferative activity of haloosmocenium ions, 483
*Candida boldinii* alcohol oxidase enantioselective oxidation 2-methyl-1-butanol, 1745
**Cannabimimetic indoles**
molecular modelling, 563
**Captopril** with thiorphan-like substituent, inhibition of endopeptidase 24.11 and angiotensin converting enzyme, 2673
**Carbacephams** access, prep optically active 4-allyl-azetidin-2-ones, 2841
**Carbacephems**
1-substit-7-(1hydroxyethyl)-deriv, bioevalution hybrid bicyclic β-lactams, 2279
functionally, topologically tricyclic β-lactams, 2285
**Carbamates**
ethenyl and oxiranol, (2-$^2H_2$) derivs, prep using Se chemistry, 291
linkage, 3'-NH-CO-O-5', non-ionic achiral, introduction into chimeric oligonucleotides giving resistance to enzymatic cleavage, 1065
**Carbapenems** β-methyl, substit thiazol-2'-ylthio side chain on C-2, anti-MRSA β-lactams, 2793
**Carbazoloquinone** bioactive alkaloid clausenaquinone-A from *Clausena excavata*, structure, synthesis, 2395
**Carbon dioxide** supercritical, resolution N-protected amino acid derivs catalysed by alcalase, 625
**5-Carboxamidotryptamine** benzofurans and dihydro-deriv analogs, serotonergic activity, 1207
**Carboxylic acids**
5-membered ring heterocyclic, angiotensin antagonists, 169
derivs, gelatinase-A inhibitors, 2747
group replacement for sulfhydryl group of ACE inhibitors, 2107
**Cardiotonics** diazinone, stereoselectivity, positive inotropic effects, 2585
**Cardiovascular activity**
pyrrolo[2,1-*c*][1,4]benzothiazin-1-ones and pyrrolo[2,1-*d*]-[1,5]-benzothiazepin-10-one derivs, 1235
**Carnitine**
octanoyltransferase inhibitors, 883
palmitoyltransferase inhibitors, 883
**Cartilage** degradation inhibition by isothiazoloquinolinones, 843
**Catechol** subunit rolipram, SARs, 1855
*Catharanthus roseus* callus, enzymatic reduction of ethyl 3-methyl-2-oxobutanoate, 907
**CCK** receptor ligands, oxopiperazines derived from BOC-CCK-4, 867
**CCK-B** receptor ligands, 5,7-diphenyl-3-ureidohexahydroazepin-2-ones, 2877
**CCNU** $N^3$-substit derivs, synthesis half-life and decomposition, 2353

**CD** peptide mimetic of L-type Ca channels, 817
*Cephalodiscus gilchristus* isolation and structures of cephalostatins 12 and 13, 1507
**Cephalostatins** 12 and 13, isolation and structures, 1507
**Channels**
Ca L-type peptide mimetic, CD, 817
cholinergic activator ABT 418, SARs pyrrolidine-modified analogs, 2389
**ChCA** ABT 418, SARs pyrrolidine-modified analogs, 2389
**Chelators** methylphosphonylated bifunctional cyclams for antibody labelling with $^{99m}$Tc, 2597
**Chemiluminescence** enzymatic hydrolysis light-emitting substrate of phosphotriesterase, 2705
**Chemocancer agents**
preventive/therapeutic, N-linked analogs of retinoid O-glucuronides, 2117
**Chemotactic tripeptides**
biological effects of ester bond at various positions, 1551
**Chirality**
effect on substitution dihydroimidazolone $AT_1$ angiotensin receptor antagonists, 163
requirements for tumor promoters, conformation, activity benzolactams, 491
**(±)-Chloramphenicol palmitate** hydrolysis by hydrolases, 2941
**Cholecystokinin** methionine incorporation, 2263
**Cholic acid** conjugates of oligonucleotides antisense applications, 1053
**Cholinergic channel activator** see ChCA
**Chorismate mutase** antibody activity, mechanistic studies, 2945
**Chromatography**
HPLC, identification fluorescent glucoside from protein-free extract human lens, 2303
HPLC separation, LY191704, LY266111 stereoisomers, *in vitro* inhibition human types 1 and 2 steroid 5α-reductases, 1365
structure phakellistatin 6 isolated from *Phakellin costata* 2677
**Chymotrypsin**
design of inhibitors, 2297
subtilisin Carlsberg, differentiated by cyclic peptide inhibitors, 2123
thermostable deriv, soluble in toluene, 917
**Ciglitazone**, metabolite, synthesis of BRL 49653, 1181
**CL329,167**, angiotensin receptor antagonist, 1135
**CL332,877** enantiomers, synthesis bio-evaluation isoxazolidinyl angiotensin receptor antagonists, 1709
*Clausena excavata* bioactive alkaloid clausenaquinone-A, structure, synthesis, 2395
**Clausenaquinone-A** bioactive alkaloid from *Clausena excavata*, structure, synthesis, 2395
**Cleavage reactions** hammerhead ribozyme, importance of purine-pyrimidine OH group and purine amino group, 2857
**Clerodane diterpenoid** from oleoresin of *Copaifera langsdorfii*, antitumour activity, 2889
**Co-oligomerization**
thymine-thymine heterodimer with peptide nucleic acid, 1081
**Cocaine** analogs modified at N, differential binding and dopamine uptake, 303
**Collagenase** human, inhibition by aminophosphonic acid derivs, modification $P_1$ residue, 2833
**Complexes** porphobilinogen deaminase, systematic specificity studies, 521
**Conduritol** related compds, modulating insulin release, synthesis, 2307
**Conformation**
activity benzolactams, chiral requirements for tumor promoters, 491
morphine glucuronides, lipophilicity dependency calculated from molecular lipophilicity potential, 737
*Copaifera langsdorfii* antitumour activity, clerodane diterpenoid from oleoresin, 2889
**Copper** chelation chemistry, 4-alkylamino substit 1,10-phenanthroline derivs, 2721
**Coproporphyrinogen oxidase**
synthetic substrates, *meso*-porphyrinogen revisited, 1607
**Corrigenda**
Cordui A.A., Serkis B., Hennig P., Mahieu J.P., Bobichon C., de Nanteuil G. and Lepagnol J.M.: vol. 4 (1994): p. 1958 lines 12-22 have been corrected, 2489
Kubo I. and Chaudhuri S.K.: vol. 4, 1131 (1994): p. 1133, 5th line last paragraph corrected; p. 1134, reference notes corrected, 1269
Wentland M.P., Perni R.B., Powles R.G., Hlavac A.G., Mattes R.C., Corbett T.H., Coughlin S.A. and Rake J.B.: vol. 4, (1994): Scheme 1 on p. 610 has been corrected; for 14a->1 the reagents have been corrected, 1171
**Cotinine** analog, synthesis 1'-N-methyl- 2'-oxo-anabasine, 515
**Coumarins**
HIV inhibitory from *Calophyllum teysmannii* latex 1961
synthesis as subtype-selective inhibitors of monoamine oxidase, 1195
*Cowania mexicana*, anti-HIV principles, cucurbitacin F derivs, 1323
**CP-71-362** rat and dog renin inhibitor, 589
**CP-96-345** substance P non-peptide antagonists, SAR, 1153
**Cromakalim**, with heterocyclic replacements at position 4, K-channel benzopyran activators, 1285
**Crown ethers** oligosaccharide drug-targetting vectors, bio-evaluation, 1123
**Cucurbitacin F** derivs, anti-HIV principles from *Cowania mexicana*, 1323
**CVFM study** CAAX-derived farnesyl transferase inhibitor, 887
**Cyano-3-pyridine-carboxamidine** vasorelaxant activity compared with amide and thioamide congeners, 2485
**Cyclams** methylphosphonylated bifunctional, as chelators for antibody labelling with $^{99m}$Tc, 2597

**Cyclases** triterpenoid evolution, role of repetitive amino acid motif, 285
**β-Cyclodextrins**, oligosaccharidyl thio derivs, drug targetting vectors, synthesis, 1127
oxime, synthesis, 2041
**Cycloheptimidazoles** 4,5,6,7-tetrahydro-8-carboxy-methylidene angiotensin receptor antagonists, 1637
**Cyclohexane** piperidine analogs, inhibitors HIV proteinase, 2759
**Cyclohexyl analogs** restricticin, synthesis, 733
**Cyclopentanespiro-3H-dihydro-pyrimidinones** angiotensin receptor antagonists, 157
**Cyclopentanones** 2-(1-cyclopenten-1-yl)-2-[2-(dimethylamino)ethyl]-5-(*E*)-benzylidene hydrochlorides, cytotoxic agents, 2701
**Cyclosporin** side-chain residue 4, tight-binding pocket of calcineurin, 267
**Cyclothiazide** isomers, potentiating AMPA current, identification, characterization, 1957
**Cysteine/methionine** linked by carbon pseudopeptides, farnseyl transferase inhibition, 2775
**Cytidine** 2'-deoxy and 5'-methyl-2'-deoxy-derivs, spin-labeled oligo-nucleotides as probes for structural motifs of DNA, 977
protonated analog, triple helix binding study, synthesis 6-amino-2'-O-methylcytidine 1025
**Cytochrome** P-450 systems, metallo-porphyrin mimics, 2867
**Cytomegalovirus** human, inhibition by stereoisomers of 2'-deoxy-3'-oxa-5(*E*)-(2-bromo-vinyl)uridines and 4'-thio analogs, 2667
**Cytosine** 1-(2-deoxy-2-C-fluoromethyl-β-D-arabino-furanosyl)-deriv, antineoplastic agent, 721
**Cytotoxicity** 14-hydroxydocetaxel against human tumor cell lines, 1571
1-(2-decxy-2-C-fluoromethyl-β-D-arabinofuranosyl)-cytosine, 721
2-(1-cyclopenten-1-yl)-2-[2-(dimethylamino)-ethyl]-5-(*E*)-benzylidene cyclopentanone hydrochlorides, 2701
3'-alkyl and 3'-alkenyldephenyl-docetaxels, 2631
annonaceous acetogenins, 2,4-*cis* and *trans*-bulladecinones from *Annona bullata*, 473
antitumor activity modified enediyne chemotypes, 711
contribution omega-chain enone group, antiproliferative activity 15-oxoprostaglandins, 1739
cyclic hexapeptides prep [N-alkyl-Ala$^2$]RA-VII, 1633
diastereoisomerically modified dolastatin 15 analogs, 1947
half mustard deriv of imidazole containing analog of distamycin, 2421
*in vitro* 1,3-dioxolane-2-(2-ethan-amine)-2-methanamine Pt complexes, synthesis, 911
increased, N$^3$-substit derivs CCNU, synthesis half-life and decomposition, 2353
N-benzoyl taxol analogs, 1825
paclitaxel-2'-carbonates, evaluation as antitumor agents, 1861
RA-VII [N-alkyl-Ala$^2$] cyclic hexapeptides, 1633
taxol and taxotere analogs by conversion of C-9 carbonyl modified baccatin III, 1831
vinyl sulfone based anticancer agents, 1585

**D**

**d4T** monophosphate, pentopyranosyl analog, stereospecific synthesis, 1199
**DAG** analogs, conformationally restrained medium-sized α-lactone reaction with PK-C, 543
changes PK-C binding affinity of 2-deoxy-L-ribonolactones produced by isosteric groups, 1369
**D-EP** L-EP, Ser-Leu-Gly unit replaced by ether-containing peptide surrogate, PKA inhibitors, 553
**Deacetoxycephalosporin C** synthase gene, substrate specificity of recombinant enzyme, 1595
**Deacetylation** acetyl migration, peracetylated 1-methyl α,β-D-glucopyranosides by *Candida* lipase hydrolysis, 1629
**Deazapurines** containing oligonucleotides, duplex stability, 971
**N-Debenzoyltaxol** acylation, prep N-acyl taxol analogs, 335
**Decadeoxythymidylate** with phosphorothioate and phospho-diester likages in alternating manner, 2663
**Dehydroabietane** A-ring function-alized derivs, anti-herpes activity, 1101
**Dehydrogenase** 17β-hydroxysteroid type 1, inhibited by 16α-propyl derivs of estradiol, 2129
**Dehydrolysine** analogs of tuftsin, synthesis, bioactivity, 941
**Deiodination**, iodophenols, Se-mediated, mechanism of 5'-thyronine deiodinase model, 1353
**4-Demethoxydaunorubicin** antitumor agent, synthesis benz[*a*]anthrcycline analog, 2781
**9-Deoxo-8a-aza-8a-homoerythro-mycin A** 4''-*epi* and 4''-deoxy-4''-amino analogs, antibac-terial properties, 1111
**2-Deoxy-L-ribono-lactones** 3-O-acyl function, changes in PK-C binding affinity produced by isosteric groups, conformationally restrained DAG analogs, 1369
**3-Deoxymorphines** C3-substit, Pd catalysed synthesis, 2527
**Deoxynucleotides** 5'-dimethoxytritylated derivs, deuteriation, 789
**Deprotection** silyl nucleosides with KF/18 crown-6, 2171
silylated nucleosides nucleotides using triethylamine trihydro-fluoride, 1345
**Depsipeptide** cytostatic, diastereo-isomerically modified dolastatin 15 analogs, 1947

**Dermatan sulfate**
hexasaccharide, synthesis and heparin cofactor II activation, 619
like hexasaccharide with non-glycosaminoglycan structure, synthesis, 893
**2-Dermorphin** related D-arg-desmorphin tetrapeptide, quaternized N-methylation analogs, bioproperties, 2049
**Design** enzyme inhibition and X-ray structure of enzyme-inhibitor complex, 2199
**Deuteriation** 5'-dimethoxytritylated deoxynucleotide derivs, 789
**Diacylglycerol** conformationally restrained analogs, 355
**Diamino acids** urea and nitrosourea derivs, stability, 2697
**α,β-Diamino-α,α-difluoroketones** inhibitors of human leukocyte elastase, 2175
**Diaminopimelate** pathway to L-lysine, dihydrodipicolinic acid synthase as key enzyme, 2267
**Diacylglycerol** conformationally restrained analogs, effect side chain orientation on PK-C binding affinity of δ-lactones, 2405
**Diazepinones** bicyclic and monocyclic based mercaptoacetyls, dual metalloprotease inhibitors, 2055
**Diazinone-cardiotonics** stereoselectivity, positive inotropic effects, 2585
**Diene acids** non-steroidal, inhibitor of human type-2 steroid 5α-reductase, 2327
**Diester crowns** *Mucor miehei* lipase catalysed regioselective synthesis, macrocycles containing 1,3-bis-(1H-pyrazol-1-yl)propane unit, 2523
**N,N-Diethylamino ethylethers** microwave accelerated prep, 2627
**Difluorostatone**
type bearing (*R*)-valinol derivs as C-termini, HIV protease inhibitors, antiviral activity, 1213
type inhibitors of HIV-1 protease, replacement $P_1$ phenylalanine side chain, 241
**DIHETE** 12(*R*),20- and 12(*S*),20-, synthesis via chiral bis-lactol, 2113
**Dihydrodipicolinic acid synthase** key enzyme in diaminopimelate pathway to L-lysine, pyridine, piperidine derivs as inhibitors, 2267
**1,2-Dihydropyridin-2-ones** 3-substit-6-butyl-deriv, nonpeptide angiotensin receptor antagonists, 683
**Dihydropyridines** angiotensin antagonists, 133
**Dihydropyridinium ion** from fragmentative coupling of catharanthine and vindoline, synthesis vinblastine analogs via addition organo-Zn reagents, 1999
**Dihydroseselin** pyranocoumarins type derivs, anti-HIV agents, 593
**9(*R*)-Dihydrotaxol** C-3'-N-acyl analogs, synthesis and SARs, 1429
**Dimerization** SH3 domain-mediated, N-terminal fragment 3-kinase p85 subunit phosphatidylinositol 1755
**Dinucleosides** S-alkyl phosphorothiolates, bioreversible reaction to dinucleoside phosphorothioates, 2471
**Dinucleotide analogs** synthesis 3'-O-thymidylyl(5'-deoxy-5'-selene-thymidylyl)Se-phosphoroselenolate, O-methyl ester and methanephosphonate derivs, 1033
**1,3-Dioxane tricarboxylic acid** analogs of monocyclic squalestatin, inhibitors of squalene synthase, 2155
**Dioxetane** diethylphosphate protecting group, enzymatic properties, 2705
**1,3-Dioxolane** 2-(2-ethanamine)-2-methanamine Pt complexes, synthesis, *in vitro* cytotoxicity, 911
**Dipeptides**
chemical library, use in drug design, 1679
isosteres, HIV-1 protease inhibition, 1385
mercaptoacyl dual inhibitors ACE and NEP, SAR studies, 1783
N-phosphonomethyl and N-carboxyalkyl, dual inhibition of angiotensin converting enzyme and neutral endopeptidase, 2715
phosphonamidate analogs, inhibitors serine β-lactamase activity, 1667
Diphenyl α-aminomethyl phosphonate prodrug inhibitor neutral endopeptidase 24.11, plasma and chemical hydrolysis, 899
**Diphenylborinic acid** inhibitor of serine proteases, 2417
**Disaccharide** galactose-fucose, mimic of sialyl Lewis X synthesis, 2563
**Distamycin**
A derivs, antitumor activity, SARs, 1467
N to C linked and imidazole containing analogs, synthesis and DNA binding, 801
second chloroethyl arm of benzoic acid mustard deriv, bioevaluation of imidazole containing analog, 2421
**Diterpenoid** clerodane from oleoresin of *Copaifera langsdorfii*, antitumour activity, 2889
**1,3-Dithianes** hepatoprotectants, 1453
**1,3-Dithiolanes** hepatoprotectants, 1453
**1,3-Dithiole-2-thione** hepatoprotectant, 1453
**DMP** 581 and 811, nonpeptide angiotensin receptor antagonists, 63
**5'-O-DMT-thymidine 3'-O-(2-thio-1,3,2-oxaselenaphospholane)** synthesis, 1037
**DNA**
/RNA, DNA/DNA duplexes, melting temps and nuclease resistance of single strands, 405
arylamine adduct formation, mechanism, 2323
automatic synthesis, deuteriation 5'-dimethoxy-tritylated deoxynucleotide derivs, 789
binding:
ability, non-diynene class of dynemicins and azaanthraquinones, 2377
DnaA protein to ATP, inhibition by 3-acetoxy-2,2'-bi-1H-indol, 1771
imidazoles containing N to C linked distamycin analogs, 801
branched molecules, construction by chemical ligation, 1011

cleavage properties of unsat epoxy-C-glycoside antitumor compds, 421
cutting sequence specificity 4-alkylamino substit 1,10-phenanthroline derivs, 2721
dynamics study, synthesis of second generation nitroxide spin probe, 981
endonucleolytic, apoptosis and fragmentation, duocarmycin induction, 631
multiple binding anthracene-9-carbonyl-$N^1$-spermine probed by LD, CD, absorption and molecular modelling comparison spermine and spermidine, 2435
potential binding compds based on intercalator bile steroids, 1253
probes for structural motifs, 2'-deoxy and 5'-methyl-2'-deoxy-cytidine spin-labeled oligonucleotides, 977
selective binding agents, dicationic 2,4-diaryl pyrimidines, 2913
sequencing, 3'-modified nucleotides as chain terminators, 1975
single stranded, binding by circular oligodeoxynucleosides, solvent, pH, ionic effects, 965
topoisomerase:
cleavable complex, stabilization by mitonafide analogs, 1643
DNA inhibitors, water soluble 7-(acylhydrazono)-formyl camptothecins, 579
inhibitors, synthesis ring-A-opened isopicropodophyllins, 1513
inhibition by substit 1,2,3,4-tetrahydro-β-carboline derivs, 2411

**Docetaxel**
19-hydroxy, synthesis from baccatin, 233
3'-alkyl and 3'-alkenyl analogs, SAR, 2631

**Dolastatin 15** diastereoisomerically modified analogs, cytotoxicity, 1947

**Dopamine**
$D_3$, receptor preference increased and improved pharmacokinetic properties, C-5 modified derivs of (+)-AJ76 and (+)-UH232, 689
uptake, cocaine analogs modified at N, 303

**Drugs**
design, use dipeptide chemical library, 1679
identification of chemical lead compds by rational design, 525
library amide/ester dimers, strategy for rapid compd generation and screening, 2821
targetting vectors, bioevaluation of oligosaccharide crown ethers, 1123
synthesis oligosaccharidyl-thio-β-cyclodextrins, 1127

**Dual domain concept**
macrocyclic, FKBP12 ligands synthesis evaluation, 2507

**Duocarmycins** induction of endonucleolytic DNA fragmentation and apoptosis, 631

**DUP 721** oxazolidinone ring replaced by β,γ-butenolide, antibacterial activity, 1925

**Dynemicins** aza-anthraquinones, non-diynene compds, DNA binding ability, 2377

**E**

**Eicosanoids**
angiogenic factors and synthesis 12(*R*)- and 12(*S*)-hydroxyeicosa-5(*Z*),8(*Z*),14(*Z*)-trienoic acid and 14,15-dehydro analogs, 2689
vasoactive, 12,20-dihydroxy-eicosa-5(*Z*),8(*Z*),10(*E*),14(*Z*)-tetraenoic acid via chiral bis-lactol, 2113

**Elastase**
human leukocytes:
inhibition by peptidic α,β-diamino-α,α-difluoroketones, 2175
selective mechanism-based benzisothiazolone inhibitors, 1801

**Electrospray**
ionization MS, analysis post-synthetically modified oligodeoxynucleotides, 1869
mass spectrometry, sialyl Lewis X-Ca complex, 2863

**EMD 61753** representative arylacetamido-type K opiate receptor agonists, 677

**Enalapril** with thiorphan-like substituent, inhibition of endopeptidase 24.11 and angiotensin converting enzyme, 2673

**Enantioselective reactions**
hydrolysis, (±)-chloramphenicol palmitate by hydrolases, 2941
oxidation 2-methyl-1-butanol by alcohol oxidase from methylotrophic yeasts, 1745
reduction, ethyl 3-methyl-2-oxobutanoate by enzyme callus of *Catharanthus roseus* 907

**Enantioselective syntheses** optical isomers, broad spectrum orally active antifungal azoles, Sch 42538 and 45012, 2023
PD144723 stereospecific anticonvulsant, 823

**Enantiospecific syntheses**
polyunsat phospholipids, 827

**Endonucleolytic DNA**
duocarmycin induction, fragmentation and apoptosis, 631

**Endopeptidase**
neutral:
24.11, inhibition by 4-substit proline derivs, 2673
dual inhibition by N-phosphonomethyl and N-carboxyalkyl dipeptides, 2715
mercaptoacyl dipeptide dual inhibitors, SAR studies, 1783

**Endothelin**
aminophosphonate converting enzyme inhibitors, potency-enhancing and selectivity-improving phosphoramidon, 1257
analogs, SAR, 1157
monocyclic analogs, SARs, 567
receptor selective antagonist BQ-123Na, large scale prep, 1613

**Endothelium-free** femoral artery of sheep, reduced agonist effect of HOE140, 781

**Endotoxin** structurally non-related inhibitors, design, synthesis, biological properties, 1691

**Enediynes**
activation, aromatization, effect of propargylic substitution, 2925
chemotypes, modified, synthesis, bioactivity, 711

**Enzymatic reactions**

hydrolysis light emitting substrate of phosphotriesterase, 2705
stereospecific hydrolysis, P-S bonds in chiral organophosphate triesters, 1473
**Enzymes**
callus of *Catharanthus roseus*, reduction of ethyl 3-methyl-2-oxobutanoate, 907
design:
reusable system for prep porphyrins, 743
with different structural specificity in acyclic amide and ester substrates, β-lactam recognition, 2291
drugs metabolizing, alteration and glutathione depletion by BSO and γ-glutamylcysteine inhibitors, 935
inhibition, design, and X-ray structure of enzyme-inhibitor complex, 2199
inhibitor design, stereochemical approach, 2297
labelled oligonucleotides by reductive amination, 1005
**Epoxidase** squalene, mammalian, non-squalenoid photoaffinity labels, 2179
**Epoxy-C-glycosides** unsat, antitumor compds with DNA cleavage properties, 421
**EPR** dynamics, synthesis of second generation nitroxide spin probe, 981
**EPSP** synthase, aromatic substrate analogs and symmetrical inhibitors containing 3-phosphate mimics, 2605
**Equations** physicochemical factors governing distribution of solutes in blood and brain, 2511
**[8,9-anhydro]Erythromycin A** 6,9-hemiacetals, bioevaluation 2'- and 4''-OH groups, motilin receptor agonists, 1649
***Escherichia coli***
protein initiating chromosomal replication, ATP binding to DnaA, 3-acetoxy-2,2'-bi-1H-indol inhibitors, 1771
threonine synthase inhibitors, synthesis homoserine phosphate analogs, 273
proline auxotroph grows faster on prolinamide with leucine aminopeptidase overexpression, 2555
randomly mutated proline auxotroph, gene library, selection for growth on potential proline precursors, 2551
**Esters**
amide dimer library, synthesis, bioevaluation, rapid compd generation, screening, 2821
bioisostere, 1,2,4-triazine ring in muscarinic agonists, 1411
bond at various positions in chemotactic tripeptides, biological effects, 1551
**Estradiol**
16α-propyl derivs, inhibitors of 17β-hydroxysteroid dehydrogenase type 1, 2129
endogenous metabolite 2-methoxy-estradiol, tubulin polymerization inhibition by binding to colchicine binding site, 1725
spiro-γ-lactone deriv, 17β-HSD type 2 inhibitor, 2045
**β-Estradiol-3-benzoate-17-(succinyl-12A-tetracycline)**
bone-seeking estrogen, 1375
**Ethenyl carbamates** 2-$^2H_2$ derivs, prep using Se chemistry, 291
**Ethers**
alkyl analog of FK-506 related immunosuppressive macrolide ascomycin, 921
alkyl derivs of FK-506 related immunosuppressive macrolide C31-O-desmethyl ascomycin, 927
**Etoposide** water-soluble active prodrug, synthesis etoposide phosphate, 2567
**Eyes** insoluble protein fraction of aging human lens, synthesis associated fluorescent glycoside, 1219

**F**

**Farnesyl transferase**
CAAX-derived inhibitor, study of CVFM, 887
inhibition, cysteine and methionine linked by carbon pseudopeptides, 2775
P21ras, synthesis hydrophobic peptidomimetic inhibitors, 2579
protein, inhibitors, design of potent carboxylic acid based bisubstrate, 2107
ras, phenol tripeptide inhibitors, 1883
**Fibrinogen** nonpeptide receptor antagonists, design centrally constrained inhibitor, 1835, 1841
**FK-506**
affinity for FKBP-12, effect of C-11 Me and C-13/C-15 OMe substituents, 1457
alkyl ether deriv related immunosuppressive macrolide L-683,742, 927
non macrocyclic deriv, synthesis, study, 1581
related immunosuppressive macrolide L-683,599 alkylether analogs, 921
tricarbonyl region, FKBP binding of small molecule mimics, 1161
**FKBP12 ligands**
design and synthesis pyranose replacements, 2501
dual domain macrocyclic, synthesis evaluation, 2507
**FKBP**
dual domain ligands, design, synthesis, evaluation, 325
macrocyclic ligands, SAR, synthesis, 321
synthetic ligands as peptidyl-prolyl isomerase inhibitors, 315
**Flavone-8-acetic acid** 6-methyl deriv, anti-tumour activity, 2313
**Flavonoids** inhibitory tyrosinase from *Heterotheca inuloides* structural functions, 1443
**Fluorescence**
glycoside associated with insoluble protein fraction of aging human lens, 1219
identification glucoside from protein-free extract human lens, 2303
**Fluorinated sulfoxide chiron**
asymmetric syntheses enantiomerically pure 4'-fluoroalkyl-[2',3']-dideoxy nucleosides, 1577
**Fluorine** substit (-)-indolactam-V, synthesis activity, core structure of teleocidins, 431
**4'-Fluoroalkyl-2',3'-dideoxy nucleosides** enantiomerically pure, asymmetric synthesis, 1577
**6-Fluoropurine** acyclonucleosides, prodrugs of acyclovir and

ganciclovir, 1309
**Furochromone** dimeric, pimolin from *Pimpinella monoica*, 2425

G

**$GABA_A$** modulator, with anxiolytic activity, (±)11-amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, 279
**Galactose-fucose** mimic of sialyl Lewis X, synthesis, 2563
**β-1,4-Galactosyl transferase** bovine, acceptor analog inhibitors, 391
**Ganciclovir** 6-fluoropurine acyclonucleoside prodrugs, 1309
**Gastrointestinal** motility enhancing activity of N-3-arylated imidazolidinylidene propane-dinitrile derivs, 615
**Gelatinase-A**
inhibitors:
carboxylic and phosphonic acid derivs, 2747
hydroxamic acid derivs, 2741
**Gene library** randomly mutated in *E. coli* proline auxotroph, selection for growth on potential proline precursors, 2551
**α,β-D-Glucopyranosides** peracetylated 1-methyl deriv, deacetylation and acetyl migration via *Candida* lipase hydrolysis, 1629
**α-D-Glucopyranosylphenyldiazomethane** mechanism-based α-glucosidase inhibitors, 599
**5-[$^2$H]-D-Glucose** improved synthesis, 409
**α-Glucosidase** mechanism-based inhibitors, α-D-glucopyranosyl-phenyldiazomethane, 599
**Glucosides** fluorescent, from protein-free extract human lens, identification, 2303
**Glucuronidation** rates, effect of heteroatom substit within zileuton nucleus, 1437
**Glucuronides** retinoid, N-linked analogs, cancer chemopreventive/therapeutic agents, 2117
**Glutamate** non-NMDA antagonists, activity of 4-phosphonoalkylquinoline deriv, 2035
**γ-Glutamylcysteine** synthetase and BSO inhibitors, ability to deplete glutathione and alter drug metabolizing enzymes, 935
**Glutathione** depletion and drug metabolizing enzyme alteration by BSO and γ-glutamylcysteine synthetase inhibitors, 935
**Glycan**
non-glycosamino structure of dermatan sulfate-like hexasaccharide, synthesis, 893
O-linked with repeating lactosamine unit, stereocontrolled synthesis, 2805
**Glyceroglycolipids** anti-tumor activity relationship monogalactosyl diacylglycerols, 1619
**Glycine** N-substit peptoid oligomers, proteolytic studies, 2657
**Glycomimetics** synthesis carbohydrate phostones, 2763
**Glycoproteins** gp-120, synthesis Gal-β-(1->4)-6-O-$SO_3$Na-Glc NAc-β-(1->6)-Man-α-OR, 1501
**Glycosidases** inhibition by N-phenyl cyclic isourea deriv 5-aminocyclopentanepolyols, 2643
**Glycosides** fluorescent, associated with insoluble protein fraction of aging human lens, 1219
**Glycosylation** effect on MUC1 immuno-reactivity, 1813
**GM-611** motilin receptor agonist, acid-stable, orally active macrolide, 1347
**GPIIb/IIIa** receptor antagonists, SARs double-strand RGD peptides, 1749
**GR117289** related angiotensin II nonpeptide antagonists imidazo-pyridinylbenzofurans, 725
**GR159897** related analogs, nonpeptide neurokinin NK-2 receptor antagonists, 1951
**Graft-vs-Host**, disease model, PKC selective inhibitors, 2451
**Graves disease** therapeutic models, consequences of methimazole structure, 1357
**Growth hormones**
L-692,429, replacement 2'-tetrazole moiety, 1807
SAR of L-692,429 amino acid side-chain, 1117
**Guanidines**
heterocyclic, Ca antagonists, 351
N-cyano-, analogs of oligonucleotides with acyclic carbohydrate moiety, 1203
unsymmetrical substit, histamine $H_3$ receptor antagonists, 2907
**Guanidino prodrugs** synthesis, 1985
**Guanidinobenzoyl [Hyp$^3$,Thi$^5$,D-Tic$^7$,Oic$^8$] bradykinin reduced**
agonist effect on endothelium-free femoral artery of sheep, 781
**Guanosine** conserved residues, 1-methyl-guanosine substit inactivates Hammerhead ribozyme, 2189

H

**Haloosmocenium ions**
antiproliferative activity against human and murine cancer cell lines, 483
**Hammerhead ribozyme**
cleavage, importance of purine-pyrimidine OH group and purine amino group, 2857
inactivation by 1-methylguanosine substit of conserved guanosine residues, 2189
**HDV** antigenomic ribozyme, kinetics of RNA folding changed by total substit of adenine with 7-deaza-adenine, 987
**Helminthosporic acid** analog amylase induction, barley seeds, 1847
**Heparin**
cofactor II activation, synthesis of dermatan sulfate hexasaccharide, 619
like antiproliferative activity of sulfated tetrasaccharide, 1419
**Hepatitis delta virus** see HDV
**Hepatoprotectants** S-heterocycles, 1453
***Herpes simplex*** viruses-1 and -2, inhibition by stereoisomers of 2'-deoxy-3'-oxa-5(*E*)-(2-bromo-vinyl)uridines and 4'-thio analogs, 2667
**Heterocycles** fused ring with angiotensin antagonists, synthesis, evaluation, 173

***Heterotheca inuloides*** structural functions of tyrosinase inhibitory flavonoids, 1443
**Hexapeptides** cyclic, prep [N-alkyl-Ala$^2$]-RA-VII, anti-tumor activity, 1633
**Hexasaccharides**
dermatan with non-glycosamino glycan structure, synthesis, 893
dermatan sulfate, synthesis and heparin cofactor II activation, 619
**Histamine**
amselamine selective $H_2$-receptor agonist, 1913
$H_3$ receptor antagonists, unsymmetrical substit guanidines, 2907
**HIV**
anti-viral activity of artemisinin related trioxanes, 931
inhibitory activity of coumarins from *Calophyllum teysmanni* latex, 1961
protease inhibitors:
antiviral and oral bioavailable hydroxyethylamine, 2273
asymmetric synthesis *cis*- and *trans*-γ-lactones, 903
C-2 symmetrical peptoid mimics, 1281
C-2 symmetrical, phosphinic acid amide, 1191
C-2 symmetrical with N,N-substit ethylenediamide and ethylenediamine linkers, 653
conformationally constrained enzyme design, inhibition and X-ray structure of enzyme inhibitor complex, 2199
conformationally constrained HIV protease inhibitor, 499
conformationally constrained macrocyclic peptide-based, design, synthesis, 2217
containing heterocyclic $P_1$'-$P_2$' amide bond isostere, 2441
D-amino acids as novel $P_2$/$P_3$ ligands, 1991
difluorostatone type, replacement of phenylalanine side-chain, 241
difluorostatone type bearing (*R*)-valinol derivs as C-termini, 1213
dipeptide isosteres, 1385
nonpeptide based, 2601
nonpeptide incorporation of structural water 1247
pseudosymmetrical nonpeptidyl, design, X-ray crystallography, 583
symmetry based with hydroxy bis-urea isostere, 2343
with β-hydroxy sulfide isostere, 715
with peripheral C-2-symmetry, extended transition state mimic, 2852
proteinase inhibitors:
carbocyclic analogs hydroxyethylamine, 2759
evaluation L-735, 523 pyridyl analogs, 2769
**HO-DPAT isomers** receptor binding and stereoselective synthesis, 2589
**HOE140** reduced agonist effect on endothelium-free femoral artery of sheep, 781
**Hoechst 33342** related bisbenzimidazoles, SAR topoisomerase I poisons, 2871
**Homoserine phosphate** analogs as inhibitors of bacterial threonine synthase, 273
**Hormones**
growth L-692,429:
nonpeptidyl, SAR, 2709
replacement 2'-tetrazole moiety, 1807
SAR of amino acid side-chain, 1117
**5-HPETE** analogs, synthesis, bioevaluation, 253
**17β-HSD** type 2, inhibitors, 3-hydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,17β-carbolactone, 2045
**5-$HT_{2A}$** selective antagonists, 1,1-diphenyl-3-dialkylamino-1-silacyclopentane, 415
**5-$HT_3$**
antagonists pyrazolo[1,5-*a*]-pyridines and pyrazolo[1,5-*a*]-pyridazines, 695
receptor antagonist, synthesis (*endo*)-3,9-diaza-bicyclo[3.3.1]-nonan-7-amino derivs, 2373
receptors, irreversible ligands, N-chloro-methyl quinuclidinium derivs, 945
**5-$HT_4$** receptor:
agonists with nanomolar affinity, 1433
antagonist, ketone analog is high affinity partial agonist, 2477
antagonists, synthesis and evaluation of 2-benzyloxy substit aryl ketones, 2481
**Hybridization**
ability, design of chimeric α-anomeric oligodeoxynucleotides with β-anomeric gaps, 1041
stability oligonucleotides, effect of 2'- and 3'-substituents, 1969
thymine-thymine heterodimer with peptide nucleic acid, 1081
urea and carbamate linked thymidine dimers incorporated into oligodeoxynucleosides, 435
**Hydrolases** hydrolysis of (±)-chloramphenicol palmitate, 2941
**Hydrolysis**
bis(*p*-nitrophenyl)phosphate via Ni complex of pyrazine-2,5-dicarboxylate, 1889
enzymatic, light emitting substrate of phosphotriesterase, 2705
(±)-chloramphenicol palmitate by hydrolases, 2941
plasma and chemical, diphenyl α-aminomethyl phosphonate prodrug inhibitor neutral endopeptidase, 24.11, 899
stereospecific enzymatic, P-S bonds in chiral organophosphate triesters, 1473
**Hydrophobic functionalization**
peptidomimetic inhibitors of P21ras farnesyltransferase, 2579
**Hydroxamic acid** derivs, gelatinase-A inhibitors, 2741
**Hydroxydaphnetoxin derivs**
antileukaemic activity, 2649
**Hydroxyethylamine**
antiviral and oral bioavailable inhibitor of HIV protease, 2273
class of HIV protease antiviral and oral bioavailable inhibitors, 2273
**Hydroxyethylamines**
conformationally constrained macrocyclic peptide-based inhibitors of HIV protease, 2217
**Hydroxyethylene** based HIV protease inhibitors, $P_1$'-$P_2$' amide bond replaced by N-heterocycles, 2441
**Hydroxyl groups** 2' and 4''OH groups of 8,9-anhydroerythromycin A 6,9-hemiacetals,

assessment as motilin receptor agonists, 1649
**5-Hydroxytryptamine derivs** blood brain penetration, 1485
**Hypericin** role of oxygen in photo-production antiviral activity, 1339
**Hypoxic cells** non-protein thiol depletion and radiosensitization by 2-nitroimidazole deriv with NPSH-reactive side chain, 439

I

**ICE** inhibitors, synthesis, evaluation peptidyl aspartyl aldehydes, 2359
**ILV** benzofuran analog, protein kinase activator, 637
**Imidazo-5-acrylic acid** angiotensin $AT_1$ receptor antagonist, 23
**2H-Imidazol-2-one** $N^1$-sterically hindered angiotensin receptor antagonists, synthesis [$^3$H]-SC-54628 and, -54629, 111
**Imidazoles**
4-aminomethyl- and acylaminomethyl-derivs, balanced angiotensin receptor antagonists, 2229
angiotensin: antagonists, acyl sulfonamides and sulfamides as tetrazole replacements, 69
receptor antagonists, 4,5,6,7-tetrahydro-8-carboxymethylidene cycloheptimidazole analogs, 1637
based, aryl-fused angiotensin antagonists, 213
bearing hydroxymethyl and carboxy substituents, angiotensin receptor antagonists, 177
containing analog of distamycin, second chloroethyl arm of benzoic acid mustard deriv, bioevaluation, 2421
containing N to C linked distamycin analogs, synthesis and DNA binding, 801
DMP 581 and 811, nonpeptide angiotensin receptor antagonists, 811
Substit in 5-position, effect on balanced angiotensin receptor antagonists, 2235
**Imidazolidinones** pyrazolones, ACAT inhibitors, chemistry, activity, 1095
**Imidazolidinylidene propanedinitrile** N-3-arylated derivs, gastrointestinal motility enhancing activity, 615
**Imidazolinones** nonpeptide angiotensin receptor antagonists, 1527
**Imidazo[1,2-*b*]pyridazine** isosteres of imidazo[4,5-*b*]pyridine angiotensin antagonists, 219
**Imidazo[4,5-*b*]pyridine** incorporating heterocyclic acid equivs, nonpeptide angiotensin receptor antagonists, 41
series, SARs balanced $AT_1/AT_2$ receptor antagonists, 17
**Imidazo[1,2-*a*]pyridines** 3-substit, antiviral activity, 1937
**Imidazopyridinyl-benzofurans** related GR117289 angiotensin nonpeptide antagonists, 725
**Immunophilin**
FKBP12, affinity of FK-506, 1581
inhibitors on MDR, synthetic non-cytotoxic, investigation, 2097
**Immunoreactivity**
penta-O-glycosylated MUC1 peptide, solid phase synthesis, 1813
**Immunosensor** detection human B-lymphocytes, 2429
**Immunosuppressant activity**
cyclosporin A side-chain residue 4, tight-binding pocket of calcineurin, 267
FK-506, effect of C-11 Me and C-13/C-15 OMe substituents, 1457
macrolide L-683,599, related alkyl ether analogs of FK-506, 921
macrolide L-683,590, related alkyl ether deriv of FK-506 related alkyl ether deriv of FK-506, 927
**Indanes** trisubstit, synthesis, bio-activity, design dipeptide helical mimetics, 2825
**(-)-Indolactam** fluorine substit, synthesis activity, core structure of teleocidins, 431
**Indoles**
1,4-substit, angiotensin receptor antagonists, 145
cannabimimetic, design, synthesis, pharmacology, 563
**Indolizidinedione oxime** inhibitors of acetyl-coenzyme A carboxylase, 1983
**Indolocarbazoles**
aza analogs of staurosporine and K 252a as PKC inhibitors, 495
nitrogens linked by 3-atom bridges, PKC inhibitors, 1333
**Indolylmaleimide** mono derivs, ATP competitive PKC inhibitors, 2845
**Inhibition**
$AT_2$ specific angiotensin receptor binding by tetrahydroisoquinoline derivs, 57
β-lactamase, anacardic acids and analogs, 1423
$Ca^{2+}$-ATPase activity of thapsigargin locked analog, 657
cartilage degradation by thiazoloisoquinolinones, 843
DNA topoisomerase II by substit 1,2,3,4-tetrahydro-β-carboline derivs, 2411
dual, neutral endopeptidase and angiotensin converting enzyme by N-phosphonomethyl and N-carboxyalkyl dipeptides, 2715
effect of changes at allylic center C1 side chain squalestatins, 2683
endopeptidase 24.11 and angiotensin converting enzyme by 4-substit proline derivs, 2673
enzyme, design, and X-ray structure of enzyme-inhibitor complex, 2199
farnesyl transferase, cysteine and methionine linked by carbon pseudopeptides, 2775
HIV, activity of coumarins from *Calophyllum teysmannii* latex, 1961
HIV protease:
$C_2$-symmetrical phosphinic acid amide, 1191
dipeptide isosteres, 1385
HSV-1 and -2 and human cytomegalovirus by stereoisomers of 2'-deoxy-3'-oxa-5(*E*)-(2-bromovinyl)uridines and 4'-thio analogs, 2667
human collagenase by aminophosphonic acid derivs, modification $P_1$ residue, 2833
human types 1 and 2 steroid 5α-reductase, HPLC separation

LY191704, LY266111 stereoisomers, 1365
NE uptake combined with $\alpha_2$ antagonism, ABT-200 antidepressants, 1319
neuraminidase, 4-azido, amino and acetamido substit sialosides study, 2457
oxidosqualene cyclase by substit quinolizidines, 1317
respiratory, is an intact B/C ring system essential in rotenoids? 505
RTEM-1 β-lactamase by boronic acid, 1229
selectivity of staurosporine derivs towards protein kinase C, 399
serine β-lactamase activity, dipeptide phosphonamidate analogs, 1667
steroid 5α-reductase by inverted competitive inhibitors, 847
stromelysin-1 by peptidyl phosphinic acids, 1221
tubulin polymerization, 2-methoxyestradiol binding to colchicine binding site, 1725
tyrosinase flavonoids from *Heterotheca inuloides*, structural functions, 1443

**Inhibitors**

17β-hydroxysteroid dehydrogenase:
type 1, 16α-propyl derivs of estradiol, 2129
type 2,3-hydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,17β-carbolactone, 2045
3-acetoxy-2,2'-bi-1H-indol, ATP binding to DnaA, protein initiating chromosomal replication in *E. coli*, 1771
5-HPETE analogs, leukotriene biosynthesis, 253
5-lipoxygenase:
antiinflammatory activity, Ro-24-0553, 339
orally active benzoxepin and benzothiepin derivs, 549
PAF antagonists with antihistaminic properties, pyrrolo-1,4-benzoxazine derivs, 2383
5α-reductase, synthesis B-nor-4-aza-5α-androstane, 729
α,β-diamino-α,β-difluoroketones of human leukocyte, 2175
α-glucosidase, mechanism-based, α-D-glucopyranosyl phenyldiazomethane, 599
α-ketothiazoles of prolyl endopeptidase, 831
ACAT, chemistry, activity imidazolidinones, pyrazolones, 1095
acceptor analogs of bovine β-1,4-galactosyl transferase, 391
activity of thrombin and cell permeability of amino-heterocyclic guanidine surrogates, 2165
alkaloid penazetidine A of protein kinase C, 2447
aminophosphonate, endothelin converting enzyme, potency-enhancing and selectivity-improving phosphoramidon, 1257
angiotensin converting enzyme:
containing α-hydroxy ketomethylene dipeptide isosteres, 2799
plus neutral endopeptidase by mercaptoacyl dipeptides, SAR studies, 1783
$AT_2$ selective quinazolinone angiotensin binding, L-161,638, 1479
bacterial threonine synthase, synthesis homoserine phosphate analogs, 273
bisindolylmaleimide protein kinase C, Ro 32-0557 conformationally restricted tertiary amine side chain, 1303
BSO and γ-glutamyl-cysteine synthetase, ability to deplete glutathione and alter drug metabolizing enzymes, 935
C-2-symmetric, synthesis HIV-1 protease with N,N'-substit ethylenediamide and ethylenediamine linkers, 653
calcineurin, based on structure and SAR FK506, 2501
cAMP-dependent protein kinase inhibitor/substrate, ether based peptide analog, 553
camptothecin, synthesis, evaluation flexible analogs topoisomerase, 2753
cancer cell growth, isolation, structure of antineoplastic agent phakellistatin 5, 2091
centrally constrained, 3-dimensional requirements fibrinogen nonpeptide receptor antagonists, 1841
CP-71,362, of rat and dog renin, 589
cyclic peptides differentiating serine proteases chymotrypsin and subtilisin Carlsberg, 2123
design fibrinogen nonpeptide receptor antagonists, 1835
conformationally constrained macrocyclic peptide-based, of HIV protease, 2217
diphenylborinic acid of serine proteases, 2417
DNA topoisomerase:
synthesis ring-A-opened isopicropodophyllins, 1513
water-soluble 7-(acylhydrazono)-formyl camptothecins, 579
dual metalloprotease:
constrained peptido mimetics of mercaptoacyl dipeptides, 1789
effect of substit and stereochemistry on benzazepinone based mercaptoacetyls 1796
thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides, 2193
utilization bicyclic and monocyclic diazepinone based mercaptoacetyls, 2055
dual thromboxane synthase/thromboxane receptor antagonist, orally effective oxa-prostanoid analogs, 2073
enzyme, stereochemical approach to design, 2297
EPSPS, symmetrical 3,5-disubstit benzoate analogs, 2605
evaluation dimethyl-2-methyl-2-oxo-1,3-dioxa-4-hexadecyl-6-aza-2-phosphacyclooctane bromide derivs, 883
gelatinase-A, carboxylic and phosphonic acid derivs, 2741
glycosidase, N-phenyl cyclic isourea derivs of 5-amino and 5-amino-1-C-(hydroxymethyl)-cyclopentane-1,2,3,4-tetraols, 2643
hydroxamic acid derivs, 2741
HIV protease:
$C_2$-symmetric, peptoid mimics, 1281
conformationally constrained,

499
containing heterocyclic $P_1$-$P_2$ amino bond isostere, synthesis, activity 2441
D-amino acids as $P_2/P_3$ ligands, 1391
design of nonpeptide, incorporation of structural water, 1247
difluorostatone type, replacement of $P_1$ phenylalanine side chain, 241
difluorostatone type, bearing (R)-valinol derivs as C-terminal, antiviral activity, 1213
N-(2,3-dihalogenopropyl)- and N-allylglycine containing polypeptides, 2553
pseudosymmetrical nonpeptidyl, design, SAR, X-ray crystallography, 583
rational design, enzyme inhibition and X-ray structure of enzyme-inhibitor complex, 2199
symmetry based with hydroxy bis-urea isostere, 2343
synthesis, useful asymmetric synthesis *cis*- and *trans*-γ-lactones, 903
with β-hydroxy sulfide isostere, 715
with peripheral $C_2$-symmetry, extended transition state mimic, 2851
HIV proteinase:
carbocyclic analogs hydroxyethylamine, 2759
evaluation L-735,524 pyridyl analogs, 2769
human leukocyte elastase:
selective mechanism-based benzisothiazolones, 1801
serine proteases, synthesis, evaluation thiazinoindole derivs, 2399
hydrophobic peptidomimetic of P21ras farnesyltransferase synthesis, 2579
ICE, synthesis, evaluation peptidyl aspartyl aldehydes, 2359
immunophilin on MDR, synthetic non-cytotoxic, investigation, 2097
indolizidinedione oxime of acetyl-coenzyme A carboxylase, 1983
leukotriene biosynthesis, $LTA_4$ analogs, 257
new arachidonic acid analogs, 247
new leukotriene analogs, 261
non-peptide based, human HIV protease, 2601
non-steroidal diene acid, human type 2 steroid α-reductase, 2327
N-phenyl cyclic isourea deriv 5-aminocyclo-PDE IV, SAR
catechol subunit rolipram, 1855
peptide based P21ras farnesyl transferase, modification of tetrapeptide $CA_1A_2X$ motif, 887
peptidyl-prolyl isomerase, synthetic FKBP ligands, 315
phenol based tripeptide, of ras farnesyl protein transferase, 1883
phospholipase D, Sch 49211 and 49212 produced by *Nattrassia mangiferae*, 1539
phosphonate of neutral endopeptidase 24.11, effect of heteroatom substit, 539
phosphonate norstatine renin, prep of series, 2005
PKC:
aza analogs of staurosporine and K 252a, 495
bisubstrate, design, synthesis, 2845
indolocarbazole nitrogens linked by 3-atom bridges, 1333
plus carnitine transferase derivs by phosphacyclo-octane bromide deriv, 883
selective, in model Graft-vs-Host disease, 2451
protein-tyrosine kinase, synthesis brominated 1-phenyl-2-pyridyl-ethenes, 1729
prototypical non-peptide model for enzyme renin, 1697
pseudopeptide, aminopeptidases with Ψ[CH(CN)NH]-surrogate as transition state mimic, 1491
pyridine, piperidine derivs of dihydrodipicolinic acid synthase, key enzyme in diamino-pimelate pathway to L-lysine, 2267
renin:
identification efficacy after oral or intravenous admin, 1291
tetrahydroisoquinoline as phenylalanine replacement, 2029
reversible, of interleukin-1β converting enzyme by activated ketones, 1965
serine protease, 1,3-oxazino-[4,5-*b*]indole-2,4-(1H,7H)-diones and 5,6-dimethylpyrrolo[2,3-*d*]-1,3-oxazin-2,4-(1H,7H)-diones, 949
squalene synthase:
3-hydroxymethyl derivs squalestatins, 1931
acyclic mimics zaragozic acids, 1591
synthesis monocyclic squalestatin analogs, 2155
squalestatin, monocyclic analogs based on 1,3-dioxane ring for squalene synthase, 661
structurally non-related endotoxin, design, synthesis, biological properties, 1691
subtype-selective of monoamine oxidase, coumarin synthesis, 1195
thromboxane synthase activity combined with thromboxane receptor antagonist activity, bioevaluation, 2067
topo II, structural requirements, 1643
uroporphyrinogen III synthase, activity of hydroxymethylbilanes, 1105
**Inotropic agents** stereoselectivity, positive effects of diazinone cardiotonics, 2585
**Insecticides** organophosphate, stereospecific enzymatic hydrolysis P-S bonds, 1473
**Insulin** release from pancreatic islets by conduritols A and B, 2307
**Interleukin-1β** converting enzyme, reversible inhibition by activated ketones, 1965
**Internucleoside** achiral $O\text{-}CH_2\text{-}CH_2$ linkages, 1497
**β-Iodoethoxyl group** as stable unit radioiodination, 1687
**Iodophenols** Se-mediated de-iodination, mechanism of 5'-thyronine deiodinase model, 1353
**Ionic effects** on single stranded DNA binding by circular oligodeoxynucleosides, 965
**Isoarecolones** selective central nicotinic agonists crossing blood-

brain barrier, 573
**2-Isocephems**
dihydroxypyridone moiety at C-7, anti-pseudomonal activity, 1601
**Isomerase** peptidyl-prolyl, inhibitors, synthetic FKBP ligands, 315
**Isopicropodophyllins** ring-A-opened, synthesis DNA topoisomerase II inhibitors, 1513
**Isothiazoloquinolinones** cartilage degradation inhibition, 843
**Isourea** N-phenyl cyclic deriv 5-aminocyclopentane-polyols, enzyme inhibition of sugar hydrolases, 2643
**Isoxazolidinyl** angiotensin receptor antagonist CL332,877 and enantiomers, synthesis and bioevaluation, 1709
**6-Isoxazolinyl and isoxazolidinyl quinazolinones** angiotensin receptor antagonists, 1703

**K**

**K opiate** arylacetamido-type receptor agonists EMD 61753 representative, 677
**Ketones**
activated, reversible inhibitors, interleukin-1β converting enzyme, 1965
aryl, 2-benzyloxy substit, synthesis and evaluation as 5-$HT_4$ receptor antagonists, 2481
related benzoate 5-$HT_4$ receptor antagonists RS-23597 are high affinity partial agonists, 2477
**α-Ketothiazoles** inhibitors of prolyl endopeptidase, 831
**Kinetics**
deacetylation, acetyl migration, peracetylated 1-methyl α,β-D-glucopyranosides by *Candida* lipase hydrolysis, 1629

**L**

**L-158,809** incorporation phenylthiophene and benzoylsulfonamide groups, binding affinity to angiotensin $AT_1$ and $AT_2$ receptors, 189
**L-161,638** $AT_2$ selective quinazolinone angiotensin binding inhibitor, 1479
**L-163,579** angiotensin antagonists with equipotent affinity for human $AT_1$ and $AT_2$ receptor subtypes, 2337
**L-683,590** immunosuppressive macrolide, related alkyl ether deriv of FK-506, 921
**L-685,434** HIV-1 protease inhibitor, SAR, 499
**L-692,429**
amino acid side-chain, SAR, 1117
benzolactam growth hormone, replacement 2'-tetrazole moiety, 1807
nonpeptidyl growth hormone, SAR, 2709
**L-700,497** complex with HIV-1 protease, X-ray crystal structure, 499
**L-735,524** HIV proteinase inhibitors, evaluation pyridyl analogs, 2769
**L-aspartate** conformationally restricted analogs, neurobiological action of pyrrolidine-2,3-dicarboxylic acids, 1851
**L-EP** D-EP, Ser-Leu-Gly unit replaced by ether-containing peptide surrogate, PKA inhibitors, 553
**Labelling** antibodies with $^{99m}Tc$ using methylphosphonylated bifunctional cyclams as chelators, 2597
**β-Lactamase**
evolution, starting point?, 2291
inhibition, anacardic acids and analogs, 1423
**Lactams**
biphenyltetrazole, angiotensin mediated antihypertensive agents, 87
carbacephem structural types, 2279, 2285
recognizing enzymes exhibit different structural specificity in acyclic amide and ester substrates, 2291
**Lactones**
*cis-* and *trans-*, useful in HIV-1 protease inhibitor synthesis, 903
medium sized reaction with PK C, 543
PK-C binding affinity, effect side chain orientation of conformationally restrained diacylglycerol analogs, 2405
*Leishmania donovan* phosphoglycan fragments, synthesis, 785
**Leishmanicides**
5-cyano-6-substit-2-thiouracils and mono- and bi-cyclic derivs, 2653
quinazolinones and 1,2,4-triazoloquinazolinones, 2087
**Leucine aminopeptidase**
overexpression allows *E. coli* proline auxotroph to grow faster on prolinamide, 2555
**Leukocyte elastase**
human, inhibition by peptidic α,β-diamino-α,β-difluoroketones, 2175
serine protease, synthesis thiazinoindole derivs inhibitors, 2399
**Leukocytes** human elastase, selective mechanism-based benzisothiazolone inhibitors, 1801
**Leukotrienes**
biosynthesis inhibitors, evaluation 5-HPETE analogs, 253
$LTB_4$ analogs, biological evaluation, 257, 261
$LTB_4$ antagonists:
benzenepropanoic acids with chromanone or naphthalenone moieties, 2883
orthophenylphenol, receptor antagonists, SARs, 795
synthesis, properties, 1461
$LTB_4$ receptor antagonists:
SC-53228 with high intrinsic potency and selectivity, 811
xanthone dicarboxylic acid, in spatial LY292728 analogs, 2077
**Library** potentially 1600 amides/esters, synthesis, bioevaluation, rapid compd generation, screening, 2821
**Ligands** σ phenytoin derivs, 2185
**Ligation** assembly branched DNA molecules, 1011
**Lipase**
catalysed regioselective synthesis diester crowns, macrocycles containing 1,3-bis(1H-pyrazol-1-yl)propane unit, 2523
hydrolysis peracetylated 1-methyl α,β-D-glucopyranosides, acetyl migration and deacetylation, 1629
**Lipophilicity** morphine glucuronides conformation dependency

calculated from molecular lipophilicity potential, 737
**Lipopolysaccharides** endotoxicity, role of structure, 1691
**5-Lipoxygenase**
inhibitor with antiinflammatory activity, Ro-0553, 339
inhibitors, orally active benzoxepin and benzothiepin derivs, 549
PAF antagonists with antihistaminic properties, inhibition, design pyrrolo-1,4-benzoxazine derivs, 2383
**Lithioquinuclidin-2-ene** intermediate for muscarinic agonists and antagonists, 2837
**LY191704**, LY266111 stereoisomers HPLC separation, *in vitro* inhibition human types 1 and 2 steroid 5α-reductases, 1365
**LY289612**
HIV-1 protease inhibitor, D-amino acids as $P_2/P_3$ ligands, 1391
prep as HIV-1 protease inhibitors, 715
**LY292728** spatial analogs, xanthone dicarboxylic acid $LTB_4$ receptor antagonist, 2077
**B-Lymphocytes** human, detection by immunosensor, 2429
**Lysozyme release** role of ester bond in various positions of chemotactic tripeptides, 1551

M

**Macrophage lipid mediator production** effect of scalaradial lacking α,β-unsat aldehyde, 1873
*Maesa lanceolata* structure of maesaquinone, 1131
**Maesaquinone** structure, 1131
**MDR** immunophilin inhibitors, synthetic non-cytotoxic, investigation, 2097
**Mechanisms**
5'-thyronine deiodinase model Se-mediated deiodination iodophenols, 1353
antibody activity chorismate mutase, 2945
arylamine-DNA adduct formation, 2323
based inhibitors of human leukocyte elastase, benzisothiazolones, 1801
enzymatic inactivation bleomycin, β-amino-alaninamide moiety
enzyme-dependent molecular switch, 705
**Melatonin**
5-OMe group not essential for biological activity, 1555
biological activity indole derived analogs with restricted conformations of C-3 amidoethane side chain, 1559
receptor mapping:
  C-5 OMe group not essential for biological activity, 1555
  indole derived analogs with restricted conformation C-3 amidoethane side chain, 1559
**Mercaptoacyl**
benzo-fused azepinones, metallo-protease constrained peptido-mimetic inhibitors, 1789
dipeptides, dual inhibitors, ACE and NEP, SAR studies, 1783
metalloprotease constrained peptidomimetic inhibitors, 1789
thiazines, thiazepines as constrained peptidomimetic surrogates, 2193
**Mesoporphyrinogen** conversion to monovinylic product by coproporphyrinogen oxidase preparation, 1607
**Metalloporphyrins** mimics of cytochrome P-450 systems, 2867
**Metalloprotease**
dual inhibitors:
  bicyclic and monocyclic diazepinone based mercapto-acetyls, 2055
  thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides, 2193
inhibitors:
  constrained peptidomimetics of mercaptoacyl dipeptides, 1789
  effect of substit and stereo-chemistry on benzazepinone based mercaptoacetyls, 1795
**Methimazole** structure, consequences for therapeutic models of Graves disease, 1357
**Methionine**
cysteine, linked by carbon pseudopeptides, farnseyl transferase inhibition, 2775
replacement in biologically active peptides, 2263
**5-Methoxycarbonyl-2'-deoxyuridine** convertible nucleosides, 361
**Methyl-2-oxobutanoate** ethyl ester, reduction by enzymes callus of *Catharanthus roseus* 907
**Methyleneamino linked** pyridines, synthesis, properties, SAR, angiotensin receptor antagonists, 139
**(Methylenecyclopropyl)methyl systems** radical probes, ring opening by competition trapping reactions, 2693
**1-Methylguanosine** substit of conserved guanosine residues inactivates Hammerhead ribozyme, 2189
**2'-O-Methyloligo(pyrimidine)-nucleotides** effects of 5-methyl-substit on triple helix formation, 1029
**Methylotrophic yeasts** alcohol oxidase 2-methyl-1-butanol oxidation, 1745
**5-Methylthioribose 1-α-phosphate** synthesis phosphonate analog,1537
**Mezerein** antileukaemic activity of 12-hydroxydaphnetoxin derivs, 2649
**Microtubules** binding taxol analogs, analysis, comparative molecular field derived model, 2211
**Microwaves** accelerated prep aryl-2-(N,N-diethylamino)-ethylethers, 2627
**Mimetics**
dipeptide helical, synthesis, bio-activity trisubstit indanes, 2825
neurotensin, partially nonpeptide, synthesis, 1241
**Mimics**
β-turn, adamantane and nipecotic acid derivs, 1361
cytochrome P-450 systems, metalloporphyrins, 2867
peptoid, HIV-1 protease $C_2$-symmetric inhibitor, 1281
**Mitonafide analogs** stabilization DNA topoisomerase II cleavable complex, 1643

**MMP-3** inhibition by peptidyl phosphinic acids, 1221
**Models**
comparative molecular field derived, analysis binding taxol analogs to microtubules, 2211
mechanism 5'-thyronine deiodinase, Se- mediated deiodination iodophenols, 1353
molecular:
2'-O-methyl-6,3'-ethanouridine, synthesis, introduction into antisense oligonucleotides, 237
cannabimimetic indoles, 563
neocarzinostatin activation, 309
prototype, NK-2 tachykinin receptor antagonists, 1397
non-peptide inhibitors for enzyme renin, design, synthesis, 1697
therapeutic, Graves disease, consequences of methimazole structure, 1357
**Molecular field analysis**
benzopyran-4-carbothioamide K-channel opener, 2903
**Monoamine oxidase**
subtype-selective coumarin inhibitors, 1195
**Monogalactosyl diacylglycerols**
anti-tumor activity relationship, 1619
**Monosaccharides** δ-phostones, synthesis glycomimetics, 2763
**Morphine**
glucuronides, conformation dependency of lipophilicity calculated from molecular lipophilicity potential, 737
stereochemically defines analogs with C3-substituents, 2527
**Morpholine** analogs substance P antagonists, assessment 3-point binding model, 1917
**Motilin**
receptor agonist:
acid-stable, orally active macrolide GM-611 and derivs, 1347
bioevaluation 2'- and 4''-OH groups of [8,9]-anhydroerythromycin A 6,9-hemiacetals, 1649
**MUC1** penta-O-glycosylated peptide, solid phase synthesis and immunoreactivity, 1813
*Mucor miehei* lipase catalysed regioselective synthesis diester crowns, macrocycles containing 1,3-bis(1H-pyrazol-1-yl)propane unit, 2523
**Muscarine**
activity, antagonists 3-(5-alkoxy-oxazol-2-yl)-1,2,5,6-tetrahydropyridines, 1721
agonists, 1,2,5,6-tetrahydropyridine oxime ethers with electron withdrawing groups, 557
agonists and antagonists, lithioquinuclidin-2-ene intermediate, 2837
receptor, functional $M_1$ selective agonist xanomeline, SARs alkyl substit analogs, 2205
**Mustard** deriv of imidazole containing analog of distamycin, bio-evaluation, 2421

N

**Nanomolar affinity** 5-$HT_4$ receptor agonists, 1433
**1,8-Naphthyridin-2(1H)-one** ring system, angular tricyclic ether derivs, anti-allergy agents, 1327
*Nattrassia mangiferae* Sch 49211 and 49212 phospholipase D inhibitors, 1539
**Neocarzinostatin** DNA complex, molecular modelling, 309
**Neplanocin** 6'*R*-config essential for antiviral activity of 6'-C-methyl-3-deazaneplanocin A's, 605
**Neuraminidase** inhibition, 4-azido, amino and acetamido substit sialosides study, 2457
**Neurobiological action**
pyrrolidine-2,3-dicarboxylic acids conformationally restricted analog L-aspartate, 1851
**Neurokinin** NK-2 receptor antagonists, nonpeptide, GR159897 and related analogs, 1951
**Neurotensin mimetics** partially nonpeptide, synthesis, 1241
**Nickel** complex of pyrazine-2,5-dicarboxylate, bis(*p*-nitrophenyl)phosphate hydrolysis, 1889
**Nicotine** selective central agonists isoarecolones and arecolones crossing blood-brain barrier, 573
**Nipecotic acid** derivs, adamantane, β-turn mimics, 1361
**2-Nitroimidazole** deriv with NPSH-reactive side chain, radiosensitization and non-protein thiol depletion of hypoxic cells, 439
**Nitrosoureas**
diamino acid derivs, stability, 2697
more stable than CCNU, 2353
**Nitroxide** second generation spin probe for DNA dynamics study, 981
**NK-1**
acyclic antagonists, replacement for benzhydryl group, 2161
human, piperidine-ether based antagonists, stereochemical requirements, 2545
nonpeptide antagonists, perhydropyranopyrroles, 669
prototype, RPR 100893, synthesis triarylperhydroisoindols, 673
receptor, interaction with benzylic heteroatom morpholine based substance P antagonists, 1917
recognition of conformation, role of quinuclidines framework, 1903
**NK-2 receptor**
neurokinin antagonists, nonpeptide, GR159897 and related analogs, 1951
tachykinin antagonists, design, synthesis prototype model, 1397
**NMDA** receptor-channel complex, glycine antagonists, synthesis, SAR 2H-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivs, 2735
**NMR**
identification fluorescent glucoside from protein-free extract human lens, 2303
structure pimolin dimeric furochromone isolated from *Pimpinella monoica*, 2425
**B-Nor-4-aza-5α-androstane**
5α-reductase inhibitors, 729
**Norstatine renin** phosphonate inhibitors, prep of series, 2005
**Noviosylcoumarin**
antibacterial antibiotics with C-3' ester introduction, 1623
**NS 257** AMPA receptor antagonist, 371
**Nuclease resistance** design of chimeric α-anomeric oligodeoxynucleotides with β-anomeric

gaps, 1041
**Nucleosides**
2'-deoxy- and 2',3'-dideoxy-derivs, with antiviral activity, stereoselective syntheses, 861
4'-fluoroalkyl-2',3'-dideoxy enantiomerically pure, asymmetric syntheses, 1577
(2'*S*)-2'-deoxy-C-methyl-5-iodo-uridine anti-herpes virus agent, 367
achiral internucleoside O-$CH_2$-$CH_2$ linkages, 1497
anti-HIV analog AZT, diaryl phosphate derivs as pro-drugs with reduced cytotoxicity, 427
antiviral [(2'*S*,3'*S*)-bis(hydroxy-methyl)azetidin-1-yl]pyrimidine nucleosides, oxetanocin-A analogs, 2083
convertible, 5-methoxycarbonyl-2'-deoxyuridine, 361
disubstit 1,3-dioxolanes and 1,3-oxathiolanes containing (*E*)-5-(2-bromovinyl)-uracil, activity against HSV-1, -2 and HCMV replication, 2667
enantiomerically pure 4'-fluoro-alkyl-2',3'-dideoxy-, asymmetric synthesis, 1577
nucleotides, silylated, deprotection using triethylamine trihydrofluoride, 1345
phosphoramidite, with masked thioalkyl function in 2'-position, 995
silyl, deprotection with KF/18 crown-6, 2171
**Nucleotides**
3'-modified as chain terminators for DNA sequencing, 1975
abasic, incorporation stem-loop II hammerhead ribozymes, synthesis 1-deoxy-D-ribofuranose phosphor-amidite, 1715

O

**Octanoamide** phenoxyproline, chiral recognition angiotensin receptor antagonists, 51
**Octapeptide** axinastatin 5 inhibition of cancer cell growth, isolation from *Axinella carteri*, 2935
**Oligosaccharides** crown ethers, drug-targetting vectors, bio-evaluation, 1123
**Oligodeoxynucleosides**
circular, binding single stranded DNA, solvent, pH, ionic effects, 965
incorporation of urea and carbamate linked thymidine dimers, synthesis, hybridization, 435
**Oligodeoxynucleotides**
5-(1-propynyl)-2'-deoxyuridine formacetal and thioformacetal dimer synthons, 1061
chimeric α-anomeric with β-anomeric gaps, design, hybridizing ability and nuclease resistance, 1041
containing 3'-ribothioformacetal phosphate analog, prep, character-ization and binding properties, 807
post-synthetically modified, analysis by electrospray ionization MS, 1869
stereospecific tethering reporter groups to phosphate backbone, 1001
**Oligodeoxyribonucleotides**
amino linkers at 5-position of 2'-deoxyuridine, post synthetic modification method, 361
containing dimers with carbamate moieties as replacement of phosphodiester linkage, 405
phosphorothioates, antisense, synthesis, 2017
synthesis using various sulfurizing reagents, 1519
**Oligo(nucleoside phosphorothio-ate)s** stereocontrolled synthesis, 1037
**Oligonucleotides**
2-5A, 5'-dephosphorylation when phosphodiesterase resistance is built into 2-5A analog, 2609
2'- and 3'-substituents, effect on hybridization, stability, 1969
antisense:
application, cholic acid, conjugates, 1053
comparison of flexible and rigid backbones, 395
introduction of 2'-O-methyl-6,3'-ethanouridine, 237
modified linear and folded, with sequences containing secondary structure elements, 1019
phosphorothioates with segments of oligodeoxynucleotides and 2'-O-methyloligoribonucleo-tides, 2929
containing modified adenine or guanine bases, duplex stability, 971
enzyme labelled by reductive amination, 1005
incorporation:
6-amino-2'-O-methylcytidine, 1025
di-, tri- and tetrameric building blocks with carbamate internucleoside linkages, 1065
mixed analogs with acyclic carbohydrate moiety and N-cyano-guanidine function, 1203
site-specific polyamine conjugates synthesis, 1733
solid phase biotinylation, synthesis biotin phosphoramidites, 1761
sulfonamide containing, synthesis, properties, 1071
thiol mediated labeling in minor groove, 995
with spin-labelled 2'-deoxycytidine and 2-methyl-2'-deoxycytidine, probes for structural motifs of DNA, 977
**Oligosaccharides**
O-linked glycan with repeating lactosamine unit, stereocontrolled synthesis, 2805
thio-β-cyclodextrins drug targetting vectors, synthesis, 1127
**Oligothymidylate analogs** with stereoregulated phosphorothioate and phosphodiester likages in alternating manner, 2663
**Organophosphates** chiral triesters, stereospecific enzymatic hydrolysis P-S bonds, 1473
**Oxa-prostanoids** analogs, orally effective dual thromboxane receptor antagonist/thromboxane synthase inhibitor, 2073
**Oxazepino[3,2-*a*]indole derivs** 5-$HT_4$ receptor antagonists, 667
**1,3-Oxazin-2,4-diones** derivs as serine protease inhibitors, 949
**Oxazino[3,2-*a*]indole derivs** 5-$HT_4$ receptor antagonists, 667
**Oxaziridines** chiral, N-centered radical, use in *cis*-δ-phenyl-

methyl-D-proline synthesis, 2461
**Oxazolo[3,2-*a*]indole** derivs, 5-$HT_4$ receptor antagonists, 667
**Oxetanes** 2,2,4-trisubstit, azole antifungal agents, 1313
**Oxetanocin-A**
analogs, antiviral [(2'*S*,3'*S*)-bis-(hydroxymethyl)-azetidin-1-yl]-pyrimidine nucleosides, 2083
antiviral activity of alkylphosphonic acid derivs, 1991
**Oxidation** 2-methyl-1-butanol by alcohol oxidase from methylotrophic yeasts, 1745
**Oxidosqualene cyclase** inhibition by substit quinolizidines, 1317
**Oximes** primary and secondary derivs cyclodextrin, synthesis, 2041
**Oxiranol carbamates**
2-$^2H_2$ derivs, prep using Se chemistry, 291
thermolysis and reaction with adenosine, 291
**2'-Oxoanabasine**
1'-N-methyl-deriv, cotinine analog, synthesis, 515
**15-Oxoprostaglandins** antiproliferative activity, contribution ω-chain enone group to cytotoxicity, 1739
**5-Oxopyrrolidine-2-carboxylic acids** hydrazides, 1-(substit benzenesulfonyl) deriv, antineoplastic agents, 377
**OXTP** muscarinic antagonist activity, 1721

**P**

**Paclitaxel-2'-carbonates**
evaluation as antitumor agents, 1861
**Palladium** cross-coupling, synthesis 1,2,4-triazine-(2H,4H)-3,5-dione anti-coccidial agent, 835
synthesis C3-substit 3-deoxymorphines, 2527
**Papain** 3-acetyl-pyridinium and quinolinium derivs, reaction with pyruvate giving stable adduct, 1415
**PD144723** stereospecific anticonvulsant, enantioselective synthesis, 823
**Penazetidine A** alkaloid inhibitor of protein kinase C, 2447
**D-Penicillamine derivs**
antiarthritic agents, 1167
**Penicillin**
G, acylase immobilized, substrate specificity, 345
prodrug benzyl-penicillin methyl phosphate, RTEM β-lactamase inactivation, 1225
**Pentapeptides**
containing N-(2,3-dihalogenopropyl)- and N-allyl-glycine, anti-HIV activity, 2533
cyclic, prep in solution, 1613
synthesis in soln, prep representative $ET_A$-selective antagonist BQ-123Na, 1613
**Pentopyranosyl analog** of D4T monophosphate, stereospecific synthesis, 1199
**Peptides**,
biologically active, methionine replacement, 2263
bond, role chemotactic For-Met-Leu-Phe-OMe focused by depsipeptide analogs, 1551
conformationally mobile, inclusion light-switchable amino acid, 2145
cyclic, inhibitors differentiating serine proteases chymotrypsin and subtilisin Carlsberg, 2123
double-strand RGD as GPIIb/IIIa receptor antagonists, SARs, 1749
mimetic of L-type Ca channels, CD, 817
nucleic acid, with chiral backbone based on alanine, 1077
thymine-thymine heterodimer, co-oligomerization and hybridization, 1081
**Peptidomimetic surrogates**
constrained, thiazines, thiazepines in mercaptoacyl dipeptides, 2193
**Peptidyl aspartyl aldehydes**
evaluation as ICE inhibitors, 2359
**Peptidyl-prolyl isomerase**
inhibitors, synthetic FKBP ligands, 315
**Peptoids**, NSG, proteolytic studies, 2657
**Peracetylated 1-methyl α,β-D-glucopyranosides** hydrolysis by *Candida* lipase deacetylation and acetyl migration, 1629
**Perhydrothiopyranopyrroles**
derivs, nonpeptide $NK_1$ antagonists, 669
**Peroxidase** mediated uricolysis, silylation, structure of $C_5H_4N_4O_4$ trapped species, 1685
**$PGE_2$** antagonist and analgesic, SC-51322, 509
**pH** effects on single stranded DNA binding by circular oligodeoxynucleosides, 965
**Phagocytic activity** dehydrolysine analogs of tuftsin, 941
*Phakellia costa* isolation structure phakellistatin 6, antineoplastic activity, 2677
**Phakellistatin** cancer cell growth inhibitor, isolation, structure of antineoplastic agent, 2091
**Pharmacophore driven strategy** discovery substance P antagonists, 1865
**1,10-Phenanthroline** 4-alkylamino substit derivs, Cu-chelation chemistry and DNA cutting specificity, 2721
**Phenols**
acidic nonpeptide, angiotensin receptor antagonists, 207
tripeptides inhibitors Ras farnesyl protein transferase, 1883
**Phenoxyproline octanoamide**
chiral recognition angiotensin receptor antagonists, 51
***cis*-δ-Phenylmethyl-D-proline**
synthesis using N-centered derived chiral oxaziridine radical, 2461
**N-Phenylpyridinylmethyl** analogs of SC-50560, 1H-1,2,4-triazole angiotensin receptor antagonists, 99
**Phenylthiophene benzoylsulfonamides** substit, binding affinity to angiotensin $AT_1$ and $AT_2$ receptors, 189
**Phenytoin** derivs as σ ligands, 2185
**Phosphotriesterase** light emitting substrate, synthesis and enzymatic hydrolysis, 2705
**Phosphates** diaryl derivs as prodrugs of AZT, reduced cytotoxicity compared to parent nucleoside, 427
**Phosphatidylinositol** 3-kinase p85 subunit, N-terminal fragment, SH3 domain-mediated dimerization, 1755

**Phosphinic acids**
amide, $C_2$-symmetrical, HIV protease inhibition, 1191
peptidyl, MMP-3 inhibition, 1221
**Phosphoglycan fragments**
*Leishmania donovani* synthesis, 785
**Phosphoglycerate kinase** binding of phosphonate analogs of 1,3-bisphosphoglyceric acid, 2567
**Phospholipase**
$A_2$, human synovial fluid, effect of scalaradial lacking α,β-unsat aldehyde, 1873
D, inhibitors Sch 49211 and 49212 produced by *Nattrassia mangiferae*, 1539
**Phospholipids** polyunsat, enantiospecific synthesis, 827
**Phosphonamidate analogs**
dipeptides, inhibitors serine β-lactamase activity, 1667
**Phosphonates**
9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy]guanine isostere PMEG monoethyl ester, synthesis and anti-HCMV activity, 2241
analog of 5-methylthioribose 1-α-phosphate, 1537
analogs, 1,3-bisphosphoglyceric acid, synthesis and binding to yeast phosphoglycerate kinase, 2567
antiviral activity of alkylphosphonic acid derivs oxetanocin-A, 1991
inhibitors of neutral endopeptidase 24.11, effect of hetero-atom substit, 539
norstatine renin, inhibitors, prep of series, 2005
**Phosphonic acid** derivs, gelatinase-A inhibitors, 2747
**Phosphonomethyl** and N-carboxyalkyl dipeptides, dual inhibition of angiotensin converting enzyme and neutral endopeptidase, 2715
**Phosphoramidites**
2'-O-(2-thioethyl)-uridine deriv, prep, 995
biotin, synthesis for solid phase biotinylation of oligonucleotides, 1761
**Phosphoramidon**
potency-enhancing and selectivity-improving modification, aminophosphonate endothelin converting enzyme inhibitors, 1257
**Phosphorothioates** antisense oligodeoxynucleotides with segments of oligodeoxynucleotides and 2'-O-methyloligoribonucleotides, 2929
**Phosphorothiolates** S-alkyl dinucleoside, bio-reversible reaction to dinucleoside phosphorothioates, 2471
**Phostones** carbohydrate, synthesis glycomimetics, 2763
**Photoaffinity labels**
non-squalenoid for mammalian squalene epoxidase, 2179
synthesis, bio-evaluation N-(4-azidobenzoyl)-N-debenzoyltaxol and 7-(4-azido-2,3,5,6-tetrafluorobenzoyl)-taxol, 487
**Phycocyanobilin** long-wavelength absorbing derivs, new structural aspects on phytochrome, 2517
**Phytochrome** new structural aspects, long-wavelength absorbing derivs of phycocyanobilin, 2517
**Piezoelectric immunosensor**
detection human B-lymphocytes, 2429
*Pimpinella monoica* dimeric furochromone, pimolin isolation, 2425
**Pimobendan** related (6-oxo-3-pyridazinyl)benzimidazoles, angiotensin receptor antagonists, 1297
**Pimolin** dimeric furochromone from *Pimpinella monoica* 2425
**Pipecolinate dilactones**
macrocyclic mimics, binding domain of FK506, 321
**Piperidines**
aromatic conformationally restricted, selective sigma receptor ligands, 329
cyclohexane analogs, inhibitors HIV proteinase, 2759
ethers, $hNK_1$ antagonists, stereochemical requirements, 2545
*gem*-disubstit, substance P antagonists, 2733
**PKC**
activator, benzofuran analog of ILV, 637
alkaloid penazetidine A inhibition, 2447
binding affinity:
3-O-acyl-2-deoxy-L-ribonolactones with different acyl chains, changes, 355
δ-lactones, effect side chain orientation of conformationally restrain diacylglycerol analogs, 2405
2-deoxy-L-ribonolactones produced by isosteric groups, conformationally restrained DAG analogs, 1369
bisindolylmaleimide inhibitors, Ro 32-0557 conformationally restricted tertiary amine side chain, 1303
cAMP-dependent, inhibitor/substrate, ether-based peptide analog, 553
inhibitors, 883
aza analogs of staurosporine and K 252a, 495
selective inhibitors in model Graft-vs-Host disease, 2451
**Platinum**
1,3-dioxolane-2-(2-ethanamine-2-methanamine complexes, synthesis, *in vitro* cytotoxicity, 911
**PMEG** monoethyl ester, 9-[[(ethoxyhydroxyphosphinyl)-methoxy]methoxy]guanine isostere, synthesis and anti-HCMV activity, 2241
**Polyamines**
co-valent attachment at $N^4$ of 5-MedC, incorporation into oligonucleotides, 1733
derived artificial ribonuclease, synthesis, RNA cleaving activity, 1979
**Poly(cysteic) acid** synthesis and anti-HIV activity, 2245
**2'-Polyethyleneglycol** esters of taxol, potential water soluble prodrugs, 2465
**Polymerization** tubulin inhibition, 2-methoxyestradiol binding to colchicine binding site, 1725
**Porphobilinogen deaminase**
systematic specificity studies, 521
**Porphyrins** design of reusable enzymatic system for prep, 743
**Potassium channel**
benzopyran activators related to cromakalim with heterocyclic replacements at position 4, 1285

openers:
2-fluoromethylbenzopyran vasorelaxants, 2893
comparative molecular field analysis of benzopyran-4-carbothioamide, 2903
N-imino-2-(benzopyran-4-yl)-pyridine vasorelaxants, 2899
substituent effects of benzopyran-4-(N-cyano)carboxamidines for selectivity to guinea pig trachealis, 1995
**Prodrugs**
β-estradiol-3-benzoate-17-(succinyl-12a-tetracycline), synthesis bone-seeking estrogen, 1375
acyclovir and ganciclovir, 6-fluoropurine acyclonucleosides, 1309
benzylpenicillin methyl phosphate, RTEM β-lactamase inactivation, 1225
bio-reversible reaction dinucleosides S-alkyl phosphorothiolates to dinucleoside phosphorothioates, 2471
diaryl phosphate derivs, AZT, reduced cytotoxicity compared to parent nucleoside, 427
diphenyl α-amino-methyl phosphonate, inhibitor neutral endopeptidase 24.11, chemical and plasma hydrolyses, 899
etoposide, water-soluble, synthesis etoposide phosphate, 2567
guanidino, synthesis, 1985
water soluble 2'-polyethyleneglycol esters of taxol, 2465
**Proline**
4-substit derivs inhibition of angiotensin converting enzyme and neutral endopeptidase, 24.11 2673
*E. coli* auxotroph grows faster on prolinamide with leucine aminopeptidase overexpression, 2555
deriv, synthesis *cis*-δ-phenylmethyl-O-proline using N-centered derived chiral oxaziridine radical, 2461
precursors, evolved growth, randomly mutated gene library in *E. coli* proline auxotroph, 2551
**Prolyl endopeptidase**
α-ketothiazoles inhibitors, 831
**C-5-Propyn-2'-deoxyuridine**
formacetal and thioformacetal dimer containing oligodeoxynucleotides, 1061
**Protease**
HIV:
$C_2$-symmetric inhibitor, peptoid mimics, 1281
conformationally constrained inhibitors, rational design, enzyme inhibition and X-ray structure of enzyme-inhibitor complex, 2199
inhibited by conformationally constrained macrocyclic peptide-based inhibitors, 2217
inhibitors:
containing heterocyclic $P_1/P_2$ amide bond isostere, antiviral activity, 2441
D-amino acids as $P_2/P_3$ ligands, 1391
dipeptide isosteres, 1385
human, nonpeptide based, 2601
pyridyl analogs of L-735,524, evaluation, 2769
symmetry based, with hydroxy bis-urea isostere, 2343
serine:
chymotrypsin and subtilisin Carlsberg, differentiated by cyclic peptide inhibitors, 2123
inhibition by diphenylborinic acid, 2417
**Protein Kinase C,**
(see also PKC) inhibition, selectivity of staurosporine derivs, 399
inhibitors:
ATP competitive, monoindolylmaleimide derivs, 2845
indolocarbazole nitrogens linked by 3-atom bridges, 1333
interaction with medium sized ε-lactone, 543
**Proteinase**
HIV inhibitors, carbocyclic analogs hydroxyethylamine, 2759
**Proteins**
DnaA, ATP binding, 3-acetoxy-2,2'- bi-1H-indol inhibitors, 1771
tyrosine kinase, inhibitors, synthesis brominated 1-phenyl-2-pyridylethenes, 1729
**Proteolytic studies** homologous peptide and N-substit glycine peptoid oligomers, 2657
**Protoberberine**
alkaloid analogs with *in vitro* antimalarial activity, 1663
*Pseudomonas aeruginosa*
antibacterial activity of 2-isocephems with dihydroxypyridone moiety at C-7, 1601
**Pseudopeptides** Ψ[CH(CN)NH] bond as transition state mimic surrogate, aminopeptidases pseudopeptide inhibitors, 1491
**Pyranocoumarins** dihydroseselin type derivs, anti-HIV agents, 593
**Pyranose ring** FK506, replaced by more accessible groups, 2501
**Pyrazine-2,5-dicarboxylate** Ni complex, bis(*p*-nitrophenyl)-phosphate hydrolysis, 1889
**Pyrazoles**
C-linked biaryl tetrazoles, angiotensin antagonists, pharmacokinetics and regioselective synthesis, 151
hepatoprotectant, activity, 1453
**Pyrazolo[4,3-*e*]-1,2,4-triazolo-[1,5-*c*]pyrimidine** and 1,2,3-triazolo[4,5-*e*]-1,2,4-triazolo[1,5-*c*]pyrimidine, $A_{2a}$ adenosine receptor antagonist activity, 2539
**Pyrazolo[1,5-*a*]pyridazines** 5-$HT_3$ antagonists, 695
**Pyridines** inhibitors of dihydrodipicolinic acid synthase, key enzyme in diamino-pimelate pathway to L-lysine, 2267
methyleneamino linked, synthesis, properties, SAR, angiotensin receptor antagonists, 139
**Pyridinium** 3-acetyl deriv of papain, reaction with pyruvate giving stable adduct, 1415
**2(1H)-Pyridinones**
annelated, SAR, nonpeptide angiotensin receptor antagonists, 127
SAR, nonpeptide angiotensin receptor antagonists, 121
series, SAR, nonpeptide angiotensin receptor antagonists, 121
**N-Pyridinylphenylmethyl** analogs of SC-50560, 1H-1,2,4-triazole angiotensin receptor antagonists,

99
**4H-Pyrido[1,2-*a*]pyrimidin-4-one** angiotensin receptor antagonists, 183
**Pyrido[4,3-*b*]thiazine** renin inhibitor with efficacy after oral or intravenous admin, 1291
**2-Pyridylethenes** brominated 1-phenyl-derivs, protein-tyrosine kinase inhibitors, 1729
**Pyrimidines**
2,4-diaryl dicationic derivs, DNA selective binding agents, 2913
1,2,3-triazolo[4,5-*e*]-1,2,4-triazolo- and pyrazolo[4,3-*e*]-1,2,4-triazolo-derivs, $A_{2a}$ adenosine receptor antagonist activity, 2539
**Pyrroles** bearing hydroxymethyl and carboxy substituents, angiotensin receptor antagonists, 177
**Pyrrolidine** *gem*-disubstit, substance P antagonists, 2733
**Pyrrolidine-2,3-dicarboxylic acids** conformationally restricted analogs L-aspartate, neurobiological actions, 1851
**Pyrrolo-1,4-benzoxazines** derivs design, inhibitors of 5-lipoxygenase and PAF antagonists with antihistaminic properties, 2383
**Pyrrolo[2,1-*c*][1,4]benzothiazin-1-ones and pyrrolo[2,1-*d*]-1,5-benzothiazepin-10-one derivs** cardiovascular activity, 1235
**Pyruvate** reaction with 3-acetyl quinolinium and pyridinium derivs of papain giving stable adduct, 1415

## Q

**Quaternary N-methylation analogs** D-Arg-2-dermorphin tetrapeptide, bioproperties, 2049
**Quinazolinones**
6-isoxazolinyl and isoxazolidinyl derivs, angiotensin receptor antagonists, 1703
6-substit, angiotensin receptor antagonists, 1819
2,3-dihydro deriv, angiotensin receptor antagonists, 1141
1,2,4-triazoloquinazolinones, leishmanicidal activity, 2087
biphenyl acylsulfonamides, angiotensin receptor antagonists, 75
**Quinindolinones** (±)11-amino 2,6-dimethyl-1,2,3,4-tetrahydro deriv, $GABA_A$ modulator with anxiolytic activity, 279
**Quinoline-4-carboxylic acids** angiotensin receptor antagonists, 195
orally active prodrugs, 201
**Quinolines** activity of 4-phosphonoalkyl derivs, glutamate non-NMDA antagonists, 2035
**Quinolinium** 3-acetyl deriv of papain, reaction with pyruvate giving stable adduct, 1415
**Quinolizidines** substit, oxido-squalene cyclase inhibition, 1317
**Quinuclidines** framework, role conformation for recognition by NK-1 receptor and N-atom modification reduced activity L-type $Ca^{++}$ channel, 1903
**Quinuclidinium** N-chloromethyl derivs, irreversible ligands for 5-$HT_3$ receptors, 945

## R

**RA-VII**
[N-alkyl-Ala$^2$] cyclic hexapeptides, anti-tumor activity, 1633
**Radicals** (methylenecyclopropyl)methyl, ring opening by competition trapping reactions, 2693
**Radioiodination** β-iodoethoxyl group as stable unit, 1687
**Radiosensitization** and non-protein thiol depletion of hypoxic cells by 2-nitroimidazole deriv with NPSH-reactive side chain, 439
**Receptors**
5-$HT_3$, irreversible ligands, N-chloromethyl quinuclidinium derivs, 945
adrenergic, cloned human, synthesis, bioevaluation 2-amino-2-oxazolines, 2317
angiotensin:
$AT_2$, binding affinity of substit 1,3-benzodioxole and 1,3-benzothiol carboxylates and tetrazole analogs, 747
$AT_2$ and $AT_1$, binding affinity, substit phenylthiophene benzoyl sulfonamides, 189
angiotensin antagonists:
2,3-dihydro-4(1H)-quinazolinone, synthesis, 1141
2,3,6-substit quinazolinones, 1135
6-isoxazolinyl and isoxazolidinyl substit quinazolinones, 1819
6-oxo-3-pyridazinyl-benzimidazoles, 1297
balanced, 4-aminomethyl-and acylaminomethyl-imidazoles 2229
CL332 and enantiomers, synthesis, bio-evaluation, 1709
cycloheptimidazole based, 4,5,6,7-tetrahydro-8-carboxymethylidene, 1637
effects:
biphenyl *'ortho'*-substit on $AT_1/AT_2$ affinities, 2011
substit at imidazole 5-position, 2235
nonpeptide:
conformationally restricted, 2591
imidazolinones, 1527
triazolinone-based, with equivalent affinity for both $AT_1$ and $AT_2$ subtypes, 2787
with equipotent affinity for human $AT_1$ and $AT_2$ receptor subtypes, 2337
agonists:
$H_2$, amselamine histamine selective, 1913
5-$HT_4$ with nanomolar affinity, 1433
arylacetamindo-type κ opiate, EMD-66,735 as steroid representative, 677
melatonin, indole derived lacking C-5 methoxyl group, 1555
motilin:
biological value 2'- and 4'-OH groups 8,9-anhydro-erythromycin A 6,9-hemi-acetals, 1649
macrolide-type, GM-611 and derivs, 1347
antagonists:
5-$HT_3$, synthesis (*endo*)-3,9-diazabicyclo[3.3.1]nonan-7-

amino derivs, 2373
5HT$_4$, 2-benzyloxy substit aryl ketones, synthesis, bio-evaluation, 2481
AMPA, 1,2,3,6,7,8-hexa-hydro-3-(hydroxyimino)-N,N,7-trimethyl-2-oxo-benzo[2,1-*b*:-3,4-*c*']di-pyrrole-5-sulfonamide, 371
CCK-B, importance of 5-aryl group, synthesis, 2877
histamine $H_3$, unsymmetrically substit guanidines, 2907
LBT$_4$, SC 53228 with high intrinsic potency and selectivity, 811
melatonin, 5-OH group not essential for bioactivity, 1555
melatonin analogs with restricted conformations of C-3 amidoethane side chain, 1559
NK-2 tachykinin, design, synthesis prototype model, 1397
nonpeptide:
fibrinogen design centrally constrained inhibitor, 1835, 1841
neurokinin NK$_2$, GR159897 and related analogs, 1951
NK1, perhydrothiopyrano-pyrrole derivs, 669
*ortho*-phenylphenol LBT$_4$, SARs, 795
selective, tachykinin NK$_3$, dipeptide library in drug design, 1679
sigma ligands, conformationally restricted aromatic piperidines, 329
thromboxane:
combined synthase inhibitor, activities of prostanoid analogs, 2067
subtypes, series of 3-oxo-2,4-dioxobicyclo[3.2.1]octanes, synthesis, 2103
xanthone dicarboxylic acid LTB$_4$, in spatial LY292728, 2077
binding studies
(±)-AJ76 derivs, affinities at 5-HTTA and dopamine receptors, 689
CCK, effect of substit and stereochemistry of oxopiper-azine, 867
HO-DPAT, stereoselective synthesis, 2589
**5α-Reductase**
human type-2 steroid, non-steroidal diene acid inhibitor, 2327
inhibitors, synthesis B-nor-4-aza-5α-androstane, 729
steroid, inhibition by inverted competitive inhibitors, 847
**Reduction** ethyl 3-methyl-2-oxobutanoate by enzymes callus of *Catharanthus roseus*, 907
**Regioselective reactions** ring opening (methylene-cyclopropyl)-methyl radical, 2693
**Regioselective syntheses** diester crowns, *Mucor miehei* lipase catalysed, macrocycles containing 1,3-bis-(1H-pyrazol-1-yl)propane unit, 2523
**Renin**
inhibitors:
efficacy after oral or intravenous admin, 1291
prototypical non-peptide model, design, synthesis, 1697
rat and dog, CP-71,362, 589
tetrahydroisoquinoline as phenyl-alanine replacement, 2029
**Resolution** N-protected amino acid derivs in supercritical carbon dioxide catalysed by alcalase, 625
**Respiration** inhibition, is an intact B/C ring system essential in rotenoids?, 505
**Restricticin** synthesis cyclohexyl analogs, 733
**9-*cis*-Retinoic acid** prep, 349
**Retinoids**
O-glucuronides, N-linked analogs, cancer chemo-preventive/ therapeutic agents, 2117
RXR-active stilbene analogs, structural basis for RAR and RXR activation, 1447
**RGD peptides** double-strand as GPIIb/IIIa receptor antagonists, SARs, 1749
**Ribavirin** amino acid esters, synthesis, antiviral activity, 2831
**D-Ribofuranose** 1-deoxy phosphoramidite deriv, abasic nucleotide incorporation stem-loop II hammerhead ribozymes, 1715
**L-Ribonolactones**
3-O-acyl-2-deoxy deriv with different acyl chains, changes in PK-C binding affinity, 355
**Ribonuclease**
2-5A dependent, 5'-thiophosphate analog of 2-5A, phosphatase resistant activator, 2609
artificial, polyamine derived, synthesis, RNA cleaving activity, 1979
**Ribozymes**
hammerhead cleavage, importance of purine-pyrimidine OH group and purine amino group, 2857
inactivation by 1-methylguanosine substit of conserved guanosine residues, 2189
stem-loop II, abasic nucleotide incorporation, synthesis 1-deoxy-D-ribofuranose phosphoramidite, 1715
**Rilmenidine** efficacy at cloned human α-adrenergic receptors, 2317
**RNA**
cleaving activity, polyamine derived artificial ribonuclease, 1979
folding kinetics changed in HDV antigenomic ribozyme by total substit of adenine with 7-deaza-adenine, 987
**Ro 24-0553** 5-lipoxygenase inhibitor with antiinflammatory activity, 339
**Rolipram** SAR catechol subunit, 1855
**Rotenoids** is an intact B/C ring system essential for respiratory inhibition?, 505
**RPR 100893** prototype, NK1 nonpeptide antagonists triarylperhydroisoindols, 673
**RPR 104632** NMDA receptor-channel complex glycine antagonists, 2735
**RTEM**
β-lactamase:
inactivation by BPMP, 1225
inhibition by boronic acid, 1229
**RXR-active stilbene** retinoid analogs, structural basis for RAR and RXR activation, 1447

**S**

**SARs**

16α-propyl derivs of estradiols, 2129
2(1H)-pyridinone series, nonpeptide angiotensin receptor antagonists, 121
2H-1,2,4-benzothiadiazine-1,4-dioxide-3-carboxylic acid derivs, NMDA receptor-channel complex glycine antagonists, 2735
3'-alkyl and 3'-alkenyl-3-dephenyldocetaxels, 2631
3-D, investigation series taxol analogs, 2211
alkyl substit analogs of functional $M_1$ selective muscarinic receptor agonist xanomeline, 2205
annelated 2(1H)-pyridinones, nonpeptide angiotensin receptor antagonists, 127
β-lactamase inhibition anacardic acids and analogs, 1423
balanced $AT_1/AT_2$ receptor antagonists in imidazo[4,5-*b*]-pyridine series, 17
C-3'-N-acyl analogs 9(*R*)-dihydrotaxol, 1429
catechol subunit rolipram, 1855
diacidic nonpeptide angiotensin receptor antagonists, 35
distamycin A derivs, antitumor activity, 1467
double-strand RGD peptides as GPIIb/IIIa receptor antagonists, 1749
dual-acting ACE/NEP inhibitors, benzazepinone based mercapto-acetyls, 1795
endopeptidase 24.11 neutral, phosphonate inhibitors, effect of hetero-atom substit, 539
endothelin-1 analogs, 1157
HIV protease pseudo-symmetrical nonpeptidyl inhibitors, 583
L-692,429:
  amino acid side-chain, 1117
  nonpeptidyl growth hormone, 2709
macrocyclic FKBP ligands synthesis, 321
mercaptoacyl dipeptide inhibition of ACE and NEP, 1783
monocyclic analogs of endothelin, 567
N-alkylquinuclidinium substance P non-peptide antagonists, 1153
N-benzoyl analogs taxol, Topliss synthesis, 1825
N-cyano-3-pyridine-carbox-amidines and amide and thioamide congeners, 2485
north-west region kappa opioid agonist U-50,488, 2139
*ortho*-phenylphenol $LBT_4$ receptor antagonists, 795
profile for locus of A-ring side chain of taxol, 1531
pyrrolidine-modified analogs of ABT 418, CHCA, 2389
role of ester bond in various positions of chemotactic tripeptides, 1551
substit dihydroimidazolones, $AT_1$ angiotensin receptor affinity, 163
synthesis, bio-evaluation C2 taxol analogs, 479
synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors, 315
taxol, synthesis and bioevaluation analogs modified at C-7, 2223
topoisomerase I poisons, Hoechst 33342 related bisbenzimidazoles, 2871
urea and nitrosourea derivs diamino acids, 2697
valsartan angiotensin orally active antagonist developed from amino acid series, 29
**SB 203220** naphthyl analog of SK&F 108566, long-acting $AT_1$ antagonist, 23
**SC-50560** angiotensin receptor antagonists:
C-linked analogs, 1H-1,2,4-triazole 105
N-phenylpyridinylmethyl and N-pyridinylphenylmethyl analogs, 1H-1,2,4-triazole, 99
**SC-51322** $PGE_2$ antagonist and analgesic, 509
**SC-53228** synthesis, leukotriene $B_4$ receptor antagonist with high intrinsic potency and selectivity, 811
**$^3$H-SC-54628 and -54629** synthesis, $N^1$-sterically hindered 2H-imidazol-2-one angiotensin receptor antagonists, 111
**Scalaradial** $PLA_2$ inhibitor, lacking α,β-unsat aldehyde, effect on human synovial fluid phospholipase $A_2$ and macrophage lipid mediator production, 1873
**Sch**
42538 and 45012, antifungal agents, broad spectrum orally active azole optical isomers, 2023
49211 and 49212, produced by *Nattrassia mangiferae* phospholipase D inhibitors, 1539
**Schotten-Baumann** acylation of N-debenzoyltaxol, prep N-acyl taxol analogs, 335
**Secretagogues**
benzolactam growth hormone, replacement 2'-tetrazole moiety, 1807
L-692,429, nonpeptidyl growth hormone, SAR, 2709
**Seeds** barley, helminthosporic acid analog amylase induction, 1847
**Selenium** mediated deiodination iodophenols, mechanism of 5'-thyronine deiodinase model, 1353
**Serine**
β-lactamase activity inhibition by dipeptide phosphonamidate analogs, 1667
protease:
  inhibition by diphenylborinic acid, 2417
  inhibitors, 1,3-oxazin-2,4-dione derivs, 949
related to human leukocyte elastase, synthesis thiazinoindole derivs inhibitors, 2399
**Serotonergic activity** benzofuran and dihydro-deriv analogs of 5-carboxamidotryptamine, 1207
**Sialosides** 4-azido, amino and acetamido derivs, neuraminidase inhibition study, 2457
**Sialyl Lewis X**
Ca complex, electrospray mass spectrometry, 2863
mimic, synthesis galactose-fucose, 2563
**Silacyclopentane**
1,2-diphenyl-3-di-alkyamino-derivs, $5\text{-}HT_{2A}$ antagonists, 415
**Silyl nucleosides** deprotection with KF/18 crown-6, 2171
**Silylated compds** nucleosides nucleotides, deprotection using triethylamine trihydrofluoride, 1345
**Silylation** peroxidase mediated uricolysis, structure of $C_5H_4N_4O_4$

trapped species, 1685
**Simvastatin** 3'(*S*)-hydroxy deriv, synthesis, 1767
**SMIU** (2'*S*)-2'-deoxy-C-methyl-5-iodouridine anti-herpes virus agent, 367
**Solubilization** thermostable chymotrypsin deriv in toluene, 917
**Solutes** blood brain distribution, physicochemical analysis of governing factors, 2511
**Solvent** effects on single stranded DNA binding by circular oligodeoxynucleosides, 965
**Spermidine** spermine, DNA stabilizes anthracene-9-carbonyl-$N^1$-spermine to a greater extent, 2435
**Spin labels** oligonucleotides with 2'-deoxy-cytidine and 5'-methyl-deriv as probes for structural motifs of DNA, 977
**Spiro-γ-lactone** estradiol deriv, 17β-HSD type 2 inhibitor, 2045
**Squalene**
epoxidase, mammalian, non-squalenoid photo-affinity labels, 2179
synthase inhibitors:
3-hydroxymethyl derivs of squalestatins, 1931
acyclic mimics zaragozic acids, 1591
monocyclic analogs, 2155
synthesis monocyclic squalestatin analogs, 2155
**Squalestatins**
3-hydroxymethyl derivs, squalene synthase inhibitors, 1931
effects of changes at allylic center in C1 sidechain, 2683
monocyclic analogs as inhibitors of squalene synthase, 2155
monocyclic 1,3-dioxane analogs, 661
**SR**
47436, substit 3H-dihydro-pyrimidinone homologs, $AT_1$ receptor antagonists, 157
59062A, selective atypical β-adrenergic agonist, synthesis, 1921
**Staurosporine**
aza analogs and K252a as PKC inhibitors, 495
derivs, inhibition, selectivity towards protein kinase C, 399
**Stereocontrolled syntheses**
O-linked glycan with repeating lactosamine unit 2805
oligonucleoside-phosphorothioates, 1037
**Stereoisomers** LY191704, LY266111 HPLC separation, *in vitro* inhibition human types 1 and 2 steroid 5α-reductases, 1365
**Stereoregulation** oligothymidylate analogs with phosphorothioate and phosphodiester likages in alternating manner, 2663
**Stereoselective syntheses**
analogs 2'-deoxy- and 2',3'-di-deoxynucleosides with antiviral activity, 861
gp-120, Gal-β-(1->4)-6-O-$SO_3$Na-GlcNAc-β-(1->6)-Man-α-OR, 1501
receptor binding of HO-DPAT isomers, 2589
**Stereoselectivity** positive inotropic effects of diazinone cardiotonics, 2585
**Stereospecific reactions**
bio-reversibility of dinucleoside-S-alkyl phosphorothiolates to phosphorothioates, 2471
enzymatic hydrolysis, P-S bonds in chiral organophosphate triesters, 1473
reporter groups introduced into oligodeoxynucleotides by labelling P diastereomers, 1001
**Stereospecific syntheses**
pentopyranosyl analog of D4T monophosphate, 1199
**Stereospecificity** enzyme property, approach to inhibitor design, 2297
**Steroids**
5α-reductase inhibitors:
by competitive inverted, 847
human types 1 and 2 HPLC separation LY191704 and LY266111 stereoisomers, 1365
**Stilbene** RXR-active retinoid analogs, structural basis for RAR and RXR activation, 1447
*Streptomyces clavuligerus*
recombinant deacetoxycephalosporin C synthase, substrate specificity, 1595
**Stromelysin-1** inhibition by peptidyl phosphinic acids, 1221
**Structures** methimazole, consequences for therapeutic models of Graves disease, 1357
**Substance P**
antagonists:
discovery by pharmacophore driven strategy, 1865
*gem*-disubstit amino-ether based, 2733
morpholine based, assessment 3-point binding model, 1917
nonpeptide:
2-aryl-1-aza-bicyclo[2.2.2]-octanes, 839
methionine incorporation, 2263
**Substrates**
specificity:
immobilized penicillin-G acylase towards penicillin and cephalosporin derivs, 345
recombinant deacetoxy-cephalosporin C synthase of *Streptomyces clavuligerus*, 1505
synthetic, coproporphyrinogen oxidase, 1607
uroporphyrinogen III synthase, activity of hydroxymethylbilanes, 1105
**Subtilisin Carlsberg**
chymotrypsin, differentiated by cyclic peptide inhibitors, 2123
**Sugar hydrolases** inhibition by N-phenyl cyclic isourea deriv 5-aminocyclopentane polyols, 2643
**Sulfamides** acyl derivs as tetrazole replacements, imidazole angiotensin antagonists, 69
**Sulfonamides**
angiotensin antagonists:
acyl and sulfonyl-carbamate quinazolinone acidic functions, balanced $AT_1/AT_2$, 81 acyl deriv as tetrazole imidazole replacement, 69
nonpeptide, triazolinone acyl deriv, 115
receptor, quinazolinone bi-phenyl acyl deriv, 75
containing oligonucleotides, synthesis, properties, 1071
**Sulfonylcarbamate** and acylsulfonamide quinazolinone acidic functions, balanced $AT_1/AT_2$ angiotensin antagonists, 81
**Sulfurization** efficient in synthesis

oligodeoxyribonucleotide phosphorothioates, 1519
**Superoxide anion** production, role of ester bond in various positions of chemotactic tripeptides, 1551
**Surrogates** ΨCH(CN)NH peptide bond as transition state mimic, aminopeptidases pseudopeptide inhibitors, 1491
**Synthase**
deacetoxy-cephalosporin C gene, substrate specificity of recombinant enzyme, 1595
EPSP, aromatic substrate analogs and symmetrical inhibitors containing 3-phosphate mimics, 2605
recombinant deacetoxycephalosporin C of *Streptomyces clavuligerus*, substrate specificity, 1595
squalene, inhibitors, acyclic zaragozic acid mimics, 1591

T

**Tachykinin**
$NK_3$, selective receptor antagonists, dipeptide library in drug design, 1679
$NK_2$ receptor antagonists, design, synthesis prototype model, 1397
**Taxanes** 3'-furyl and 3'-pyridyl substit derivs, bioactivity, 1381
**Taxol** see also docetaxel
14-β-hydroxy-deriv and related analogs, synthesis, antitumor activity, 1565
14-hydroxydocetaxel, synthesis, biological activity, 1571
3'-phenyl analogs, synthesis biology, 2331
analogs binding to microtubules, analysis, comparative molecular field derived model, 2211
biological activity and synthesis 14-hydroxydocetaxel, 1571
C2 analogs, synthesis, SARs, bioevaluation, 479
heteroaromatic analogs, bioactivity 3'-furyl and 3'-pyridyl substit taxanes, 1381
N-acyl analogs via Schotten-Baumann acylation of N-debenzoyltaxol, 335
N-benzoyl analogs, Topliss synthesis, 1825
photoaffinity labels, synthesis, bioevaluation N-(4-azidobenzoyl)-N-debenzoyltaxol and 7-(4-azido-2,3,5,6-tetrafluorobenzoyl)-taxol, 487
SARs:
  profile for locus of A-ring side chain, bio-activity, 1531
  synthesis and bioevaluation analogs modified at C-7, 2223
synthesis and antitumor activity 14-β-hydroxytaxol and analogs, 1565
taxotere analogs by conversion of C-9 carbonyl modified baccatin III, 1831
water soluble 2'-polyethyleneglycol esters as potential prodrugs, 2465
**Taxotere** synthesis of 19-hydroxy docetaxel from baccatin, 233
**Teleocidins** core structure fluorine substit (-)-indolactam-V, synthesis, bioactivity, 431
**Tetrahydro-β-carboline** substit derivs, DNA topoisomerase II inhibition, 2411
**Tetrahydroisoquinolines**
derivs with $AT_2$ specific angiotensin receptor binding inhibition, 57
phenylalanine replacement in renin inhibitors, 2029
**Tetrahydropyridines**
muscarinic agonists:
  bridged esters and oxime ethers related to arecoline, 1185
  oxime ethers with electron with drawing groups, 557
**Tetrahydroquinoline** synthesis, activity angiotensin antagonists with substit biphenyltetrazole group, 2615
**Tetramerization** PBG into hydroxymethylbilane, 521
**Tetrapeptide**
D-Arg-2-dermorphin, quaternized N-methylation analogs, bioproperties, 2049
**Tetrasaccharide** with heparin-like antiproliferative activity, 1419
**Tetrazoles**
antagonists:
angiotensin, biaryl C-linked pyrazoles, pharmacokinetics and regioselective synthesis, 151
angiotensin, bioisosteres, development, 45
$AT_1$ receptor nonpeptide, acidic heterocyclic substit, 45
**Thapsigargin** locked analog, $Ca^{2+}$-ATPase inhibitory activity, 657
**Therapeutic agents** identification of chemical lead compds by rational design, 525
**Therapeutic models** Graves disease, consequences of methimazole structure, 1357
**Thermolysis** oxiranol carbamate, reaction with adenosine, 291
**Thermostability** chymotrypsin deriv, soluble in toluene, 917
**Thia-prostanoid** analogs with thromboxane receptor antagonist/thromboxane synthase inhibitor activities, bioevaluation, 2067
**1,2,4-Thiadiazoles** amino deriv, anti-rheumatoid arthritic agents, 1673
**Thiazepines** thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides, 2193
**Thiazinoindoles** derivs, inhibitors of human leukocyte elastase and serine proteases, 2399
**Thio-β-cyclodextrins** oligosaccharidyl, drug targetting vectors, synthesis, 1127
**3'-riboThioformacetal phosphate** analog of oligodeoxynucleotides, prep, characterization and binding properties, 807
**Thiols**
activation, aromatization of bicyclo[7.1.0]enediynes, effect of propargylic substitution, 2925
mediated labeling in minor groove of oligonucleotides, 995
non-protein depletion and radiosensitization of hypoxic cells by 2-nitroimidazole deriv with NPSH-reactive side chain, 439
**5'-Thiophosphate analog** 2-5A phosphatase resistant activator of 2-5A-dependent ribonuclease, 2609
**2H-Thiopyran-2-thione** hepatoprotectant, 1453
**Thiouracils** 5-cyano-6-substit, and their mono- and bicyclic derivs, leishmanicides, 2653

**Threonine synthase** bacterial, inhibitors, synthesis homoserine phosphate analogs, 273
**Thrombin** inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates, synthesis, 2165
**Thromboxane**
receptors:
antagonist/thromboxane synthase inhibitor activities of thia-prostanoid analogs, bioevaluation, 2067
dual antagonist/thromboxane synthase inhibitor, orally effective oxa-prostanoid analogs, 2073
subtypes, 3-oxo-2,4-dioxobicyclo[3.2.1]octanes, 2103
**Thymidine** containing dimers with carbamate moieties as replacement of phosphodiester linkage, 405
**3'-O-Thymidylyl-(5'-deoxy--5'-selene-thymidylyl)Se-phosphoroselenolate** O-methyl ester and methanephosphonate derivs, 1033
**Thymine** heterodimer of peptide nucleic acid, co-oligomerization and hybridization, 1081
**Topliss**
operational scheme, biological activity 3'-phenyl taxol analogs, 2331
synthesis bioactive substit N-benzoyl taxol analogs, 1825
**Topoisomerase**
DNA cleavable complex, stabilization by mitonafide analogs, 1643
inhibition by substit 1,2,3,4-tetrahydro-β-carboline derivs, 2411
inhibitors:
synthesis ring-A-opened isopicropodophyllins, 1513
water-soluble 7-(acylhydrazono)-formyl camptothecins, 579
inhibitory evaluation flexible analogs, camptothecin, 2753
poisons related to Hoechst, structure activity, 2871
**Toxicity** hypericin, role of oxygen in photoproduction antiviral activity, 1339
**Trachealis** guinea pig, selectivity, substituent effects of benzopyran-4-(N-cyano)-carboxamidines K-channel openers, 1995
**Trestatin A sulfate** substructures, analogs, tetrasaccharide with heparin-like antiproliferative activity, 1419
**Triarylperhydroisoindols**
RPR 100893 prototype NK1 nonpeptide antagonists, 673
**1,2,4-Triazine ring** as ester bioisostere in muscarinic agonists, 1411
**1,2,4-Triazine-(2H,4H)-3,5-dione** anticoccidial agent via Pd-catalysed cross-coupling, 835
**1H-1,2,4-Triazoles**
angiotensin receptor antagonists, C-linked analogs of SC-50560, 105
N-phenylpyridinylmethyl and N-pyridinylphenylmethyl analogs of SC-50560, 99
**Triazolinones**
based angiotensin receptor antagonists with affinity for $AT_1$ and $AT_2$ subtypes, 2787
nonpeptide angiotensin antagonists, discovery triazolinone acylsulfonamide, 115
**1,2,3-Triazolo[4,5-*e*]1,2,4-triazolo[1,5-*c*]pyrimidine**
$A_{2a}$ adenosine receptor antagonist activity, 2539
**1,2,4-Triazoloquinazolinones**
leishmanicidal activity, 2087
**Tricyclic β-lactams** functionally, topologically carbacephems, 2285
**Tridepsipeptides** synthesis, role peptide bond in SARs, 1551
**Triethylamine trihydrofluoride** deprotection silylated nucleosides nucleotides, 1345
**Trioxanes** artemisinin related, anti-viral activity HIV-1, 931
**Tripeptides** phenol, inhibitors Ras farnesyl protein transferase, 1883
**N-Triphenylacetylcystamine** backbone tether to oligodeoxynucleotides, 1001
**Triple helix**
binding study, 6-amino-2'-O-methylcytidine incorporated in oligonucleotides, 1025
formation, effects of 5-methyl substit in 2'-O-methyloligo-(pyrimidine)nucleotides, 1029
**Triterpenoids** cyclase evolution, role of repetitive amino acid motif, 285
**Trypanothione disulfide** solid phase synthesis, 2559
**Tubulin** polymerization inhibition, 2-methoxyestradiol binding to colchicine binding site, 1725
**Tuftsin** dehydrolysine analogs, synthesis, bioactivity, 941
**Tumors** chiral requirements for promoters, conformation, activity benzolactams, 491
**Tunicamine** O,N-protected, synthesis, 879
**Tunicamycins** undecose part, synthesis O,N-protected tunicamine, 879
**β-Turn mimics** adamantane and nipecotic acid derivs, 1361
**Tyrosinase** inhibitory flavonoids from *Heterotheca inuloides*, structural functions, 1443

## U

**U050488**, kappa opioid agonist, SAR north-west region, 2139
**(+)-UH232** synthesis C-5 modified derivs, increased dopamine $D_3$ receptor preference and improved pharmacokinetic properties, 689
**Urea**
carbamate linked thymidine dimers, incorporation into oligodeoxynucleosides, synthesis, hybridization, 435
nitrosourea diamino acid derivs, stability, 2697
**Uricolysis** peroxidase mediated, silylation, structure of $C_5H_4N_4O_4$ trapped species, 1685
**Uridines** C(6-3')-ethano-bridged analog, antisense oligonucleotides, 237
**Uroporphyrinogen III** synthase, substrates/inhibitors activities of hydroxymethylbilane analogs, 1105
**UV spectroscopy**, dynemicins and aza-anthraquinones, non-diynene compds with DNA binding ability, 2377

## V

**Valsartan** angiotensin orally active antagonist developed from amino acid series, 29
**Vasoactive eicosanoids**
12,20-dihydroxy-eicosa-5(*Z*),8(*Z*), 10(*E*),14(*Z*)-tetraenoic acid via chiral bis-lactol, 2113
**Vasorelaxants**
2-fluoromethylbenzopyran $K^+$ channel openers, 2893
N-cyano-3-pyridine carboxamidine compared with amide and thioamide congeners, 2485
N-imino-2-(benzopyran-4-yl)-pyridine $K^+$ channel openers, 2899
**Vinblastine** analogs via addition organo-Zn to dihydropyridinium ion from fragmentative coupling of catharanthine and vindoline, 1999
**Vinyl sulfone**
based anticancer agents, cytotoxicity, 1585
pharmacological evaluation, 1585
**Viruses** anti-human immunodeficient *in vitro* activity of artemisinin-related trioxanes, 931
**Vitamins**
1α,25-dihydroxyvitamin $D_3$ hybrid analogs, structural changes at both A-ring and C,D-ring side-chain, 2919
$D_3$ β-hydroxylated analogs, synthesis, biological character, 1523

**W**

**WIN 33377** anti-solid tumor efficacy, prep and related derivs, 609

**X**

**X-Rays**
crystallography, HIV protease pseudo-symmetrical nonpeptidyl inhibitors, 583
structure of enzyme-inhibitor complex, design of enzyme inhibition, 2199
**Xanomeline** functional $M_1$ selective muscarinic receptor, SARs alkyl substit analogs, 2205
**Xanthone** dicarboxylic acid $LTB_4$ receptor antagonist, spatial LY292728 analogs, 2077

**Z**

**Zaragozic acids**
acyclic mimics synthesis squalene synthase inhibitors, 1591
**ZD6888** with additional substituent on biphenyl, angiotensin antagonists, 2615
**Zileuton nucleus** heteroatom substit, effect on glucuronidation rates, 1437
**Zinc** organo, addition to dihydropyridinium ion from fragmentative coupling of catharanthine and vindoline, synthesis vinblastine analogs, 1999

# Author Index 1994


**Abell A. D. Brandt M. Levy M. A. and Holt D. A.** A non-steroidal diene acid inhibitor of human type 2 steroid 5α-reductase 2327

**Abell A. D. Erhard K. F. Yen H.-K. Yamashita D. S. Brandt M. Mohammed H. Levy M. A. and Holt D. A.** Preparative chiral HPLC separation of all possible stereoisomers of LY191704 and LY266111 and their *in vitro* inhibition of human types 1 and 2 steroid 5α-reductases 1365

**Abou-Issa H.** see Robarge M. J. 2117

**Abraham M. H.** see Chadha H. S. 2511

**Achard D. Truchon A. and Peyronel J.-F.** Perhydrothiopyranopyrroles derivatives: a novel series of potent and selective non peptide NK1 antagonists 669

**Ackermann K.** see Harrington E. M. 2775

**Ackermann K. A.** see Gottschlich R. 677

**Adams H. S.** see Cooper A. W. J. 1951

**Addo M. F.** see Murray W. V. 87

**Adlam G. Blagbrough I. S. Taylor S. Latham H. C. Haworth I. S. and Rodger A.** Multiple binding modes with DNA of anthracene-9-carbonyl-$N^1$-spermine probed by LD, CD, normal absorption, and molecular modelling compared with those of spermidine and spermine 2435

**Adlington R. M.** see Morgan N. 1595

**Agrawal S.** see Habus I. 1065

**Agrawal S.** see Iyer R. P. 2471

**Agrawal S.** see Metelev V. 2929

**Ahle D.** see Dolinnaya N. 1011

**Aislaitner G. Hutt A. J. and Gorrod J. W.** The synthesis of 1'-*N*-methyl-2'-oxoanabasine, an analogue of cotinine 515

**Aitken R. A. Bibby M. C. Double J. A. Phillips R. M. and Sharma S. K.** Synthesis and anti-tumour activity of 6-methyl derivatives of flavone-8-acetic acid (FAA) 2313

**Aiyar N.** see Weinstock J. 23

**Al-Barazanji K. A.** see Smith S. A. 1291

**Aldinger C. E.** see Wester R. T. 133

**Alexander J.** see McCall D. L. C. 1663

**Allen D. G.** see Judd D. B. 725

**Aloup J.-C.** see Jimonet P. 2735

**Altenbach R. J.** see Zydowsky T. M. 173

**Altmann K.-H.** see Schmit C. 1969

**Alvi K. A. Jaspars M. Crews P. Strulovici B. and Oto E.** Penazetidine A, an alkaloid inhibitor of protein kinase C 2447

**Amann C. M.** see Ojima I. 1749

**Amano Y.** see Fukami T. 1257

**Ambo A.** see Sasaki Y. 2049

**Amemiya Y.** see Yanagisawa H. 177

**Andersen A. Treiman M. Poulsen J.-C. J. Cornett C. Moldt P. Olsen C. E. and Christensen S. B.** $Ca^{2+}$-ATPase inhibitory activity of a locked analogue of thapsigargin 657

**Andersen J. V.** see Chorghade M. S. 2867

**Andersen N. H. and Palmer R. B.** CD Studies of a peptide mimetic of L-type calcium channels 817

**Anderson D. J.** see Lin N.-H. 2389

**Anderson L. Suckling C. J. and Zhu L.-M.** An unusual stable adduct in the reaction of pyruvate with papain chemically modified by 3-acetyl pyridinium and quinolinium derivatives 1415

**Anderson P. S.** see Dorsey B. D. 2769

**Anderson P. S.** see Kim B. M. 2199

**Anderson P. S.** see Kim B. M. 2273

**Anderson P. S.** see Vacca J. P. 499

**Andersson I. A.** see Morgan N. 1595

**Andrade M. Scozzari A. Cole D. L. and Ravikumar V. T.** Efficient synthesis of antisense oligodeoxyribonucleotide phosphorothioates 2017

**Andrade-Gordon P.** see Hoekstra W. J. 1361

**Andrei G.** see Elhakmaoui A. 1937

**Angelastro M. R.** see Marquart A. L. 1317

**Anglin C. P.** see Djuric S. W. 811

**Antonakis K.** see Herscovici J. 421

**Arai Y.** see Fukami T. 1257

**Arasappan A.** see Li C. 1585

**Arefieg T.** see Beard R. L. 1447

**Arford-Bickerstaff D. J.** see Kim B. M. 2199

**Argentieri T. M.** see Soll R. M. 769

**Armstrong D. R.** see Garner M. 1357

**Arner E. C.** see Miller W. H. 843

**Arrang J.-M.** see Stark H. 2907

**Arshava B. M.** see Shutalev A. D. 761

**Arthur J. C.** see Coleman R. S. 1869

**Asaad M. M.** see Das J. 2193

**Asaad M. M.** see Delaney N. G. 1783

**Asaad M. M.** see Robl J. A. 1789
**Asaad M. M.** see Robl J. A. 1795
**Asaad M. M.** see Robl J. A. 2055
**Asami T.** see Kim B.-T. 1847
**Ashendel C. L.** see Kumaravel G. 883
**Ashida N.** see Yoshimura Y. 721
**Ashton W. T.** see Chang L. L. 115
**Ashton W. T.** see Chang L. L. 2787
**Assens J. L.** see Bernhart C. A. 157
**Aston N. M.** see Judd D. B. 725
**Atchison K.** see Kamal A. 1513
**Atshaves B. P.** see Pichon C. 1105
**Attioui F.** see de Robertis L. 1127
**Aubé J. Gülgeze B. and Peng X.** Synthesis of *cis*-δ-phenylmethyl-D-proline using a nitrogen-centered radical derived from a chiral oxaziridine 2461
**Aubé J.** see Datta A. 1831
**Audiau F.** see Jimonet P. 2735
**Augelli-Szafran C. E. Roth B. D. Essenburg A. Hamelehle K. L. Krause B. R. and Stanfield R. L.** Imidazolidinones and pyrazolones as novel ACAT inhibitors: chemistry and biological activity 1095
**Auger S. Luu-The V. Sam K. M. and Poirier D.** 3-Hydroxy-19-nor-17α-pregna-1,3,5(10)-triene-21,17β-carbolactone as inhibitor of 17β-hydroxysteroid dehydrogenase type 2 2045
**Auger S.** see Sam K. M. 2129
**Augert G.** see Demonchaux P. 2383
**Aungst B. J.** see Carini D. J. 63
**Awano H. Shuto S. Baba M. Kira T. Shigeta S. and Matsuda A.** Nucleosides and nucleotides—CXXVIII. (2'*S*)-2'-Deoxy-2'-*C*-methyl-5-iodouridine (SMIU) as a novel potent anti-herpes virus agent 367

**Baba H.** see Ueyama N. 1637
**Baba M.** see Awano H. 367
**Babine R. E. Zhang N. Schow S. R. Xu Z. Byrn R. A. Hastings R. C. Semmelhack M. F. Wick M. M. and Kerwar S. S.** Design, structure activity and X-ray crystallographic studies of pseudo-symmetrical nonpeptidyl HIV-1 protease inhibitors 583
**Babu S.** see Hanessian S. 2763
**Bach N. J.** see Sawyer J. S. 2077
**Badger A.** see Yamashita D. S. 325
**Badone D. and Guzzi U.** Synthesis of the potent and selective atypical β-adrenergic agonist SR 59062A 1921
**Bahador A.** see Marquez V. E. 355
**Bailey T.** see Levin J. I. 1135
**Bailey T.** see Levin J. I. 1141
**Bailey T.** see Venkatesan A. M. 183
**Bailey T. K.** see Levin J. I. 1703
**Bailey T. K.** see Levin J. I. 1709
**Bailey T. K.** see Levin J. I. 1819
**Baker J. S.** see Levin J. I. 1135
**Baker J. S.** see Venkatesan A. M. 183
**Baker R.** see Williams B. J. 1903
**Baker S. R.** see Sawyer J. S. 2077
**Baldwin J. E.** see Morgan N. 1595
**Ball R. G.** see Harrison T. 2545
**Baltzer S.** see Schirlin D. 241
**Baltzer S.** see Van Dorsselaer V. 1213
**Balzarini J.** see McGuigan C. 427
**Banaszek A.** see Karpiesiuk W. 879
**Bandaru R.** see McElroy E. B. 1071
**Banerji A.** see Pradhan P. 2425
**Banks M. N.** see Smith P. W. 2821
**Bannwarth W. and Schmidt D.** Oligonucleotides containing spin-labeled 2'-deoxycytidine and 5-methyl-2'-deoxycytidine as probes for structural motifs of DNA 977
**Bantick J. R. Beaton H. G. Cooper S. L. Hill S. Hirst S. C. McInally T. Spencer J. Tinker A. C. and Willis P. A.** New non-peptide angiotensin II receptor antagonists—I. Structure–activity relationships of a series of 2(1*H*)-pyridinones 121
**Bantick J. R. Beaton H. G. Cooper S. L. Hill S. Hirst S. C. McInally T. Spencer J. Tinker A. C. and Willis P. A.** New non-peptide angiotensin II receptor antagonists—II. Structure–activity relationships of a series of annelated 2(1*H*)-pyridinones 127
**Bapat C. P.** see Venugopalan B. 751
**Baraldi P. G. Manfredini S. Simoni D. Zappaterra L. Zocchi C. Dionisotti S. and Ongini E.** Synthesis of new pyrazolo[4,3-*e*]1,2,4-triazolo[1,5-*c*]pyrimidine and 1,2,3-triazolo[4,5-*e*]1,2,4-triazolo[1,5-*c*]pyrimidine displaying potent and selective activity as $A_{2a}$ adenosine receptor antagonists 2539
**Barash L.** see DeVita R. J. 1807
**Barawkar D. A.** see Prakash T. P. 1733
**Barber A.** see Gottschlich R. 677
**Barber J.** see McCall D. L. C. 1663
**Barchi, Jr J. J.** see Roller P. P. 1879
**Barnett C. J.** see Steinberg M. I. 51
**Barreau M.** see Damour D. 415
**Barreau M.** see Jimonet P. 2735
**Barrish J. C.** see Delaney N. G. 1783
**Barrish J. C.** see Robl J. A. 1789
**Barrish J. C.** see Robl J. A. 2055
**Bartoszyk G. D.** see Gottschlich R. 677
**Basha F. Z.** see Zelle R. E. 1319
**Basha F. Z.** see Zydowsky T. M. 173
**Basten J. E. M. van Boeckel C. A. A. Jaurand G. Petitou M. Spijker N. M. and Westerduin P.** Synthesis of a dermatan sulphate-like hexasaccharide with a 'non-glycosamino' glycan structure 893
**Bateson J. H. Gasson B. C. Khushi T. Neale J. E. Payne D. J. Tolson D. A. and Walker G.** The synthesis and serine β-lactamase inhibitory activity of some phosphonamidate analogues of dipeptides 1667
**Batley B. L.** see Steinbaugh B. A. 2029
**Batt A. R. Kendrick D. A. Mathews E. Rooker D. P. Ryder H. Semple G. and Szelke M.** Novel cholecystokinin receptor ligands: oxopiperazines derived from Boc–CCK-4 867
**Bauer J.** see Glaser K. B. 1873
**Baxter A. J.** see Cho S. Y. S. 715
**Baxter A. J.** see Shepherd T. A. 1391
**Baxter R. L. and Ziegler M. F.** Antileukaemic properties of 12-hydroxydaphnetoxin derivatives 2649

**Bayliss M. K.** see Judd D. B. 725
**Bayliss M. K.** see Watson S. P. 151
**Beard R. L. Gil D. W. Marler D. K. Henry E. Colon D. F. Gillett S. J. Arefieg T. Breen T. S. Krauss H. Davies P. J. A. and Chandraratna R. A. S.**
Structural basis for the differential RXR and RAR activity of stilbene retinoid analogs 1447
**Beaton H. G.** see Bantick J. R. 121
**Beaton H. G.** see Bantick J. R. 127
**Beaubras S.** see Billington D. C. 2307
**Beck C. Jensen S. B. and Reglinski J.**
The selenium mediated de-iodination of iodophenols: a model for the mechanism of 5' thyronine de-iodinase 1353
**Bednar D.** see Hamilton G. S. 2035
**Bednarski K. Dixit D. M. Wang W. Evans C. A. Jin H. Yuen L. Mansour T. S. Knight D. J. Walcott S. M. and Coates J. A. V.**
Inhibitory activities of herpes simplex viruses type 1 and 2 and human cytomegalovirus by stereoisomers of 2'-deoxy-3'-oxa-5(*E*)-(2-bromovinyl)uridines and their 4'-thio analogues 2667
**Beeley N. R. A.** see Morphy J. R. 2747
**Beeley N. R. A.** see Porter J. R. 2741
**Beer M. S.** see Russell M. G. N. 1207
**Beier N.** see Dorsch D. 1297
**Beier N.** see Osswald M. 683
**Beigelman L. Karpeisky A. and Usman N.**
Synthesis of 1-deoxy-D-ribofuranose phosphoramidite and the incorporation of abasic nucleotides in Stem–Loop II of a hammerhead ribozyme 1715
**Beijer B.** see Douglas M. E. 995
**Bell M. R.** see Hlasta D. J. 1801
**Bell R.** see Cooper A. W. J. 1951
**Bellamy F.** see de Montarby L. 261
**Bellamy F.** see Le Gall T. 247
**Bellamy F.** see Le Gall T. 253
**Bellamy F.** see Le Gall T. 257
**Belley M.** see Labelle M. 463
**Bemis K. G.** see Steinberg M. I. 51
**Bemis K. G.** see Wikel J. H. 795
**Bendesky R. J.** see Chang L. L. 115
**Benjamin C. W.** see Morris J. 2621
**Bennett C. F.** see Manoharan M. 1053
**Benseler F.** see Limauro S. 2189
**Berg R. H.** see Lagriffoul P.-H. 1081
**Berger G. D.** see Kuo C. H. 1591
**Bergmann J. S.** see Stoelwinder J. 303
**Bergstrom J. D.** see Kuo C. H. 1591
**Berke H.** see Wester R. T. 133
**Bermudez J. Gaster L. Gregory J. Jerman J. Joiner G. F. King F. D. and Rahman S. K.**
Synthesis and 5-$HT_3$ receptor antagonist potency of novel (*endo*) 3,9-diazabicyclo-[3.3.1]nonan-7-amino derivatives 2373
**Bernacki R. J.** see Ojima I. 1571
**Bernacki R. J.** see Ojima I. 2631
**Bernhart C.** see Ferrari B. 45
**Bernhart C. A. Haudricourt F. B. Assens J. L. Gougat J. Lacour C. Roccon A. Cazaubon C. Brelière J. C. Le Fur G. and Nisato D.**
Cyclopentanespiro-3*H*-dihydro-pyrimidinones as angiotensin II $AT_1$ receptor antagonists 157
**Bernstein P. R. Kosmider B. J. Vacek E. P. Veale C. A. and Gomes B. C.**
Examination of peptidic α',β-diamino-α,α-difluoroketones as inhibitors of human leukocyte elastase 2175
**Berry C.** see Bhagwat S. S. 2673
**Berry C.** see De Lombaert S. 2715
**Bettiol J.-L.** see Sundberg R. J. 1999
**Bévierre M.-O. De Mesmaeker A. Wolf R. M. and Freier S. M.**
Synthesis of 2'-O-methyl-6,3'-ethanouridine and its introduction into antisense oligonucleotides 237
**Bévierre M.-O.** see Schmit C. 1969
**Bézard D.** see Margraff R. 233
**Bhagwat S. S. Fink C. A. Gude C. Chan K. Qiao Y. Sakane Y. Berry C. and Ghai R. D.**
4-Substituted proline derivatives that inhibit angiotensin converting enzyme and neutral endopeptidase 24.11 2673
**Bhatia D.** see Kumar P. 1761
**Bhide R. S. Patel D. V. Patel M. M. Robinson S. P. Hunihan L. W. and Gordon E. M.**
Rational design of potent carboxylic acid based bisubstrate inhibitors of ras farnesyl protein transferase 2107
**Biasoli G.** see D'Alessio R. 1467
**Bibby M. C.** see Aitken R. A. 2313
**Bien J. T.** see Steiner S. J. 2417
**Bigge C. F.** see Wätjen F. 371
**Billich A.** see Ettmayer P. 2851
**Billington D. C. Perron-Sierra F. Picard I. Beaubras S. Duhault J. Espinal J. and Challal S.**
Total synthesis of novel conduritol related compounds capable of modulating insulin release 2307
**Birchenough L. A.** see Naylor A. M. 1841
**Bird J.** see Hunter D. J. 2833
**Bird J. E.** see Das J. 2193
**Bird J. E.** see Delaney N. G. 1783
**Bird J. E.** see Lloyd J. 195
**Bird J. E.** see Poss M. A. 145
**Bird J. E.** see Robl J. A. 1789
**Bird J. E.** see Robl J. A. 1795
**Bird J. E.** see Ryono D. E. 201
**Birkenshaw T. N. Caffrey M. V. Cladingboel D. E. Cooper M. E. Donald D. K. Furber M. Hardern D. N. Harrison R. P. Marriott D. P. Perry M. W. D. Stocks M. J. Teague S. J. and Withnall W. J.**
Synthetic FKBP12 ligands. Design and synthesis of pyranose replacements 2501
**Birkinshaw T. N.** see Stocks M. J. 1457
**Bischofberger N.** see Lin K.-Y. 1061
**Bishop W. R.** see Vice S. F. 1333
**Bizzarro F. T.** see Cohen N. 2883
**Blache Y.** see Elhakmaoui A. 1937
**Blackburn G. M. Jakeman D. L. Ivory A. J. and Williamson M. P.**
Synthesis of phosphonate analogues of 1,3-bisphosphoglyceric acid and their binding to yeast phosphoglycerate kinase 2573
**Blackburn T. P. Bolton D. Forbes I. T. Johnson C. N. Martin R. T. Thomas D. R. Thompson M. and Upton N.**
(±)11-Amino-2,6-dimethyl-1,2,3,4-tetrahydro-6H-quinindolin-1-one, a novel $GABA_A$ modulator with

potential anxiolytic activity 279
**Blagbrough I. S.** see Adlam G. 2435
**Blaine E. H.** see Huang H.-C. 2591
**Blair K. T.** see Cooper C. B. 835
**Blanchard J.-C.** see Jimonet P. 2735
**Blanchard L.** see De Lombaert S. 899
**Blaskovich M. A.** see Qian Y. 2579
**Bleasdale C. Golding B. T. and Kitson S. L.** Preparation of ethenyl and oxiranol carbamate and their (2-$^2H_2$)-derivatives using selenium chemistry; thermolysis of oxiranol carbamate and reaction with adenosine 291
**Blizzard T. A.** see Shankaran K. 1111
**Blohm T. R.** see McDonald I. A. 847
**Blumberg P. M.** see Kozikowski A. P. 637
**Blumberg P. M.** see Lee J. 1369
**Blumberg P. M.** see Lee J. 2405
**Blumberg P. M.** see Lee J. 543
**Blumberg P. M.** see Marquez V. E. 355
**Blythin D. J. Shue H.-J. Carlon E. Spitler J. and Kreutner W.** Anti-allergy agents—III. Angular tricyclic ether derivatives of the 1,8-naphthyridin-2(1*H*)-one ring system 1327
**Boaz N. W.** see Hlasta D. J. 1801
**Bobichon C.** see Cordi A. A. 1957
**Boden P. Eden J. M. Hodgson J. Horwell D. C. Howson W. Hughes J. McKnight A. T. Meecham K. Pritchard M. C. Raphy J. Ratcliffe G. S. Suman-Chauhan N. and Woodruff G. N.** The rational development of small molecule tachykinin $NK_3$ receptor selective antagonists—the utilisation of a dipeptide chemical library in drug design 1679
**Boge T. C.** see Georg G. I. 1825
**Boge T. C.** see Georg G. I. 335
**Boger D. L.** see Wrasidlo W. 631
**Bohme A.** see Jimonet P. 2735
**Boireau A.** see Jimonet P. 2735
**Boivin D.** see Dupradeau F.-Y. 1813
**Boivin R. P.** see Sam K. M. 2129
**Bokesch H. R.** see Fuller R. W. 1961
**Bolikal D.** see Greenwald R. B. 2465
**Bolton D.** see Blackburn T. P. 279
**Bonaly R.** see de Robertis L. 1127
**Bondo Hansen J. Weis J. Suzdak P. D. and Eskesen K.** Pyrazolo[1,5-*a*]pyridines and pyrazolo[1,5-*b*]pyridazines as $5HT_3$-antagonists 695
**Bonhaus D. W.** see Clark R. D. 2481
**Bonner M. P.** see Hoekstra W. J. 1361
**Borcherding S. M.** see Villalobos A. 2781
**Bordner J.** see Lowe, III J. A. 1153
**Bordner J.** see Lowe, III J. A. 2877
**Bordner J.** see Lowe, III J. A. 839
**Borer X.** see Papageorgiou C. 267
**Borges L. F.** see Campbell L. J. 2627
**Borosky S. A.** see Hamilton G. S. 2035
**Bossard M. J.** see Holt D. A. 315
**Bossard M. J.** see Yamashita D. S. 325
**Boswell G. A.** see Quan M. L. 1527
**Botta M.** see Campiani G. 1235
**Boulay R.** see Mazaleyrat J.-P. 1281
**Boulay R.** see Mazaleyrat J.-P. 653
**Boulay R.** see Wakselman M. 2533
**Bourel L.** see Fauchet V. 2559
**Bourzat J. D.** see Margraff R. 233
**Bousseau A.** see Wakselman M. 2533
**Boxer P. A.** see Wätjen F. 371
**Boyce B. A.** see Morphy J. R. 2747
**Boyce B. A.** see Porter J. R. 2741
**Boyd D. B.** see Steinberg M. I. 51
**Boyd M. R.** see Pettit G. R. 2091
**Boyd M. R.** see Fuller R. W. 1961
**Boyd M. R.** see Pettit G. R. 1507
**Boyd S. A.** see Zydowsky T. M. 173
**Boykin D. W.** see Kumar A. 2913
**Braccolino D. S.** see Miller M. J. 2605
**Bradbury R. H. Edwards M. P. Fisher E. Girdwood J. A. Major J. S. Oldham A. A. Patel M. L. Pearce R. J. Revill J. and Ratcliffe A. H.** New nonpeptide angiotensin II receptor antagonists. Synthesis, biological properties and structure–activity relationships of 3-substituted 2,6-dialkyl-4-(biphenylyl)methylamino-pyridine derivatives 139
**Branchek T. A.** see Wong W. C. 2317
**Brandt M.** see Abell A. D. 1365
**Brandt M.** see Abell A. D. 2327
**Brandt M.** see Holt D. A. 315
**Brandt M.** see Luengo J. I. 321
**Brandt M.** see Yamashita D. S. 325
**Brandtner S.** see Faulstich K. 1975
**Bravo P. Mele A. Salani G. and Viani F.** Asymmetric synthesis of enantiomerically pure 4'-fluoroalkyl-2',3'-dideoxy nucleosides 1577
**Brawley E. S.** see Stafford J. A. 1855
**Brechbiel M. W.** see Wu C. 449
**Breen T. S.** see Beard R. L. 1447
**Brelière J.-C.** see Perreaut P. 163
**Brelière J. C.** see Bernhart C. A. 157
**Brelière J. C.** see Ferrari B. 45
**Brémont B.** see Langlois M. 1433
**Brémont B.** see Langlois M. 945
**Brennan T.** see Schirlin D. 241
**Brennan T.** see Van Dorsselaer V. 1213
**Brimacombe J. S.** see Nikolaev A. V. 785
**Bromidge S. M. Brown F. Cassidy F. Clark M. S. G. Collings E. J. Dabbs S. Faulkner R. E. Loudon J. M. Orlek B. S. and Riley G. J.** 1,2,5,6-Tetrahydropyridine oxime ethers incorporating electron withdrawing groups are potent and selective muscarinic agonists 557
**Bromidge S. M. Cassidy F. Clark M. S. G. Faulkner R. E. Hadley M. S. Orlek B. S. Riley G. J. and Stemp G.** Bridged 1,2,5,6-tetrahydro-pyridine esters and oxime ethers related to arecoline are novel and potent muscarinic agonists 1185
**Brooks D. P.** see Weinstock J. 23
**Broughton H. B.** see Russell M. G. N. 1207
**Brown A. M.** see Gaster L. M. 667
**Brown B. R.** see Das J. 2193

**Brown B. R.** see Misra R. N. 2165
**Brown C. L. Harding M. M. Kalman J. R. Marjo C. E. Rainone S. and Webster L. K.** Synthesis and biological activity of intercalator substituted bile steroids 1253
**Brown F.** see Bromidge S. M. 557
**Brown J. E.** see DeVita R. J. 1807
**Brown J. E.** see Ok D. 2709
**Brownlee R. T. C.** see Chiu F. C. K. 2721
**Brune D. C.** see Pettit G. R. 2091
**Bruni G.** see Campiani G. 1235
**Bryce D. K.** see Desai M. C. 1865
**Bryce D. K.** see Lowe, III J. A. 1153
**Bryce D. K.** see Lowe, III J. A. 2877
**Buchardt O.** see Dueholm K. L. 1077
**Buchardt O.** see Lagriffoul P.-H. 1081
**Buckingham R. E.** see Smith S. A. 1291
**Buckner S.** see Pratt J. 169
**Buckner S. A.** see Zelle R. E. 1319
**Buckner S. A.** see Zydowsky T. M. 173
**Budriesi R.** see Campiani G. 1235
**Budt K.-H.** see Peyman A. 1191
**Budt K.-H.** see Peyman A. 2601
**Bühlmayer P. Furet P. Criscione L. de Gasparo M. Whitebread S. Schmidlin T. Lattmann R. and Wood J.** Valsartan, a potent, orally active angiotensin II antagonist developed from the structurally new amino acid series 29
**Buisine E.** see He M. 2845
**Buote J.** see Lloyd J. 195
**Buote J.** see Ryono D. E. 201
**Bureau P.** see Chênevert R. 2941
**Burgess C.** see Shaw R. E. 2155
**Burk R. M. Gac T. S. Garst M. E. Gibson L. L. Krauss A. H. Protzman C. E. and Woodward D. F.** Synthesis of a novel series of 3-oxo-2,4-dioxobicyclo-[3.2.1]octanes: additional evidence for two thromboxane receptor subtypes 2103
**Burkard M. R.** see Carpino P. A. 93
**Burkard M. R.** see Wester R. T. 133
**Burke J.** see Munk S. A. 459
**Burke, Jr T. R.** see Roller P. P. 1879
**Burrell G. Evans J. M. Hadley M. S. Hicks F. and Stemp G.** Benzopyran potassium channel activators related to cromakalim—heterocyclic amide replacements at position 4 1285
**Burt S.** see Randad R. S. 1247
**Bushnell D. J.** see Thomas G. J. 2759
**Bussolotti D. L.** see Wester R. T. 133
**Butler B. S.** see DeVita R. J. 1807
**Butler B. S.** see DeVita R. J. 2249
**Butler B. S.** see Ok D. 2709
**Butler B. S.** see Schoen W. R. 1117
**Butt A.** see Watson S. P. 151
**Butt A. U.** see Judd D. B. 725
**Bymaster F. P.** see Mitch C. H. 1721
**Bymaster F. P.** see Quimby S. J. 2205
**Bymaster F. P.** see Ward J. S. 573
**Byrn R. A.** see Babine R. E. 583

**Cacciapuoti A.** see Saksena A. K. 2023
**Caffrey M. V. Cladingboel D. E. Cooper M. E. Donald D. K. Furber M. Hardern D. N. Harrison R. P. Stocks M. J. and Teague S. J.** Synthesis and evaluation of dual domain macrocyclic FKBP12 ligands 2507
**Caffrey M. V.** see Birkenshaw T. N. 2501
**Cain G. A. Christos T. E. Eyermann C. J. Gilligan P. J. Grigoriadis D. E. Johnson A. L. and Tam S. W.** Novel conformationally restricted aromatic piperidines as selective sigma receptor ligands 329
**Cain G. A.** see Christos T. E. 2347
**Calligaro D. O.** see Mitch C. H. 1721
**Calligaro D. O.** see Ward J. S. 573
**Campbell G. W.** see Wätjen F. 371
**Campbell L. J. Borges L. F. and Heldrich F. J.** Microwave accelerated preparation of aryl 2-(*N,N*-diethylamino)ethyl ethers 2627
**Campbell W. B.** see Falck J. R. 2113
**Campiani G. Garofalo A. Fiorini I. Nacci V. Botta M. Tafi A. Chiarini A. Budriesi R. Bruni G. and Romeo M. R.** Synthesis and *in vitro* cardiovascular activity of 4-aryl-2,3,3a,4-tetrahydro-1*H*-pyrrolo[2,1-*c*][1,4]benzo-thiazin-1-ones and 7-acetoxy-6-phenyl-7a,8,-9,10-tetrahydropyrrolo-[2,1-*d*][1,5]benzothiazepin-10-one 1235
**Canet E.** see Thurieau C. 781
**Cantello B. C. C. Cawthorne M. A. Haigh D. Hindley R. M. Smith S. A. and Thurlby P. L.** The synthesis of BRL 49653—a novel and potent antihyperglycaemic agent 1181
**Cao X. and Matteucci M. D.** Preparation, characterization and binding properties of an oligodeoxynucleotide containing the 3'-ribothio-formacetal phosphate analog 807
**Caravatti G. Meyer T. Fredenhagen A. Trinks U. Mett H. and Fabbro D.** Inhibitory activity and selectivity of staurosporine derivatives towards protein kinase C 399
**Cardellina, II J. H.** see Fuller R. W. 1961
**Cardwell K. S.** see Judd D. B. 725
**Carini D. J. Ardecky R. J. Ensinger C. L. Pruitt J. R. Wexler R. R. Wong P. C. Huang S.-M. Aungst B. J. and Timmermans P. B. M. W. M.** Nonpeptide angiotensin II receptor antagonists: the discovery of DMP 581 and DMP 811 63
**Carini D. J.** see Naylor E. M. 69
**Carini D. J.** see Quan M. L. 2011
**Carini D. J.** see Santella, III J. B. 2235
**Carlon E.** see Blythin D. J. 1327
**Carlsson A.** see Haadsma-Svensson S. R. 689
**Carpenter S. L.** see Fehr M. J. 1339
**Carpino P. A. Sneddon S. F. da Silva Jardine P. Magnus-Ayritey G. T. Rauch A. L. and Burkard M. R.** A conformationally restrained series of $AT_1$-selective angiotensin II antagonists 93
**Carpino P. A.** see Wester R. T. 133
**Carr A. A.** see Kane J. M. 351
**Carrière J.** see Smith R. A. 2217
**Carrupt P.-A.** see Gaillard P. 737

**Carson M.** see LeMahieu R. A. 339
**Casazza A.** see Chen S.-H. 2223
**Casazza A. M.** see Ueda Y. 1861
**Cascieri M. A.** see Ladduwahetty T. 1917
**Cascieri M. A.** see Swain C. J. 2161
**Cascieri M. A.** see Williams B. J. 1903
**Case R. D.** see Roller P. P. 1879
**Casscles, Jr W. T.** see Trova M. P. 903
**Cassidy F.** see Bromidge S. M. 1185
**Cassidy F.** see Bromidge S. M. 557
**Cassidy F.** see Hunter D. J. 2833
**Cassidy F.** see Orlek B. S. 1411
**Cassidy F.** see Smith S. A. 1291
**Castro J. L.** see Russell M. G. N. 1207
**Caulfield T. J. Prasad C. V. C. Delecki D. J. Prouty C. P. Saha A. K. Upson D. A. and Kruse L. I.** Achiral internucleoside linkages—II. O-$CH_2$-$CH_2$ linkage 1497
**Cavicchioni G. Vertuani G. Scatturin A. and Spisani S.** The role of peptide bond in chemotactic For-Met-Leu-Phe-OMe focused by depsipeptide analogs 1551
**Cawthorne M. A.** see Cantello B. C. C. 1181
**Cayley J.** see Levett P. C. 505
**Cazaubon C.** see Bernhart C. A. 157
**Cazaubon C.** see Ferrari B. 45
**Cazaubon C.** see Perreaut P. 163
**Cerny R. L.** see Pettit G. R. 2091
**Cerny R. L.** see Pettit G. R. 2677
**Cerny R. L.** see Pettit G. R. 2935
**Ceruso M. and Prestwich G. D.** Novel non-squalenoid photoaffinity labels for mammalian squalene epoxidase 2179
**Chabin R.** see Romeo G. 2399
**Chadha H. S. Abraham M. H. and Mitchell R. C.** Physicochemical analysis of the factors governing distribution of solutes between blood and brain 2511
**Chae M. Y. Postula J. F. and Raushel F. M.** Stereospecific enzymatic hydrolysis of phosphorus–sulfur bonds in chiral organophosphate triesters 1473
**Chae Y.-B.** see Kim D.-K. 1309
**Chakrabarti J. K.** see Smith C. W. 1673
**Chakravarty P. K. Strelitz R. A. Chen T.-B. Chang R. S. L. Lotti V. J. Zingaro G. J. Schorn T. W. Kivlighn S. D. Siegl P. K. S. Patchett A. A. and Greenlee W. J.** Quinazolinone biphenyl acylsulfonamides: a potent new class of angiotensin-II receptor antagonists 75
**Chakravarty P. K.** see Chang L. L. 115
**Chakravarty P. K.** see Naylor E. M. 69
**Challal S.** see Billington D. C. 2307
**Chamberlain T. S.** see Huang H.-C. 2591
**Chambers R. J.** see Wester R. T. 2005
**Champion E.** see Labelle M. 463
**Chan K.** see Bhagwat S. S. 2673
**Chan P. S.** see Levin J. I. 1135
**Chan P. S.** see Levin J. I. 1141
**Chan P. S.** see Levin J. I. 1703
**Chan P. S.** see Levin J. I. 1709
**Chan P. S.** see Levin J. I. 1819
**Chan P. S.** see Venkatesan A. M. 183
**Chan W. W.-S.** see DeVita R. J. 1807
**Chan W. W.-S.** see DeVita R. J. 2249
**Chan W. W.-S.** see Ok D. 2709
**Chan W. W.-S.** see Schoen W. R. 1117
**Chandraratna R. A. S.** see Beard R. L. 1447
**Chang C.-A.** see Dolinnaya N. 1011
**Chang L. L. Ashton W. T. Flanagan K. L. Naylor E. M. Chakravarty P. K. Patchett A. A. Greenlee W. J. Bendesky R. J. Chen T.-B. Faust K. A. Kling P. J. Schaffer L. W. Schorn T. W. Zingaro G. J. Chang R. S. L. Lotti V. J. Kivlighn S. D. and Siegl P. K. S.** Triazolinones as nonpeptide angiotensin II antagonists—II. Discovery of a potent and orally active triazolinone acylsulfonamide 115
**Chang L. L. Ashton W. T. Flanagan K. L. Rivero R. A. Chen T.-B. O'Malley S. S. Zingaro G. J. Kivlighn S. D. Siegl P. K. S. Lotti V. J. Chang R. S. L. and Greenlee W. J.** Potent triazolinone-based angiotensin II receptor antagonists with equivalent affinity for both the $AT_1$ and $AT_2$ subtypes 2787
**Chang R. S.** see Glinka T. W. 1479
**Chang R. S.** see Glinka T. W. 2337
**Chang R. S.** see Glinka T. W. 81
**Chang R. S.** see Naylor E. M. 69
**Chang R. S. L.** see Chakravarty P. K. 75
**Chang R. S. L.** see Chang L. L. 115
**Chang R. S. L.** see Chang L. L. 2787
**Chang R. S. L.** see Kevin N. J. 189
**Chang R. S. L.** see Kim D. 207
**Chang R. S. L.** see Kim D. 41
**Chang R. S. L.** see Mantlo N. B. 17
**Chang R. S. L.** see Rivero R. A. 747
**Chang R. S. L.** see Walsh T. F. 219
**Chapat J.-P.** see Elhakmaoui A. 1937
**Chapleur Y.** see Dumont B. 1123
**Chapman K. T.** see Mjalli A. M. M. 1965
**Chapuis J.-C.** see Pettit G. R. 2677
**Chapuis J.-C.** see Pettit G. R. 2935
**Charubala R.** see Pfleiderer W. 1047
**Chatman K. S.** see Siuzdak G. 2863
**Chaudhuri S. K.** see Kubo I. 1131
**Chaudhuri S. K.** see Kubo I. 1443
**Chauhan K. Ravi D. Falck J. R. Stoltz R. A. and Laniado-Schwartzman M.** Angiogenic factors: syntheses of 12(*R*)- and 12(*S*)-hydroxy-eicosa-5(*Z*),8(*Z*),14(*Z*)-trienoic acid and their 14,15-dehydro analogs 2689
**Chauhan K.** see Falck J. R. 2113
**Chauhan V. S.** see Gupta S. D. 941
**Chavignon O.** see Elhakmaoui A. 1937
**Chen C.-R.** see Chen S.-T. 789
**Chen H. Ji Z. Wong L. K. Siuda J. F. and Narayanan V. L.** 2-(1-Cyclopenten-1-yl)-2-[2-(dimethylamino)ethyl]-5-(*E*)-benzylidene cyclopentanone hydrochlorides: a new series of moderate cytotoxic agents 2701
**Chen I.-W.** see Dorsey B. D. 2769
**Chen I.-W.** see Kim B. M. 2273
**Chen J. J.** see Smith R. A. 2217

**Chen J. K. and Schreiber S. L.** SH3 Domain-mediated dimerization of an N-terminal fragment of the phosphatidylinositol 3-kinase p85 subunit 1755
**Chen K.** see Tang R. 455
**Chen L. J.** see Vacca J. P. 499
**Chen S.-H. Farina V. Wei J.-M. Long B. Fairchild C. Mamber S. W. Kadow J. F. Vyas D. and Doyle T. W.** Structure–activity relationships of Taxol®: synthesis and biological evaluation of $C_2$ taxol analogs 479
**Chen S.-H. Kant J. Mamber S. W. Roth G. P. Wei J.-M. Marshall D. Vyas D. M. Farina V. Casazza A. Long B. H. Rose W. C. Johnston K. and Fairchild C.** Taxol® structure–activity relationships: synthesis and biological evaluation of Taxol analogs modified at C-7 2223
**Chen S.-T. Chen S.-Y. Chou S.-H. Chen C.-R. Huang W.-C. and Wang K.-T.** One-pot selective deuteriation of 5'-dimethoxytritylated deoxynucleotide derivatives 789
**Chen S.-T. Chen S.-Y. Kao C.-L. and Wang K.-T.** Proline as nucleophile in kinetically controlled peptide synthesis catalyzed by alcalase in 2-methyl-2-propanol 443
**Chen S.-T. Tsai C.-F. and Wang K.-T.** Resolution of N-protected amino acid derivatives in supercritical carbon dioxide catalyzed by 'alcalase' 625
**Chen S.-T. Yang M.-T. Wu C.-Y. and Wang K.-T.** Engineering of cyclic peptides with novel inhibiting properties to differentiate two serine proteases, chymotrypsin and subtilisin Carlsberg 2123
**Chen S.-Y.** see Chen S.-T. 443
**Chen S.-Y.** see Chen S.-T. 789
**Chen S. T.** see Huang H.-C. 2591
**Chen T.** see Kim D. 207
**Chen T.-B.** see Chakravarty P. K. 75
**Chen T.-B.** see Chang L. L. 115
**Chen T.-B.** see Chang L. L. 2787
**Chen T.-B.** see Glinka T. W. 1479
**Chen T.-B.** see Glinka T. W. 2337
**Chen T.-B.** see Glinka T. W. 81
**Chen T.-B.** see Naylor E. M. 69
**Chen T. B.** see Kevin N. J. 189
**Chênevert R. Pouliot R. and Bureau P.** Enantioselective hydrolysis of (±)-chloramphenicol palmitate by hydrolases 2941
**Cheng B. K.** see Reitz D. B. 99
**Cheng H. C.** see Kane J. M. 351
**Cheng K.** see DeVita R. J. 1807
**Cheng K.** see DeVita R. J. 2249
**Cheng K.** see Ok D. 2709
**Cheng K.** see Schoen W. R. 1117
**Cheruvallath Z. S.** see Georg G. I. 1825
**Cheruvallath Z. S.** see Georg G. I. 2331
**Cheruvallath Z. S.** see Georg G. I. 335
**Cheung H. S.** see Delaney N. G. 1783
**Chevé M.** see Jimonet P. 2735
**Chiarini A.** see Campiani G. 1235
**Chiu A. T.** see Olson R. E. 2229
**Chiu A. T.** see Quan M. L. 1527
**Chiu A. T.** see Quan M. L. 2011
**Chiu A. T.** see Santella, III J. B. 2235
**Chiu F. C. K. Brownlee R. T. C. Mitchell K. and Phillips D. R.** The unique DNA cutting sequence specificity of a 4-(*N,N*-dimethyl-2-aminoethyl)-amino-1,10-phenanthroline and its 9-aminoacridine conjugate 2721
**Chmielewski J.** see Ulysse L. 2145
**Cho H. S.** see Suh J. 1889
**Cho N. Kubo K. Furuya S. Sugiura Y. Yasuma T. Kohara Y. Ojima M. Inada Y. Nishikawa K. and Naka T.** A new class of diacidic nonpeptide angiotensin II receptor antagonists 35
**Cho S. Y. S. Jungheim L. N. and Baxter A. J.** Novel HIV-1 protease inhibitors containing a β-hydroxy sulfide isostere 715
**Cho Y. H.** see Leftheris K. 887
**Chong S.** see Misra R. N. 2165
**Chong S.** see Ryono D. E. 201
**Chorghade M. S. Dezaro D. A. Hill D. R. Lee E. C. Pariza R. J. Andersen J. V. Hansen K. T. and Dolphin D. H.** Metalloporphyrins as chemical mimics of cytochrome P-450 systems 2867
**Chou S.-H.** see Chen S.-T. 789
**Christensen B. G.** see Tsutsumi S. 831
**Christensen S. B.** see Andersen A. 657
**Christos T. E. Cain G. A. Johnson A. L. Schmidt W. K. and Tam S. W.** Novel ether derivatives of alkyl piperidines as potential sigma/$5HT_2$ antipsychotic agents 2347
**Christos T. E.** see Cain G. A. 329
**Chrystal E. J. T.** see Couper L. 2267
**Chu M. Truumees I. Patel M. G. Gullo V. P. Pai J.-K. Das P. R. and Puar M. S.** Two new phospholipase D inhibitors, Sch 49211 and Sch 49212, produced by the fungus *Nattrassia mangiferae* 1539
**Chuang J. M.** see Ueda Y. 1623
**Chung Y. J.** see Kim B. H. 2799
**Cicero D. O. Neuner P. J. S. Franzese O. D'Onofrio C. and Iribarren A. M.** Stereoselective synthesis of novel analogues of 2'-deoxy- and 2',3'-dideoxynucleosides with potential antiviral activity 861
**Cichacz Z. A.** see Pettit G. R. 2091
**Cichacz Z. A.** see Pettit G. R. 2677
**Cladingboel D. E.** see Birkenshaw T. N. 2501
**Cladingboel D. E.** see Caffrey M. V. 2507
**Claes P.** see Pannecouque C. 1203
**Clagett-Dame M.** see Robarge M. J. 2117
**Clark D. S. Geresh S. and Di Cosimo R.** Enantioselective oxidation of 2-methyl-1-butanol by alcohol oxidase from methylotrophic yeasts 1745
**Clark M. S. G.** see Bromidge S. M. 557
**Clark M. S. G.** see Bromidge S. M. 1185
**Clark M. S. G.** see Orlek B. S. 1411
**Clark R. D. Jahangir A. Langston J. A. Weinhardt K. K. Miller A. B. Leung E. Bonhaus D. W. Wong E. H. F. and Eglen R. M.** Synthesis and preliminary pharmacological evaluation of 2-benzyloxy substituted aryl ketones as 5-$HT_4$ receptor antagonists 2481
**Clark R. D. Jahangir A. Langston J. A. Weinhardt K. K. Miller A. B. Leung E. and Eglen R. M.** Ketones related to the benzoate 5-$HT_4$ receptor antagonist RS-23597 are high affinity partial agonists 2477
**Clarke F.** see Vlattas I. 2067
**Clarke F.** see Vlattas I. 2073

**Cleary D. G.** see Miller M. J. 2605
**Clemens K. R. Pichon C. Jacobson A. R. Yon-Hin P. Gonzalez M. D. and Scott A. I.**
Systematic specificity studies on porphobilinogen deaminase 521
**Clément J.** see Perreaut P. 163
**Coates J. A. V.** see Bednarski K. 2667
**Cobuzzi A.** see Levin J. I. 1703
**Cobuzzi A.** see Levin J. I. 1709
**Cockerill G. S.** see Levett P. C. 505
**Cody W. L. He J. X. DePue P. L. Rapundalo S. T. Hingorani G. P. Dudley D. T. Hill K. E. Reynolds E. E. and Doherty A. M.**
Structure–activity relationships in a series of monocyclic endothelin analogues 567
**Coe J. W. and O'Connell T.**
Convenient preparation of 9-*cis*-retinoic acid 349
**Cohen D. S.** see Vlattas I. 2067
**Cohen D. S.** see Vlattas I. 2073
**Cohen M.** see Delaney N. G. 1783
**Cohen N. Bizzarro F. T. May W. P. Toth K. Lee F. K. Heslin P. H. Holland G. W. Kwoh S. C. Franco L. S. Simko B. A. and Yagaloff K. A.**
Benzenepropanoic acids containing chromanone or naphthalenone moieties are potent and orally active leukotriene $B_4$ antagonists 2883
**Colatsky T.** see Soll R. M. 769
**Colborn D.** see Villalobos A. 2781
**Coldwell M. C.** see Smith S. A. 1291
**Cole D. L.** see Andrade M. 2017
**Cole S. C. J.** see Morgan N. 1595
**Coleman R. S. Kesicki E. A. Arthur J. C. and Cotham W. E.**
Analysis of post-synthetically modified oligodeoxy-nucleotides by electrospray ionization mass spectrometry 1869
**Coles P. J.** see Smith R. A. 2217
**Coller B. S.** see Ojima I. 1749
**Collings E. J.** see Bromidge S. M. 557
**Collings E. J.** see Orlek B. S. 1411
**Colon D. F.** see Beard R. L. 1447
**Cominelli F.** see LeMahieu R. A. 339
**Commerçon A.** see Margraff R. 233
**Compton D. R.** see Huffman J. W. 563
**Conde S.** see Fierros M. 2523
**Condon S. L.** see Zydowsky T. M. 173
**Constantine J. W.** see Lowe, III J. A. 839
**Cook J. J.** see Egbertson M. S. 1835
**Cook P. D.** see Manoharan M. 1053
**Cooper A. W. J. Adams H. S. Bell R. Gore P. M. McElroy A. B. Pritchard J. M. Smith P. W. and Ward P.**
GR159897 and related analogues as highly potent, orally active non-peptide neurokinin $NK_2$ receptor antagonists 1951
**Cooper C. B. McFarland J. W. Blair K. T. Fontaine E. H. Jones C. S. and Muzzi M. L.**
Synthesis of 1,2,4-triazine-(2*H*,4*H*)-3,5-dione anticoccidial agents via palladium-catalyzed cross-coupling reactions 835
**Cooper K.** see Ragan J. A. 2563
**Cooper K.** see Wester R. T. 133
**Cooper M. E.** see Birkenshaw T. N. 2501
**Cooper M. E.** see Caffrey M. V. 2507
**Cooper M. E.** see Teague S. J. 1581
**Cooper S. L.** see Bantick J. R. 121
**Cooper S. L.** see Bantick J. R. 127
**Corbett T. H.** see Wentland M. P. 609
**Cordi A. A. Serkiz B. Hennig P. Mahieu J.-P. Bobichon C. de Nanteuil G. and Lepagnol J. M.**
Identification and characterisation of the isomers of cyclothiazide responsible for potentiating AMPA current 1957
**Cornett C.** see Andersen A. 657
**Corpus V. M.** see Huang H.-C. 2591
**Corpus V. M.** see Reitz D. B. 99
**Corpus V. M.** see Reitz D. B. 105
**Cosentino L. M.** see Huang L. 593
**Cosentino L. M.** see Konoshima T. 1323
**Cosentino M.** see Tang R. 455
**Costello C. A.** see Naylor E. M. 69
**Cotham W. E.** see Coleman R. S. 1869
**Coughenour L. L.** see Wätjen F. 371
**Coughlin S. A.** see Wentland M. P. 609
**Couper L. McKendrick J. E. Robins D. J. and Chrystal E. J. T.**
Pyridine and piperidine derivatives as inhibitors of dihydrodipicolinic acid synthase, a key enzyme in the diaminopimelate pathway to L-lysine 2267
**Coupet J.** see Levin J. I. 1135
**Coupet J.** see Levin J. I. 1703
**Coupet J.** see Levin J. I. 1709
**Coupet J.** see Levin J. I. 1819
**Coupet J.** see Venkatesan A. M. 183
**Court J. J.** see Hlasta D. J. 1801
**Cousins R. P. C.** see Shaw R. E. 2155
**Cowsert L. M.** see Manoharan M. 1053
**Cox B. Hutson J. L. Keeling S. E. Kirk B. E. Srikantha A. R. P. and Watson N. S.**
The squalestatins: potent inhibitors of squalene synthase, 3-hydroxymethyl derivatives 1931
**Cox B.** see Smith P. W. 2821
**Cragg G. M.** see Fuller R. W. 1961
**Crawford R. T.** see Lowe, III J. A. 1153
**Crawford R. T.** see Lowe, III J. A. 2877
**Cressman E. N. K.**
Synthesis of an indolizidinedione oxime inhibitor of acetyl-coenzyme A carboxylase (ACCase) 1983
**Crews P.** see Alvi K. A. 2447
**Criscione L.** see Bühlmayer P. 29
**Croci T.** see Langlois M. 1433
**Cros S.** see Roux F. 1947
**Crouch N. P.** see Morgan N. 1595
**Crowell T. A.** see Kaldor S. W. 1385
**Cryan J. G.** see Goulet M. T. 921
**Curley, Jr R. W.** see Robarge M. J. 2117
**Currie G. S.** see Judd D. B. 725
**Cusack B.** see Dodd D. S. 1241
**Cushman M.** see He H.-M. 1725
**Cushman M.** see He H.-M. 1729
**Cushman M.** see Oh Y. 2245
**Czaplinski K.-H. A. and Grunewald G. L.**
A comparative molecular field analysis derived model of the binding of Taxol® analogues to microtubules 2211
**Czarnik A. W.** see Mortellaro M. A. 2041

**Dabbs S.** see Bromidge S. M. 557
**Dai D.** see Huffman J. W. 563
**D'Alessio R. Geroni C. Biasoli G. Pesenti E. Grandi M. and Mongelli N.** Structure–activity relationship of novel distamycin A derivatives: synthesis and antitumor activity 1467
**Damour D. Barreau M. Dutruc-Rosset G. Doble A. Piot O. and Mignani S.** 1,1-Diphenyl-3-dialkylamino-1-silacyclopentane derivatives: a new class of potent and selective 5-$HT_{2A}$ antagonists 415
**Damour D.** see Jimonet P. 2735
**Daneshtalab M.** see Kamal A. 1513
**Dao H.** see Vice S. F. 1333
**Darcy M. G.** see Thompson S. K. 2441
**Darganzanli G.** see Le Gall T. 253
**Darke P. L.** see Dorsey B. D. 2769
**Darke P. L.** see Kim B. M. 2199
**Darke P. L.** see Kim B. M. 2273
**Darke P. L.** see Vacca J. P. 499
**Das J. Robl J. A. Reid J. A. Sun C.-Q. Misra R. N. Brown B. R. Ryono D. E. Asaad M. M. Bird J. E. Trippodo N. C. Petrillo E. W. and Karanewsky D. S.** Dual metalloprotease inhibitors—IV. Utilization of thiazepines and thiazines as constrained peptidomimetic surrogates in mercaptoacyl dipeptides 2193
**Das P. R.** see Chu M. 1539
**Das S. K. and Saha U. K.** Synthesis of 2-amino-3-hydroxyacetophenone-*O*-β-D-glucopyranoside: a fluorescent compound from insoluble protein fraction of aging human lens 1219
**da Silva Jardine P.** see Carpino P. A. 93
**da Silva Jardine P.** see Wester R. T. 133
**Datta A. Aubé J. Georg G. I. Mitscher L. A. and Jayasinghe L. R.** The first synthesis of a C-9 carbonyl modified baccatin III derivative and its conversion to novel Taxol® and Taxotere® analogues 1831
**Davies M. P. H.** see McGuigan C. 427
**Davies P. J. A.** see Beard R. L. 1447
**Davis P. D. Hallam T. J. Harris W. Hill C. H. Lawton G. Nixon J. S. Smith J. L. Vesey D. R. and Wilkinson S. E.** Bisindolylmaleimide inhibitors of protein kinase C. Further conformational restriction of a tertiary amine side chain 1303
**De A. U.** see Purkayastha S. K. 377
**De B.** see Zydowsky T. M. 173
**Dean A. W.** see Judd D. B. 725
**Dean A. W.** see Watson S. P. 151
**Debart F. Tosquellas G. Rayner B. and Imbach J.-L.** Optimization of hybridizing abilities and nuclease resistance in the design of chimeric α-anomeric oligodeoxynucleotides containing β-anomeric gaps 1041
**DeBernardis J.** see Pratt J. 169
**DeBernardis J. F.** see Zelle R. E. 1319
**DeBernardis J. F.** see Zydowsky T. M. 173
**De Clercq E.** see Elhakmaoui A. 1937
**De Clercq E.** see McGuigan C. 427
**Deeter J. B.** see Steinberg M. I. 51
**de Gasparo M.** see Bühlmayer P. 29
**DeHaven-Hudkins D. L.** see Hudkins R. L. 2185
**de Jesus R.** see Stanton J. L. 539
**Dejneka T.** see Lloyd J. 195
**Dejneka T.** see Poss M. A. 145
**Dejneka T.** see Ryono D. E. 201
**Delaney C. L.** see Lloyd J. 195
**Delaney C. L.** see Poss M. A. 145
**Delaney N. G. Barrish J. C. Neubeck R. Natarajan S. Cohen M. Rovnyak G. C. Huber G. Murugesan N. Girotra R. Sieber-McMaster E. Robl J. A. Asaad M. M. Cheung H. S. Bird J. E. Waldron T. and Petrillo E. W.** Mercaptoacyl dipeptides as dual inhibitors of angiotensin-converting enzyme and neutral endopeptidase. Preliminary structure–activity studies 1783
**de Laszlo S. E.** see Glinka T. W. 1479
**de Laszlo S. E.** see Glinka T. W. 2337
**de Laszlo S. E.** see Glinka T. W. 81
**Delecki D. J.** see Caulfield T. J. 1497
**Dellureficio J.** see Vlattas I. 2067
**Dellureficio J.** see Vlattas I. 2073
**De Lombaert S. Singh K. Blanchard L. and Soliman V. F.** Chemical and plasma hydrolyses of a diphenyl α-aminomethyl phosphonate prodrug inhibitor of neutral endopeptidase 24.11 899
**De Lombaert S. Tan J. Stamford L. J. Sakane Y. Berry C. and Ghai R. D.** Dual inhibition of neutral endopeptidase and angiotensin-converting enzyme by *N*-phosphonomethyl and *N*-carboxyalkyl dipeptides 2715
**DeLucca I.** see Quan M. L. 1527
**De Mello R. C.** see Hunter D. J. 2833
**Demers J. P. Hageman W. E. Johnson S. G. Klaubert D. H. Look R. A. and Moore J. B.** Selective inhibitors of protein kinase C in a model of Graft-vs-Host disease 2451
**De Mesmaeker A.** see Bévierre M.-O. 237
**De Mesmaeker A. Lebreton J. Waldner A. Fritsch V. and Wolf R. M.** Replacement of the phosphodiester linkage in oligonucleotides: comparison of two structural amide isomers 873
**De Mesmaeker A. Waldner A. Sanghvi Y. S. and Lebreton J.** Comparison of rigid and flexible backbones in antisense oligonucleotides 395
**De Mesmaeker A.** see Schmit C. 1969
**De Mesmaeker A.** see Waldner A. 405
**Demonchaux P. Lenoir P. Augert G. and Dupassieux P.** Design of pyrrolo-1,4-benzoxazine derivatives as inhibitors of 5-lipoxygenase and PAF antagonists with antihistaminic properties 2383
**de Montarby L. Mosset P. Grée R. Millet J. Sepulchre C. and Bellamy F.** Synthesis and biological evaluation of new leukotriene analogs 261
**de Montarby L.** see Le Gall T. 247
**de Nanteuil G.** see Cordi A. A. 1957
**Denis A. and Villette T.** 5-Aryl-β,γ butenolide, a new class of antibacterial derived from the N-aryl oxazolidinone DUP 721 1925
**Dennis E. A.** see Yu L. 641

**DePue P. L.** see Cody W. L. 567
**de Robertis L. Lancelon-Pin C. Driguez H. Attioui F. Bonaly R. and Marsura A.** Synthesis of new oligosaccharidyl-thio-β-cyclodextrins (CDS): a novel family of potent drug-targetting vectors 1127
**Desai J. A.** see Saksena A. K. 2023
**Desai M. C. and Lefkowitz S. L.** Additions and Corrections 641
**Desai M. C. Lefkowitz S. L. Bryce D. K. and McLean S.** Articulating a pharmacophore driven synthetic strategy: discovery of a potent substance P antagonist 1865
**Desai R. C.** see Hlasta D. J. 1801
**Deshpande M. S.** see Saulnier M. G. 1985
**DeVirgilio M. K.** see Leftheris K. 887
**DeVita R. J. Schoen W. R. Fisher M. H. Frontier A. J. Pisano J. M. Wyvratt, Jr M. J. Cheng K. Chan W. W.-S. Butler B. S. Hickey G. J. Jacks T. M. and Smith R. G.** Benzolactam growth hormone secretagogues: carboxamides as replacements for the 2'-tetrazole moiety of L-692,429 2249
**DeVita R. J. Schoen W. R. Ok D. Barash L. Brown J. E. Fisher M. H. Hodges P. Wyvratt, Jr M. J. Cheng K. Chan W. W.-S. Butler B. S. and Smith R. G.** Benzolactam growth hormone secretagogues: replacements for the 2'-tetrazole moiety of L-692 429 1807
**DeVita R. J.** see Ok D. 2709
**DeVita R. J.** see Schoen W. R. 1117
**de Vroom E.** see van der Mey M. 345
**Dextraze P.** see Yevich J. P. 1941
**Dezaro D. A.** see Chorghade M. S. 2867
**Dhanoa D.** see Kim D. 207
**DiBrino J.** see Hauske J. R. 2097
**Dickinson K. E. J.** see Lloyd J. 195
**Dickinson K. E. J.** see Poss M. A. 145
**Dickinson K. E. J.** see Ryono D. E. 201
**Di Cosimo R.** see Clark D. S. 1745
**Dietrich H. and Schmidt R. R.** α-D-Glucopyranosyl-phenyldiazomethane, a mechanism based α-glucosidase inhibitor 599
**Dinter-Gottlieb G.** see Wieczorek A. 987
**Dionisotti S.** see Baraldi P. G. 2539
**Dixit D. M.** see Bednarski K. 2667
**Djuric S. W. Docter S. H. Yu S. S. Spangler D. Tsai B.-S. Anglin C. P. Gaginella T. S. Kachur J. F. Keith R. H. Maziasz T. J. Villani-Price D. Rao T. S. Walsh R. E. Widomski D. L. and Fretland D. J.** Synthesis and pharmacological activity of SC-53228, a leukotriene $B_4$ receptor antagonist with high intrinsic potency and selectivity 811
**Doble A.** see Damour D. 415
**Doble A.** see Jimonet P. 2735
**Docter S. H.** see Djuric S. W. 811
**Dodd D. S. Kozikowski A. P. Cusack B. and Richelson E.** Synthesis of partially non-peptidic neurotensin mimetics 1241
**Doherty A. M.** see Cody W. L. 567
**Dolan P.** see Posner G. H. 2919
**Dolby L.** see Munk S. A. 459
**Dolinnaya N. Gryaznov S. Ahle D. Chang C.-A. Shabarova Z. A. Urdea M. S. and Horn T.** Construction of branched DNA (bDNA) molecules by chemical ligation 1011
**Dollings P. J.** see Soll R. M. 769
**Dolphin D. H.** see Chorghade M. S. 2867
**Domanico P. L.** see Stafford J. A. 1855
**Donald D. K.** see Birkenshaw T. N. 2501
**Donald D. K.** see Caffrey M. V. 2507
**Donald D. K.** see Teague S. J. 1581
**Dong B.** see Xiao W. 2609
**Dong Q.** see Ojima I. 1749
**Donnelly M.** see Watson S. P. 151
**Donnelly M. C.** see Judd D. B. 725
**D'Onofrio C.** see Cicero D. O. 861
**Dorff P.** see Hauske J. R. 2097
**Dorsaz A.-C.** see Pettit G. R. 2091
**Dorsch D. Mederski W. W. K. R. Beier N. Lues I. Minck K.-O. and Schelling P.** (6-Oxo-3-pyridazinyl)-benzimidazoles as potent angiotensin II receptor antagonists 1297
**Dorsey B. D. McDaniel S. L. Levin R. B. Vacca J. P. Darke P. L. Zugay J. A. Emini E. A. Schleif W. A. Lin J. H. Chen I.-W. Holloway M. K. Anderson P. S. and Huff J. R.** Synthesis and evaluation of pyridyl analogs of L-735,524: potent HIV-1 protease inhibitors 2769
**Dotson R.** see Vlattas I. 2067
**Dotson R.** see Vlattas I. 2073
**Double J. A.** see Aitken R. A. 2313
**Dougherty R. W.** see Stafford J. A. 1855
**Dougherty T. J.** see Pandey R. K. 1263
**Douglas M. E. Beijer B. and Sproat B. S.** An approach towards thiol mediated labelling in the minor groove of oligonucleotides 995
**Doyle T. W.** see Chen S.-H. 479
**Doyle T. W.** see Saulnier M. G. 2567
**Drejer J.** see Wätjen F. 371
**Dressman B. A.** see Kaldor S. W. 1385
**Drew G. M.** see Judd D. B. 725
**Driguez H.** see de Robertis L. 1127
**Drinan M. A.** see Lash T. D. 1607
**Drozda S. E.** see Lowe, III J. A. 1153
**D'Souza D. J. and Kool E. T.** Solvent, pH, and ionic effects on the binding of single-stranded DNA by circular oligodeoxynucleotides 965
**Du L.** see Kozikowski A. P. 637
**Duclos O.** see Ojima I. 2631
**Dudley D. T.** see Cody W. L. 567
**Dudley M. W.** see Kane J. M. 351
**Dueholm K. L. Petersen K. H. Jensen D. K. Egholm M. Nielsen P. E. and Buchardt O.** Peptide nucleic acid (PNA) with a chiral backbone based on alanine 1077
**Duhault J.** see Billington D. C. 2307
**Dulude H. Salvador R. and Gallant G.** Chemical stability of new urea and nitrosourea derivatives of diamino acids 2697
**Dulude H.** see Gallant G. 2353
**Dumont B. Joly J.-P. Chapleur Y. and Marsura A.** New oligosaccharidic crown ethers as potential drug-targetting vectors: synthesis and biological evaluation 1123

**Dumont F. J.** see Goulet M. T. 921
**Dumont F. J.** see Goulet M. T. 927
**Duncan J. N.** see Haadsma-Svensson S. R. 689
**Duncia J. V.** see Santella, III J. B. 2235
**Dunlap R. P.** see Hlasta D. J. 1801
**Dupassieux P.** see Demonchaux P. 2383
**Dupradeau F.-Y. Stroud M. R. Boivin D. Li L. Hakomori S. Singhal A. K. and Toyokuni T.**
Solid-phase synthesis and immunoreactivity of penta-*O*-(*N*-acetyl-α-D-galactosaminyl)-MUC1 eicosapeptide, a glycosylated counter part of the highly immunogenic tandem repeat sequence of carcinoma-associated mucin 1813
**Dupraz B.** see Fillion G. 1485
**Durette P. L.** see Goulet J. L. 1221
**Durkin K. A.** see Hoekstra W. J. 1361
**Dutruc-Rosset G.** see Damour D. 415
**Dutruc-Rosset G.** see Jimonet P. 2735

**Ecker D. J.** see Manoharan M. 1053
**Edatsugi H.** see Ohsaki A. 2889
**Eden J. M.** see Boden P. 1679
**Edwards M. P.** see Bradbury R. H. 139
**Edwards R. M.** see Weinstock J. 23
**Egbertson M. S. Naylor A. M. Hartman G. D. Cook J. J. Gould R. J. Holahan M. A. Lynch, Jr J. J. Lynch R. J. Stranieri M. T. and Vassallo L. M.**
Non-peptide fibrinogen receptor antagonists—III. Design and discovery of a centrally constrained inhibitor 1835
**Egbertson M. S.** see Naylor A. M. 1841
**Eggleston D. S.** see Luengo J. I. 321
**Eggleston D. S.** see Weinstock J. 23
**Egholm M.** see Dueholm K. L. 1077
**Egholm M.** see Lagriffoul P.-H. 1081
**Eglen R. M.** see Clark R. D. 2477
**Eglen R. M.** see Clark R. D. 2481
**Eguchi M.** see Ojima I. 1749
**Elbaum D. and Schreiber S. L.**
Neocarzinostatin activation: molecular modeling revisited 309
**Elhakmaoui A. Gueiffier A. Milhavet J.-C. Blache Y. Chapat J.-P. Chavignon O. Teulade J.-C. Snoeck R. Andrei G. and De Clercq E.**
Synthesis and antiviral activity of 3-substituted imidazo[1,2-*a*]pyridines 1937
**Ellis C. D.** see Quan M. L. 2011
**Ellis E. S.** see Gaster L. M. 667
**Emini E. A.** see Dorsey B. D. 2769
**Emini E. A.** see Kim B. M. 2273
**Endo T.** see Tanaka H. 2857
**Endo Y. Ohno M. Hirano M. Takeda M. Itai A. and Shudo K.**
Chiral requirements for tumor promoters: conformations and activity of benzolactams 491
**Engels J. W.** see Faulstich K. 1975
**Engels J. W.** see Frauendorf A. 1019
**Ensinger C. L.** see Carini D. J. 63
**Ensinger C. L.** see Santella, III J. B. 2235
**Eppley A. M.** see Thompson S. K. 2441
**Erhard K. F.** see Abell A. D. 1365
**Erhard K. F.** see Holt D. A. 315
**Erickson J. W.** see Randad R. S. 1247
**Erickson J. W.** see Randad R. S. 2343
**Eriks J. Ch.** see van der Goot H. 1913
**Eskesen K.** see Bondo Hansen J. 695
**Espinal J.** see Billington D. C. 2307
**Essenburg A.** see Augelli-Szafran C. E. 1095
**Ettmayer P. Hübner M. Billich A. Rosenwirth B. and Gstach H.**
Novel, extended transition state mimic in HIV-1 protease inhibitors with peripheral $C_2$-symmetry 2851
**Evans C. A.** see Bednarski K. 2667
**Evans G. L.** see Lester M. G. 2683
**Evans J. M.** see Burrell G. 1285
**Evans P. L.** see Mullican M. D. 2359
**Ewing F. E.** see Lowe, III J. A. 839
**Eyermann C. J.** see Cain G. A. 329

**Fabbro D.** see Caravatti G. 399
**Fairchild C.** see Chen S.-H. 479
**Fairchild C.** see Chen S.-H. 2223
**Fairchild C.** see Kant J. 1565
**Fairchild C.** see Ueda Y. 1861
**Falck J. R. Chauhan K. Rosolowsky M. and Campbell W. B.**
Vasoactive eicosanoids: synthesis of 12,20-dihydroxy-eicosa-5(*Z*),8(*Z*),10(*E*),14(*Z*)-tetraenoic acid via a novel chiral bis-lactol 2113
**Falck J. R.** see Chauhan K. 2689
**Fallon L.** see Pirrung M. C. 1345
**Falotico R.** see Murray W. V. 87
**Fan S.** see Huang L. 593
**Fang X.** see Gu Z. 473
**Farina V.** see Chen S.-H. 479
**Farina V.** see Chen S.-H. 2223
**Farina V.** see Kant J. 1565
**Farina V.** see Ueda Y. 1861
**Farr R.** see Schirlin D. 241
**Fauchère J.-L.** see Thurieau C. 781
**Fauchet V. Bourel L. Tartar A. and Sergheraert C.**
Solid phase synthesis of trypanothione disulfide 2559
**Faulkner R. E.** see Bromidge S. M. 557
**Faulkner R. E.** see Bromidge S. M. 1185
**Faulkner R. E.** see Orlek B. S. 1411
**Faulstich K. Herrlein M. K. Brandtner S. Konrad R. E. Griesinger C. and Engels J. W.**
A new class of 3'-modified nucleotides as chain-terminators for DNA-sequencing 1975
**Faust K. A.** see Chang L. L. 115
**Faust K. A.** see Glinka T. W. 81
**Faust K. A.** see Glinka T. W. 2337
**Faust K. A.** see Naylor E. M. 69
**Fehr M. J. Carpenter S. L. and Petrich J. W.**
The role of oxygen in the photoinduced antiviral activity of hypericin 1339
**Feldman P. L.** see Stafford J. A. 1855
**Félétou M.** see Thurieau C. 781
**Fenoglio I.** see Ojima I. 1571
**Ferguson M. A. J.** see Field R. A. 391
**Ferguson M. A. J.** see Nikolaev A. V. 785
**Ferkany J. W.** see Hamilton G. S. 2035
**Fernandez A. V.** see Thompson S. K. 2441
**Ferrari B. Taillades J. Perreaut P. Bernhart C. Gougat J. Guiraudou P. Cazaubon C. Roccon A. Nisato D. Le Fur G. and Brelière J. C.**
Development of tetrazole

bioisosteres in angiotensin II antagonists 45
**Fesik S. W.** see Wang G. T. 1161
**Field R. A. Neville D. C. A. Smith R. W. and Ferguson M. A. J.** Acceptor analogues as potential inhibitors of bovine β-1,4-galactosyl transferase 391
**Fierros M. Rodríguez-Franco M. I. Navarro P. and Conde S.** First regioselective *Mucor miehei* lipase catalyzed synthesis of diester crowns. New macrocycles containing a 1,3-bis(1*H*-pyrazol-1-yl)propane unit 2523
**Fillion G. Dupraz B. Prudhomme N. and Huynh-Dinh T.** Blood–brain penetration of 5-hydroxytryptamine derivatives 1485
**Fink C. A.** see Bhagwat S. S. 2673
**Finney F. J. L.** see Smith S. A. 1291
**Fiorini I.** see Campiani G. 1235
**Fisher E.** see Bradbury R. H. 139
**Fisher M. H.** see DeVita R. J. 1807
**Fisher M. H.** see DeVita R. J. 2249
**Fisher M. H.** see Ok D. 2709
**Fisher M. H.** see Schoen W. R. 1117
**Fitch K.** see Kim D. 207
**Fitch K. J.** see Walsh T. F. 219
**Fitzgerald P. M. D.** see Kim B. M. 2199
**Fitzgerald P. M. D.** see Vacca J. P. 499
**Flanagan K. L.** see Chang L. L. 115
**Flanagan K. L.** see Chang L. L. 2787
**Flippi J. A.** see Villalobos A. 2781
**Fontaine E. H.** see Cooper C. B. 835
**Forbes I. T.** see Blackburn T. P. 279
**Ford-Hutchinson A. W.** see Labelle M. 463
**Forray C.** see Wong W. C. 2317
**Forrow S. M.** see Wyatt M. D. 801
**Fowler C. J.** see Hedberg M. H. 2527
**Francisco G.** see Levin J. I. 1135
**Franco L. S.** see Cohen N. 2883
**Frank E.** see Vice S. F. 1333
**Franke C. A.** see Hlasta D. J. 1801
**Franklin M. R. and Roberts J. C.** The relative ability of BSO and other γ-glutamylcysteine synthetase inhibitors to both deplete glutathione and alter drug metabolizing enzyme activities 935
**Franz R. G.** see Weinstock J. 23
**Franzese O.** see Cicero D. O. 861
**Frauendorf A. and Engels J. W.** Interaction of linear and folded modified antisense oligonucleotides with sequences containing secondary structure elements 1019
**Fray A. H.** see Kleinman E. F. 589
**Frazee J. S.** see Thompson S. K. 2441
**Fredenhagen A.** see Caravatti G. 399
**Frederickson T. A.** see Weinstock J. 23
**Freeman J. P.** see Zhao S. 2139
**Freier S. M.** see Bévierre M.-O. 237
**Freier S. M.** see Manoharan M. 1053
**French R. R.** see Papageorgiou C. 267
**Frennesson D. B.** see Saulnier M. G. 1985
**Fretland D. J.** see Djuric S. W. 811
**Fritsch V.** see De Mesmaeker A. 873
**Fritz J. E.** see Kaldor S. W. 1385
**Froehler B. C.** see Lin K.-Y. 1061
**Froelich L. L.** see Sawyer J. S. 2077
**Fronczek F. R.** see Kumaravel G. 883
**Frontier A. J.** see DeVita R. J. 2249
**Fuchs P. L.** see Li C. 1585
**Fujimoto K.** see Yanagisawa H. 177
**Fujimoto Y.** see Tsukuda T. 733
**Fujimoto Y.** see Yanagisawa H. 177
**Fujita K.** see Fukami T. 1613
**Fukami T. Hayama T. Amano Y. Nakamura Y. Arai Y. Matsuyama K. Yano M. and Ishikawa K.** Aminophosphonate endothelin converting enzyme inhibitors: potency-enhancing and selectivity-improving modifications of phosphoramidon 1257
**Fukami T. Nagase T. Mase T. Naya A. Fujita K. Niiyama K. and Ishikawa K.** Practical synthesis of a cyclic pentapeptide in solution: large-scale preparation of a representative $ET_A$-selective antagonist BQ-123Na 1613
**Fuller R. W. Bokesch H. R. Gustafson K. R. McKee T. C. Cardellina, II J. H. McMahon J. B. Cragg G. M. Soejarto D. D. and Boyd M. R.** HIV-Inhibitory coumarins from latex of the tropical rainforest tree *Calophyllum teysmannii* var. *inophylloide* 1961
**Funahashi M.** see Hamada H. 907
**Fung-Tomc J.** see Ueda Y. 1623
**Furber M.** see Birkenshaw T. N. 2501
**Furber M.** see Caffrey M. V. 2507
**Furber M.** see Teague S. J. 1581
**Furet P.** see Bühlmayer P. 29
**Furuya S.** see Cho N. 35

**Gac T. S.** see Burk R. M. 2103
**Gadamasetti K. G.** see Sundberg R. J. 1999
**Gaeta F. C. A.** see Siuzdak G. 2863
**Gaginella T. S.** see Djuric S. W. 811
**Gaillard P. Carrupt P.-A. and Testa B.** The conformation-dependent lipophilicity of morphine glucuronides as calculated from their molecular lipophilicity potential 737
**Gaitanopoulos D. E.** see Weinstock J. 23
**Galabov A. S.** see Zakharieva R. D. 2831
**Galeazzi E. Guzman A. Kluge A. Morgans, Jr D. Muchowski J. Jamil-Panah S. Saavedra P. Salazar M. A. Talamas F. X. Teitelbaum P. Young J. and Yamamoto D.** A congener study of zileuton reveals interesting effects on glucuronidation rates 1437
**Galéotti N.** see Hanessian S. 2763
**Galéotti N.** see Roux F. 1947
**Gallacher D.** see Judd D. B. 725
**Gallais C.** see Langlois M. 945
**Gallant G. Salvador R. and Dulude H.** Synthesis, chemical half-life and decomposition of new $N^3$-(substituted) derivatives of CCNU 2353
**Gallant G.** see Dulude H. 2697
**Gallion S. L.** see Marquart A. L. 1317
**Gam J.** see Kim D.-K. 911
**Gandour R. D.** see Kumaravel G. 883

**Ganesh K. N.** see Prakash T. P. 1733
**Ganguly A. K.** see Saksena A. K. 2023
**Ganguly A. K.** see Shankar B. B. 495
**Ganguly A. K.** see Tagat J. R. 1101
**Ganguly A. K.** see Vice S. F. 1333
**Gansow O. A.** see Wu C. 449
**Gao F.** see Pettit G. R. 2935
**Garbiras B. J.** see Hartley J. A. 2421
**Garbiras B. J.** see Wyatt M. D. 801
**Garcia A. M.** see Harrington E. M. 2775
**García-López M. T.** see Suárez-Gea M. L. 1491
**Garg B. S.** see Kumar P. 1761
**Garland D. J.** see Reitz D. B. 111
**Garner M. Armstrong D. R. Reglinski J. Smith W. E. Wilson R. and McKillop J. H.** The structure of methimazole and its consequences for current therapeutic models of Graves' disease 1357
**Garofalo A.** see Campiani G. 1235
**Garratt P. J. Jones R. Rowe S. J. and Sugden D.** Mapping the melatonin receptor—I. The 5-methoxyl group of melatonin is not an essential requirement for biological activity 1555
**Garratt P. J. Vonhoff S. Rowe S. J. and Sugden D.** Mapping the melatonin receptor—II. Synthesis and biological activity of indole derived melatonin analogues with restricted conformations of the C-3 amidoethane side chain 1559
**Garst M.** see Munk S. A. 459
**Garst M. E.** see Burk R. M. 2103
**Gasson B. C.** see Bateson J. H. 1667
**Gaster L.** see Bermudez J. 2373
**Gaster L. M. Wyman P. A. Ellis E. S. Brown A. M. and Young T. J.** 5-$HT_4$ Receptor antagonists: oxazolo, oxazino and oxazepino[3,2-*a*]indole derivatives 667
**Gates C. A.** see McDonald I. A. 847
**Gatto B.** see Sun Q. 2871
**Geahlen R. L.** see He H.-M. 1729
**Gellai M.** see Weinstock J. 23
**Georg G. I. Boge T. C. Cheruvallath Z. S. Harriman G. C. B. Hepperle M. Park H. and Himes R. H.** Schotten–Baumann acylation of *N*-debenzoyltaxol; an efficient route to *N*-acyl taxol analogues and their biological evaluation 335
**Georg G. I. Boge T. C. Cheruvallath Z. S. Harriman G. C. B. Hepperle M. Park H. and Himes R. H.** Topliss approach to the synthesis of biologically active substituted *N*-benzoyl taxol analogues 1825
**Georg G. I. Cheruvallath Z. S. Harriman G. C. B. Hepperle M. Park H. and Himes R. H.** Synthesis and biology of substituted 3'-phenyl taxol analogues 2331
**Georg G. I. Harriman G. C. B. Hepperle M. and Himes R. H.** Heteroaromatic taxol analogues: the chemistry and biological activities of 3'-furyl and 3'-pyridyl substituted taxanes 1381
**Georg G. I. Harriman G. C. B. Park H. and Himes R. H.** Taxol photoaffinity labels—II. Synthesis and biological evaluation of *N*-(4-azido-benzoyl)-*N*-debenzoyltaxol, *N*-(4-azido-2,3,5,6-tetrafluoro-benzoyl)-*N*-debenzoyltaxol, and 7-(4-azido-2,3,5,6-tetrafluorobenzoyl)taxol 487
**Georg G. I.** see Datta A. 1831
**Gerbling K.-P.** see Harde C. 273
**Geresh S.** see Clark D. S. 1745
**Geroni C.** see D'Alessio R. 1467
**Ghai R. D.** see Bhagwat S. S. 2673
**Ghai R. D.** see De Lombaert S. 2715
**Giblin G. M. P.** see Shaw R. E. 2155
**Gibson L. L.** see Burk R. M. 2103
**Gil D. W.** see Beard R. L. 1447
**Gilbert C. W.** see Greenwald R. B. 2465
**Gill A.** see Murray W. V. 87
**Gillespie R. J.** see Mullican M. D. 2359
**Gillett S. J.** see Beard R. L. 1447
**Gilligan P. J.** see Cain G. A. 329
**Girard G. R.** see Weinstock J. 23
**Girdwood J. A.** see Bradbury R. H. 139
**Girijavallabhan V. M.** see Rane D. F. 1313
**Girijavallabhan V. M.** see Saksena A. K. 2023
**Girotra R.** see Delaney N. G. 1783
**Glaser K. B. Sung M.-L. Lock Y.-W. Bauer J. Kubrak D. and Kreft A.** Analogs of the marine natural product scalaradial lacking the $\alpha,\beta$-unsaturated aldehyde: effects on human synovial fluid phospholipase $A_2$ and macrophage lipid mediator production 1873
**Gleason J. G.** see Thompson S. K. 2441
**Glinka T. W. de Laszlo S. E. Siegl P. K. S. Chang R. S. Kivlighn S. D. Schorn T. S. Faust K. A. Chen T.-B. Zingaro G. J. Lotti V. J. and Greenlee W. J.** A new class of balanced $AT_1/AT_2$ angiotensin II antagonists: quinazolinone AII antagonists with acylsulfonamide and sulfonylcarbamate acidic functionalities 81
**Glinka T. W. de Laszlo S. E. Siegl P. K. S. Chang R. S. Kivlighn S. D. Schorn T. S. Faust K. A. Chen T.-B. Zingaro G. J. Lotti V. J. and Greenlee W. J.** Development of angiotensin II antagonists with equipotent affinity for human $AT_1$ and $AT_2$ receptor subtypes 2337
**Glinka T. W. de Laszlo S. E. Tran J. Chang R. S. Chen T.-B. Lotti V. J. and Greenlee W. J.** L-161,638: A potent $AT_2$ selective quinazolinone angiotensin II binding inhibitor 1479
**Gluchowski C.** see Munk S. A. 459
**Gluchowski C.** see Wong W. C. 2317
**Gmeiner P. Hummel E. and Mierau J.** Novel HO-DPAT (hydroxy-2-dipropylaminotetralin) isomers: stereoselective synthesis and receptor binding studies 2589
**Goel A.** see Ram V. J. 2087
**Goel A.** see Ram V. J. 2653
**Gojmerac-Ivšic A.** see Modric N. 1685
**Gold M.** see Martin R. 1229
**Golding B. T.** see Bleasdale C. 291
**Golec J. M. C.** see Mullican M. D. 2359
**Gomes B. C.** see Bernstein P. R. 2175
**Gonzalez M. D. and Scott A. I.** Design of a reusable enzymatic system for the preparation of porphyrins of biological interest 743
**Gonzalez M. D.** see Clemens K. R. 521
**Gordon E. M.** see Bhide R. S. 2107
**Gordon E. M.** see Patel D. V. 1883

**Gordon R.** see Labelle M. 463
**Gore P. M.** see Cooper A. W. J. 1951
**Gorman R. R.** see Morris J. 2621
**Gorrod J. W.** see Aislaitner G. 515
**Goto F. and Ogawa T.** Synthesis of a dermatan sulfate hexasaccharide that activates heparin cofactor II 619
**Goto M.** see Yamazaki Y. 483
**Gottlieb P. A.** see Wieczorek A. 987
**Gottschlich R. Ackermann K. A. Barber A. Bartoszyk G. D. and Greiner H. E.** EMD 61 753 as a favourable representative of structurally novel arylacetamido-type κ opiate receptor agonists 677
**Gougat J.** see Bernhart C. A. 157
**Gougat J.** see Ferrari B. 45
**Gougat J.** see Perreaut P. 163
**Gould R. J.** see Egbertson M. S. 1835
**Gould R. J.** see Naylor A. M. 1841
**Goulet J. L. Kinneary J. F. Durette P. L. Stein R. L. Harrison R. K. Izquierdo-Martin M. Kuo D. W. Lin T.-Y. and Hagmann W. K.** Inhibition of stromelysin-1 (MMP-3) by peptidyl phosphinic acids 1221
**Goulet M. T. Hodkey D. W. Staruch M. J. Dumont F. J. Cryan J. G. Parsons W. H. and Wyvratt M. J.** Alkyl ether analogs of the FK-506 related, immuno-suppressive macrolide L-683,590 (ascomycin) 921
**Goulet M. T. Hodkey D. W. Staruch M. J. Dumont F. J. Lin S. Hung S. H. Y. Siekierka J. J. and Wyvratt M. J.** Alkyl ether derivatives of the FK-506 related, immuno-suppressive macrolide L-683,742 (C31-O-desmethyl ascomycin) 927
**Grace J. M.** see Miller K. E. 1643
**Graham A. C.** see Shankaran K. 1111
**Grampovnik D. J.** see Maring C. J. 1429
**Grandi M.** see D'Alessio R. 1467
**Grätzel M.** see König B. 2429
**Grée R.** see de Montarby L. 261
**Grée R.** see Le Gall T. 247
**Grée R.** see Le Gall T. 253
**Grée R.** see Le Gall T. 257
**Green M. D.** see Wester R. T. 2005
**Greenlee W. J.** see Chakravarty P. K. 75
**Greenlee W. J.** see Chang L. L. 115
**Greenlee W. J.** see Chang L. L. 2787
**Greenlee W. J.** see Glinka T. W. 81
**Greenlee W. J.** see Glinka T. W. 1479
**Greenlee W. J.** see Glinka T. W. 2337
**Greenlee W. J.** see Kevin N. J. 189
**Greenlee W. J.** see Kim D. 41
**Greenlee W. J.** see Kim D. 207
**Greenlee W. J.** see Mantlo N. B. 17
**Greenlee W. J.** see Naylor E. M. 69
**Greenlee W. J.** see Rivero R. A. 747
**Greenlee W. J.** see Walsh T. F. 219
**Greenwald R. B. Pendri A. Bolikal D. and Gilbert C. W.** Highly water soluble taxol derivatives: 2'-polyethylene-glycol esters as potential prodrugs 2465
**Gregory J.** see Bermudez J. 2373
**Grein T. Lampe S. Mersmann K. Rosemeyer H. Thomas H. and Seela F.** 3-Deaza- and 7-deazapurines: duplex stability of oligonucleotides containing modified adenine or guanine bases 971
**Greiner H. E.** see Gottschlich R. 677
**Gresk C. J.** see Reitz D. B. 111
**Griesinger C.** see Faulstich K. 1975
**Griffin E.** see Weinstock J. 23
**Grigoriadis D. E.** see Cain G. A. 329
**Gross M. L.** see Richardson P. L. 2133
**Grubmayr K.** see Micura R. 2517
**Grunewald G. L.** see Czaplinski K.-H. A. 2211
**Gryaznov S.** see Dolinnaya N. 1011
**Gstach H.** see Ettmayer P. 2851
**Gu Z. Fang X. Zeng L. Kozlowski J. F. and McLaughlin J. L.** Novel cytotoxic Annonaceous acetogenins: (2,4-*cis* and *trans*)-bulladecinones from *Annona bullata* (Annonaceae) 473
**Gu Z.** see Poss M. A. 145
**Gu Z.** see Ryono D. E. 201
**Guare J. P.** see Kim B. M. 2199
**Guare J. P.** see Kim B. M. 2273
**Guccione S.** see Romeo G. 2399
**Gude C.** see Bhagwat S. S. 2673
**Gueiffier A.** see Elhakmaoui A. 1937
**Guggino S. E.** see Posner G. H. 2919
**Guiraudou P.** see Ferrari B. 45
**Guiraudou P.** see Perreaut P. 163
**Gülgeze B.** see Aubé J. 2461
**Gullo V. P.** see Chu M. 1539
**Gulnik S. V.** see Randad R. S. 1247
**Gulnik S. V.** see Randad R. S. 2343
**Gupta K. C.** see Kumar P. 1761
**Gupta S. D. Jain R. and Chauhan V. S.** Dehydrolysine containing analogues of tuftsin: synthesis and bioactivity 941
**Gurskaya G. V.** see Shutalev A. D. 761
**Gustafson K. R.** see Fuller R. W. 1961
**Guzi T. J.** see Lehnert E. K. 2411
**Guzman A.** see Galeazzi E. 1437
**Guzzi U.** see Badone D. 1921

**Haadsma-Svensson S. R. Smith M. W. Lin C.-H. Duncan J. N. Sonesson C. Wikström H. Waters N. Carlsson A. and Svensson K.** Synthesis and biological activity of C-5 modified derivatives of (+)-AJ76 and (+)-UH232: increased dopamine $D_3$ receptor preference and improved pharmacokinetic properties 689
**Habus I. Temsamani J. and Agrawal S.** Synthesis of di-, tri-, and tetrameric building blocks with novel carbamate internucleoside linkages and their incorporation into oligonucleotides 1065
**Hacksell U.** see Hedberg M. H. 2527
**Hacksell U.** see Nordvall G. 2837
**Hadley M. S.** see Bromidge S. M. 1185
**Hadley M. S.** see Burrell G. 1285
**Hadley M. S.** see Smith S. A. 1291
**Hageman W. E.** see Demers J. P. 2451
**Haginoya N.** see Ono A. 361
**Hagmann W. K.** see Goulet J. L. 1221
**Haigh D.** see Cantello B. C. C. 1181
**Hakomori S.** see Dupradeau F.-Y. 1813
**Halaka N.** see Soll R. M. 769

**Hallam T. J.** see Davis P. D. 1303
**Hallinan E. A. Stapelfeld A. Savage M. A. and Reichman M.** 8-Chlorodibenz[*b,f*]-[1,4]oxazepine-10(11*H*)-carboxylic acid, 2-[3-[2-(furanylmethyl)thio]-1-oxopropyl]hydrazide (SC-51322): a potent $PGE_2$ antagonist and analgesic 509
**Ham P.** see Smith S. A. 1291
**Hamada H. Nakajima N. Shisa Y. Funahashi M. and Nakamura K.** Enantioselective reduction of ethyl 3-methyl-2-oxobutanoate by an enzymatic system from callus of *Catharanthus roseus* 907
**Hamano S.** see Miyake K. 213
**Hamant S. Mathieu J.-P. Morin C. Trimcev I. and Vidal M.** The β-iodoethoxyl group: a stable unit for radioiodination 1687
**Hamby J. M.** see Klutchko S. 57
**Hamelehle K. L.** see Augelli-Szafran C. E. 1095
**Hamilton A. D.** see Qian Y. 2579
**Hamilton G. S. Bednar D. Borosky S. A. Huang Z. Zubrowski R. Ferkany J. W. and Karbon E. W.** Synthesis and glutamate antagonist activity of 4-phosphonoalkylquinoline derivatives: a novel class of non-NMDA antagonist 2035
**Hamilton H. W.** see Steinbaugh B. A. 2029
**Hammond M.** see Kaldor S. W. 1385
**Han R.-J.** see LeMahieu R. A. 339
**Hancock A. A.** see Zelle R. E. 1319
**Hancock A. A.** see Zydowsky T. M. 173
**Hanessian S. and Raghavan S.** Design and synthesis of a prototypical non-peptidic inhibitor model for the enzyme renin 1697
**Hanessian S. and Reddy G. B.** Synthesis of tricyclic β-lactams—functionally and topologically novel carbacephems 2285
**Hanessian S. and Rozema M. J.** Synthesis and biological evaluation of 1-substituted-7-(1-hydroxyethyl) carba-cephems—a class of 'hybrid' bicyclic β-lactams 2279
**Hanessian S. Galéotti N. Rosen P. Oliva G. and Babu S.** Synthesis of carbohydrate phostones as potential glycomimetics 2763
**Hanessian S. Ronan B. and Laoui A.** Design and synthesis of a prototype model antagonist of tachykinin NK-2 receptor 1397
**Hanifin C. M.** see Kim B. M. 2199
**Hanifin C. M.** see Kim B. M. 2273
**Hanifin J. W.** see Reich M. F. 1167
**Hansel S. B.** see Saulnier M. G. 1985
**Hansen K. T.** see Chorghade M. S. 2867
**Hanson K. K.** see Robarge M. J. 2117
**Haque N.** see Ram V. J. 1453
**Haralambidis J. Lagniton L. and Tregear G. W.** The preparation of enzyme-labelled oligonucleotides by reductive amination 1005
**Harde C. Neff K.-H. Nordhoff E. Gerbling K.-P. Laber B. and Pohlenz H.-D.** Syntheses of homoserine phosphate analogs as potential inhibitors of bacterial threonine synthase 273
**Hardern D. N.** see Birkenshaw T. N. 2501
**Hardern D. N.** see Caffrey M. V. 2507
**Hardick D. J. and Hutchinson D. W.** An improved, practical synthesis of 5-[$^2$H]-D-glucose 409
**Harding M. M.** see Brown C. L. 1253
**Hare R. S.** see Saksena A. K. 2023
**Harper G. P.** see Hunter D. J. 2833
**Harriman G. C. B.** see Georg G. I. 335
**Harriman G. C. B.** see Georg G. I. 487
**Harriman G. C. B.** see Georg G. I. 1381
**Harriman G. C. B.** see Georg G. I. 1825
**Harriman G. C. B.** see Georg G. I. 2331
**Harrington E. M. Kowalczyk J. J. Pinnow S. L. Ackermann K. Garcia A. M. and Lewis M. D.** Cysteine and methionine linked by carbon pseudopeptides inhibit farnesyl transferase 2775
**Harris W.** see Davis P. D. 1303
**Harrison R. K.** see Goulet J. L. 1221
**Harrison R. P.** see Birkenshaw T. N. 2501
**Harrison R. P.** see Caffrey M. V. 2507
**Harrison T. Williams B. J. Swain C. J. and Ball R. G.** Piperidine-ether based $hNK_1$ antagonists—I. Determination of the relative and absolute stereochemical requirements 2545
**Harrison T. Williams B. J. and Swain C. J.** *gem*-Disubstituted amino-ether based substance P antagonists 2733
**Harrison T.** see Williams B. J. 1903
**Hartley J. A. Wyatt M. D. Garbiras B. J. Richter C. and Lee M.** Probing the importance of the second chloroethyl arm of a benzoic acid mustard derivative of an imidazole-containing analogue of distamycin 2421
**Hartley J. A.** see Wyatt M. D. 801
**Hartman G. D.** see Egbertson M. S. 1835
**Hartman G. D.** see Naylor A. M. 1841
**Hasegawa K. Hirata M. Koshi T. Ohshima T. Miyashita Y. Sasaki S. and Okabe T.** Quantitative structure–activity relationships study of endothelin-1 analogs 1157
**Hashimoto K. Yamamoto O. Horikawa M. Ohfune Y. and Shirahama H.** Synthesis and neurobiological actions of pyrrolidine-2,3-dicarboxylic acids (PRDA). Conformationally restricted analogues of L-aspartate 1851
**Hashimoto M.** see Nagatsu A. 1619
**Hashimoto T.** see Sasaki S. 1771
**Hashimoto Y.** see Shimazawa R. 2377
**Hastings R. C.** see Babine R. E. 583
**Hatakeyama S.** see Kubodera N. 753
**Haudricourt F. B.** see Bernhart C. A. 157
**Hauser K. L.** see Steinberg M. I. 51
**Hauske J. R. Kajiji S. Dorff P. Julin S. DiBrino J. and Paillet S.** Investigation of the effects of synthetic non-cytotoxic immunophilin inhibitors on MDR 2097
**Havens C.** see Soll R. M. 769
**Hawkins J.** see Orlek B. S. 1411
**Haworth I. S.** see Adlam G. 2435
**Hayama T.** see Fukami T. 1257

**Hayashi H.** see Ueyama N. 1637
**He H.-M. Geahlen R. L. and Cushman M.** Synthesis of a series of brominated 1-phenyl-2-pyridylethenes as inhibitors of the protein-tyrosine kinase $p56^{lck}$ 1729
**He H.-M. and Cushman M.** A versatile synthesis of 2-methoxyestradiol, an endogenous metabolite of estradiol which inhibits tubulin polymerization by binding to the colchicine binding site 1725
**He J. X.** see Cody W. L. 567
**He M. Buisine E. Tartar A. and Sergheraert C.** Design and synthesis of new leads for PKC bisubstrate inhibitors 2845
**He Y.** see Lin N.-H. 2389
**Heald A.** see Russell M. G. N. 1207
**Hebert N.** see O'Donnell M. J. 1001
**Heck J. V.** see Shankaran K. 1111
**Hedberg M. H. Johansson A. M. Fowler C. J. Terenius L. and Hacksell U.** Palladium-catalyzed synthesis of C3-substituted 3-deoxymorphines 2527
**Hedberg S. A.** see Poss M. A. 145
**Heerding J. M.** see Swindell C. S. 1531
**Heldrich F. J.** see Campbell L. J. 2627
**Hénin Y.** see Wakselman M. 2533
**Hennig P.** see Cordi A. A. 1957
**Henry E.** see Beard R. L. 1447
**Henson R. A.** see Lester M. G. 2683
**Hepperle M.** see Georg G. I. 335
**Hepperle M.** see Georg G. I. 1381
**Hepperle M.** see Georg G. I. 1825
**Hepperle M.** see Georg G. I. 2331
**Herbert C. M.** see Shankaran K. 1111
**Herdewijn P.** see Pannecouque C. 1203
**Herdewijn P.** see Pérez-Pérez M.-J. 1199
**Hermann R. A.** see Kaldor S. W. 1385
**Heron N. M.** see Watson S. P. 151
**Heron N. M.** see Judd D. B. 725
**Herranz R.** see Suárez-Gea M. L. 1491
**Herrlein M. K.** see Faulstich K. 1975
**Herscovici J. Uriel C. Uriel J. and Antonakis K.** Unsaturated epoxy-C-glycosides. A new class of antitumor compounds with DNA cleavage properties 421
**Heslin P. H.** see Cohen N. 2883
**Hickey G. J.** see DeVita R. J. 2249
**Hicks F.** see Burrell G. 1285
**Hicks G. W.** see Steinbaugh B. A. 2029
**Hilditch A.** see Judd D. B. 725
**Hill C. H.** see Davis P. D. 1303
**Hill D. R.** see Chorghade M. S. 2867
**Hill D. T.** see Weinstock J. 23
**Hill K. E.** see Cody W. L. 567
**Hill S.** see Bantick J. R. 121
**Hill S.** see Bantick J. R. 127
**Hillyer G. L.** see Quan M. L. 2011
**Hilton S.** see Shevlin C. G. 297
**Hilvert D.** see Shin J. A. 2945
**Himes R. H.** see Georg G. I. 335
**Himes R. H.** see Georg G. I. 487
**Himes R. H.** see Georg G. I. 1381
**Himes R. H.** see Georg G. I. 1825
**Himes R. H.** see Georg G. I. 2331
**Himmelsbach F.** see Pfleiderer W. 1047
**Hindley R. M.** see Cantello B. C. C. 1181
**Hingorani G. P.** see Cody W. L. 567
**Hirano M.** see Endo Y. 491
**Hirata M.** see Hasegawa K. 1157
**Hird N. W. and Milner P. H.** Synthesis and β-lactamase inhibition of anacardic acids and their analogues 1423
**Hiroshima O.** see Miyake K. 213
**Hirst S. C.** see Bantick J. R. 121
**Hirst S. C.** see Bantick J. R. 127
**Hitotsuyanagi Y. Suzuki J. Takeya K. and Itokawa H.** Preparation and antitumor activity of [*N*-alkyl-Ala$^2$]RA-VII, antitumor cyclic hexapeptide 1633
**Hlasta D. J. Bell M. R. Boaz N. W. Court J. J. Desai R. C. Franke C. A. Mura A. J. Subramanyam C. and Duniap R. P.** A benzisothiazolone class of potent, selective mechanism-based inhibitors of human leukocyte elastase 1801
**Hlavac A. G.** see Wentland M. P. 609
**Ho M. Uhrin A. and Huang M.** An ether-based peptide analog as cAMP-dependent protein kinase inhibitor/substrate 553
**Hobson J. E.** see Judd D. B. 725
**Hodges J. C.** see Klutchko S. 57
**Hodges P.** see DeVita R. J. 1807
**Hodges P.** see Ok D. 2709
**Hodges P.** see Schoen W. R. 1117
**Hodgson J.** see Boden P. 1679
**Hodkey D. W.** see Goulet M. T. 921
**Hodkey D. W.** see Goulet M. T. 927
**Hoekstra W. J. Press J. B. Bonner M. P. Andrade-Gordon P. Keane P. M. Durkin K. A. Liotta D. C. and Mayo K. H.** Adamantane and nipecotic acid derivatives as novel β-turn mimics 1361
**Holahan M. A.** see Egbertson M. S. 1835
**Holland G. W.** see Cohen N. 2883
**Hollingsworth R. I.** see Kim K.-I. 1691
**Holloway M. K.** see Dorsey B. D. 2769
**Holloway M. K.** see Kim B. M. 2199
**Holloway M. K.** see Vacca J. P. 499
**Holt D. A. Konialian-Beck A. L. Oh H.-J. Yen H.-K. Rozamus L. W. Krog A. J. Erhard K. F. Ortiz E. Levy M. A. Brandt M. Bossard M. J. and Luengo J. I.** Structure–activity studies of synthetic FKBP ligands as peptidyl-prolyl isomerase inhibitors 315
**Holt D. A.** see Abell A. D. 1365
**Holt D. A.** see Abell A. D. 2327
**Holt D. A.** see Luengo J. I. 321
**Holt D. A.** see Yamashita D. S. 325
**Holt W. F.** see Kleinman E. F. 589
**Hong S. and Raushel F. M.** Synthesis and enzymatic hydrolysis of a light-emitting substrate for phospho-triesterase 2705
**Hong S.** see Mortellaro M. A. 2041
**Hoogsteen K.** see Labelle M. 463
**Hoover K. W.** see Wester R. T. 133
**Hopkins P. B.** see Miller T. R. 981
**Horikawa M.** see Hashimoto K. 1851
**Horikoshi H.** see Ishibashi K. 729
**Horn T.** see Dolinnaya N. 1011
**Horner J. H. Johnson C. C. Lai M. Liu H. Martin-Esker**

**A. A. Newcomb M. and Oh E.** Highly regioselective and rapid ring opening of the (methylenecyclopropyl)methyl radical 2693
**Horwell D. C. Howson W. Ratcliffe G. and Willems H.** The design of dipeptide helical mimetics: the synthesis and biological activity of trisubstituted indanes 2825
**Horwell D. C. Lennon I. C. and Roberts E.** Alternative strategies towards the identification of chemical lead compounds by rational design 525
**Horwell D. C. Nichols P. D. and Roberts E.** Methionine replacements in biologically active peptides 2263
**Horwell D. C.** see Boden P. 1679
**Horwitz S. B.** see Swindell C. S. 1531
**Hosaka H.** see Tanaka H. 2857
**Hosang M.** see Wessel H. P. 1419
**Hosono F. Nishiyama S. Yamamura S. Izawa T. and Kato K.** Synthesis and antiviral evaluation of [(2'*S*,3'*S*)-bis(hydroxymethyl)azetidin-1-yl]pyrimidine nucleosides: analogs of oxetanocin-A 2083
**Houchigai H.** see Sunagawa M. 2793
**Houston J. G.** see Smith P. W. 2821
**Howe W. J.** see Zhao S. 2139
**Howson W.** see Boden P. 1679
**Howson W.** see Horwell D. C. 2825
**Hsiao K.-F. Lin H.-J. Leu D.-L. Wu S.-H. and Wang K.-T.** Kinetic study of deacetylation and acetyl migration of peracetylated 1-methyl α,β-D-glucopyranosides by *Candida* lipase-catalyzed hydrolysis 1629
**Hsu G. C.** see Trova M. P. 903
**Huang H.-C. Chamberlain T. S. Olins G. M. Corpus V. M. Chen S. T. McMahon E. G. Palomo M. A. Blaine E. H. and Manning R. E.** Discovery of nonpeptide, potent conformationally restricted angiotensin II receptor antagonists 2591
**Huang J.** see McElroy E. B. 1071
**Huang L. Kashiwada Y. Cosentino L. M. Fan S. and Lee K.-H.** 3',4'-Di-*O*-(−)-camphanoyl-(+)-*cis*-khellactone and related compounds: a new class of potent anti-HIV agents 593
**Huang M.** see Ho M. 553
**Huang S.-C.** see Wu T.-S. 2395
**Huang S.-M.** see Carini D. J. 63
**Huang W.-C.** see Chen S.-T. 789
**Huang Z.** see Hamilton G. S. 2035
**Hubbard T.** see Judd D. B. 725
**Hubbard T.** see Watson S. P. 151
**Huber E. W.** see Marquart A. L. 1317
**Huber G.** see Delaney N. G. 1783
**Hübner M.** see Ettmayer P. 2851
**Hudkins R. L. and DeHaven-Hudkins D. L.** Phenytoin derivatives as potent σ ligands 2185
**Huff J. R.** see Dorsey B. D. 2769
**Huff J. R.** see Kim B. M. 2199
**Huff J. R.** see Kim B. M. 2273
**Huff J. R.** see Vacca J. P. 499
**Huffman J. W. Dai D. Martin B. R. and Compton D. R.** Design, synthesis and pharmacology of cannabimimetic indoles 563
**Hughes J.** see Boden P. 1679
**Hummel E.** see Gmeiner P. 2589
**Humphrey W. R.** see Morris J. 2621
**Hung S. H. Y.** see Goulet M. T. 927
**Hungate R. W.** see Vacca J. P. 499
**Hunihan L. W.** see Bhide R. S. 2107
**Hunter D. J. Bird J. Cassidy F. De Mello R. C. Harper G. P. Karran E. H. Markwell R. E. Miles-Williams A. J. and Ward R. W.** Aminophosphonic acid containing inhibitors of human collagenase: modification of the $P_1$ residue 2833
**Hutchinson D. W.** see Hardick D. J. 409
**Hutson J. L.** see Cox B. 1931
**Hutson J. L.** see Sharratt P. J. 661
**Hutt A. J.** see Aislaitner G. 515
**Huynh-Dinh T.** see Fillion G. 1485
**Hwang K.-M.** see Wang H.-K. 579

**Iberg N.** see Wessel H. P. 1419
**Ichihara Y.** see Pettit G. R. 1507
**Ichikawa S.** see Sasho S. 615
**Ichikawa Y.** see Siuzdak G. 2863
**Ikemoto K.** see Nagatsu A. 1619
**Imagawa J.** see Taka N. 2893
**Imagawa J.** see Takahashi T. 2899
**Imbach J.-L.** see Debart F. 1041
**Inada Y.** see Cho N. 35
**Inglis G. G. A.** see Sharratt P. J. 661
**Inoue A. and Satoh K.** Identification of a fluorescent glucoside isolated from the protein-free extract of human lens 2303
**Inoue H.** see Shimizu M. 1029
**Iribarren A. M.** see Cicero D. O. 861
**Irie K.** see Okuno S. 431
**Ishibashi K. Kurata H. Kojima K. and Horikoshi H.** Synthesis of B-nor-4-aza-5α-androstane compound as 5α-reductase inhibitor 729
**Ishiguro K.** see Kubo I. 1443
**Ishihara H.** see Miyake K. 213
**Ishii A.** see Sasho S. 615
**Ishikawa H. Tsubouchi H. and Yasumura K.** Synthesis and biological activity of new optically active 2-oxaisocephems: 3-(*N*-alkylpyridinium-4'-thio)methyl derivatives 1147
**Ishikawa H.** see Tsuji K. 1601
**Ishikawa K.** see Fukami T. 1257
**Ishikawa K.** see Fukami T. 1613
**Ishizawa T. Koga H. Sato H. Makino T. Taka N. Takahashi T. Sato T. and Nabata H.** Substituent effects of benzopyran-4-(*N*-cyano)-carboxamidine potassium channel openers for selectivity to guinea pig trachealis 1995
**Ishizawa T.** see Ohta M. 2903
**Ishizawa T.** see Taka N. 2893
**Ishizawa T.** see Takahashi T. 2899
**Itai A.** see Endo Y. 491
**Ito S.** see Ohsaki A. 2889
**Ito Y.** see Wang Z.-G. 2805
**Itokawa H.** see Hitotsuyanagi Y. 1633
**Ivanoff L. A.** see Thompson S. K. 2441
**Ivory A. J.** see Blackburn G. M. 2573
**Iwasaki S.** see Shimazawa R. 2377
**Iwasaki S.** see Shirai R. 699
**Iwashima A.** see Nagatsu A. 1619
**Iwashima A.** see Okuno S. 431
**Iwata D.** see Ohsaki A. 2889
**Iyer R. P. Yu D. and Agrawal S.** Stereospecific bio-reversibility of dinucleoside S-alkyl phosphorothiolates to dinucleoside phosphorothioates 2471
**Izawa T.** see Hosono F. 2083
**Izawa T.** see Nakajima T. 2485
**Izawa T.** see Ogino Y. 1991

**Izquierdo-Martin M.** see Goulet J. L. 1221

**Jack T. I.** see Judd D. B. 725
**Jacks T. M.** see DeVita R. J. 2249
**Jackson W. T.** see Sawyer J. S. 2077
**Jacobson A. R.** see Clemens K. R. 521
**Jae H.-S.** see Pratt J. 169
**Jahangir A.** see Clark R. D. 2477
**Jahangir A.** see Clark R. D. 2481
**Jain R.** see Gupta S. D. 941
**Jain R. K.** see Liu X.-G. 1501
**Jakeman D. L.** see Blackburn G. M. 2573
**Jamil-Panah S.** see Galeazzi E. 1437
**Janda K. D.** see Shevlin C. G. 297
**Janowick D.** see Schirlin D. 241
**Janowick D.** see Van Dorsselaer V. 1213
**Jaouhari R. G.** see McCall D. L. C. 1663
**Jas'ko M. V.** see Shutalev A. D. 761
**Jaspars M.** see Alvi K. A. 2447
**Jaurand G.** see Basten J. E. M. 893
**Jayasinghe L. R.** see Datta A. 1831
**Jensen D. K.** see Dueholm K. L. 1077
**Jensen L. H.** see Wätjen F. 371
**Jensen S. B.** see Beck C. 1353
**Jerman J.** see Bermudez J. 2373
**Ji Z.** see Chen H. 2701
**Jimonet P. Audiau F. Aloup J.-C. Barreau M. Blanchard J.-C. Bohme A. Boireau A. Chevé M. Damour D. Doble A. Lavayre J. Dutruc-Rosset G. Randle J. C. R. Rataud J. Stutzmann J.-M. and Mignani S.**
Synthesis and SAR of 2*H*-1,2,4-benzothiadiazine-1,1-dioxide-3-carboxylic acid derivatives as novel potent glycine antagonists of the NMDA receptor–channel complex 2735
**Jin H.** see Bednarski K. 2667
**Johansson A. M.** see Hedberg M. H. 2527
**Johnson A. L.** see Cain G. A. 329
**Johnson A. L.** see Christos T. E. 2347
**Johnson B. D.** see Reich M. F. 1167
**Johnson C. C.** see Horner J. H. 2693
**Johnson C. N.** see Blackburn T. P. 279
**Johnson D. S.** see Wrasidlo W. 631
**Johnson K. M.** see Stoelwinder J. 303
**Johnson L. K.** see Manoharan M. 1053
**Johnson S. G.** see Demers J. P. 2451
**Johnston K.** see Chen S.-H. 2223
**Joiner G. F.** see Bermudez J. 2373
**Joly J.-P.** see Dumont B. 1123
**Jonas R. Klockow M. Lues I. and Wurziger H.**
Stereoselectivity of the positive inotropic effects of newer diazinone-cardiotonics 2585
**Jones C. S.** see Cooper C. B. 835
**Jones J. B.** see Martin R. 1229
**Jones M. A.** see Lash T. D. 1607
**Jones R.** see Garratt P. J. 1555
**Jones R. J.** see Lin K.-Y. 1061
**Jones T. R.** see Labelle M. 463
**Jouin P.** see Roux F. 1947
**Judd D. B. Cardwell K. S. Panchal T. A. Jack T. I. Pass M. Hubbard T. Dean A. W. Butt A. U. Hobson J. E. Heron N. M. Watson S. P. Currie G. S. Middlemiss D. Allen D. G. Aston N. M. Paton J. M. S. Drew G. M. Hilditch A. Gallacher D. Bayliss M. K. and Donnelly M. C.**
Benzofuran based non-peptide antagonists of angiotensin II related to GR117289—IV. Imidazo-pyridinylbenzofurans 725
**Julin S.** see Hauske J. R. 2097
**Jung M. and Schinazi R. F.**
Synthesis and *in vitro* anti-human immunodeficiency virus activity of artemisinin (qinghaosu)-related trioxanes 931
**Jungheim L. N.** see Cho S. Y. S. 715
**Jungheim L. N.** see Shepherd T. A. 1391
**Just G.** see Kutterer K. M. K. 435

**Kachur J. F.** see Djuric S. W. 811
**Kadow J. F.** see Chen S.-H. 479
**Kadow J. F.** see Kant J. 1565
**Kadow J. F.** see Roth G. P. 711
**Kadow J. F.** see Saulnier M. G. 2567
**Kadow J. F.** see Wittman M. D. 2925
**Kageyama S.** see Wozniak L. A. 1033
**Kajiji S.** see Hauske J. R. 2097
**Kaldor S. W. Hammond M. Dressman B. A. Fritz J. E. Crowell T. A. and Hermann R. A.**
New dipeptide isosteres useful for the inhibition of HIV-1 protease 1385
**Kalman J. R.** see Brown C. L. 1253
**Kam C.-M.** see Player M. R. 949
**Kamal A. Daneshtalab M. Atchison K. and Micetich R. G.**
Synthesis of ring-A-opened isopicropodophyllins as potential DNA topoisomerase II inhibitors 1513
**Kanazaki T.** see Yanagisawa H. 177
**Kane J. M. Carr A. A. Cheng H. C. Dudley M. W. Rampe D. and Staeger M. A.**
Heterocyclic guanidines as calcium antagonists 351
**Kant J. Farina V. Fairchild C. Kadow J. F. Langley D. R. Long B. H. Rose W. C. and Vyas D. M.**
Synthesis and antitumor properties of novel 14-β-hydroxytaxol and related analogues 1565
**Kant J.** see Chen S.-H. 2223
**Kanter G. D.** see Yuen P. 823
**Kao C.-L.** see Chen S.-T. 443
**Kapil A.** see Ram V. J. 2087
**Karanewsky D. S.** see Das J. 2193
**Karanewsky D. S.** see Robl J. A. 1789
**Karanewsky D. S.** see Robl J. A. 1795
**Karanewsky D. S.** see Robl J. A. 2055
**Karbon E. W.** see Hamilton G. S. 2035
**Karnik P. J.** see Venugopalan B. 751
**Karpeisky A.** see Beigelman L. 1715
**Karpiesiuk W. and Banaszek A.**
Simple synthesis of *O,N*-protected tunicamine—the undecose part of tunicamycins 879
**Karran E. H.** see Hunter D. J. 2833
**Kashiwabara T.** see Nakajima T. 2485
**Kashiwada Y.** see Huang L. 593
**Kashiwada Y.** see Konoshima T. 1323
**Kasson R.** see Lin N.-H. 2389
**Kato K.** see Hosono F. 2083
**Kato K.** see Ogino Y. 1991
**Katocs A.** see Levin J. I. 1135
**Katocs, Jr A. S.** see Levin J. I. 1141
**Kaul I. B.** see Ram V. J. 2087

**Kawakami H. Ohmi N. and Nagata H.**
Synthesis of new potent leukotriene $B_4$ antagonists and their biological properties—II 1461
**Kawase A.** see Ono Y. 1523
**Kay D.** see Mullican M. D. 2359
**Kazanietz M. G.** see Marquez V. E. 355
**Keane P. M.** see Hoekstra W. J. 1361
**Keeling S. E.** see Cox B. 1931
**Keenan R. M.** see Weinstock J. 23
**Keith R. H.** see Djuric S. W. 811
**Kelly Y. F.** see Misra R. N. 2165
**Kelly Y. F.** see Robl J. A. 1795
**Kelsh L.** see Sundberg R. J. 1999
**Kendrick D. A.** see Batt A. R. 867
**Kennedy C. A.** see Wester R. T. 133
**Kensler T. W.** see Posner G. H. 2919
**Keown L.** see Ladduwahetty T. 1917
**Kerkman D.** see Pratt J. 169
**Kerkman D. J.** see Zydowsky T. M. 173
**Kerns E. H.** see Ueda Y. 1861
**Kerr J. M.** see Miller S. M. 2657
**Kerwar S. S.** see Babine R. E. 583
**Kesicki E. A.** see Coleman R. S. 1869
**Kevin N. J. Rivero R. A. Greenlee W. J. Chang R. S. L. and Chen T. B.**
Substituted phenylthiophene benzoylsulfonamides with potent binding affinity to angiotensin II $AT_1$ and $AT_2$ receptors 189
**Khalimskaya L. M. Levina A. S. and Zarytova V. F.**
Sequence-specific modification of DNA fragments by oligonucleotide derivatives containing alkylating groups at the C5 position of deoxyuridine 1083
**Kharlamb A.** see Munk S. A. 459
**Khushi T.** see Bateson J. H. 1667
**Kim B. H. Ryu E. J. and Chung Y. J.**
Novel angiotensin converting enzyme inhibitors containing α-hydroxy ketomethylene dipeptide isosteres 2799
**Kim B. M. Vacca J. P. Fitzgerald P. M. D. Darke P. L. Holloway M. K. Guare J. P. Hanifin C. M. Arford-Bickerstaff D. J. Zugay J. A. Wai J. M. Anderson P. S. and Huff J. R.**
Novel conformationally constrained HIV-1 protease inhibitors: rational design enzyme inhibition, and X-ray structure of an enzyme–inhibitor complex 2199
**Kim B. M. Vacca J. P. Guare J. P. Hanifin C. M. Michelson S. R. Darke P. L. Zugay J. A. Emini E. A. Schleif W. Lin J. H. Chen I.-W. Vastag K. Ostovic D. Anderson P. S. and Huff J. R.**
A new hydroxyethylamine class of HIV-1 protease inhibitors with high anti-viral potency and oral bioavailability 2273
**Kim B.-T. Asami T. Soh C.-H. Murofushi N. and Yoshida S.**
Novel compound stimulates amylase induction in barley seeds 1847
**Kim D. Mantlo N. B. Chang R. S. L. Kivlighn S. D. and Greenlee W. J.**
Evaluation of heterocyclic acid equivalents as tetrazole replacements in imidazopyridine-based nonpeptide angiotensin II receptor antagonists 41
**Kim D. Mantlo N. B. Tata J. R. Fitch K. Dhanoa D. Owens K. Levorse D. Siegl P. K. S. Chang R. S. L. Chen T. Scheck S. Zingaro G. J. Kivlighn S. D. and Greenlee W. J.**
Acidic phenols: a new class of potent nonpeptide angiotensin II receptor antagonists 207
**Kim D.** see Mantlo N. B. 17
**Kim D. H. and Li Z.-H.**
Stereochemical approach for enzyme inhibitor design 2297
**Kim D.-K. Gam J. and Kim K. H.**
Synthesis and *in vitro* cytotoxicity of 1,3-dioxolane-2-(2-ethanamine)-2-methanamine platinum(II) complexes 911
**Kim D.-K. Kim H.-K. and Chae Y.-B.**
Design and synthesis of 6-fluoropurine acyclonucleosides: potential prodrugs of acyclovir and ganciclovir 1309
**Kim D.-K. Kim Y.-W. and Kim K. H.**
Synthesis and anti-HCMV activity of 9-[[(ethoxyhydroxy-phosphinyl)methoxy]methoxy] guanine, an isostere of PMEG monoethyl ester 2241
**Kim H.-K.** see Kim D.-K. 1309
**Kim K. H.** see Kim D.-K. 2241
**Kim K. H.** see Kim D.-K. 911
**Kim K.-I. Lill-Elghanian D. A. and Hollingsworth R. I.**
Design, synthesis and biological properties of structurally non-related endotoxin inhibitors 1691
**Kim N.** see Suh J. 1889
**Kim Y.-W.** see Kim D.-K. 2241
**Kimble E. F.** see Satoh Y. 549
**Kimura H.** see Uchida C. 2643
**King F. D.** see Bermudez J. 2373
**Kinneary J. F.** see Goulet J. L. 1221
**Kinst-Hori I.** see Kubo I. 1443
**Kira T.** see Awano H. 367
**Kirk B. E.** see Cox B. 1931
**Kirkup M. P.** see Shankar B. B. 495
**Kiron M. A. R.** see Kleinman E. F. 589
**Kitson S. L.** see Bleasdale C. 291
**Kivlighn S. D.** see Chakravarty P. K. 75
**Kivlighn S. D.** see Chang L. L. 115
**Kivlighn S. D.** see Chang L. L. 2787
**Kivlighn S. D.** see Kim D. 41
**Kivlighn S. D.** see Kim D. 207
**Kivlighn S. D.** see Glinka T. W. 81
**Kivlighn S. D.** see Glinka T. W. 2337
**Kivlighn S. D.** see Mantlo N. B. 17
**Kivlighn S. D.** see Naylor E. M. 69
**Kivlighn S. D.** see Walsh T. F. 219
**Kiyokawa M.** see Ono A. 361
**Klaubert D. H.** see Demers J. P. 2451
**Klein L. L.** see Maring C. J. 1429
**Klein R. S.** see Megati S. 469
**Kleinman E. F. Fray A. H. Holt W. F. Kiron M. A. R. Murphy W. R. Purcell I. M. and Rosati R. L.**
CP-71,362, an unusually potent inhibitor of rat and dog renin 589
**Kline T.** see Leftheris K. 887
**Kling P. J.** see Chang L. L. 115
**Klockow M.** see Jonas R. 2585
**Kluge A.** see Galeazzi E. 1437
**Kluger R.** see Song Y. 1225
**Klutchko S. Hamby J. M. and Hodges J. C. Ardecky R. J.** see Carini D. J. 63
**Knight D. J.** see Bednarski K. 2667
**Knight W. B.** see Romeo G. 2399
**Knipe J. O.** see Saulnier M. G. 2567
**Kobayashi K.** see Yamazaki Y. 483
**Kobayashi S.** see Sugiyama T. 705

**Kobayashi T.** see Ono Y. 1523
**Koga H. Sato T. Tsuzuki K. Onoda H. Kuboniwa H. and Takanashi H.**
Potent, acid-stable and orally active macrolide-type motilin receptor agonists, GM-611 and the derivatives 1347
**Koga H. Sato T. Tsuzuki K. and Takanashi H.**
Macrolide-type motilin receptor agonists: assessment of the biological value of the 2'- and 4"-hydroxyl groups of acid-stable 8,9-anhydroerythromycin A 6,9-hemiacetals 1649
**Koga H.** see Ishizawa T. 1995
**Koga H.** see Ohta M. 2903
**Koga H.** see Taka N. 2893
**Koga H.** see Takahashi T. 2899
**Kohara Y.** see Cho N. 35
**Koike H.** see Yanagisawa H. 177
**Koiso Y.** see Shirai R. 699
**Koizumi T.** see Shimizu M. 1029
**Kojima K.** see Ishibashi K. 729
**Komoda Y.** see Ohsaki A. 2889
**Konialian-Beck A.** see Luengo J. I. 321
**Konialian-Beck A. L.** see Holt D. A. 315
**König B. and Grätzel M.**
An immunosensor for the detection of human B-lymphocytes 2429
**Konoshima T. Kashiwada Y. Takasaki M. Kozuka M. Yasuda I. Cosentino L. M. and Lee K.-H.**
Cucurbitacin F derivatives, anti-HIV principles from *Cowania mexicana* 1323
**Konrad R. E.** see Faulstich K. 1975
**Kool E. T.** see D'Souza D. J. 965
**Koshi T.** see Hasegawa K. 1157
**Koshimizu K.** see Okuno S. 431
**Kosmider B. J.** see Bernstein P. R. 2175
**Kosugi Y.** see Shuto S. 605
**Kowalczyk J. J.** see Harrington E. M. 2775
**Kowalski T. J.** see Satoh Y. 549
**Kozak R. W.** see Wu C. 449
**Kozikowski A. P. Ma D. Du L. Lewin N. E. and Blumberg P. M.**
Synthesis of the benzofuran analogue of ILV, a new protein kinase C (PKC) activator 637
**Kozikowski A. P.** see Dodd D. S. 1241
**Kozikowski A. P.** see Stoelwinder J. 303
**Kozlowski J. F.** see Gu Z. 473
**Kozuka M.** see Konoshima T. 1323
**Krafft G. A.** see Wang G. T. 1161
**Krantz A.** see Smith R. A. 2217
**Krause B. R.** see Augelli-Szafran C. E. 1095
**Krause M.** see Stark H. 2907
**Krauss A. H.** see Burk R. M. 2103
**Krauss H.** see Beard R. L. 1447
**Krauss N. E.** see Swindell C. S. 1531
**Kreft A.** see Glaser K. B. 1873
**Kremsky J. N. and Sinha N. D.**
Facile deprotection of silyl nucleosides with potassium fluoride/18-crown-6 2171
**Kreutner W.** see Blythin D. J. 1327
**Krog A. J.** see Holt D. A. 315
**Kruse L. I.** see Caulfield T. J. 1497
**Ksander G. M.** see Stanton J. L. 539
**Kubo I. Kinst-Hori I. Ishiguro K. Chaudhuri S. K. Sanchez Y. and Ogura T.**
Tyrosinase inhibitory flavonoids from *Heterotheca inuloides* and their structural functions 1443
**Kubo I. and Chaudhuri S. K.**
Structure of maesaquinone 1131
**Kubo K.** see Cho N. 35
**Kubodera N. Watanabe H. Hatakeyama S. Tazumi K. and Takano S.**
Synthesis of postulated metabolites of 1α,25-dihydroxy-22-oxavitamin $D_3$ 753
**Kubodera N.** see Ono Y. 1523
**Kuboniwa H.** see Koga H. 1347
**Kubrak D.** see Glaser K. B. 1873
**Kuduk S. D.** see Ojima I. 2631
**Kuhlmann L.** see Stahl W. 2597
**Kumar A. Zhao M. Wilson W. D. and Boykin D. W.**
Dicationic 2,4-diaryl pyrimidines as DNA selective binding agents 2913
**Kumar P. Bhatia D. Garg B. S. and Gupta K. C.**
An improved method for synthesis of biotin phosphoramidites for solid phase biotinylation of oligonucleotides 1761
**Kumar V.** see Prakash T. P. 1733
**Kumaravel G. Nic a' Bháird N. Fronczek F. R. Ramsay R. R. Ashendel C. L. and Gandour R. D.**
Evaluation of (2*S*,4*S*)/(2*R*,4*R*) and (2*S*,4*R*)/(2*R*,4*S*) 6,6-*N*,*N*-dimethyl-2-methyl-2-oxo-1,3-dioxa-4-hexadecyl-6-aza-2-phosphacyclooctane bromide as inhibitors for protein kinase C, carnitine octanoyl-transferase, and carnitine palmitoyltransferase 883
**Kuo C. H. Robichaud A. J. Rew D. J. Bergstrom J. D. and Berger G. D.**
Design and synthesis of squalene synthase inhibitors— acyclic mimics of the zaragozic acids 1591
**Kuo D.** see Romeo G. 2399
**Kuo D. W.** see Goulet J. L. 1221
**Kurata H.** see Ishibashi K. 729
**Kuroiwa K.** see Ueyama N. 1637
**Kutterer K. M. K. and Just G.**
Synthesis and hybridization studies of urea and carbamate linked thymidine dimers incorporated into oligodeoxy-nucleosides 435
**Kwoh S. C.** see Cohen N. 2883

**Labelle M. Belley M. Champion E. Gordon R. Hoogsteen K. Jones T. R. Leblanc Y. Lord A. McAuliffe M. McFarlane C. Masson P. Metters K. M. Nicoll-Griffith D. Ouimet N. Piechuta H. Rochette C. Sawyer N. Xiang Y. B. Yergey J. Ford-Hutchinson A. W. Pickett C. B. Zamboni R. J. and Young R. N.**
The discovery of L-699,392, a novel potent and orally active leukotriene $D_4$ receptor antagonist 463
**Laber B.** see Harde C. 273
**Labroo V. M.** see Orme M. W. 1375
**Lacour C.** see Bernhart C. A. 157
**Lacour C.** see Perreaut P. 163
**Ladduwahetty T. Keown L. Cascieri M. A. and Sadowski S.**
Morpholine-based substance P antagonists: assessment of the 3-point binding model 1917
**LaFlamme J. A.** see Wester R. T. 133
**Lagniton L.** see Haralambidis J. 1005
**Lagriffoul P.-H. Egholm M. Nielsen P. E. Berg R. H. and Buchardt O.**
The synthesis, co-oligomerization and hybridization of a thymine–thymine heterodimer containing PNA 1081
**Lai F.** see Levin J. I. 1135
**Lai F.** see Levin J. I. 1703
**Lai F.** see Levin J. I. 1709

**Lai J. Y. Q.** see Smith P. W. 2821
**Lai M.** see Horner J. H. 2693
**Lalan P.** see Murray W. V. 87
**Lalka G. K.** see Olson R. E. 2229
**Lalka G. K.** see Quan M. L. 2011
**Lambert D. M.** see Thompson S. K. 2441
**Lampe S.** see Grein T. 971
**Lancelon-Pin C.** see de Robertis L. 1127
**Lane B.** see Wang G. T. 1161
**Langley D. R.** see Kant J. 1565
**Langley D. R.** see Saulnier M. G. 2567
**Langlois M. Soulier J. L. Mathé-Allainmat M. Gallais C. Brémont B. and Shen S.** *N*-Chloromethyl quinuclidinium derivatives: a new class of irreversible ligands for 5-$HT_3$ receptors 945
**Langlois M. Zhang L. Yang D. Brémont B. Shen S. Manara L. and Croci T.** Design of a potent 5-$HT_4$ receptor agonist with nanomolar affinity 1433
**Langston J. A.** see Clark R. D. 2477
**Langston J. A.** see Clark R. D. 2481
**Laniado-Schwartzman M.** see Chauhan K. 2689
**Laoui A.** see Hanessian S. 1397
**Lash T. D. Drinan M. A. Zhen C. Mani U. N. and Jones M. A.** Synthetic substrates for coproporphyrinogen oxidase: mesoporphyrinogen-VI revisited 1607
**Latham H. C.** see Adlam G. 2435
**Lattmann R.** see Bühlmayer P. 29
**Lauffer D. J.** see Mullican M. D. 2359
**Laughlin M. E.** see McDonald I. A. 847
**Lavayre J.** see Jimonet P. 2735
**Lavelle F.** see Ojima I. 2631
**LaVoie E. J.** see Sun Q. 2871
**Lawrence S. A.** see Smith S. A. 1291
**Lawton G.** see Davis P. D. 1303
**Lebel W. S.** see Lowe, III J. A. 839
**Leblanc Y.** see Labelle M. 463
**Lebreton J.** see De Mesmaeker A. 395
**Lebreton J.** see De Mesmaeker A. 873
**Lebreton J.** see Waldner A. 405
**Lee D. K. H.** see Murray W. V. 87
**Lee E. C.** see Chorghade M. S. 2867
**Lee F. K.** see Cohen N. 2883
**Lee J. Lewin N. E. Blumberg P. M. and Marquez V. E.** Conformationally constrained analogues of diacylglycerol—IX. The effect of side-chain orientation on the protein kinase C (PK-C) binding affinity of δ-lactones 2405
**Lee J. Marquez V. E. Lewin N. E. and Blumberg P. M.** Conformationally constrained analogues of DAG—VII. Interaction of a medium-size ε-lactone with protein kinase C (PK-C) 543
**Lee J. Sharma R. Teng K. Lewin N. E. Blumberg P. M. and Marquez V. E.** Conformationally constrained analogues of DAG—VIII. Changes in PK-C binding affinity produced by isosteric groups of the 3-*O*-acyl function in 2-deoxy-L-ribonolactones 1369
**Lee J.** see Marquez V. E. 355
**Lee J. Y.** see Zydowsky T. M. 173
**Lee K.-H.** see Huang L. 593
**Lee K.-H.** see Konoshima T. 1323
**Lee K.-H.** see Tang R. 455
**Lee K.-H.** see Wang H.-K. 579
**Lee K.-H.** see Wu T.-S. 2395
**Lee M.** see Hartley J. A. 2421
**Lee M.** see Wyatt M. D. 801
**Lee V. J.** see Shutalev A. D. 761
**Lee W.** see Vlattas I. 2067
**Lee W.** see Vlattas I. 2073
**Leesnitzer M. A.** see Stafford J. A. 1855
**Lefkowitz S. L.** see Desai M. C. 641
**Lefkowitz S. L.** see Desai M. C. 1865
**Leftheris K. Kline T. Natarajan S. DeVirgilio M. K. Cho Y. H. Pluscec J. Ricca C. Robinson S. Seizinger B. R. Manne V. and Meyers C. A.** Peptide based $p21^{ras}$ farnesyl transferase inhibitors: systematic modification of the tetrapeptide $CA_1A_2X$ motif 887
**Le Fur G.** see Ferrari B. 45
**Le Fur G.** see Bernhart C. A. 157
**Le Fur G.** see Perreaut P. 163
**Le Gall T. Darganzanli G. Grée R. Millet J. Sepulchre C. and Bellamy F.** Synthesis and biological evaluation of new 5-HPETE analogs 253
**Le Gall T. de Montarby L. Grée R. Millet J. Sepulchre C. and Bellamy F.** Synthesis and biological evaluation of new arachidonic acid analogs 247
**Le Gall T. Grée R. Millet J. Sepulchre C. and Bellamy F.** Synthesis and biological evaluation of new $LTA_4$ analogs 257
**Lehnert E. K. Miller K. E. Madalengoitia J. S. Guzi T. J. and Macdonald T. L.** DNA Topoisomerase II inhibition by substituted 1,2,3,4-tetrahydro-β-carboline derivatives 2411
**Lelièvre Y.** see Mazaleyrat J.-P. 1281
**Lelièvre Y.** see Mazaleyrat J.-P. 653
**Lelièvre Y.** see Wakselman M. 2533
**LeMahieu R. A. Carson M. Han R.-J. Will P. C. Thomas T. K. Nagy C. and Cominelli F.** 4-[5-(2,3-Dihydroxyphenyl)-pentyloxy]-2-hydroxy-3-propylbenzoic acid (RO 24-0553): an orally active 5-lipoxygenase inhibitor with antiinflammatory activity 339
**Lenhard R. H.** see Reich M. F. 1167
**Lennon I. C.** see Horwell D. C. 525
**Lenoir P.** see Demonchaux P. 2383
**Leonard J.** see Morphy J. R. 2747
**Leonard J.** see Porter J. R. 2741
**Lepagnol J. M.** see Cordi A. A. 1957
**Lescosky L. J.** see Wätjen F. 371
**Lesiak K.** see Xiao W. 2609
**Lester M. G. Evans G. L. Henson R. A. Procopiou P. A. Sareen M. Snowden M. A. Spooner S. J. Srikantha A. A. P. and Watson N. S.** The squalestatins: effects of changes at the allylic centre in the C1 side-chain 2683
**Lester M. G.** see Sharratt P. J. 661
**Leu D.-L.** see Hsiao K.-F. 1629
**Leung E.** see Clark R. D. 2477
**Leung E.** see Clark R. D. 2481
**Leung K.** see Wittman M. D. 2925
**Leurs R.** see van der Goot H. 1913
**Lever D. C.** see Pirrung M. C. 1345
**Levett P. C. Whiting D. A. Cayley J. Cockerill G. S. and Weston J. B.** Structural requirements for respiratory inhibition by rotenoids; is an intact B/C ring system essential? 505

**Levin J. I. Chan P. S. Bailey T. Katocs, Jr A. S. and Venkatesan A. M.**
The synthesis of 2,3-dihydro-4(1*H*)-quinazolinone angiotensin II receptor antagonists 1141
**Levin J. I. Chan P. S. Coupet J. Bailey T. K. Vice G. Thibault L. Lai F. Venkatesan A. M. and Cobuzzi A.**
6-Isoxazolinyl and isoxazolidinyl substituted quinazolinones as angiotensin II receptor antagonists 1703
**Levin J. I. Chan P. S. Coupet J. Thibault L. Venkatesan A. M. Bailey T. K. Vice G. Cobuzzi A. Lai F. and Mellish N.**
Synthesis and biological evaluation of the potent isoxazolidinyl angiotensin II receptor antagonist CL332,877 and its enantiomers 1709
**Levin J. I. Venkatesan A. M. Chan P. S. Bailey T. K. Vice G. and Coupet J.**
6-Substituted quinazolinone angiotensin II receptor antagonists 1819
**Levin J. I. Venkatesan A. M. Chan P. S. Baker J. S. Francisco G. Bailey T. Vice G. Katocs A. Lai F. and Coupet J.**
2,3,6-Substituted quinazolinones as angiotensin II receptor antagonists 1135
**Levin J. I.** see Venkatesan A. M. 183
**Levin R. B.** see Dorsey B. D. 2769
**Levina A. S.** see Khalimskaya L. M. 1083
**Levorse D.** see Kim D. 207
**Levy M. A.** see Abell A. D. 1365
**Levy M. A.** see Abell A. D. 2327
**Levy M. A.** see Holt D. A. 315
**Levy M. A.** see Luengo J. I. 321
**Levy M. A.** see Yamashita D. S. 325
**Lewin N. E.** see Kozikowski A. P. 637
**Lewin N. E.** see Lee J. 543
**Lewin N. E.** see Lee J. 1369
**Lewin N. E.** see Lee J. 2405
**Lewin N. E.** see Marquez V. E. 355
**Lewis J. M.** see Murray W. V. 87
**Lewis M. D.** see Harrington E. M. 2775
**Li C. Mahadevan A. Arasappan A. Phillips J. R. Merriman R. L. Tanzer L. R. and Fuchs P. L.**
Synthesis and pharmacological evaluation of vinyl sulfone based anticancer agents 1585
**Li G.** see Xiao W. 2609
**Li L.** see Dupradeau F.-Y. 1813
**Li L.** see Maring C. J. 1429
**Li Z.-H.** see Kim D. H. 2297
**Libby A. H.** see Satoh Y. 549
**Lifer S. L.** see Steinberg M. I. 51
**Light-Wahl K. J.** see Richardson P. L. 2133
**Ligneau X.** see Stark H. 2907
**Lill-Elghanian D. A.** see Kim K.-I. 1691
**Lille Ü.** see Lopp M. 1739
**Limauro S. Benseler F. and McLaughlin L. W.**
1-Methylguanosine substitutions of the conserved guanosine residues inactivate the hammerhead ribozyme 2189
**Lin A. H.** see Morris J. 2621
**Lin C.-H.** see Haadsma-Svensson S. R. 689
**Lin H.-J.** see Hsiao K.-F. 1629
**Lin J. H.** see Dorsey B. D. 2769
**Lin J. H.** see Kim B. M. 2273
**Lin K.-Y. Pudlo J. S. Jones R. J. Bischofberger N. Matteucci M. D. and Froehler B. C.**
Oligodeoxynucleotides containing 5-(1-propynyl)-2'-deoxyuridine formacetal and thioformacetal dimer synthons 1061
**Lin N.-H. He Y. Anderson D. J. Wasicak J. T. Kasson R. Sweeny D. and Sullivan J. P.**
Synthesis and structure–activity relationships of pyrrolidine-modified analogs of the potent cholinergic channel activator, ABT 418 2389
**Lin S.** see Goulet M. T. 927
**Lin T.-Y.** see Goulet J. L. 1221
**Liotta D. C.** see Hoekstra W. J. 1361
**Lisziewicz J.** see Metelev V. 2929
**Litschgi J. W.** see Reitz D. B. 111
**Little A. J. Sutherland J. D. Wilson E. J. and Wood-Collins D. A. J.**
Directed evolution of novel biosynthetic pathways: overexpression of leucine aminopeptidase allows an *Escherichia coli* proline auxotroph to grow faster on prolinamide 2555
**Liu A.** see Sun Q. 2871
**Liu H.** see Horner J. H. 2693
**Liu J.** see Olson R. E. 2229
**Liu J.** see Quan M. L. 2011
**Liu L. F.** see Sun Q. 2871
**Liu S.-Y.** see Wang H.-K. 579
**Liu X.-G. Jain R. K. Saha R. and Matta K. L.**
Synthesis of Gal-β-(1→4)-6-O-$SO_3$Na-GlcNAc-β-(1→6)-Man-α-OR as a part of gp 120 1501
**Livermore D. G. H.** see Shaw R. E. 2155
**Livingston D. J.** see Mullican M. D. 2359
**Lloyd J. Ryono D. E. Bird J. E. Buote J. Delaney C. L. Dejneka T. Dickinson K. E. J. Moreland S. Normandin D. E. Skwish S. Spitzmiller E. R. and Waldron T. L.**
Quinoline-4-carboxylic acids as angiotensin II receptor antagonists 195
**Lloyd J.** see Ryono D. E. 201
**Lock Y.-W.** see Glaser K. B. 1873
**Lodge N.** see Soll R. M. 769
**Loebenberg D.** see Rane D. F. 1313
**Loebenberg D.** see Saksena A. K. 2023
**Long B.** see Chen S.-H. 479
**Long B. H.** see Chen S.-H. 2223
**Long B. H.** see Kant J. 1565
**Long B. H.** see Ueda Y. 1861
**Longo K. P.** see Lowe, III J. A. 839
**Look R. A.** see Demers J. P. 2451
**Lopp A.** see Lopp M. 1739
**Lopp M. Lopp A. Paju A. Lille Ü. and Pehk T.**
Synthesis and antiproliferative activity of 15-oxoprostaglandins: contribution of the ω-chain enone group to cytotoxicity 1739
**Lord A.** see Labelle M. 463
**Lotti V. J.** see Chakravarty P. K. 75
**Lotti V. J.** see Chang L. L. 115
**Lotti V. J.** see Chang L. L. 2787
**Lotti V. J.** see Glinka T. W. 81
**Lotti V. J.** see Glinka T. W. 1479
**Lotti V. J.** see Glinka T. W. 2337
**Lotti V. J.** see Naylor E. M. 69
**Lotti V. J.** see Walsh T. F. 219
**Loudon J. M.** see Bromidge S. M. 557
**Lovey R. G.** see Saksena A. K. 2023
**Lowe, III J. A. Drozda S. E. McLean S. Crawford R. T. Bryce D. K. and Bordner J.**
*N*-Alkyl quinuclidinium substance P antagonists 1153
**Lowe, III J. A. Ewing F. E. Snider R. M. Longo K. P. Constantine J. W. Lebel W. S. Woody H. A. and Bordner J.**
2-Aryl-1-azabicyclo[2.2.2]-octanes as novel nonpeptide substance P antagonists 839
**Lowe, III J. A. Qian W. Scott P. J. McLean S. Bryce D. K.**

**Crawford R. T. and Bordner J.**
5,7-Diphenyl-3-ureidohexahydroazepin-2-ones as cholecystokinin-B receptor ligands 2877
**Luengo J. I. Konialian-Beck A. Levy M. A. Brandt M. Eggleston D. S. and Holt D. A.**
Synthesis and structure–activity relationships of macrocyclic FKBP ligands 321
**Luengo J. I.** see Holt D. A. 315
**Luengo J. I.** see Yamashita D. S. 325
**Lues I.** see Dorsch D. 1297
**Lues I.** see Jonas R. 2585
**Lues I.** see Osswald M. 683
**Luly J.** see Wang G. T. 1161
**Lum R. T.** see Thompson S. K. 2441
**Lunney E. A.** see Steinbaugh B. A. 2029
**Luong Y.-P.** see Mullican M. D. 2359
**Luthria D. L.** see Pradhan P. 2425
**Luu-The V.** see Auger S. 2045
**Lynch R. J.** see Egbertson M. S. 1835
**Lynch, Jr J. J.** see Egbertson M. S. 1835

**Ma D.** see Kozikowski A. P. 637
**MacCoss M.** see Mjalli A. M. M. 1965
**MacCoss M.** see Walsh T. F. 219
**MacDonald I. D.** see Smith R. A. 2217
**Macdonald T. L.** see Lehnert E. K. 2411
**Macdonald T. L.** see Miller K. E. 1643
**Macdonald T. L.** see Werbovetz K. A. 2323
**Madalengoitia J. S.** see Lehnert E. K. 2411
**Maeda K.** see Sugiyama T. 705
**Maeda M.** see Sasaki S. 1771
**Magnus-Ayritey G. T.** see Carpino P. A. 93
**Magnus-Ayritey G. T.** see Wester R. T. 133
**Magolda R. L.** see Miller W. H. 843
**Mahadevan A.** see Li C. 1585
**Mahieu J.-P.** see Cordi A. A. 1957
**Major J. S.** see Bradbury R. H. 139
**Makino T.** see Ishizawa T. 1995
**Malone T. C.** see Wätjen F. 371
**Mamber S. W.** see Chen S.-H. 479
**Mamber S. W.** see Chen S.-H. 2223
**Mamber S. W.** see Roth G. P. 711
**Mamber S. W.** see Ueda Y. 1861
**Manara L.** see Langlois M. 1433
**Mane R. B.** see Patil S. V. 2663
**Manfredini S.** see Baraldi P. G. 2539
**Mangiapane M. L.** see Wester R. T. 133
**Mani U. N.** see Lash T. D. 1607
**Manlapaz C.** see Munk S. A. 459
**Manne V.** see Leftheris K. 887
**Manning R. E.** see Huang H.-C. 2591
**Manoharan M. Johnson L. K. Bennett C. F. Vickers T. A. Ecker D. J. Cowsert L. M. Freier S. M. and Cook P. D.**
Cholic acid–oligonucleotide conjugates for antisense applications 1053
**Mansour T. S.** see Bednarski K. 2667
**Mantei R. A.** see Zydowsky T. M. 173
**Mantlo N. B. Kim D. Ondeyka D. Chang R. S. L. Kivlighn S. D. Siegl P. K. S. and Greenlee W. J.**
Imidazo[4,5-*b*]pyridine-based $AT_1/AT_2$ angiotensin II receptor antagonists 17
**Mantlo N. B.** see Kim D. 207
**Mantlo N. B.** see Kim D. 41
**Marcoux F. W.** see Wätjen F. 371
**Marder P.** see Sawyer J. S. 2077
**Margraff R. Bézard D. Bourzat J. D. and Commerçon A.**
Synthesis of 19-hydroxy docetaxel from a novel baccatin 233
**Maring C. J. Grampovnik D. J. Yeung C. M. Klein L. L. Li L. Thomas S. A. and Plattner J. J.**
C-3'-N-Acyl analogs of 9(*R*)-dihydrotaxol: synthesis and structure–activity relationships 1429
**Marjo C. E.** see Brown C. L. 1253
**Markos C. S.** see Reitz D. B. 111
**Markwell R. E.** see Hunter D. J. 2833
**Marler D. K.** see Beard R. L. 1447
**Marquart A. L. Schatzman G. L. Peet N. P. Moore W. R. Huber E. W. Gallion S. L. and Angelastro M. R.**
Inhibition of oxidosqualene cyclase by substituted quinolizidines 1317
**Marquez V. E. Lee J. Sharma R. Teng K. Wang S. Lewin N. E. Bahador A. Kazanietz M. G. and Blumberg P. M.**
Conformationally constrained analogues of diacylglycerol—VI. Changes in PK-C binding affinity for 3-O-acyl-2-deoxy-L-ribonolactones bearing different acyl chains 355
**Marquez V. E.** see Lee J. 543
**Marquez V. E.** see Lee J. 1369
**Marquez V. E.** see Lee J. 2405
**Marriott D. P.** see Birkenshaw T. N. 2501
**Marron B. E.** see Stafford J. A. 1855
**Marshall D.** see Chen S.-H. 2223
**Marshall D. R.** see Roth G. P. 711
**Marshall W. S.** see Steinberg M. I. 51
**Marshalla M.** see Sundberg R. J. 1999
**Marsura A.** see de Robertis L. 1127
**Marsura A.** see Dumont B. 1123
**Martin B. R.** see Huffman J. W. 563
**Martin J. A.** see Thomas G. J. 2759
**Martin R. Gold M. and Jones J. B.**
Inhibition of the RTEM-1 β-lactamase by boronic acids 1229
**Martin R. T.** see Blackburn T. P. 279
**Martin-Esker A. A.** see Horner J. H. 2693
**Mase T.** see Fukami T. 1613
**Mason B.** see Morphy J. R. 2747
**Mason B.** see Porter J. R. 2741
**Masson P.** see Labelle M. 463
**Mastalerz H. A.** see Wittman M. D. 2925
**Matassa V. G.** see Russell M. G. N. 1207
**Matharu S. S.** see Mullican M. D. 2359
**Mathé-Allainmat M.** see Langlois M. 945
**Mathers P.** see Ryono D. E. 201
**Mathews E.** see Batt A. R. 867
**Mathieu J.-P.** see Hamant S. 1687
**Mathis J.** see Vlattas I. 2067
**Mathis J.** see Vlattas I. 2073
**Matiskella J. D.** see Ueda Y. 1861
**Matsuda A.** see Awano H. 367
**Matsuda A.** see Ono A. 361
**Matsuda A.** see Shuto S. 605
**Matsuda A.** see Yoshimura Y. 721
**Matsukura M.** see Miyake K. 213
**Matsuoka T.** see Miyake K. 213
**Matsuyama K.** see Fukami T. 1257
**Matta K. L.** see Liu X.-G. 1501
**Mattes K. C.** see Wentland M. P. 609

**Matteucci M. D.** see Cao X. 807
**Matteucci M. D.** see Lin K.-Y. 1061
**Matteucci M. D.** see Pudlo J. S. 1025
**May W. P.** see Cohen N. 2883
**Mayo K. H.** see Hoekstra W. J. 1361
**Mazaleyrat J.-P. Rage I. Mouna A. M. Šavrda J. Wakselman M. Boulay R. and Lelièvre Y.**
Peptoid mimics of a $C_2$-symmetric inhibitor of the HIV-1 protease 1281
**Mazaleyrat J.-P. Rage I. Šavrda J. Mouna M. Wakselman M. Boulay R. and Lelièvre Y.**
Synthesis of $C_2$-symmetric inhibitors of the HIV-1 protease, with *N,N'*-substituted ethylenediamide and ethylenediamine linkers 653
**Mazaleyrat J.-P.** see Wakselman M. 2533
**Maziasz T. J.** see Djuric S. W. 811
**McAuliffe M.** see Labelle M. 463
**McCall D. E.** see Olson R. E. 2229
**McCall D. L. C. Alexander J. Barber J. Jaouhari R. G. Satoskar A. and Waigh R. D.**
The first protoberberine alkaloid analogue with *in vivo* antimalarial activity 1663
**McCaully R. J.** see Soll R. M. 769
**McClard R. W. and Witte J. F.**
The phosphonate analog of 5-methylthioribose 1-α-phosphate 1537
**McCombie S. W.** see Shankar B. B. 495
**McCombie S. W.** see Tagat J. R. 1101
**McCombie S. W.** see Vice S. F. 1333
**McDaniel S. L.** see Dorsey B. D. 2769
**McDonald I. A. Nyce P. L. Muench D. M. Gates C. A. Blohm T. R. Laughlin M. E. and Weintraub P. M.**
Inhibition of steroid 5α-reductase by 'inverted', competitive inhibitors 847
**McElroy A. B.** see Cooper A. W. J. 1951
**McElroy E. B. Bandaru R. Huang J. and Widlanski T. S.**
Synthesis and physical properties of sulfonamide-containing oligonucleotides 1071
**McFarland J. W.** see Cooper C. B. 835
**McFarlane C.** see Labelle M. 463
**McGraw D. E.** see Reitz D. B. 105
**McGraw D. E.** see Reitz D. B. 99
**McGuigan C. Pathirana R. N. Davies M. P. H. Balzarini J. and De Clercq E.**
Diaryl phosphate derivatives act as pro-drugs of AZT with reduced cytotoxicity compared to the parent nucleoside 427
**McHugh, Jr R. J.** see Miller W. H. 843
**McInally T.** see Bantick J. R. 121
**McInally T.** see Bantick J. R. 127
**McKee T. C.** see Fuller R. W. 1961
**McKendrick J. E.** see Couper L. 2267
**Mc Kenna J.** see Williams B. J. 1903
**McKillop J. H.** see Garner M. 1357
**McKinnis B. R.** see Reitz D. B. 111
**McKnight A. T.** see Boden P. 1679
**McLaughlin J. L.** see Gu Z. 473
**McLaughlin L. W.** see Limauro S. 2189
**McLaughlin L. W.** see O'Donnell M. J. 1001
**McLean S.** see Desai M. C. 1865
**McLean S.** see Lowe, III J. A. 1153
**McLean S.** see Lowe, III J. A. 2877
**McMahon E. G.** see Huang H.-C. 2591
**McMahon E. G.** see Reitz D. B. 99
**McMahon E. G.** see Reitz D. B. 105
**McMahon J. B.** see Fuller R. W. 1961
**Mederski W. W. K. R.** see Dorsch D. 1297
**Mederski W. W. K. R.** see Osswald M. 683
**Meecham K.** see Boden P. 1679
**Meek T. D.** see Thompson S. K. 2441
**Megati S. Sodum R. Otter G. M. Klein R. S. and Otter B. A.**
Synthesis and *in vitro* cytotoxicity of 6-vinyluridine and related compounds 469
**Meichsner C.** see Peyman A. 1191
**Mele A.** see Bravo P. 1577
**Mellish N.** see Levin J. I. 1709
**Merriman R. L.** see Li C. 1585
**Merritt L.** see Ward J. S. 573
**Mersmann K.** see Grein T. 971
**Metcalf B. W.** see Thompson S. K. 2441
**Metelev V. Lisziewicz J. and Agrawal S.**
Study of antisense oligonucleotide phosphorothioates containing segments of oligodeoxynucleotides and 2'-O-methyloligoribonucleotides 2929
**Mett H.** see Caravatti G. 399
**Metters K. M.** see Labelle M. 463
**Meyer M. D.** see Zelle R. E. 1319
**Meyer T.** see Caravatti G. 399
**Meyers C. A.** see Leftheris K. 887
**Micetich R. G.** see Kamal A. 1513
**Michelson S. R.** see Kim B. M. 2273
**Micura R. and Grubmayr K.**
Long-wavelength absorbing derivatives of phycocyanobilin: new structural aspects on phytochrome 2517
**Middlemiss D.** see Judd D. B. 725
**Middlemiss D.** see Watson S. P. 151
**Mierau J.** see Gmeiner P. 2589
**Mignani S.** see Damour D. 415
**Mignani S.** see Jimonet P. 2735
**Mikerin I. E.** see Shutalev A. D. 761
**Mikkilineni A. B.** see Ueda Y. 1861
**Miles-Williams A. J.** see Hunter D. J. 2833
**Milhavet J.-C.** see Elhakmaoui A. 1937
**Millar K.** see Morphy J. R. 2747
**Millar K.** see Porter J. R. 2741
**Miller A. B.** see Clark R. D. 2477
**Miller A. B.** see Clark R. D. 2481
**Miller K. E. Grace J. M. and Macdonald T. L.**
The stabilization of DNA topoisomerase II cleavable complex by mitonafide analogs 1643
**Miller K. E.** see Lehnert E. K. 2411
**Miller M. J. Braccolino D. S. Cleary D. G. Ream J. E. Walker M. C. and Sikorski J. A.**
EPSP Synthase inhibitor design—IV. New aromatic substrate analogs and symmetrical inhibitors containing novel 3-phosphate mimics 2605
**Miller S. M. Simon R. J. Ng S. Zuckermann R. N. Kerr J. M. and Moos W. H.**
Proteolytic studies of

homologous peptide and N-substituted glycine peptoid oligomers 2657
**Miller T. R. and Hopkins P. B.** Toward the synthesis of a second-generation nitroxide spin probe for DNA dynamics studies 981
**Miller W. H. Pinto D. J. P. McHugh, Jr R. J. Arner E. C. Pratta M. A. and Magolda R. L.** Inhibition of cartilage degradation by isothiazoloquinolinones 843
**Millet J.** see de Montarby L. 261
**Millet J.** see Le Gall T. 247
**Millet J.** see Le Gall T. 253
**Millet J.** see Le Gall T. 257
**Millican A.** see Morphy J. R. 2747
**Millican A.** see Porter J. R. 2741
**Milligan J. F.** see Pudlo J. S. 1025
**Milner P. H.** see Hird N. W. 1423
**Minakawa N.** see Ono A. 361
**Minami N.** see Miyake K. 213
**Minck K.-O.** see Dorsch D. 1297
**Minck K.-O.** see Osswald M. 683
**Misiura K. and Stec W. J.** The synthesis of 5'-*O*-DMT-thymidine 3'-*O*-(2-thio-1,3,2-oxaselenaphospholane) and its possible application in stereocontrolled synthesis of oligo(nucleoside phosphoro-thioate)s 1037
**Misra R. N. Kelly Y. F. Brown B. R. Roberts D. G. M. Chong S. and Seiler S. M.** Argatroban analogs: synthesis, thrombin inhibitory activity and cell permeability of aminoheterocyclic guanidine surrogates 2165
**Misra R. N.** see Das J. 2193
**Misra R. N.** see Robl J. A. 1795
**Mitch C. H. Bymaster F. P. Calligaro D. O. Quimby S. J. Schoepp D. D. Wong D. T. and Shannon H. E.** Muscarinic antagonist activity of 3-(5-alkoxy-oxazol-2-yl)-1,2,5,6-tetrahydropyridines 1721
**Mitch C. H.** see Quimby S. J. 2205
**Mitchell K.** see Chiu F. C. K. 2721
**Mitchell R. C.** see Chadha H. S. 2511
**Mitscher L. A.** see Datta A. 1831
**Mitscher L. A.** see Villalobos A. 2781
**Mitsuya H.** see Wozniak L. A. 1033
**Miyake K. Matsukura M. Yoneda N. Hiroshima O. Mori N. Ishihara H. Musha T. Matsuoka T. Shoji T. Minami N. Hamano S. and Saito I.** Discovery and development of aryl-fused imidazole-based angiotensin II antagonists 213
**Miyashita Y.** see Hasegawa K. 1157
**Mizuno M.** see Yanagisawa H. 177
**Mizushima T.** see Sasaki S. 1771
**Mjalli A. M. M. Chapman K. T. MacCoss M. Thornberry N. A. and Peterson E. P.** Activated ketones as potent reversible inhibitors of interleukin-1β converting enzyme 1965
**Modric N. Poje M. and Gojmerac-Ivšic A.** The structure of a $C_5H_4N_4O_4$ species trapped by silylation in peroxidase mediated uricolysis. A reactive ring-contraction to spirodi-hydantoin 1685
**Mohammed H.** see Abell A. D. 1365
**Moldt P.** see Andersen A. 657
**Mongelli N.** see D'Alessio R. 1467
**Moon S. L.** see Yevich J. P. 1941
**Moore J. B.** see Demers J. P. 2451
**Moore W. R.** see Marquart A. L. 1317
**Moos W. H.** see Miller S. M. 2657
**Moreland S.** see Lloyd J. 195
**Moreland S.** see Poss M. A. 145
**Moreland S.** see Ryono D. E. 201
**Morgan N. Pereira I. A. C. Andersson I. A. Adlington R. M. Baldwin J. E. Cole S. C. J. Crouch N. P. and Sutherland J. D.** Substrate specificity of recombinant *Streptomyces clavuligerus* deacetoxy-cephalosporin C synthase 1595
**Morgans, Jr D. Ramesha C. Romero M. and Talamas F. X.** Improved methodology for the enantiospecific synthesis of polyunsaturated phospholipids 827
**Morgans, Jr D.** see Galeazzi E. 1437
**Mori N.** see Miyake K. 213
**Morin C.** see Hamant S. 1687
**Morphy J. R. Beeley N. R. A. Boyce B. A. Leonard J. Mason B. Millican A. Millar K. O'Connell J. P. and Porter J.** Potent and selective inhibitors of gelatinase-A—II. Carboxylic and phosphonic acid derivatives 2747
**Morphy J. R.** see Porter J. R. 2741
**Morris J. Wishka D. G. Humphrey W. R. Lin A. H. Wiltse A. L. Benjamin C. W. Gorman R. R. and Shebuski R. J.** Synthesis and biological activity of a potent antiplatelet 7-aminofurochromone 2621
**Morris J. F.** see Thompson S. K. 2441
**Morrison R. A.** see Ryono D. E. 201
**Mortellaro M. A. Hong S. Winn D. T. and Czarnik A. W.** Synthesis of β-cyclodextrin oximes 2041
**Mosset P.** see de Montarby L. 261
**Mouna A. M.** see Mazaleyrat J.-P. 1281
**Mouna A. M.** see Wakselman M. 2533
**Mouna M.** see Mazaleyrat J.-P. 653
**Muchowski J.** see Galeazzi E. 1437
**Muench D. M.** see McDonald I. A. 847
**Mularski C. J.** see Wester R. T. 133
**Mullican M. D. Lauffer D. J. Gillespie R. J. Matharu S. S. Kay D. Porritt G. M. Evans P. L. Golec J. M. C. Murcko M. A. Luong Y.-P. Raybuck S. A. and Livingston D. J.** The synthesis and evaluation of peptidyl aspartyl aldehydes as inhibitors of ICE 2359
**Muneaux C.** see Perreaut P. 163
**Muneaux Y.** see Perreaut P. 163
**Munk S. A. Gluchowski C. Dolby L. Wong H. Burke J. Kharlamb A. Manlapaz C. Padillo E. Rodgers D. Ohta B. Wheeler L. and Garst M.** Analogs of UK 14,304 as $\alpha_2$-adrenoceptor agonists. Twist and agent polarity as design elements 459
**Mura A. J.** see Hlasta D. J. 1801
**Murakami N.** see Nagatsu A. 1619
**Murcko M. A.** see Mullican M. D. 2359
**Murofushi N.** see Kim B.-T. 1847
**Murphy W. R.** see Kleinman E. F. 589
**Murphy W. R.** see Wester R. T. 2005

**Murray W. V. Lalan P. Gill A. Lee D. K. H. Falotico R. Lewis J. M. Addo M. F. and Wachter M. P.** Substituted lactam biphenyltetrazoles as angiotensin II mediated antihypertensives 87
**Murugesan N.** see Delaney N. G. 1783
**Murugesan N.** see Robl J. A. 1789
**Musha T.** see Miyake K. 213
**Muzzi M. L.** see Cooper C. B. 835

**Nabata H.** see Ishizawa T. 1995
**Nacci V.** see Campiani G. 1235
**Nachmansohn C.** see Wakselman M. 2533
**Nagase T.** see Fukami T. 1613
**Nagata H.** see Kawakami H. 1461
**Nagatsu A. Watanabe M. Ikemoto K. Hashimoto M. Murakami N. Sakakibara J. Tokuda H. Nishino H. Iwashima A. and Yazawa K.** Synthesis and structure–anti-tumor-promoting activity relationship of monogalactosyl diacylglycerols 1619
**Nagy C.** see LeMahieu R. A. 339
**Naik R. H.** see Randad R. S. 2343
**Naka T.** see Cho N. 35
**Nakahara Y.** see Wang Z.-G. 2805
**Nakajima N.** see Hamada H. 907
**Nakajima S.** see Nakajima T. 2485
**Nakajima T. Kashiwabara T. Izawa T. and Nakajima S.** Structure–activity studies of *N*-cyano-3-pyridinecarboxamidines and their amide and thioamide congeners 2485
**Nakamura K.** see Hamada H. 907
**Nakamura Y.** see Fukami T. 1257
**Nakashima Y.** see Shinozuka K. 1979
**Narayanan V. L.** see Chen H. 2701
**Nash D. J.** see Smith S. A. 1291
**Natarajan S.** see Delaney N. G. 1783
**Natarajan S.** see Leftheris K. 887
**Nath M.** see Ram V. J. 1453
**Nath M.** see Ram V. J. 2653
**Navarro P.** see Fierros M. 2523
**Naya A.** see Fukami T. 1613
**Naylor A. M. Egbertson M. S. Vassallo L. M. Birchenough L. A. Zhang G. X. Gould R. J. and Hartman G. D.** Non-peptide fibrinogen receptor antagonists—IV. Proposed three-dimensional requirements in centrally constrained inhibitors 1841
**Naylor A. M.** see Egbertson M. S. 1835
**Naylor E. M. Chakravarty P. K. Costello C. A. Chang R. S. Chen T.-B. Faust K. A. Lotti V. J. Kivlighn S. D. Zingaro G. J. Siegl P. K. S. Wong P. C. Carini D. J. Wexler R. R. Patchett A. A. and Greenlee W. J.** Potent imidazole angiotensin II antagonists: acyl sulfonamides and acyl sulfamides as tetrazole replacements 69
**Naylor E. M.** see Chang L. L. 115
**Nazareno D. V.** see Tagat J. R. 1101
**Neale J. E.** see Bateson J. H. 1667
**Neff K.-H.** see Harde C. 273
**Neubeck R.** see Delaney N. G. 1783
**Neuner P. J. S.** see Cicero D. O. 861
**Neville D. C. A.** see Field R. A. 391
**Newcomb M.** see Horner J. H. 2693
**Newman-Tarr T.** see Yamashita D. S. 325
**Ng S.** see Miller S. M. 2657
**Nguyen T. T.** see Olson R. E. 2229
**Nic a' Bháird N.** see Kumaravel G. 883
**Nichols P. D.** see Horwell D. C. 2263
**Nicolaou K. C.** see Siuzdak G. 2863
**Nicoll-Griffith D.** see Labelle M. 463
**Nielsen E. Ø.** see Wätjen F. 371
**Nielsen P. E.** see Dueholm K. L. 1077
**Nielsen P. E.** see Lagriffoul P.-H. 1081
**Niiyama K.** see Fukami T. 1613
**Nikitenko A. A.** see Shutalev A. D. 761
**Nikolaev A. V. Rutherford T. J. Ferguson M. A. J. and Brimacombe J. S.** The chemical synthesis of *Leishmania donovani* phosphoglycan fragments 785
**Nikolova N.** see Zakharieva R. D. 2831
**Nilvebrant L.** see Nordvall G. 2837
**Nisato D.** see Bernhart C. A. 157
**Nisato D.** see Ferrari B. 45
**Nisato D.** see Perreaut P. 163
**Nishikawa K.** see Cho N. 35
**Nishimoto S. and Zhou L.** Cellular non-protein thiol depletion and radio-sensitization of hypoxic cells by a novel 2-nitroimidazole derivative possessing an NPSH-reactive side chain 439
**Nishino H.** see Nagatsu A. 1619
**Nishino H.** see Okuno S. 431
**Nishiyama S.** see Hosono F. 2083
**Nishiyama S.** see Ogino Y. 1991
**Nixon J. S.** see Davis P. D. 1303
**Nomizu M.** see Roller P. P. 1879
**Nordhoff E.** see Harde C. 273
**Nordvall G. Sundquist S. Nilvebrant L. and Hacksell U.** 3-Lithioquinuclidin-2-ene: a novel intermediate for the synthesis of muscarinic agonists and antagonists 2837
**Normandin D. E.** see Lloyd J. 195
**Norton M. B.** see Reitz D. B. 105
**Norton N. W.** see Soll R. M. 769
**Novosad E.** see Pratt J. 169
**Novosad E. I.** see Zydowsky T. M. 173
**Nyce P. L.** see McDonald I. A. 847

**Obara T.** see Shuto S. 605
**Obase H.** see Sasho S. 615
**O'Connell J. P.** see Morphy J. R. 2747
**O'Connell J. P.** see Porter J. R. 2741
**O'Connell T.** see Coe J. W. 349
**O'Donnell M. J. Hebert N. and McLaughlin L. W.** The stereospecific introduction of reporter groups to oligodeoxynucleotides by the labeling of individual phosphorus diastereomers 1001
**Ogawa S.** see Uchida C. 2643
**Ogawa T.** see Goto F. 619
**Ogawa T.** see Wang Z.-G. 2805
**Ogawa Y. Yamazaki Y. and Okuno H.** Stereoselectivity in the hydrolysis of synthetic esters by cultured cancer cells and normal tissue extracts of rat 757
**Ogawa Y.** see Yamazaki Y. 483
**Ogino Y. Nishiyama S. Yamamura S. Izawa T. and Kato K.** Synthesis and antiviral activity of alkylphosphonic acid

derivatives of oxetanocin-A 1991
**Ogura T.** see Kubo I. 1443
**Oh E.** see Horner J. H. 2693
**Oh H.-J.** see Holt D. A. 315
**Oh H.-J.** see Yamashita D. S. 325
**Oh Y. and Cushman M.** Synthesis and anti-HIV activity of poly(cysteic acid) 2245
**Oh Y.** see Ojima I. 1749
**Ohfune Y.** see Hashimoto K. 1851
**Ohlstein E.** see Weinstock J. 23
**Ohmi N.** see Kawakami H. 1461
**Ohno M.** see Endo Y. 491
**Ohno M.** see Sugiyama T. 705
**Ohsaki A. Yan L. T. Ito S. Edatsugi H. Iwata D. and Komoda Y.** The isolation and *in vivo* potent antitumor activity of clerodane diterpenoid from the oleoresin of the Brazilian medicinal plant, *Copaifera langsdorfii* Desfon. 2889
**Ohshima T.** see Hasegawa K. 1157
**Ohta B.** see Munk S. A. 459
**Ohta M. Koga H. Sato H. and Ishizawa T.** Comparative molecular field analysis of benzopyran-4-carbothioamide potassium channel openers 2903
**Ohtsuka E.** see Shimizu M. 1029
**Ojima I. Dong Q. Eguchi M. Oh Y. Amann C. M. and Coller B. S.** Structure–activity relationships of double-strand RGD peptides as GPIIb/IIIa receptor antagonists 1749
**Ojima I. Duclos O. Kuduk S. D. Sun C.-M. Slater J. C. Lavelle F. Veith J. M. and Bernacki R. J.** Synthesis and biological activity of 3'-alkyl- and 3'-alkenyl-3'-dephenyldocetaxels 2631
**Ojima I. Fenoglio I. Park Y. H. Pera P. and Bernacki R. J.** Synthesis and biological activity of 14-hydroxydocetaxel 1571
**Ojima M.** see Cho N. 35
**Ok D. Schoen W. R. Hodges P. DeVita R. J. Brown J. E. Cheng K. Chan W. W.-S. Butler B. S. Smith R. G. Fisher M. H. and Wyvratt M. J.** Structure–activity relationships of the non-peptidyl growth hormone secretagogue L-692,429 2709
**Ok D.** see DeVita R. J. 1807
**Ok D.** see Schoen W. R. 1117
**Oka S.** see Yamazaki Y. 483
**Okabe T.** see Hasegawa K. 1157
**Okano T.** see Ono Y. 1523
**Okonogi T.** see Tsutsumi S. 831
**Okuno H.** see Ogawa Y. 757
**Okuno H.** see Yamazaki Y. 483
**Okuno S. Irie K. Suzuki Y. Koshimizu K. Nishino H. and Iwashima A.** Synthesis and biological activities of fluorine-substituted (–)-indolactam-V, the core structure of tumor promoter teleocidins 431
**Oldham A. A.** see Bradbury R. H. 139
**Olesen P. H.** see Quimby S. J. 2205
**Olins G. M.** see Huang H.-C. 2591
**Olins G. M.** see Reitz D. B. 99
**Olins G. M.** see Reitz D. B. 105
**Olins G. M.** see Reitz D. B. 111
**Oliva G.** see Hanessian S. 2763
**Olsen C. E.** see Andersen A. 657
**Olson R. E. Liu J. Lalka G. K. VanAtten M. K. Wexler R. R. Chiu A. T. Nguyen T. T. McCall D. E. Wong P. C. and Timmermans P. B. M. W. M.** Balanced angiotensin II receptor antagonists—II. 4-Aminomethyl- and acylaminomethylimidazoles 2229
**Olson R. E.** see Quan M. L. 2011
**O'Malley S. S.** see Chang L. L. 2787
**Ondeyka D.** see Mantlo N. B. 17
**Ongini E.** see Baraldi P. G. 2539
**Ono A. Haginoya N. Kiyokawa M. Minakawa N. and Matsuda A.** Nucleosides and nucleotides— CXXVII. A novel and convenient post-synthetic modification method for the synthesis of oligodeoxy-ribonucleotides carrying amino linkers at the 5-position of 2'-deoxyuridine 361
**Ono Y. Watanabe H. Kawase A. Kubodera N. Okano T. Tsugawa N. and Kobayashi T.** Synthesis and biological character of 1β-hydroxylated vitamin $D_3$ analogues 1523
**Onoda H.** see Koga H. 1347
**Ontsuka H.** see Tsukuda T. 733
**Opgenorth T.** see Pratt J. 169
**Opgenorth T. J.** see Zydowsky T. M. 173
**Orlek B. S. Cassidy F. Clark M. S. G. Faulkner R. E. Collings E. J. Hawkins J. and Riley G. J.** Design and synthesis of novel muscarinic agonists containing the 1,2,4-triazine ring as an ester bioisostere 1411
**Orlek B. S.** see Bromidge S. M. 557
**Orlek B. S.** see Bromidge S. M. 1185
**Orme M. W. and Labroo V. M.** Synthesis of β-estradiol-3-benzoate-17-(succinyl-12a-tetracycline): a potential bone-seeking estrogen 1375
**Ortiz E.** see Holt D. A. 315
**Oshiro G.** see Soll R. M. 769
**Osswald M. Mederski W. W. K. R. Schwarz M. Beier N. Lues I. and Minck K.-O.** 3-Substituted 6-butyl-1,2-dihydropyridin-2-ones: a new series of potent nonpeptide angiotensin II receptor antagonists 683
**Ostovic D.** see Kim B. M. 2273
**Otaka A.** see Roller P. P. 1879
**Oto E.** see Alvi K. A. 2447
**Otsuka M.** see Sugiyama T. 705
**Otter B. A.** see Megati S. 469
**Otter G. M.** see Megati S. 469
**Ouimet N.** see Labelle M. 463
**Oumoch S. and Rousseau G.** Preparation of optically active 4-allylazetidin-2-ones. An access to carbacephams 2841
**Owens A.** see Swain C. J. 2161
**Owens K.** see Kim D. 207

**Padillo E.** see Munk S. A. 459
**Paessens A.** see Peyman A. 1191
**Pai J.-K.** see Chu M. 1539
**Paillet S.** see Hauske J. R. 2097
**Paju A.** see Lopp M. 1739
**Palkowitz A. D.** see Steinberg M. I. 51
**Palmer R. B.** see Andersen N. H. 817
**Palomo M. A.** see Huang H.-C. 2591
**Palomo M. A.** see Reitz D. B. 99
**Palomo M. A.** see Reitz D. B. 105
**Pan W.** see Randad R. S. 1247
**Panchal T. A.** see Judd D. B. 725
**Panchal T. A.** see Watson S. P. 151
**Pandey R. K. Shiau F.-Y. Sumlin A. B. Dougherty T. J. and Smith K. M.** Syntheses of new

bacteriochlorins and their antitumor activity 1263
**Pannecouque C. Schepers G. Rozenski J. Van Aerschot A. Claes P. and Herdewijn P.**
Mixed oligonucleotide analogues with an acyclic carbohydrate moiety and a *N*-cyanoguanidine functionality 1203
**Papageorgiou C. Borer X. and French R. R.**
Calcineurin has a very tight-binding pocket for the side chain of residue 4 of cyclosporin 267
**Pariza R. J.** see Chorghade M. S. 2867
**Park H.** see Georg G. I. 335
**Park H.** see Georg G. I. 487
**Park H.** see Georg G. I. 1825
**Park H.** see Georg G. I. 2331
**Park H. S. and Suh J.**
A thermostable chymotrypsin derivative soluble in toluene 917
**Park Y. H.** see Ojima I. 1571
**Parmegiani R. M.** see Rane D. F. 1313
**Parmegiani R. M.** see Saksena A. K. 2023
**Parsons W. H.** see Goulet M. T. 921
**Partyka R. A.** see Ueda Y. 1623
**Pass M.** see Judd D. B. 725
**Pass M.** see Watson S. P. 151
**Patchett A. A.** see Chakravarty P. K. 75
**Patchett A. A.** see Chang L. L. 115
**Patchett A. A.** see Naylor E. M. 69
**Patchett A. A.** see Tsutsumi S. 831
**Patchett A. A.** see Walsh T. F. 219
**Patel D. V. Patel M. M. Robinson S. S. and Gordon E. M.**
Phenol based tripeptide inhibitors of ras farnesyl protein transferase 1883
**Patel D. V.** see Bhide R. S. 2107
**Patel M. G.** see Chu M. 1539
**Patel M. L.** see Bradbury R. H. 139
**Patel M. M.** see Bhide R. S. 2107
**Patel M. M.** see Patel D. V. 1883
**Pathirana R. N.** see McGuigan C. 427
**Patil G. S.** see Player M. R. 949
**Patil S. V. Mane R. B. and Salunkhe M. M.**
Syntheses and properties of oligothymidylate analogs containing stereoregulated phosphorothioate and phosphodiester linkages in an alternating manner 2663
**Patnaik G. K.** see Ram V. J. 1453
**Paton J. M. S.** see Judd D. B. 725
**Paton J. M. S.** see Watson S. P. 151
**Patt W. C.** see Steinbaugh B. A. 2029
**Payne D. J.** see Bateson J. H. 1667
**Pearce R. J.** see Bradbury R. H. 139
**Peel M. R. and Sternbach D. D.**
The synthesis and evaluation of flexible analogues of the topoisomerase I inhibitor, camptothecin 2753
**Peet N. P.** see Marquart A. L. 1317
**Pehk T.** see Lopp M. 1739
**Pendri A.** see Greenwald R. B. 2465
**Peng X.** see Aubé J. 2461
**Penick M. A.** see Reitz D. B. 99
**Penick M. A.** see Reitz D. B. 105
**Pera P.** see Ojima I. 1571
**Pereira I. A. C.** see Morgan N. 1595
**Pérez C.** see Suárez-Gea M. L. 1491
**Pérez-Pérez M.-J. Rozenski J. and Herdewijn P.**
Stereospecific synthesis of a pentopyranosyl analogue of d4T monophosphate 1199
**Perni R. B.** see Wentland M. P. 609
**Perreaut P. Clément J. Muneaux C. Muneaux Y. Cazaubon C. Gougat J. Guiraudou P. Lacour C. Nisato D. Le Fur G. and Brelière J.-C.**
Dihydro-imidazolone derivatives as angiotensin II receptor antagonists: chiral effect on the activity 163
**Perreaut P.** see Ferrari B. 45
**Perron-Sierra F.** see Billington D. C. 2307
**Perry M. W. D.** see Birkenshaw T. N. 2501
**Pesenti E.** see D'Alessio R. 1467
**Petersen K. H.** see Dueholm K. L. 1077
**Peterson E. P.** see Mjalli A. M. M. 1965
**Petitou M.** see Basten J. E. M. 893
**Petrich J. W.** see Fehr M. J. 1339
**Petrillo E. W.** see Das J. 2193
**Petrillo E. W.** see Delaney N. G. 1783
**Petrillo E. W.** see Poss M. A. 145
**Petrillo E. W.** see Robl J. A. 1789
**Petrillo E. W.** see Ryono D. E. 201
**Petros A.** see Wang G. T. 1161
**Petteway, Jr S. R.** see Thompson S. K. 2441
**Pettit G. R. Gao F. Schmidt J. M. Chapuis J.-C. and Cerny R. L.**
Isolation and structure of axinastatin 5 from a Republic of Comoros marine sponge 2935
**Pettit G. R. Ichihara Y. Xu J. Boyd M. R. and Williams M. D.**
Isolation and structure of the symmetrical disteroidal alkaloids cephalostatin 12 and cephalostatin 13 1507
**Pettit G. R. Xu J. Cichacz Z. A. Williams M. D. Chapuis J.-C. and Cerny R. L.**
Antineoplastic agents—CCCXXIII. Isolation and structure of phakellistatin 6 from a Chuuk archipelago marine sponge 2677
**Pettit G. R. Xu J. Cichacz Z. A. Williams M. D. Dorsaz A.-C. Brune D. C. Boyd M. R. and Cerny R. L.**
Antineoplastic agents—CCCXV. Isolation and structure of the marine sponge cancer cell growth inhibitor phakellistatin 5 2091
**Peyman A. Stahl W. Wagner K. Ruppert D. and Budt K.-H.**
Non-peptide-based inhibitors of human immunodeficiency virus-1 protease 2601
**Peyman A. Wagner K. Budt K.-H. Spanig J. Ruppert D. Meichsner C. and Paessens A.**
Inhibition of human immunodeficiency virus-1 protease by a $C_2$-symmetrical phosphinic acid amide 1191
**Peyronel J.-F.** see Achard D. 669
**Peyronel J.-F.** see Tabart M. 673
**Pfeifer W.** see Steinberg M. I. 51
**Pfleiderer W. Himmelsbach F. and Charubala R.**
Synthesis of new modified 2',5'-adenylate trimers carrying 3'-amino-3'-deoxyadenosine at the 2'-terminus 1047
**Pfleiderer W.** see Resmini M. 1909
**Pham K.** see Wittman M. D. 2925
**Phillips D. R.** see Chiu F. C. K. 2721
**Phillips J. R.** see Li C. 1585
**Phillips R. M.** see Aitken R. A. 2313

**Picard I.** see Billington D. C. 2307
**Pichon C. Atshaves B. P. Xue T. Stolowich N. J. and Scott A. I.** Studies on Uro'gen III synthase with modified bilanes 1105
**Pichon C.** see Clemens K. R. 521
**Pickett C. B.** see Labelle M. 463
**Piechuta H.** see Labelle M. 463
**Pike R. E.** see Saksena A. K. 2023
**Pinnow S. L.** see Harrington E. M. 2775
**Pinto D. J. P.** see Miller W. H. 843
**Piot O.** see Damour D. 415
**Pirrung M. C. Shuey S. W. Lever D. C. and Fallon L.** A convenient procedure for the deprotection of silylated nucleosides and nucleotides using triethylamine trihydrofluoride 1345
**Pisano J. M.** see DeVita R. J. 2249
**Pisano J. M.** see Schoen W. R. 1117
**Plattner J. J.** see Maring C. J. 1429
**Player M. R. Sowell, Sr J. W. Patil G. S. Kam C.-M. and Powers J. C.** 1,3-Oxazino[4,5-*b*]indole-2,4-(1*H*,9*H*)-diones and 5,6-dimethylpyrrolo[2,3-*d*]-1,3-oxazin-2,4-(1*H*,7*H*)-diones as serine protease inhibitors 949
**Pluscec J.** see Leftheris K. 887
**Pohlenz H.-D.** see Harde C. 273
**Poirier D.** see Auger S. 2045
**Poirier D.** see Sam K. M. 2129
**Poje M.** see Modric N. 1685
**Poncet J.** see Roux F. 1947
**Poralla K.** The possible role of a repetitive amino acid motif in evolution of triterpenoid cyclases 285
**Porritt G. M.** see Mullican M. D. 2359
**Porter J.** see Morphy J. R. 2747
**Porter J. R. Beeley N. R. A. Boyce B. A. Mason B. Millican A. Millar K. Leonard J. Morphy J. R. and O'Connell J. P.** Potent and selective inhibitors of gelatinase-A—I. Hydroxamic acid derivatives 2741
**Posner G. H. White M. C. Dolan P. Kensler T. W. Yukihiro S. and Guggino S. E.** 1α,25-Dihydroxyvitamin $D_3$ hybrid analogs with structural changes at both the A-ring and the C,D-ring side-chain 2919
**Poss M. A. Gu Z. Ryono D. E. Reid J. A. Sieber-McMaster E. Spitzmiller E. R. Dejneka T. Dickinson K. E. J. Williams S. B. Moreland S. Delaney C. L. Bird J. E. Waldron T. L. Schaeffer T. R. Hedberg S. A. and Petrillo E. W.** 1,4-Substituted indoles: a potent and selective class of angiotensin II receptor antagonists 145
**Poss M. A.** see Ryono D. E. 201
**Postula J. F.** see Chae M. Y. 1473
**Pouliot R.** see Chênevert R. 2941
**Poulsen J.-C. J.** see Andersen A. 657
**Powell J. R.** see Ryono D. E. 201
**Powers C.** see Satoh Y. 549
**Powers J. C.** see Player M. R. 949
**Powles R. G.** see Wentland M. P. 609
**Pradhan P. Luthria D. L. and Banerji A.** Pimolin, a new class of natural product from *Pimpinella monoica*: a novel dimeric furochromone 2425
**Prakash T. P. Barawkar D. A. Kumar V. and Ganesh K. N.** Synthesis of site-specific oligonucleotide–polyamine conjugates 1733
**Prasad C. V. C.** see Caulfield T. J. 1497
**Pratt J. Jae H.-S. Rosenberg S. Spina K. Winn M. Buckner S. Novosad E. Kerkman D. Shiosaki K. Opgenorth T. and DeBernardis J.** 5-Membered ring heterocyclic carboxylic acids as angiotensin II antagonists 169
**Pratt R. F.** see Xu Y. 2291
**Pratta M. A.** see Miller W. H. 843
**Press J. B.** see Hoekstra W. J. 1361
**Prestwich G. D.** see Ceruso M. 2179
**Pritchard J. M.** see Cooper A. W. J. 1951
**Pritchard M. C.** see Boden P. 1679
**Procopiou P. A.** see Lester M. G. 2683
**Procopiou P. A.** see Sharratt P. J. 661
**Protzman C. E.** see Burk R. M. 2103
**Prouty C. P.** see Caulfield T. J. 1497
**Prudhomme N.** see Fillion G. 1485
**Pruitt J. R.** see Carini D. J. 63
**Puar M. S.** see Chu M. 1539
**Puar M. S.** see Rane D. F. 1313
**Puar M. S.** see Tagat J. R. 1101
**Pudlo J. S. Wadwani S. Milligan J. F. and Matteucci M. D.** Synthesis of 6-amino-2'-*O*-methylcytidine, a protonated cytidine analog for triple helix binding studies 1025
**Pudlo J. S.** see Lin K.-Y. 1061
**Purcell I. M.** see Kleinman E. F. 589
**Purkayastha S. K. and De A. U.** Possible antineoplastic agents—XIV. Synthesis, activity and QSAR studies of some 1-(substituted benzenesulphonyl)-5-oxopyrrolidine-2-carboxylic acid hydrazides 377

**Qian W.** see Lowe, III J. A. 2877
**Qian Y. Blaskovich M. A. Seong C.-M. Vogt A. Hamilton A. D. and Sebti S. M.** Peptidomimetic inhibitors of p21ras farnesyltransferase: hydrophobic functionalization leads to disruption of p21ras membrane association in whole cells 2579
**Qiao Y.** see Bhagwat S. S. 2673
**Quan M. L. DeLucca I. Boswell G. A. Chiu A. T. Wong P. C. Wexler R. R. and Timmermans P. B. M. W. M.** Imidazolinones as nonpeptide angiotensin II receptor antagonists 1527
**Quan M. L. Olson R. E. Carini D. J. Ellis C. D. Hillyer G. L. Lalka G. K. Liu J. VanAtten M. K. Chiu A. T. Wong P. C. Wexler R. R. and Timmermans P. B. M. W. M.** Balanced angiotensin II receptor antagonists—I. The effects of biphenyl *'ortho'*-substitution on $AT_1/AT_2$ affinities 2011
**Quimby S. J. Shannon H. E. Bymaster F. P. Sauerberg P. Olesen P. H. Sheardown M. J. Suzdak P. D. and Mitch C. H.** Synthesis and structure–activity relationships of alkyl substituted analogues of the functional $M_1$ selective muscarinic receptor agonist xanomeline 2205
**Quimby S. J.** see Mitch C. H. 1721

**Ragan J. A. and Cooper K.** Synthesis of a galactose–fucose disaccharide mimic of sialyl Lewis X 2563
**Rage I.** see Mazaleyrat J.-P. 653
**Rage I.** see Mazaleyrat J.-P. 1281
**Raghavan S.** see Hanessian S. 1697
**Rahman S. K.** see Bermudez J. 2373
**Raifeld Y. E.** see Shutalev A. D. 761
**Rainone S.** see Brown C. L. 1253
**Rake J. B.** see Wentland M. P. 609
**Ram V. J. Goel A. Nath M. and Srivastava P.** 5-Cyano-2-thiouracils and their derivatives: a new class of leishmanicides 2653
**Ram V. J. Goel A. Verma M. Kaul I. B. and Kapil A.** Latent leishmanicidal activity of quinazolinones and 1,2,4-triazoloquinazolinones 2087
**Ram V. J. Haque N. Singh S. K. Nath M. Shoeb A. Tripathi S. C. and Patnaik G. K.** Synthesis of sulphur heterocycles as hepatoprotectants—I 1453
**Ramesha C.** see Morgans, Jr D. 827
**Rampe D.** see Kane J. M. 351
**Ramsay R. R.** see Kumaravel G. 883
**Randad R. S. Naik R. H. Gulnik S. V. Yu B. and Erickson J. W.** Symmetry-based HIV protease inhibitors containing a hydroxy bis-urea isostere 2343
**Randad R. S. Pan W. Gulnik S. V. Burt S. and Erickson J. W.** *De novo* design of nonpeptidic HIV-1 protease inhibitors: incorporation of structural water 1247
**Randle J. C. R.** see Jimonet P. 2735
**Rane D. F. Girijavallabhan V. M. Puar M. S. Saksena A. K. Loebenberg D. and Parmegiani R. M.** The synthesis of 2,2,4-trisubstituted oxetanes as new azole antifungal agents 1313
**Rao T. S.** see Djuric S. W. 811
**Raphy J.** see Boden P. 1679
**Rapundalo S. T.** see Cody W. L. 567
**Rapundalo S. T.** see Steinbaugh B. A. 2029
**Rataud J.** see Jimonet P. 2735
**Ratcliffe A. H.** see Bradbury R. H. 139
**Ratcliffe G.** see Horwell D. C. 2825
**Ratcliffe G. S.** see Boden P. 1679
**Ratcliffe R. W.** see Shankaran K. 1111
**Rauch A. L.** see Carpino P. A. 93
**Rauch A. L.** see Wester R. T. 133
**Raushel F. M.** see Chae M. Y. 1473
**Raushel F. M.** see Hong S. 2705
**Ravi D.** see Chauhan K. 2689
**Ravikumar V. T.** see Andrade M. 2017
**Ravikumar V. T.** see Wyrzykiewicz T. K. 1519
**Raybuck S. A.** see Mullican M. D. 2359
**Rayner B.** see Debart F. 1041
**Ream J. E.** see Miller M. J. 2605
**Reddy G. B.** see Hanessian S. 2285
**Reel J. K.** see Steinberg M. I. 51
**Reglinski J.** see Beck C. 1353
**Reglinski J.** see Garner M. 1357
**Reich M. F. Johnson B. D. Lenhard R. H. and Hanifin J. W.** Derivatives of D-penicillamine as potential antiarthritic agents 1167
**Reichman M.** see Hallinan E. A. 509
**Reid J. A.** see Das J. 2193
**Reid J. A.** see Poss M. A. 145
**Reinhard E. J.** see Reitz D. B. 105
**Reinhard E. J.** see Reitz D. B. 99
**Reitz D. B. Garland D. J. Olins G. M. Markos C. S. Gresk C. J. Litschgi J. W. and McKinnis B. R.** $N^1$-Sterically hindered 2*H*-imidazol-2-one angiotensin II receptor antagonists: the synthesis of [$^3$H]-SC-54628 and [$^3$H]-SC-54629 111
**Reitz D. B. Penick M. A. Norton M. B. Reinhard E. J. Olins G. M. Corpus V. M. Palomo M. A. McGraw D. E. and McMahon E. G.** 1*H*-1,2,4-Triazole angiotensin II receptor antagonists: 'C-linked' analogs of SC-50560 105
**Reitz D. B. Penick M. A. Reinhard E. J. Cheng B. K. Olins G. M. Corpus V. M. Palomo M. A. McGraw D. E. and McMahon E. G.** 1*H*-1,2,4-Triazole angiotensin II receptor antagonists: N-phenylpyridinylmethyl and N-pyridinylphenylmethyl analogs of SC-50560 99
**Remy J. M.** see Schirlin D. 241
**Remy J. M.** see Van Dorsselaer V. 1213
**Rendenbach-Müller B. Schlecker R. Traut M. and Weifenbach H.** Synthesis of coumarins as subtype-selective inhibitors of monoamine oxidase 1195
**Repa J. J.** see Robarge M. J. 2117
**Resmini M. and Pfleiderer W.** Synthesis of an arabinonucleic acid (tANA) 1909
**Revill J.** see Bradbury R. H. 139
**Rew D. J.** see Kuo C. H. 1591
**Reynolds E. E.** see Cody W. L. 567
**Rhamphal J. Y.** see Siuzdak G. 2863
**Ricca C.** see Leftheris K. 887
**Richardson P. L. Gross M. L. Light-Wahl K. J. Smith R. D. and Schepartz A.** A uniquely modified RNA: introduction of a single RNA cleavage agent into the M1 ribozyme 2133
**Richelson E.** see Dodd D. S. 1241
**Richter C.** see Hartley J. A. 2421
**Riley G. J.** see Bromidge S. M. 557
**Riley G. J.** see Bromidge S. M. 1185
**Riley G. J.** see Orlek B. S. 1411
**Ringel I.** see Swindell C. S. 1531
**Rivero R. A. Greenlee W. J. and Chang R. S. L.** Substituted 1,3-benzodioxole and 1,3-benzodithiole -2-carboxylates and their tetrazole analogs with potent binding affinity to the angiotensin II $AT_1$ receptor 747
**Rivero R. A.** see Chang L. L. 2787
**Rivero R. A.** see Kevin N. J. 189
**Rizvi R.** see Shankar B. B. 495
**Robarge M. J. Repa J. J. Hanson K. K. Seth S. Clagett-Dame M. Abou-Issa H. and Curley, Jr R. W.** N-Linked analogs of retinoid O-glucuronides: potential cancer chemopreventive/chemotherapeutic agents 2117
**Roberti M.** see Stoelwinder J. 303
**Roberts D. A.** see Thomas A. P. 2615
**Roberts D. G. M.** see Misra R. N. 2165

**Roberts E.** see Horwell D. C. 525
**Roberts E.** see Horwell D. C. 2263
**Roberts J. C.** see Franklin M. R. 935
**Robichaud A. J.** see Kuo C. H. 1591
**Robins D. J.** see Couper L. 2267
**Robinson S.** see Leftheris K. 887
**Robinson S. P.** see Bhide R. S. 2107
**Robinson S. S.** see Patel D. V. 1883
**Robinson V. J.** see Smith R. A. 2217
**Robl J. A. Simpkins L. M. Stevenson J. Sun C.-Q. Murugesan N. Barrish J. C. Asaad M. M. Bird J. E. Schaeffer T. R. Trippodo N. C. Petrillo E. W. and Karanewsky D. S.**
Dual metalloprotease inhibitors—I. Constrained peptidomimetics of mercaptoacyl dipeptides 1789
**Robl J. A. Simpkins L. M. Sulsky R. Sieber-McMaster E. Stevenson J. Kelly Y. F. Sun C.-Q. Misra R. N. Ryono D. E. Asaad M. M. Bird J. E. Trippodo N. C. and Karanewsky D. S.**
Dual metalloprotease inhibitors—II. Effect of substitution and stereochemistry on benzazepinone based mercaptoacetyls 1795
**Robl J. A. Sun C.-Q. Simpkins L. M. Ryono D. E. Barrish J. C. Karanewsky D. S. Asaad M. M. Schaeffer T. R. and Trippodo N. C.**
Dual metalloprotease inhibitors—III. Utilization of bicyclic and monocyclic diazepinone based mercaptoacetyls 2055
**Robl J. A.** see Das J. 2193
**Robl J. A.** see Delaney N. G. 1783
**Roccon A.** see Bernhart C. A. 157
**Roccon A.** see Ferrari B. 45
**Rochette C.** see Labelle M. 463
**Rock D. M.** see Wätjen F. 371
**Rodger A.** see Adlam G. 2435
**Rodgers D.** see Munk S. A. 459
**Rodríguez-Franco M. I.** see Fierros M. 2523
**Roller P. P. Otaka A. Nomizu M. Smyth M. S. Barchi, Jr J. J. Burke, Jr T. R. Case R. D. Wolf G. and Shoelson S. E.**
Norleucine as a replacement for methionine in phosphatase-resistant linear and cyclic peptides which bind to p85 SH2 domains 1879
**Romeo G. Russo F. Guccione S. Chabin R. Kuo D. and Knight W. B.**
Synthesis of new thiazinoindole derivatives and their evaluation as inhibitors of human leukocyte elastase and other related serine proteases 2399
**Romeo M. R.** see Campiani G. 1235
**Romero M.** see Morgans, Jr D. 827
**Ronan B.** see Hanessian S. 1397
**Rooker D. P.** see Batt A. R. 867
**Rosati R. L.** see Kleinman E. F. 589
**Rose D. A.** see Stafford J. A. 1855
**Rose W. C.** see Chen S.-H. 2223
**Rose W. C.** see Kant J. 1565
**Rose W. C.** see Roth G. P. 711
**Rose W. C.** see Ueda Y. 1861
**Rose W. C.** see Wittman M. D. 2925
**Rosemeyer H.** see Grein T. 971
**Rosen P.** see Hanessian S. 2763
**Rosenberg S.** see Pratt J. 169
**Rosenwirth B.** see Ettmayer P. 2851
**Rosolowsky M.** see Falck J. R. 2113
**Roth B. D.** see Augelli-Szafran C. E. 1095
**Roth G. P. Marshall D. R. Kadow J. F. Mamber S. W. Rose W. C. Solomon W. and Zein N.**
Synthesis and biological activity of modified enediyne chemotypes 711
**Roth G. P.** see Chen S.-H. 2223
**Rousseau G.** see Oumoch S. 2841
**Roux F. Galéotti N. Poncet J. Jouin P. Cros S. and Zenke G.**
Synthesis and *in vitro* cytotoxicity of diastereo-isomerically modified dolastatin 15 analogues 1947
**Rovnyak G. C.** see Delaney N. G. 1783
**Rowe S. J.** see Garratt P. J. 1555
**Rowe S. J.** see Garratt P. J. 1559
**Rozamus L. W.** see Holt D. A. 315
**Rozema M. J.** see Hanessian S. 2279
**Rozenski J.** see Pannecouque C. 1203
**Rozenski J.** see Pérez-Pérez M.-J. 1199
**Ruppert D.** see Peyman A. 1191
**Ruppert D.** see Peyman A. 2601
**Russell M. G. N. Castro J. L. Matassa V. G. Beer M. S. Heald A. Scholey K. Stanton J. A. and Broughton H. B.**
Synthesis and serotonergic activity of benzofuran and dihydrobenzofuran analogues of 5-carboxamidotryptamine 1207
**Russo F.** see Romeo G. 2399
**Rutherford T. J.** see Nikolaev A. V. 785
**Ryan M. J.** see Steinbaugh B. A. 2029
**Ryder H.** see Batt A. R. 867
**Ryono D. E. Lloyd J. Poss M. A. Bird J. E. Buote J. Chong S. Dejneka T. Dickinson K. E. J. Gu Z. Mathers P. Moreland S. Morrison R. A. Petrillo E. W. Powell J. R. Schaeffer T. Spitzmiller E. R. and White R. E.**
Orally active prodrugs of quinoline-4-carboxylic acid angiotensin II receptor antagonists 201
**Ryono D. E.** see Das J. 2193
**Ryono D. E.** see Lloyd J. 195
**Ryono D. E.** see Poss M. A. 145
**Ryono D. E.** see Robl J. A. 1795
**Ryono D. E.** see Robl J. A. 2055
**Ryu E. J.** see Kim B. H. 2799

**Saari W.** see Swain C. J. 2161
**Saavedra P.** see Galeazzi E. 1437
**Sabesan S.**
Synthesis and neuraminidase inhibition studies of 4-azido, amino and acetamido substituted sialosides 2457
**Sada T.** see Yanagisawa H. 177
**Sadowski S.** see Ladduwahetty T. 1917
**Sadowski S.** see Swain C. J. 2161
**Sadowski S.** see Williams B. J. 1903
**Saha A. K.** see Caulfield T. J. 1497
**Saha R.** see Liu X.-G. 1501
**Saha U. K.** see Das S. K. 1219
**Saito I.** see Miyake K. 213
**Saito Y.** see Shuto S. 605
**Saitoh K.** see Yoshimura Y. 721
**Sakakibara J.** see Nagatsu A. 1619
**Sakane Y.** see Bhagwat S. S. 2673

**Sakane Y.** see De Lombaert S. 2715
**Sakata S.** see Yoshimura Y. 721
**Saksena A. K. Girijavallabhan V. M. Lovey R. G. Pike R. E. Desai J. A. Ganguly A. K. Hare R. S. Loebenberg D. Cacciapuoti A. and Parmegiani R. M.** Enantioselective synthesis of the optical isomers of broad-spectrum orally active antifungal azoles, Sch 42538 and Sch 45012 2023
**Saksena A. K.** see Rane D. F. 1313
**Salani G.** see Bravo P. 1577
**Salazar M. A.** see Galeazzi E. 1437
**Salunkhe M. M.** see Patil S. V. 2663
**Salvador R.** see Dulude H. 2697
**Salvador R.** see Gallant G. 2353
**Sam K. M. Boivin R. P. Auger S. and Poirier D.** 16α-Propyl derivatives of estradiol as inhibitors of 17β-hydroxysteroid dehydrogenase type 1 2129
**Sam K. M.** see Auger S. 2045
**Sanchez Y.** see Kubo I. 1443
**Sanghvi Y. S.** see De Mesmaeker A. 395
**Santella, III J. B. Duncia J. V. Ensinger C. L. VanAtten M. K. Carini D. J. Wexler R. R. Chiu A. T. Wong P. C. and Timmermans P. B. M. W. M.** Balanced angiotensin II receptor antagonists—III. The effects of substitution at the imidazole 5-position 2235
**Sareen M.** see Lester M. G. 2683
**Sasaki S. Mizushima T. Hashimoto T. Maeda M. and Sekimizu K.** 3-Acetoxy-2,2'-bi-1*H*-indol as a novel inhibitor of ATP binding to DnaA, the protein initiating chromosomal replication in *Escherichia coli* 1771
**Sasaki S.** see Hasegawa K. 1157
**Sasaki Y. Watanabe Y. Ambo A. and Suzuki K.** Synthesis and biological properties of quaternized N-methylation analogs of D-Arg-2-dermorphin tetrapeptide 2049
**Sasho S. Obase H. Ichikawa S. Yoshizaki R. Ishii A. and Shuto K.** Synthesis and *in vitro* gastrointestinal motility enhancing activity of 3-aryl-2-imidazolidinylidene propanedinitrile derivatives 615
**Sato H.** see Ishizawa T. 1995
**Sato H.** see Ohta M. 2903
**Sato H.** see Taka N. 2893
**Sato H.** see Takahashi T. 2899
**Sato T.** see Ishizawa T. 1995
**Sato T.** see Koga H. 1347
**Sato T.** see Koga H. 1649
**Satoh K.** see Inoue A. 2303
**Satoh Y. Libby A. H. Powers C. Kowalski T. J. White D. H. and Kimble E. F.** Benzoxepin and benzothiepin derivatives as potent, orally active inhibitors of 5-lipoxygenase 549
**Satoskar A.** see McCall D. L. C. 1663
**Sauerberg P.** see Quimby S. J. 2205
**Saulnier M. G. Frennesson D. B. Deshpande M. S. Hansel S. B. and Vyas D. M.** An efficient method for the synthesis of guanidino prodrugs 1985
**Saulnier M. G. Langley D. R. Kadow J. F. Senter P. D. Knipe J. O. Tun M. M. Vyas D. M. and Doyle T. W.** Synthesis of etoposide phosphate, BMY-40481: a water-soluble clinically active prodrug of etoposide 2567
**Saussy, Jr D. L.** see Sawyer J. S. 2077
**Saussy, Jr D. L.** see Wikel J. H. 795
**Savage M. A.** see Hallinan E. A. 509
**Šavrda J.** see Mazaleyrat J.-P. 1281
**Šavrda J.** see Mazaleyrat J.-P. 653
**Sawai H.** see Shinozuka K. 1979
**Sawyer J. S. Schmittling E. A. Bach N. J. Baker S. R. Froelich L. L. Saussy, Jr D. L. Marder P. and Jackson W. T.** Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene $B_4$ receptor antagonist: spatial positioning of the secondary acid group 2077
**Sawyer N.** see Labelle M. 463
**Scatturin A.** see Cavicchioni G. 1551
**Schaeffer T.** see Ryono D. E. 201
**Schaeffer T. R.** see Poss M. A. 145
**Schaeffer T. R.** see Robl J. A. 1789
**Schaeffer T. R.** see Robl J. A. 2055
**Schaffer L. W.** see Chang L. L. 115
**Schatzman G. L.** see Marquart A. L. 1317
**Scheck S.** see Kim D. 207
**Schelling P.** see Dorsch D. 1297
**Schepartz A.** see Richardson P. L. 2133
**Schepers G.** see Pannecouque C. 1203
**Schinazi R. F.** see Jung M. 931
**Schirlin D. Van Dorsselaer V. Tarnus C. Taylor D. L. Tyms A. S. Baltzer S. Weber F. Remy J. M. Brennan T. Farr R. and Janowick D.** Beneficial replacement of the $P_1$ phenylalanine side chain in HIV-1 protease inhibitors of the difluorostatone type 241
**Schirlin D.** see Van Dorsselaer V. 1213
**Schlecker R.** see Rendenbach-Müller B. 1195
**Schleif W.** see Kim B. M. 2273
**Schleif W. A.** see Dorsey B. D. 2769
**Schmidlin T.** see Bühlmayer P. 29
**Schmidt D.** see Bannwarth W. 977
**Schmidt J. M.** see Pettit G. R. 2935
**Schmidt R. R.** see Dietrich H. 599
**Schmidt W. K.** see Christos T. E. 2347
**Schmit C. Bévierre M.-O. De Mesmaeker A. and Altmann K.-H.** The effects of 2'- and 3'-alkyl substituents on oligonucleotide hybridization and stability 1969
**Schmittling E. A.** see Sawyer J. S. 2077
**Schoen W. R. Ok D. DeVita R. J. Pisano J. M. Hodges P. Cheng K. Chan W. W.-S. Butler B. S. Smith R. G. Wyvratt M. J. and Fisher M. H.** Structure–activity relationships in the amino acid sidechain of L-692,429 1117
**Schoen W. R.** see DeVita R. J. 1807
**Schoen W. R.** see DeVita R. J. 2249
**Schoen W. R.** see Ok D. 2709
**Schoenen F. J.** see Stafford J. A. 1855
**Schoepp D. D.** see Mitch C. H. 1721
**Scholey K.** see Russell M. G. N. 1207
**Schorn T. S.** see Glinka T. W. 81
**Schorn T. S.** see Glinka T. W. 2337
**Schorn T. W.** see Chakravarty P. K. 75

**Schorn T. W.** see Chang L. L. 115
**Schow S. R.** see Babine R. E. 583
**Schreiber S. L.** see Chen J. K. 1755
**Schreiber S. L.** see Elbaum D. 309
**Schunack W.** see Stark H. 2907
**Schwartz J.-C.** see Stark H. 2907
**Schwarz M.** see Osswald M. 683
**Scott A. I.** see Clemens K. R. 521
**Scott A. I.** see Gonzalez M. D. 743
**Scott A. I.** see Pichon C. 1105
**Scott P. J.** see Lowe, III J. A. 2877
**Scozzari A.** see Andrade M. 2017
**Sebti S. M.** see Qian Y. 2579
**Seela F.** see Grein T. 971
**Seiler S. M.** see Misra R. N. 2165
**Seizinger B. R.** see Leftheris K. 887
**Sekimizu K.** see Sasaki S. 1771
**Semizarov D. G.** see Shutalev A. D. 761
**Semmelhack M. F.** see Babine R. E. 583
**Semple G.** see Batt A. R. 867
**Senter P. D.** see Saulnier M. G. 2567
**Seong C.-M.** see Qian Y. 2579
**Sepulchre C.** see de Montarby L. 261
**Sepulchre C.** see Le Gall T. 247
**Sepulchre C.** see Le Gall T. 253
**Sepulchre C.** see Le Gall T. 257
**Sergheraert C.** see Fauchet V. 2559
**Sergheraert C.** see He M. 2845
**Serkiz B.** see Cordi A. A. 1957
**Seth S.** see Robarge M. J. 2117
**Shabarova Z. A.** see Dolinnaya N. 1011
**Shankar B. B. Viet A. Q. Rizvi R. Kirkup M. P. McCombie S. W. and Ganguly A. K.** Indolocarbazoles—III. Synthesis of novel aza analogs of staurosporine and K 252a as PKC inhibitors 495
**Shankaran K. Wilkening R. R. Blizzard T. A. Ratcliffe R. W. Heck J. V. Graham A. C. and Herbert C. M.** Preparation and activities of 4"-*epi* and 4"-deoxy-4"-amino analogs derived from 9-deoxo-8a-aza-8a-homoerythromycin A 1111
**Shannon H. E.** see Mitch C. H. 1721
**Shannon H. E.** see Quimby S. J. 2205
**Sharma R.** see Lee J. 1369
**Sharma R.** see Marquez V. E. 355
**Sharma S. K.** see Aitken R. A. 2313
**Sharratt P. J. Hutson J. L. Inglis G. G. A. Lester M. G. Procopiou P. A. and Watson N. S.** Structurally simplified squalestatins: monocyclic 1,3-dioxane analogues 661
**Shaw R. E. Burgess C. Cousins R. P. C. Giblin G. M. P. Livermore D. G. H. Shingler A. H. Smith C. and Youds P. M.** Synthesis of novel monocyclic squalestatin analogues as potential inhibitors of squalene synthase 2155
**Sheardown M. J.** see Quimby S. J. 2205
**Shebuski R. J.** see Morris J. 2621
**Shen S.** see Langlois M. 945
**Shen S.** see Langlois M. 1433
**Shepherd T. A. Jungheim L. N. and Baxter A. J.** D-Amino acids as novel $P_2/P_3$ ligands for inhibitors of HIV-1 protease 1391
**Shevlin C. G. Hilton S. and Janda K. D.** Automation of antibody catalysis: a practical methodology for the use of catalytic antibodies in organic synthesis 297
**Shiau F.-Y.** see Pandey R. K. 1263
**Shibahara S.** see Tsutsumi S. 831
**Shibasaki M.** see Sugiyama T. 705
**Shigeta S.** see Awano H. 367
**Shigeta S.** see Shuto S. 605
**Shimazawa R. Shirai R. Hashimoto Y. and Iwasaki S.** DNA-Binding ability of non-diynene class of dynemicins and aza-anthraquinones 2377
**Shimizu K.** see Shinozuka K. 1979
**Shimizu M. Koizumi T. Inoue H. and Ohtsuka E.** Effects of 5-methyl substitution in 2'-*O*-methyloligo(pyrimidine)-nucleotides on triple-helix formation 1029
**Shimma N.** see Tsukuda T. 733
**Shimoji Y.** see Yanagisawa H. 177
**Shimura T.** see Yamazaki Y. 483
**Shin J. A. and Hilvert D.** Mechanistic studies of an antibody with chorismate mutase activity 2945
**Shinagawa H.** see Sunagawa M. 2793
**Shingler A. H.** see Shaw R. E. 2155
**Shinozuka K. Shimizu K. Nakashima Y. and Sawai H.** Synthesis and RNA cleaving activities of polyamine derived novel artificial ribonuclease 1979
**Shiosaki K.** see Pratt J. 169
**Shiosaki K.** see Zydowsky T. M. 173
**Shirahama H.** see Hashimoto K. 1851
**Shirai R. Tokuda K. Koiso Y. and Iwasaki S.** Synthesis and anti-tubulin activity of aza-combretastatins 699
**Shirai R.** see Shimazawa R. 2377
**Shisa Y.** see Hamada H. 907
**Shoeb A.** see Ram V. J. 1453
**Shoelson S. E.** see Roller P. P. 1879
**Shoji T.** see Miyake K. 213
**Shudo K.** see Endo Y. 491
**Shue H.-J.** see Blythin D. J. 1327
**Shuey S. W.** see Pirrung M. C. 1345
**Shutalev A. D. Mikerin I. E. Arshava B. M. Nikitenko A. A. Raifeld Y. E. Vid G. Ya. Lee V. J. Gurskaya G. V. Viktorova L. S. Jas'ko M. V. Semizarov D. G. and Zavodnik V. E.** Synthesis and crystal structure of 3'-fluoro-3'-methyl-2',3'-dideoxy-thymidine. Inhibitory properties of 3'-fluoro-3'-methyl-2',3'-dideoxy-thymidine-5'-triphosphate in the synthesis of DNA in cell-free media 761
**Shuto K.** see Sasho S. 615
**Shuto S. Obara T. Kosugi Y. Saito Y. Toriya M. Yaginuma S. Shigeta S. and Matsuda A.** New neplanocin analogues—III. 6'*R*-Configuration is essential for the antiviral activity of 6'-*C*-methyl-3-deazaneplanocin A's 605
**Shuto S.** see Awano H. 367
**Sieber-McMaster E.** see Delaney N. G. 1783
**Sieber-McMaster E.** see Poss M. A. 145
**Sieber-McMaster E.** see Robl J. A. 1795
**Siegl P. K. S.** see Chakravarty P. K. 75
**Siegl P. K. S.** see Chang L. L. 115
**Siegl P. K. S.** see Chang L. L. 2787
**Siegl P. K. S.** see Glinka T. W. 81

**Siegl P. K. S.** see Glinka T. W. 2337
**Siegl P. K. S.** see Kim D. 207
**Siegl P. K. S.** see Mantlo N. B. 17
**Siegl P. K. S.** see Naylor E. M. 69
**Siegl P. K. S.** see Walsh T. F. 219
**Siekierka J. J.** see Goulet M. T. 927
**Sikorski J. A.** see Miller M. J. 2605
**Silverman R. H.** see Xiao W. 2609
**Simko B. A.** see Cohen N. 2883
**Simon R. J.** see Miller S. M. 2657
**Simon R. L.** see Steinberg M. I. 51
**Simoni D.** see Baraldi P. G. 2539
**Simpkins L. M.** see Robl J. A. 1789
**Simpkins L. M.** see Robl J. A. 1795
**Simpkins L. M.** see Robl J. A. 2055
**Singh K.** see De Lombaert S. 899
**Singh S. K.** see Ram V. J. 1453
**Singhal A. K.** see Dupradeau F.-Y. 1813
**Sinha N. D.** see Kremsky J. N. 2171
**Siuda J. F.** see Chen H. 2701
**Siuzdak G. Zheng Z.-L. Rhamphal J. Y. Ichikawa Y. Nicolaou K. C. Gaeta F. C. A. Chatman K. S. and Wong C.-H.** Examination of the sialyl Lewis x–calcium complex by electrospray mass spectrometry 2863
**Skwish S.** see Lloyd J. 195
**Slater J. C.** see Ojima I. 2631
**Smith B. D.** see Steiner S. J. 2417
**Smith C.** see Shaw R. E. 2155
**Smith C. W. Chakrabarti J. K. and Williamson W. R. N.** Five-membered heterocyclic amines as potential anti-rheumatoid arthritis agents 1673
**Smith J. L.** see Davis P. D. 1303
**Smith K. M.** see Pandey R. K. 1263
**Smith M. W.** see Haadsma-Svensson S. R. 689
**Smith P. W. Lai J. Y. Q. Whittington A. R. Cox B. Houston J. G. Stylli C. H. Banks M. N. and Tiller P. R.** Synthesis and biological evaluation of a library containing potentially 1600 amides/esters. A strategy for rapid compound generation and screening 2821
**Smith P. W.** see Cooper A. W. J. 1951
**Smith R. A. Coles P. J. Chen J. J. Robinson V. J. MacDonald I. D. Carrière J. and Krantz A.** Design, synthesis, and activity of conformationally-constrained macrocyclic peptide-based inhibitors of HIV protease 2217
**Smith R. D.** see Richardson P. L. 2133
**Smith R. G.** see DeVita R. J. 1807
**Smith R. G.** see DeVita R. J. 2249
**Smith R. G.** see Ok D. 2709
**Smith R. G.** see Schoen W. R. 1117
**Smith R. W.** see Field R. A. 391
**Smith S. A. Al-Barazanji K. A. Buckingham R. E. Cassidy F. Coldwell M. C. Finney F. J. L. Hadley M. S. Ham P. Lawrence S. A. Nash D. J. Tingley E. J. R. and Watson J. M.** The identification of a novel renin inhibitor of equivalent efficacy following oral or intravenous administration 1291
**Smith S. A.** see Cantello B. C. C. 1181
**Smith W. E.** see Garner M. 1357
**Smyth M. S.** see Roller P. P. 1879
**Sneddon S. F.** see Carpino P. A. 93
**Snider R. M.** see Lowe, III J. A. 839
**Snoeck R.** see Elhakmaoui A. 1937
**Snowden M. A.** see Lester M. G. 2683
**Sochacki M.** see Wozniak L. A. 1033
**Sodum R.** see Megati S. 469
**Soejarto D. D.** see Fuller R. W. 1961
**Sofia M. J.** see Wikel J. H. 795
**Soh C.-H.** see Kim B.-T. 1847
**Soliman V. F.** see De Lombaert S. 899
**Soll R. M. Dollings P. J. McCaully R. J. Argentieri T. M. Lodge N. Oshiro G. Colatsky T. Norton N. W. Zebick D. Havens C. and Halaka N.** N-Sulfonamides of benzopyran-related potassium channel openers: conversion of glyburide insensitive smooth muscle relaxants to potent smooth muscle contractors 769
**Solomon W.** see Roth G. P. 711
**Solomon W.** see Wittman M. D. 2925
**Sonegawa M.** see Ueyama N. 1637
**Sonesson C.** see Haadsma-Svensson S. R. 689
**Song Y. and Kluger R.** Benzylpenicillin methyl phosphate. A penicillin prodrug that inactivates RTEM β-lactamase 1225
**Sorensen B. K.** see Zydowsky T. M. 173
**Soulier J. L.** see Langlois M. 945
**Sowell, Sr J. W.** see Player M. R. 949
**Spangler D.** see Djuric S. W. 811
**Spanig J.** see Peyman A. 1191
**Spencer J.** see Bantick J. R. 121
**Spencer J.** see Bantick J. R. 127
**Sperbeck D. M.** see Stanton J. L. 539
**Spijker N. M.** see Basten J. E. M. 893
**Spina K.** see Pratt J. 169
**Spisani S.** see Cavicchioni G. 1551
**Spitler J.** see Blythin D. J. 1327
**Spitzmiller E. R.** see Lloyd J. 195
**Spitzmiller E. R.** see Poss M. A. 145
**Spitzmiller E. R.** see Ryono D. E. 201
**Spooner S. J.** see Lester M. G. 2683
**Sproat B. S.** see Douglas M. E. 995
**Srikantha A. A. P.** see Lester M. G. 2683
**Srikantha A. R. P.** see Cox B. 1931
**Srivastava P.** see Ram V. J. 2653
**Staeger M. A.** see Kane J. M. 351
**Stafford J. A. Feldman P. L. Marron B. E. Schoenen F. J. Valvano N. L. Unwalla R. J. Domanico P. L. Brawley E. S. Leesnitzer M. A. Rose D. A. and Dougherty R. W.** Structure–activity relationships involving the catechol subunit of rolipram 1855
**Stahl W. Kuhlmann L. Wiesner M. and Walch A.** $^{99m}$Technetium labelling of antibodies using methylphosphonylated, bifunctional cyclams as chelators 2597
**Stahl W.** see Peyman A. 2601
**Stamford L. J.** see De Lombaert S. 2715
**Stanfield R. L.** see Augelli-Szafran C. E. 1095
**Stanton J. L. Ksander G. M. de Jesus R. and Sperbeck D. M.**

The effect of heteroatom substitution on a series of phosphonate inhibitors of neutral endopeptidase 24.11 539
**Stanton J. A.** see Russell M. G. N. 1207
**Stapelfeld A.** see Hallinan E. A. 509
**Starbuck K. E.** see Vacca J. P. 499
**Stark H. Krause M. Arrang J.-M. Ligneau X. Schwartz J.-C. and Schunack W.** Unsymmetrically substituted guanidines as potent histamine $H_3$-receptor antagonists 2907
**Staruch M. J.** see Goulet M. T. 921
**Staruch M. J.** see Goulet M. T. 927
**Stec W. J.** see Misiura K. 1037
**Stec W. J.** see Wozniak L. A. 1033
**Stein R. L.** see Goulet J. L. 1221
**Steinbaugh B. A. Hamilton H. W. Patt W. C. Rapundalo S. T. Batley B. L. Lunney E. A. Ryan M. J. and Hicks G. W.** Tetrahydroisoquinoline as a phenylalanine replacement in renin inhibitors 2029
**Steinberg M. I. Palkowitz A. D. Thrasher K. J. Reel J. K. Zimmerman K. M. Whitesitt C. A. Simon R. L. Hauser K. L. Lifer S. L. Pfeifer W. Takeuchi K. Wiest S. A. Vasudevan V. Bemis K. G. Deeter J. B. Barnett C. J. Wilson T. M. Marshall W. S. and Boyd D. B.** Chiral recognition of the angiotensin II ($AT_1$) receptor by a highly potent phenoxyproline octanoamide 51
**Steiner S. J. Bien J. T. and Smith B. D.** Diphenylborinic acid is a strong inhibitor of serine proteases 2417
**Stemp G.** see Bromidge S. M. 1185
**Stemp G.** see Burrell G. 1285
**Sternbach D. D.** see Peel M. R. 2753
**Sternberg E. J.** see Thompson S. K. 2441
**Stevenson J.** see Robl J. A. 1789
**Stevenson J.** see Robl J. A. 1795
**Stocks M. J. Birkinshaw T. N. and Teague S. J.** The contribution to binding of the pyranoside substituents in the excised binding domain of FK-506 1457
**Stocks M. J.** see Birkenshaw T. N. 2501
**Stocks M. J.** see Caffrey M. V. 2507
**Stoelwinder J. Roberti M. Kozikowski A. P. Johnson K. M. and Bergmann J. S.** Differential binding and dopamine uptake activity of cocaine analogues modified at nitrogen 303
**Stokker G. E.** Synthesis of the 3'(*S*)-hydroxy derivative of simvastatin 1767
**Stolowich N. J.** see Pichon C. 1105
**Stoltz R. A.** see Chauhan K. 2689
**Strader C.** see Swain C. J. 2161
**Strader C.** see Williams B. J. 1903
**Stranieri M. T.** see Egbertson M. S. 1835
**Strelitz R. A.** see Chakravarty P. K. 75
**Stroud M. R.** see Dupradeau F.-Y. 1813
**Strulovici B.** see Alvi K. A. 2447
**Stutzmann J.-M.** see Jimonet P. 2735
**Stylli C. H.** see Smith P. W. 2821
**Suárez-Gea M. L. García-López M. T. Pérez C. and Herranz R.** Pseudopeptide inhibitors of aminopeptidases containing the Ψ[CH(CN)NH] surrogate as a transition-state mimic 1491
**Subramanyam C.** see Hlasta D. J. 1801
**Suckling C. J.** see Anderson L. 1415
**Sugden D.** see Garratt P. J. 1555
**Sugden D.** see Garratt P. J. 1559
**Sugiura Y.** see Cho N. 35
**Sugiura Y.** see Sugiyama T. 705
**Sugiyama T. Ohno M. Shibasaki M. Otsuka M. Sugiura Y. Kobayashi S. and Maeda K.** On the mechanism of enzymatic inactivation of bleomycin. The β-aminoalaninamide moiety as an enzyme-dependent molecular switch 705
**Suh J. Kim N. and Cho H. S.** Hydrolysis of bis(*p*-nitrophenyl) phosphate promoted by $Ni^{II}$ complex of pyrazine-2,5-dicarboxylate 1889
**Suh J.** see Park H. S. 917
**Sullivan J. P.** see Lin N.-H. 2389
**Sulsky R.** see Robl J. A. 1795
**Suman-Chauhan N.** see Boden P. 1679
**Sumita Y.** see Sunagawa M. 2793
**Sumlin A. B.** see Pandey R. K. 1263
**Sun C.-M.** see Ojima I. 2631
**Sun C.-Q.** see Das J. 2193
**Sun C.-Q.** see Robl J. A. 1789
**Sun C.-Q.** see Robl J. A. 1795
**Sun C.-Q.** see Robl J. A. 2055
**Sun Q. Gatto B. Yu C. Liu A. Liu L. F. and LaVoie E. J.** Structure activity of topoisomerase I poisons related to Hoechst 33342 2871
**Sunagawa M. Yamaga H. Shinagawa H. Houchigai H. and Sumita Y.** Synthesis and biological properties of a new series of anti-MRSA β-lactams; 2-(thiazol-2'-ylthio)carbapenems 2793
**Sundberg R. J. Bettiol J.-L. Gadamasetti K. G. Marshalla M. and Kelsh L.** A new approach to synthesis of vinblastine analogs. Addition of organozinc reagents to the dihydropyridinium ion generated by fragmentative coupling of catharanthine and vindoline 1999
**Sundquist S.** see Nordvall G. 2837
**Sung M.-L.** see Glaser K. B. 1873
**Sutherland J. D. Wilson E. J. and Wright M. C.** Directed evolution of novel biosynthetic pathways: construction of a randomly mutated gene library in an *Escherichia coli* proline auxotroph and selection for growth on potential proline precursors 2551
**Sutherland J. D.** see Little A. J. 2555
**Sutherland J. D.** see Morgan N. 1595
**Suzdak P. D.** see Bondo Hansen J. 695
**Suzdak P. D.** see Quimby S. J. 2205
**Suzuki J.** see Hitotsuyanagi Y. 1633
**Suzuki K.** see Sasaki Y. 2049
**Suzuki Y.** see Okuno S. 431
**Svensson K.** see Haadsma-Svensson S. R. 689
**Swain C. J. Cascieri M. A. Owens A. Saari W. Sadowski S. Strader C. Teall M. Van Niel M. B. and Williams B. J.** Acyclic $NK_1$ antagonists: replacements for the benzhydryl group 2161

**Swain C. J.** see Harrison T. 2545
**Swain C. J.** see Harrison T. 2733
**Swain C. J.** see Williams B. J. 1903
**Sweeny D.** see Lin N.-H. 2389
**Swindell C. S. Heerding J. M. Krauss N. E. Horwitz S. B. and Ringel I.** Characterization of the taxol structure–activity profile for the locus of the A-ring side chain 1531
**Szelke M.** see Batt A. R. 867
**Szmuszkovicz J.** see Zhao S. 2139

**Tabart M. and Peyronel J.-F.** Synthesis of RPR 100893, prototype of a new series of potent and selective non peptide NK1 antagonists: the triarylperhydroisoindolols 673
**Tafi A.** see Campiani G. 1235
**Tagat J. R. Nazareno D. V. Puar M. S. McCombie S. W. and Ganguly A. K.** Synthesis and anti-herpes activity of some A-ring functionalized dehydroabietane derivatives 1101
**Taillades J.** see Ferrari B. 45
**Taka N. Koga H. Sato H. Ishizawa T. Takahashi T. and Imagawa J.** Vasorelaxant activity of 2-fluoromethylbenzopyran $K^+$ channel openers 2893
**Taka N.** see Ishizawa T. 1995
**Taka N.** see Takahashi T. 2899
**Takahashi T. Koga H. Sato H. Ishizawa T. Taka N. and Imagawa J.** Synthesis and vasorelaxant activity of *N*-imino-2-(benzopyran-4-yl)pyridine $K^+$ channel openers 2899
**Takahashi T.** see Ishizawa T. 1995
**Takahashi T.** see Taka N. 2893
**Takai K.** see Tanaka H. 2857
**Takaku H.** see Tanaka H. 2857
**Takanashi H.** see Koga H. 1347
**Takanashi H.** see Koga H. 1649
**Takano S.** see Kubodera N. 753
**Takasaki M.** see Konoshima T. 1323
**Takeda M.** see Endo Y. 491
**Takeuchi K.** see Steinberg M. I. 51
**Takeya K.** see Hitotsuyanagi Y. 1633
**Talamas F. X.** see Galeazzi E. 1437
**Talamas F. X.** see Morgans, Jr D. 827
**Tam S. W.** see Cain G. A. 329
**Tam S. W.** see Christos T. E. 2347
**Tan J.** see De Lombaert S. 2715
**Tanaka H. Endo T. Hosaka H. Takai K. Yokoyama S. and Takaku H.** Importance of purine–pyrimidine hydroxyl and purine amino groups for hammerhead ribozyme cleavage 2857
**Tang R. Chen K. Cosentino M. and Lee K.-H.** Apigenin-7-O-β-D-gluco-pyranoside, an anti-HIV principle from *Kummerowia striata* 455
**Tanzer L. R.** see Li C. 1585
**Tarnus C.** see Schirlin D. 241
**Tarnus C.** see Van Dorsselaer V. 1213
**Tartar A.** see Fauchet V. 2559
**Tartar A.** see He M. 2845
**Tasker A. S.** see Zydowsky T. M. 173
**Tata J. R.** see Kim D. 207
**Taylor C. P.** see Yuen P. 823
**Taylor D. L.** see Schirlin D. 241
**Taylor D. L.** see Van Dorsselaer V. 1213
**Taylor D. P.** see Yevich J. P. 1941
**Taylor G.** see Wang H.-K. 579
**Taylor S.** see Adlam G. 2435
**Tazumi K.** see Kubodera N. 753
**Teague S. J. Cooper M. E. Donald D. K. and Furber M.** Synthesis and study of a non macrocyclic FK506 derivative 1581
**Teague S. J.** see Birkenshaw T. N. 2501
**Teague S. J.** see Caffrey M. V. 2507
**Teague S. J.** see Stocks M. J. 1457
**Teall M.** see Swain C. J. 2161
**Teall M.** see Williams B. J. 1903
**Teitelbaum P.** see Galeazzi E. 1437
**Temsamani J.** see Habus I. 1065
**Teng K.** see Lee J. 1369
**Teng K.** see Marquez V. E. 355
**Terenius L.** see Hedberg M. H. 2527
**Testa B.** see Gaillard P. 737
**Teulade J.-C.** see Elhakmaoui A. 1937
**Thibault L.** see Levin J. I. 1703
**Thibault L.** see Levin J. I. 1709
**Thomas A. P. Roberts D. A. and Thomason D. A.** The synthesis and biological activity of tetrahydroquinoline angiotensin II antagonists containing a substituted biphenyltetrazole group 2615
**Thomas D. R.** see Blackburn T. P. 279
**Thomas G. J. Bushnell D. J. and Martin J. A.** Carbocyclic analogues of hydroxyethylamine containing inhibitors of HIV proteinase 2759
**Thomas H.** see Grein T. 971
**Thomas S. A.** see Maring C. J. 1429
**Thomas T. K.** see LeMahieu R. A. 339
**Thomason D. A.** see Thomas A. P. 2615
**Thompson M.** see Blackburn T. P. 279
**Thompson S. K. Eppley A. M. Frazee J. S. Darcy M. G. Lum R. T. Tomaszek, Jr T. A. Ivanoff L. A. Morris J. F. Sternberg E. J. Lambert D. M. Fernandez A. V. Petteway, Jr S. R. Meek T. D. Metcalf B. W. and Gleason J. G.** Synthesis and antiviral activity of a novel class of HIV-1 protease inhibitors containing a heterocyclic $P_1'$–$P_2'$ amide bond isostere 2441
**Thornberry N. A.** see Mjalli A. M. M. 1965
**Thrasher K. J.** see Steinberg M. I. 51
**Thurieau C. Félétou M. Canet E. and Fauchère J.-L.** *p*-Guanidinobenzoyl-[Hyp$^3$, Thi$^5$, D-Tic$^7$, Oic$^8$]bradykinin is almost completely devoid of the agonist effect of HOE140 on the endothelium-free femoral artery of sheep 781
**Thurlby P. L.** see Cantello B. C. C. 1181
**Tietje K.** see Zelle R. E. 1319
**Tiller P. R.** see Smith P. W. 2821
**Timmerman H.** see van der Goot H. 1913
**Timmermans P. B. M. W. M.** see Carini D. J. 63
**Timmermans P. B. M. W. M.** see Olson R. E. 2229
**Timmermans P. B. M. W. M.** see Quan M. L. 1527
**Timmermans P. B. M. W. M.** see Quan M. L. 2011
**Timmermans P. B. M. W. M.** see Santella, III J. B. 2235
**Tingley E. J. R.** see Smith S. A. 1291
**Tinker A. C.** see Bantick J. R. 121
**Tinker A. C.** see Bantick J. R. 127
**Tokuda H.** see Nagatsu A. 1619
**Tokuda K.** see Shirai R. 699
**Tolson D. A.** see Bateson J. H. 1667
**Tomaszek, Jr T. A.** see Thompson S. K. 2441
**Tomiyama T.** see Ueyama N. 1637

**Toriya M.** see Shuto S. 605
**Torrence P. F.** see Xiao W. 2609
**Tosquellas G.** see Debart F. 1041
**Toth K.** see Cohen N. 2883
**Toyokuni T.** see Dupradeau F.-Y. 1813
**Tran J.** see Glinka T. W. 1479
**Traut M.** see Rendenbach-Müller B. 1195
**Tregear G. W.** see Haralambidis J. 1005
**Treiman M.** see Andersen A. 657
**Trimcev I.** see Hamant S. 1687
**Trinks U.** see Caravatti G. 399
**Tripathi S. C.** see Ram V. J. 1453
**Trippodo N. C.** see Das J. 2193
**Trippodo N. C.** see Robl J. A. 1789
**Trippodo N. C.** see Robl J. A. 1795
**Trippodo N. C.** see Robl J. A. 2055
**Trova M. P. Wissner A. Casscles, Jr W. T. and Hsu G. C.**
Asymmetric synthesis of *cis*- and *trans*-γ-lactones useful in HIV-1 protease inhibitor synthesis 903
**Truchon A.** see Achard D. 669
**Truumees I.** see Chu M. 1539
**Tsai B.-S.** see Djuric S. W. 811
**Tsai C.-F.** see Chen S.-T. 625
**Tschopp T. B.** see Wessel H. P. 1419
**Tsubouchi H.** see Ishikawa H. 1147
**Tsugawa N.** see Ono Y. 1523
**Tsuji K. and Ishikawa H.**
Synthesis and anti-pseudomonal activity of new 2-isocephems with a dihydroxypyridone moiety at C-7 1601
**Tsukuda T. Watanabe M. Ontsuka H. Fujimoto Y. and Shimma N.**
Synthesis of cyclohexyl analogs of restricticin 733
**Tsutsumi S. Okonogi T. Shibahara S. Patchett A. A. and Christensen B. G.**
α-Ketothiazole inhibitors of prolyl endopeptidase 831
**Tsuzuki K.** see Koga H. 1347
**Tsuzuki K.** see Koga H. 1649
**Tun M. M.** see Saulnier M. G. 2567
**Tyms A. S.** see Schirlin D. 241
**Tyms A. S.** see Van Dorsselaer V. 1213

**Uchida C. Kimura H. and Ogawa S.**
Potent glycosidase inhibitors, *N*-phenyl cyclic isourea derivatives of 5-amino- and 5-amino-1-*C*-(hydroxymethyl)-cyclopentane-1,2,3,4-tetraols 2643
**Ueda Y. Chuang J. M. Fung-Tomc J. and Partyka R. A.**
Synthesis and *in vitro* antibacterial activity of new semi-synthetic noviosylcoumarin antibiotics: chemical modification at the C-3' ester 1623
**Ueda Y. Wong H. Matiskella J. D. Mikkilineni A. B. Farina V. Fairchild C. Rose W. C. Mamber S. W. Long B. H. Kerns E. H. Casazza A. M. and Vyas D. M.**
Synthesis and antitumor evaluation of 2'-oxycarbonylpaclitaxels (paclitaxel-2'-carbonates) 1861
**Ueyama N. Yanagisawa T. Baba H. Kuroiwa K. Hayashi H. Sonegawa M. and Tomiyama T.**
Cycloheptimidazole based angiotensin II receptor antagonists. 4,5,6,7-Tetrahydro-8-carboxymethylidene cycloheptimidazoles 1637
**Uhrin A.** see Ho M. 553
**Ulysse L. and Chmielewski J.**
The synthesis of a light-switchable amino acid for inclusion into conformationally mobile peptides 2145
**Unwalla R. J.** see Stafford J. A. 1855
**Upson D. A.** see Caulfield T. J. 1497
**Upton N.** see Blackburn T. P. 279
**Urdea M. S.** see Dolinnaya N. 1011
**Uriel C.** see Herscovici J. 421
**Uriel J.** see Herscovici J. 421
**Usman N.** see Beigelman L. 1715

**Vacca J. P. Fitzgerald P. M. D. Holloway M. K. Hungate R. W. Starbuck K. E. Chen L. J. Darke P. L. Anderson P. S. and Huff J. R.**
Conformationally constrained HIV-1 protease inhibitors 499
**Vacca J. P.** see Dorsey B. D. 2769
**Vacca J. P.** see Kim B. M. 2199
**Vacca J. P.** see Kim B. M. 2273
**Vacek E. P.** see Bernstein P. R. 2175
**Valvano N. L.** see Stafford J. A. 1855
**Van Aerschot A.** see Pannecouque C. 1203
**VanAtten M. K.** see Olson R. E. 2229
**VanAtten M. K.** see Quan M. L. 2011
**VanAtten M. K.** see Santella, III J. B. 2235
**van Boeckel C. A. A.** see Basten J. E. M. 893
**van der Goot H. Eriks J. Ch. Leurs R. and Timmerman H.**
Amselamine, a new selective histamine $H_2$-receptor agonist 1913
**van der Mey M. and de Vroom E.**
Substrate specificity of immobilized penicillin-G acylase 345
**Van Dorsselaer V.** see Schirlin D. 241
**Van Dorsselaer V. Schirlin D. Tarnus C. Taylor D. L. Tyms A. S. Weber F. Baltzer S. Remy J. M. Brennan T. and Janowick D.**
Increased antiviral activity of HIV protease inhibitors of the difluorostatone type bearing (*R*)-valinol derivatives as novel C-termini 1213
**Van Niel M. B.** see Swain C. J. 2161
**Vartanian M. G.** see Yuen P. 823
**Vassallo L. M.** see Egbertson M. S. 1835
**Vassallo L. M.** see Naylor A. M. 1841
**Vastag K.** see Kim B. M. 2273
**Vasudevan V.** see Steinberg M. I. 51
**Vaysse P. J.-J.** see Wong W. C. 2317
**Veale C. A.** see Bernstein P. R. 2175
**Veith J. M.** see Ojima I. 2631
**Venkatesan A. M. Levin J. I. Baker J. S. Chan P. S. Bailey T. and Coupet J.**
Substituted 4*H*-pyrido[1,2-*a*]pyrimidin-4-one angiotensin II receptor antagonists 183
**Venkatesan A. M.** see Levin J. I. 1135
**Venkatesan A. M.** see Levin J. I. 1141
**Venkatesan A. M.** see Levin J. I. 1703
**Venkatesan A. M.** see Levin J. I. 1709
**Venkatesan A. M.** see Levin J. I. 1819
**Venugopalan B. Bapat C. P. and Karnik P. J.**
Synthesis of a novel ring contracted artemisinin derivative 751
**Verma M.** see Ram V. J. 2087
**Vertuani G.** see Cavicchioni G. 1551
**Vesey D. R.** see Davis P. D. 1303
**Viani F.** see Bravo P. 1577
**Vice G.** see Levin J. I. 1135
**Vice G.** see Levin J. I. 1703
**Vice G.** see Levin J. I. 1709

**Vice G.** see Levin J. I. 1819
**Vice S. F. Bishop W. R. McCombie S. W. Dao H. Frank E. and Ganguly A. K.** Indolocarbazole nitrogens linked by three-atom bridges: a potent new class of PKC inhibitors 1333
**Vickers T. A.** see Manoharan M. 1053
**Vid G. Ya.** see Shutalev A. D. 761
**Vidal M.** see Hamant S. 1687
**Viet A. Q.** see Shankar B. B. 495
**Viktorova L. S.** see Shutalev A. D. 761
**Villalobos A. Borcherding S. M. Mitscher L. A. Colborn D. and Flippi J. A.** Total synthesis of a novel benz[*a*]anthracycline analog of the antitumor agent 4-demethoxydaunorubicin 2781
**Villani-Price D.** see Djuric S. W. 811
**Villette T.** see Denis A. 1925
**Vlattas I. Dellureficio J. Cohen D. S. Lee W. Clarke F. Dotson R. Mathis J. and Zoganas H.** Thia-prostanoid analogs with combined thromboxane receptor antagonist/ thromboxane synthase inhibitor activities. Synthesis and pharmacological evaluation 2067
**Vlattas I. Dellureficio J. Cohen D. S. Lee W. Clarke F. Dotson R. Mathis J. and Zoganas H.** Oxa-prostanoid analogs. Identification of an orally effective, dual thromboxane receptor antagonist/ thromboxane synthase inhibitor 2073
**Vogt A.** see Qian Y. 2579
**Vonhoff S.** see Garratt P. J. 1559
**VonVoigtlander P. F.** see Zhao S. 2139
**Vyas D.** see Chen S.-H. 479
**Vyas D. M.** see Chen S.-H. 2223
**Vyas D. M.** see Kant J. 1565
**Vyas D. M.** see Saulnier M. G. 1985
**Vyas D. M.** see Saulnier M. G. 2567
**Vyas D. M.** see Ueda Y. 1861
**Vyas D. M.** see Wittman M. D. 2925

**Wachter M. P.** see Murray W. V. 87
**Wadwani S.** see Pudlo J. S. 1025
**Wagner K.** see Peyman A. 1191
**Wagner K.** see Peyman A. 2601
**Wai J. M.** see Kim B. M. 2199
**Waigh R. D.** see McCall D. L. C. 1663
**Wakselman M. Mouna A. M. Xie J. Mazaleyrat J.-P. Boulay R. Lelièvre Y. Bousseau A. Nachmansohn C. and Hénin Y.** Anti-HIV activity of *N*-(2,3-dihalogenopropyl)- and *N*-allyl-glycine containing pentapeptides 2533
**Wakselman M.** see Mazaleyrat J.-P. 653
**Wakselman M.** see Mazaleyrat J.-P. 1281
**Walch A.** see Stahl W. 2597
**Walcott S. M.** see Bednarski K. 2667
**Waldner A. De Mesmaeker A. and Lebreton J.** Synthesis of oligodeoxy-ribonucleotides containing dimers with carbamate moieties as replacement of the natural phosphodiester linkage 405
**Waldner A.** see De Mesmaeker A. 395
**Waldner A.** see De Mesmaeker A. 873
**Waldron T.** see Delaney N. G. 1783
**Waldron T. L.** see Lloyd J. 195
**Waldron T. L.** see Poss M. A. 145
**Walker G.** see Bateson J. H. 1667
**Walker M. C.** see Miller M. J. 2605
**Walsh R. E.** see Djuric S. W. 811
**Walsh T. F. Fitch K. J. MacCoss M. Chang R. S. L. Kivlighn S. D. Lotti V. J. Siegl P. K. S. Patchett A. A. and Greenlee W. J.** Synthesis of new imidazo[1,2-*b*]pyridazine isosteres of potent imidazo[4,5-*b*]pyridine angiotensin II antagonists 219
**Wang D.** see Wong W. C. 2317
**Wang G. T. Lane B. Fesik S. W. Petros A. Luly J. and Krafft G. A.** Synthesis and FKBP binding of small molecule mimics of the tricarbonyl region of FK506 1161
**Wang H.-K. Liu S.-Y. Hwang K.-M. Taylor G. and Lee K.-H.** Novel water-soluble 7-(acylhydrazono)-formyl camptothecins as potent inhibitors of DNA topoisomerase I 579
**Wang K.-T.** see Chen S.-T. 443
**Wang K.-T.** see Chen S.-T. 625
**Wang K.-T.** see Chen S.-T. 789
**Wang K.-T.** see Chen S.-T. 2123
**Wang K.-T.** see Hsiao K.-F. 1629
**Wang S.** see Marquez V. E. 355
**Wang W.** see Bednarski K. 2667
**Wang Z.-G. Ito Y. Nakahara Y. and Ogawa T.** Experiments directed toward stereocontrolled synthesis of O-linked glycan which contains repeating lactosamine unit 2805
**Ward J. S. Merritt L. Bymaster F. P. and Calligaro D. O.** Isoarecolones and arecolones: selective central nicotinic agonists that cross the blood–brain barrier 573
**Ward P.** see Cooper A. W. J. 1951
**Ward R. W.** see Hunter D. J. 2833
**Wasicak J. T.** see Lin N.-H. 2389
**Watanabe H.** see Kubodera N. 753
**Watanabe H.** see Ono Y. 1523
**Watanabe M.** see Nagatsu A. 1619
**Watanabe M.** see Tsukuda T. 733
**Watanabe Y.** see Sasaki Y. 2049
**Waters N.** see Haadsma-Svensson S. R. 689
**Wätjen F. Bigge C. F. Jensen L. H. Boxer P. A. Lescosky L. J. Nielsen E. Ø. Malone T. C. Campbell G. W. Coughenour L. L. Rock D. M. Drejer J. and Marcoux F. W.** NS 257 (1,2,3,6,7,8-Hexahydro-3(hydroxyimino)-N,N,7-trimethyl-2-oxobenzo[2,1-*b*:3,4-*c*']dipyrrole-5-sulfonamide) is a potent, systemically active AMPA receptor antagonist 371
**Watson J. M.** see Smith S. A. 1291
**Watson N. S.** see Cox B. 1931
**Watson N. S.** see Lester M. G. 2683
**Watson N. S.** see Sharratt P. J. 661
**Watson S. P. Middlemiss D. Pass M. Hubbard T. Panchal T. A. Heron N. M. Paton J. M. S. Butt A. Dean A. W. Donnelly M. and Bayliss M. K.** C-Linked pyrazole biaryl tetrazoles as antagonists of angiotensin II—II. Pharmacokinetics and an efficient regioselective synthesis 151

**Watson S. P.** see Judd D. B. 725
**Weber F.** see Schirlin D. 241
**Weber F.** see Van Dorsselaer V. 1213
**Webster L. K.** see Brown C. L. 1253
**Wei J.-M.** see Chen S.-H. 479
**Wei J.-M.** see Chen S.-H. 2223
**Weidley E. F.** see Weinstock J. 23
**Weifenbach H.** see Rendenbach-Müller B. 1195
**Weinhardt K. K.** see Clark R. D. 2477
**Weinhardt K. K.** see Clark R. D. 2481
**Weinstock J. Hill D. T. Keenan R. M. Franz R. G. Gaitanopoulos D. E. Girard G. R. Eggleston D. S. Aiyar N. Griffin E. Ohlstein E. Brooks D. P. Gellai M. Frederickson T. A. Weidley E. F. and Edwards R. M.**
A potent long-acting imidazole-5-acrylic acid angiotensin II AT-1 receptor antagonist 23
**Weintraub P. M.** see McDonald I. A. 847
**Weis J.** see Bondo Hansen J. 695
**Wentland M. P. Perni R. B. Powles R. G. Hlavac A. G. Mattes K. C. Corbett T. H. Coughlin S. A. and Rake J. B.**
Anti-solid tumor efficacy and preparation of *N*-[[1-[[2-(diethylamino)ethyl]amino]-9-oxo-9*H*-thioxanthen-4-yl]methyl]methanesulfonamide (WIN 33377) and related derivatives 609
**Werbovetz K. A. and Macdonald T. L.**
On the mechanism of arylamine–DNA adduct formation 2323
**Wessel H. P. Tschopp T. B. Hosang M. and Iberg N.**
Identification of a sulfated tetrasaccharide with heparin-like antiproliferative activity 1419
**Wester R. T. Chambers R. J. Green M. D. and Murphy W. R.**
Preparation of a novel series of phosphonate norstatine renin inhibitors 2005
**Wester R. T. Mularski C. J. Magnus-Ayritey G. T. da Silva Jardine P. LaFlamme J. A. Berke H. Bussolotti D. L. Rauch A. L. Hoover K. W. Kennedy C. A. Burkard M. R. Mangiapane M. L. Aldinger C. E. Cooper K. and Carpino P. A.**
Dihydropyridines: a new class of angiotensin II antagonists 133
**Westerduin P.** see Basten J. E. M. 893
**Weston J. B.** see Levett P. C. 505
**Wexler R. R.** see Carini D. J. 63
**Wexler R. R.** see Naylor E. M. 69
**Wexler R. R.** see Olson R. E. 2229
**Wexler R. R.** see Quan M. L. 1527
**Wexler R. R.** see Quan M. L. 2011
**Wexler R. R.** see Santella, III J. B. 2235
**Wheeler L.** see Munk S. A. 459
**White D. H.** see Satoh Y. 549
**White M. C.** see Posner G. H. 2919
**White R. E.** see Ryono D. E. 201
**Whitebread S.** see Bühlmayer P. 29
**Whitesitt C. A.** see Steinberg M. I. 51
**Whiting D. A.** see Levett P. C. 505
**Whittington A. R.** see Smith P. W. 2821
**Wick M. M.** see Babine R. E. 583
**Widlanski T. S.** see McElroy E. B. 1071
**Widomski D. L.** see Djuric S. W. 811
**Wieczorek A. Dinter-Gottlieb G. and Gottlieb P. A.**
Evidence that total substitution of adenine with 7-deazaadenine in the HDV antigenomic ribozyme changes the kinetics of RNA folding 987
**Wiesner M.** see Stahl W. 2597
**Wiest S. A.** see Steinberg M. I. 51
**Wikel J. H. Sofia M. J. Saussy, Jr D. L. and Bemis K. G.**
QSAR Study of *ortho*-phenylphenol leukotriene $B_4$ receptor antagonists 795
**Wikström H.** see Haadsma-Svensson S. R. 689
**Wilkening R. R.** see Shankaran K. 1111
**Wilkinson S. E.** see Davis P. D. 1303
**Will P. C.** see LeMahieu R. A. 339
**Willems H.** see Horwell D. C. 2825
**Williams B. J. Teall M. Mc Kenna J. Harrison T. Swain C. J. Cascieri M. A. Sadowski S. Strader C. and Baker R.**
Acyclic NK-1 antagonists: 2-benzhydryl-2-aminoethyl ethers 1903
**Williams B. J.** see Harrison T. 2545
**Williams B. J.** see Harrison T. 2733
**Williams B. J.** see Swain C. J. 2161
**Williams M. D.** see Pettit G. R. 1507
**Williams M. D.** see Pettit G. R. 2091
**Williams M. D.** see Pettit G. R. 2677
**Williams S. B.** see Poss M. A. 145
**Williamson M. P.** see Blackburn G. M. 2573
**Williamson W. R. N.** see Smith C. W. 1673
**Willis P. A.** see Bantick J. R. 121
**Willis P. A.** see Bantick J. R. 127
**Wilson E. J.** see Little A. J. 2555
**Wilson E. J.** see Sutherland J. D. 2551
**Wilson R.** see Garner M. 1357
**Wilson T. M.** see Steinberg M. I. 51
**Wilson W. D.** see Kumar A. 2913
**Wiltse A. L.** see Morris J. 2621
**Winn D. T.** see Mortellaro M. A. 2041
**Winn M.** see Pratt J. 169
**Winn M.** see Zydowsky T. M. 173
**Wishka D. G.** see Morris J. 2621
**Wissner A.** see Trova M. P. 903
**Withnall W. J.** see Birkenshaw T. N. 2501
**Witte J. F.** see McClard R. W. 1537
**Wittman M. D. Kadow J. F. Pham K. Leung K. Mastalerz H. A. Vyas D. M. Rose W. C. Solomon W. and Zein N.**
The effect of propargylic substitution on the activation and aromatization of enediynes 2925
**Wolf G.** see Roller P. P. 1879
**Wolf R. M.** see Bévierre M.-O. 237
**Wolf R. M.** see De Mesmaeker A. 873
**Wong C.-H.** see Siuzdak G. 2863
**Wong D. T.** see Mitch C. H. 1721
**Wong E. H. F.** see Clark R. D. 2481
**Wong H.** see Munk S. A. 459
**Wong H.** see Ueda Y. 1861
**Wong L. K.** see Chen H. 2701
**Wong P. C.** see Carini D. J. 63
**Wong P. C.** see Naylor E. M. 69
**Wong P. C.** see Olson R. E. 2229

**Wong P. C.** see Quan M. L. 1527
**Wong P. C.** see Quan M. L. 2011
**Wong P. C.** see Santella, III J. B. 2235
**Wong W. C. Wang D. Forray C. Vaysse P. J.-J. Branchek T. A. and Gluchowski C.** A convenient synthesis of 2-amino-2-oxazolines and their pharmacological evaluation at cloned human α adrenergic receptors 2317
**Wood J.** see Bühlmayer P. 29
**Wood-Collins D. A. J.** see Little A. J. 2555
**Woodruff G. N.** see Boden P. 1679
**Woodward D. F.** see Burk R. M. 2103
**Woody H. A.** see Lowe, III J. A. 839
**Wozniak L. A. Sochacki M. Mitsuya H. Kageyama S. and Stec W. J.** A new class of dinucleotide analogues. The synthesis of 3'-*O*-thymidyiyl(5'-deoxy-5'-selene-thymidylyl)-Se-phosphoroselenolate, its *O*-methyl ester and methanephosphonate derivatives 1033
**Wrasidlo W. Johnson D. S. and Boger D. L.** Induction of endonucleolytic DNA fragmentation and apoptosis by the duocarmycins 631
**Wright M. C.** see Sutherland J. D. 2551
**Wu C. Brechbiel M. W. Kozak R. W. and Gansow O. A.** Metal–chelate–dendrimer–antibody constructs for use in radioimmunotherapy and imaging 449
**Wu C.-Y.** see Chen S.-T. 2123
**Wu P.-L.** see Wu T.-S. 2395
**Wu S.-H.** see Hsiao K.-F. 1629
**Wu T.-S. Huang S.-C. Wu P.-L. and Lee K.-H.** Structure and synthesis of clausenaquinone-A. A novel carbazolequinone alkaloid and bioactive principle from *Clausena excavata* 2395
**Wurziger H.** see Jonas R. 2585
**Wyatt M. D. Garbiras B. J. Lee M. Forrow S. M. and Hartley J. A.** Synthesis and DNA binding properties of a series of N to C linked and imidazole containing analogues of distamycin 801
**Wyatt M. D.** see Hartley J. A. 2421
**Wyman P. A.** see Gaster L. M. 667
**Wyrzykiewicz T. K. and Ravikumar V. T.** Efficiency of sulfurization in the synthesis of oligodeoxy-ribonucleotide phosphoro-thioates utilizing various sulfurizing reagents 1519
**Wyvratt M. J.** see Goulet M. T. 921
**Wyvratt M. J.** see Goulet M. T. 927
**Wyvratt M. J.** see Ok D. 2709
**Wyvratt M. J.** see Schoen W. R. 1117
**Wyvratt, Jr M. J.** see DeVita R. J. 1807
**Wyvratt, Jr M. J.** see DeVita R. J. 2249

**Xiang Y. B.** see Labelle M. 463
**Xiao W. Li G. Lesiak K. Dong B. Silverman R. H. and Torrence P. F.** Synthesis of a 5'-thiophosphate analogue of 2-5A, a phosphatase resistant activator of the 2-5A-dependent ribonuclease 2609
**Xie J.** see Wakselman M. 2533
**Xu J.** see Pettit G. R. 1507
**Xu J.** see Pettit G. R. 2091
**Xu J.** see Pettit G. R. 2677
**Xu Y. and Pratt R. F.** β-Lactam-recognizing enzymes exhibit different structural specificity in acyclic amide and ester substrates: a starting point in β-lactamase evolution? 2291
**Xu Z.** see Babine R. E. 583
**Xue T.** see Pichon C. 1105

**Yagaloff K. A.** see Cohen N. 2883
**Yaginuma S.** see Shuto S. 605
**Yamaga H.** see Sunagawa M. 2793
**Yamamoto D.** see Galeazzi E. 1437
**Yamamoto O.** see Hashimoto K. 1851
**Yamamura S.** see Hosono F. 2083
**Yamamura S.** see Ogino Y. 1991
**Yamashita D. S. Oh H.-J. Yen H.-K. Bossard M. J. Brandt M. Levy M. A. Newman-Tarr T. Badger A. Luengo J. I. and Holt D. A.** Design, synthesis and evaluation of dual domain FKBP ligands 325
**Yamashita D. S.** see Abell A. D. 1365
**Yamazaki Y. Goto M. Kobayashi K. Ogawa Y. Shimura T. Oka S. and Okuno H.** Antiproliferative activity of haloosmocenium ions against human and murine cancer cell lines 483
**Yamazaki Y.** see Ogawa Y. 757
**Yan L. T.** see Ohsaki A. 2889
**Yanagisawa H. Amemiya Y. Kanazaki T. Fujimoto K. Shimoji Y. Fujimoto Y. Sada T. Mizuno M. and Koike H.** Angiotensin II receptor antagonists: imidazoles and pyrroles bearing hydroxymethyl and carboxy substituents 177
**Yanagisawa T.** see Ueyama N. 1637
**Yang D.** see Langlois M. 1433
**Yang M.-T.** see Chen S.-T. 2123
**Yano M.** see Fukami T. 1257
**Yasuda I.** see Konoshima T. 1323
**Yasuma T.** see Cho N. 35
**Yasumura K.** see Ishikawa H. 1147
**Yazawa K.** see Nagatsu A. 1619
**Yen H.-K.** see Abell A. D. 1365
**Yen H.-K.** see Holt D. A. 315
**Yen H.-K.** see Yamashita D. S. 325
**Yergey J.** see Labelle M. 463
**Yeung C. M.** see Maring C. J. 1429
**Yevich J. P. Dextraze P. Taylor D. P. and Moon S. L.** Synthesis and evaluation of N-substituted 1-(5-fluoro-2-pyrimidinyl)piperazine derivatives as potential anti-ischemic agents 1941
**Yokoyama S.** see Tanaka H. 2857
**Yon-Hin P.** see Clemens K. R. 521
**Yoneda N.** see Miyake K. 213
**Yoshida S.** see Kim B.-T. 1847
**Yoshimura Y. Saitoh K. Ashida N. Sakata S. and Matsuda A.** Synthesis of 1-(2-deoxy-2-*C*-fluoromethyl-β-D-arabinofuranosyl)cytosine as a potential antineoplastic agent 721
**Yoshizaki R.** see Sasho S. 615
**Youds P. M.** see Shaw R. E. 2155
**Young J.** see Galeazzi E. 1437
**Young R. N.** see Labelle M. 463
**Young T. J.** see Gaster L. M. 667
**Yu B.** see Randad R. S. 2343
**Yu C.** see Sun Q. 2871
**Yu D.** see Iyer R. P. 2471
**Yu L. and Dennis E. A.** Additions and Corrections 641
**Yu S. S.** see Djuric S. W. 811
**Yuen L.** see Bednarski K. 2667
**Yuen P. Kanter G. D. Taylor C. P. and Vartanian M. G.**

Enantioselective synthesis of PD144723: a potent stereospecific anti-convulsant 823
**Yukihiro S.** see Posner G. H. 2919

**Zakharieva R. D. Galabov A. S. and Nikolova N.** Synthesis and antiviral activity of amino acid esters of ribavirin 2831
**Zamboni R. J.** see Labelle M. 463
**Zappaterra L.** see Baraldi P. G. 2539
**Zarytova V. F.** see Khalimskaya L. M. 1083
**Zavodnik V. E.** see Shutalev A. D. 761
**Zebick D.** see Soll R. M. 769
**Zein N.** see Roth G. P. 711
**Zein N.** see Wittman M. D. 2925
**Zelle R. E. Hancock A. A. Buckner S. A. Basha F. Z. Tietje K. DeBernardis J. F. and Meyer M. D.** Synthesis and pharmacological characterization of ABT-200: a putative novel antidepressant combining potent α-2 antagonism with moderate NE uptake inhibition 1319
**Zeng L.** see Gu Z. 473
**Zenke G.** see Roux F. 1947
**Zhang G. X.** see Naylor A. M. 1841
**Zhang L.** see Langlois M. 1433
**Zhang N.** see Babine R. E. 583
**Zhao M.** see Kumar A. 2913
**Zhao S. Freeman J. P. VonVoigtlander P. F. Howe W. J. and Szmuszkovicz J.** Structure–activity relationship pertaining to the north–west region of the kappa opioid agonist, U-50,488 2139
**Zhen C.** see Lash T. D. 1607
**Zheng Z.-L.** see Siuzdak G. 2863
**Zhou L.** see Nishimoto S. 439
**Zhu L.-M.** see Anderson L. 1415
**Ziegler M. F.** see Baxter R. L. 2649
**Zimmerman K. M.** see Steinberg M. I. 51
**Zingaro G. J.** see Chakravarty P. K. 75
**Zingaro G. J.** see Chang L. L. 115
**Zingaro G. J.** see Chang L. L. 2787
**Zingaro G. J.** see Glinka T. W. 81
**Zingaro G. J.** see Glinka T. W. 2337
**Zingaro G. J.** see Kim D. 207
**Zingaro G. J.** see Naylor E. M. 69
**Zocchi C.** see Baraldi P. G. 2539
**Zoganas H.** see Vlattas I. 2067
**Zoganas H.** see Vlattas I. 2073
**Zubrowski R.** see Hamilton G. S. 2035
**Zuckermann R. N.** see Miller S. M. 2657
**Zugay J. A.** see Dorsey B. D. 2769
**Zugay J. A.** see Kim B. M. 2199
**Zugay J. A.** see Kim B. M. 2273
**Zydowsky T. M. Winn M. De B. Condon S. L. Altenbach R. J. Basha F. Z. Boyd S. A. Buckner S. A. Hancock A. A. Lee J. Y. Mantei R. A. Novosad E. I. Sorensen B. K. Tasker A. S. Shiosaki K. Kerkman D. J. Opgenorth T. J. and DeBernardis J. F.** Synthesis and *in vitro* evaluation of fused ring heterocycle-containing angiotensin II antagonists 173

# Bioorganic & Medicinal Chemistry Letters
# Instructions to Contributors

*Bioorganic & Medicinal Chemistry Letters* seeks to publish experimental or theoretical research results of outstanding significance and timeliness in the fields of bioorganic chemistry, medicinal chemistry, bioinorganic chemistry, and related disciplines. Articles are to be in the form of communications and in order to achieve rapid publication, all contributions to the Journal are reproduced directly from the author's typescript (camera-ready manuscripts only).

**Journal Policy:** The language of submission is English only. All papers are submitted to referees who advise the Editor on the matter of acceptance in accordance with the high standards required, with the understanding that the subject matter has not been previously published and is not under consideration elsewhere. Referees will be asked to distinguish contributions meeting the above requirements and having an element of novelty, timeliness, and urgency that merits publication in rapid communication format from otherwise worthwhile work which could more properly await publication in a complete form accompanied by full experimental details. Referee names are not disclosed but their views are forwarded by the Editor to the authors for consideration. Authors accept full responsibility for the factual accuracy of the data presented and should obtain any authorization necessary for publication. As such, the contents of the papers are the sole responsibility of the authors and publication does not imply the concurrence of the Editors or Publisher. Authors are encouraged to suggest names of several experts in the field when papers are first submitted or at any time in the evaluation process. The typewritten manuscript is reproduced photographically and each communication is a separate entry in the Journal. Authors are requested to send papers of 2, 4 or 6 pages in a format that follows that established for *Tetrahedron Letters*.

**Graphical Abstracts:** Authors must supply a graphical abstract in finished, camera-ready form at the time the communication is first submitted. The abstract should summarize the contents of the paper in a concise, pictorial form designed to capture the attention of a wide readership and for compilation of databases. Carefully drawn chemical structures are desired which serve to illustrate the theme of the communication. The manuscript title, authors names and addresses, and appropriate text (i.e. abstract) should be incorporated not to exceed the space limitations (5 x 20 cm). In publication, the graphical abstracts will take a reduction of 25%.

## PREPARATION OF MANUSCRIPTS

Manuscripts should be typed in one and a half line spacing using black type on good quality white bond paper in a manner that ensures a clean, clear impression. To maintain a consistent format from article to article, it is preferable that the text of the manuscript be prepared in 12pt Times Roman font with both right and left margin justification. Any good quality paper may be used, provided the actual typing area fills the space detailed below. Manuscripts will be reduced by a factor of 25% and the Journal margins are provided during reproduction reduction. For papers composed on a computer, letter quality printers must be used; dot matrix printer manuscripts will not be accepted.

**Title:** The title should be in capital letters, preferably in bold face type (14pt Times Roman) centered on the width of page 1 with the title 2 cm from the top of the page. The title should be brief, specific, and rich in informative words.

**Authors:** After one line of space from the title, the authors' names (12pt Times Roman) and addresses (12pt Times Roman in italics) should be provided on separate lines, centered on the width of the page. The author(s) to whom correspondence should be addressed by readers of the Journal should be indicated with an asterisk.

**Abstract:** Authors must include a short abstract of no more than four lines typed in single line spacing (12pt Times Roman font). This is placed after the authors' addresses and before the text of the communication. It should be clearly labeled as the abstract, preferably with the word **Abstract** in boldface type and the text of the abstract in 12pt Times Roman font.

**Manuscript Text:** In the introductory section of the manuscript, the author should strive to define the significance of the work and the justification for its rapid publication. The typing area of page 1, including the title, must be 19 cm wide by 24 cm deep. The typing area of the remaining pages must be extended to cover an area 19 cm wide by 26 cm deep (8½" x 11" paper). It is preferred that the text of the manuscript be prepared in 12pt Times Roman font in one and a half line spacing and with right and left margin justification. Where new techniques or methods are described, a typical experimental procedure may be provided.

**Acknowledgment:** Following the manuscript text and preceding the references, an acknowledgment section may be included. This should be typed in single line spacing in regular typeface (12pt Times Roman), and clearly labeled as the acknowledgment section with the word **Acknowledgment** preferably in boldface type.

**References and Notes:** References to the literature should follow the format outlined for ACS publications and titles of journals are abbreviated according to *Chemical Abstracts Service Source Index.* References should be numbered consecutively as they appear throughout the text, and be indicated consecutively in the text with superscript numbers. This section should be typed in single or one and half line spacing (12pt Times Roman) in the format shown below and clearly labeled as the reference section with the words **References and Notes** preferably in boldface type.

Scientific Articles:

1. Doe, J. S.; Smith, J.; Roe, P. *J. Am. Chem. Soc.* **1968**, *90*, 8234.

Books:

2. Doe, J. S.; Smith, J. *Medicinal Chemistry*, Vol. 1, pp. 301–383, Roe, P., Ed.; Pergamon Press; Oxford, 1990.

**Camera-Ready Requirements. Formulae, Figures, Tables and Black and White or Color Photographs:** To maintain a finished, high quality, artistic appearance of the Journal, authors are asked to use whatever resources are available to them to produce manuscripts that are of pleasing appearance. Direct reproduction of camera-ready manuscripts requires the authors to provide the manuscript in a finished artistic format, making the best possible use of the space within an even number of completely utilized pages. If possible a system should be used that allows text and graphics to be integrated in the printout. Any materials that cannot be directly printed should be neatly glued in the appropriate place in the text just above the corresponding caption. No freehand illustration will be accepted. The size of the formulae may vary according to the nature of the illustration but these should be neither overpowering nor so small that they are hard to read after reduction by a factor of 25%. High quality glossy prints of black and white photographs (e.g. high contrast gels) can be directly reproduced with inclusion in the manuscript. Examples may be found in *Bioorg. Med. Chem. Lett.* **1993**, *3*, 2118 and **1994**, *4*, 2019. These should be submitted as originals on each of the original and review manuscripts at the time of submission. Photocopies of such gels are not acceptable. A limited number of color figures may be published in the journal at no expense to the author. The criterion for accepting the inclusion of a color figure will be that it must contribute to the scientific and informational content of the published work. Manuscripts submitted with color figures should be submitted with original glossy photographs on each of the original and review manuscripts at the time of submission. Examples may be found in *Bioorg. Med. Chem. Lett.* **1994**, *4*, 2215 and 2502. Black and white photocopies of color figures are unacceptable although high quality color copies of color photographs and original figures printed from high resolution color printers may prove acceptable. As technology in this area of publication continues to improve the Journal will strive to develop along with the technology. The Editor may return otherwise acceptable papers for modification if the quality of the figures or structural formulae is poor, or the overall layout is carelessly composed.

**Biological Data:** Biological test methods must be referenced or described in sufficient detail to permit the experiments to be repeated by others. Standard compounds and established drugs/agents should be tested in the same system for comparison. Statistical limits (statistical significance) for the biological data are usually required. If statistical limits cannot be provided, the number of determinations and an indiction of the variability and reliability of the results should be given. Doses and concentrations should be expressed in molar quantities when comparisons of potencies are made with compounds having substantial differences in molecular weights. For inactive agents, the highest concentration or dose level tested should be indicated.

**Nomenclature:** It is the responsibility of the authors to provide correct nomenclature. Chemical names for drugs are preferred. If these are not practical, generic names, names approved by the U.S. Adopted Names Council, or those approved by the World Health Organization may be used. If a generic name is used, its chemical name or structure should be provided at the point of first citation. Authors will find the following as useful reference books for recommended nomenclature.

*IUPAC Nomenclature of Organic Chemistry*, Rigaudy, J.; Klesney, S. P., Eds; Pergamon Press; Oxford, 1979.

*Enzyme Nomenclature*, Webb, E. C., Ed.; Academic Press; Orlando, 1984.

*Biochemical Nomenclature and Related Documents*, The Biochemistry Society; London, 1978.

**Trademarks:** Authors are required to acknowledge trademark protection in the standard fashion (e.g. Selectride®) although not for words which have entered general usage (e.g. pyrex).

**Hazardous Materials or Procedures:** Authors are requested to draw attention to hazards by adding the word CAUTION followed by a brief descriptive phrase and literature references if appropriate.

**X-Ray Crystallographic Data:** Manuscripts reporting X-ray crystallographic data must be accompanied by lists of refined coordinates, bond distances, bond angles, torsion angles with esd's for deposition by the Editor at the Cambridge Crystallographic Data Centre.

**Software:** Software used as part of computer-aided drug/agent design (e.g. molecular modeling, QSAR, conformational analysis) should be readily available from accepted sources and the authors may specify where the software can be obtained. Assurance of the quality of the parameters employed for the relevant potential functions should be detailed in the manuscript.

**Abbreviations:** Standard ACS journal abbreviations should be used throughout the manuscript and are employed without periods. The preferred forms for some of the more commonly used abbreviations are mp, bp, °C, °K, min, h, mL, μL, g, mg, μg, cm, mm, nm, mol, mmol, μmol, M, mM, μM, ppm, HPLC, TLC, GC, $^1$H NMR, GC-MS, UV, IR, EPR, ESR, DNase, $ED_{50}$, $ID_{50}$, $IC_{50}$, $LD_{50}$, im, ip, iv, mRNA, RNase, rRNA, tRNA, cpm, Ci, dpm, $V_{max}$, $K_m$, $k$, $t_{½}$. All nonstandard abbreviations should be defined following the first use of the abbreviation.

**Mailing of Manuscripts:** The original and three copies of the manuscript including the graphical abstract and a signed and dated copyright transfer agreement form should be sent to the editorial office provided below. In order to achieve the most rapid publication authors may wish to Fax a copy (supplying their own telephone and Fax numbers) to the Editor at the time that they mail the camera-ready manuscript.

**Submissions from Japan and other Asian countries:**

Professor M. Shibasaki
Editor, *Bioorganic & Medicinal Chemistry Letters*
Faculty of Pharmaceutical Sciences
University of Tokyo
7-3-1 Hongo, Bunkyo-ku
Tokyo 113
JAPAN

Fax: (81) 3 5684 5206
Telephone: (81) 3 3812 2111

**Submissions from Europe:**

Professor L. Ghosez
Editor, *Bioorganic & Medicinal Chemistry Letters*
Laboratoire de Chimie
Organique de Synthèse
Université Catholique de Louvain
Place L. Pasteur 1
B-1348 Louvain-la-Neuve
BELGIUM

Fax: (32) 10 47 41 68
Telephone: (32) 10 47 27 40

**All other submissions:**

Professor Dale L. Boger
Editor-in-Chief, *Bioorganic & Medicinal Chemistry Letters*
Department of Chemistry, CVN1
The Scripps Research Institute
10666 North Torrey Pines Road
La Jolla, California 92037
USA

Fax: (1) 619 554 6401
[Fax: (800) 410 1557 toll-free from the USA and Canada]
Telephone: (1) 619 554 7025

**Corrections:** If there are errors of consequence in a published paper, a correction of the error should be sent to the Editor for publication in an "Additions and Corrections" section.

**Reprints:** Any reprints required above the 50 reprints supplied free of charge must be indicated at the time of submission.

**Page Charges:** None.

**BMCL** **75%**

*Bioorganic & Medicinal Chemistry Letters*

**GRAPHICAL ABSTRACT EXAMPLE**



# *Institutional Subscription Order Card for Bioorganic & Medicinal Chemistry Letters*

Name _____

Position _____

Organization _____

Department _____

Address _____

_____ Post/Zip Code _____

Country _____

E-Mail/Internet No. _____

CH508 3/95

**PAYMENT DETAILS**

❑ Please send a proforma invoice

❑ Cheque/money order/UNESCO coupon made payable to ***Elsevier Science*** enclosed.

**PAYMENT BY CREDIT CARD**

❑ I wish to pay by credit card
Visa/MasterCard/American Express/Diners Club (delete as appropriate).

Issuing Bank _____
(MasterCard only)

Card No. _____ Expiry Date _____

Signed _____ Date _____

Prices include postage and insurance. Sterling price(s) quoted applies worldwide, except in The Americas. US dollar price(s) quoted applies in The Americas only. Advertising rate card available on request.

EU (European Union Countries, VAT equivalents and tax rates:

| | | | | | | | | |
|---|---|---|---|---|---|---|---|---|
| Austria: | AT | 10% | Belgium: | BTW | 6% | Denmark: | MOMS | 25% |
| Eire: | VAT | 21% | Finland: | FI | 0% | France, Monaco: | TVA | 5.5% |
| Germany: | MWST | 7% | Greece: | FPA | 4% | Italy: | IVA | 4% |
| Luxembourg: | TAV | 0% | Netherlands: | BTW | 6% | Portugal, Madeira: | IVA | 5% |
| Spain: | IVA | 4% | Sweden: | SE | 25% | UK: | VAT | 0% |

Tax rates quoted are correct at time of going to press, but may be subject to change at any time by individual governments. Elsevier Science UK VAT number: GB 490 6384 25 000.

**SAVE**
**£875.00/US$1306.00**
Subscribe jointly to all 5 Tetrahedron journals

❑ Please enter my 1995 institutional subscription to ***all 5 Tetrahedron Journals*** (00876) @ £7755.00/ US$11555.00

❑ Please enter my joint 1995 institutional subscription to ***Bioorganic & Medicinal Chemistry Letters/ Tetrahedron Letters*** (00107) @ £3885.00/US$5789.00

❑ Please enter my joint 1995 institutional subscription to ***Bioorganic & Medicinal Chemistry Letters/ Bioorganic & Medicinal Chemistry*** (00131) @ £1030.00/US$1535.00

❑ Please enter my 1995 institutional subscription to ***Bioorganic & Medicinal Chemistry Letters*** (00972) @ £660.00/US$984.00

Order value sub-total £/US$ _____

EU residents must either: state VAT number here _____

or: add VAT @ _____ %
(see table for appropriate tax rate)

VAT £/US$ _____

Total Payment £/US$ _____

**PERGAMON**
*An imprint of Elsevier Science*

# *Associated Personal & Student Rate Subscription Order Card for Bioorganic & Medicinal Chemistry Letters*

Name _____

Position _____

Organization _____

Department _____

Address _____

_____ Post/Zip Code _____

Country _____

E-Mail/Internet No. _____

My library _____ subscribes to the journal

CH508 3/95

**PAYMENT DETAILS**

❑ Please send a proforma invoice

❑ Cheque/money order/UNESCO coupon made payable to ***Elsevier Science*** enclosed.

**PAYMENT BY CREDIT CARD**

❑ I wish to pay by credit card
Visa/MasterCard/American Express/Diners Club (delete as appropriate).

Issuing Bank _____
(MasterCard only)

Card No. _____ Expiry Date _____

Signed _____ Date _____

Prices include postage and insurance. Sterling price(s) quoted applies worldwide, except in The Americas. US dollar price(s) quoted applies in The Americas only. Advertising rate card available on request.

❑ Please enter my 1995 *associated personal subscription to ***Bioorganic & Medicinal Chemistry Letters*** (00972) @ £105.00/US$157.00

❑ Please enter my 1995 student subscription to ***Bioorganic & Medicinal Chemistry Letters*** (00972) @ £50.00/US$74.00

This offer is limited to registered students for a maximum of 3 years, and restricted to those institutions which already have a library subscription to the journal.

Order value sub-total £/US$ _____

EU residents must either: state VAT number here _____

or: add VAT @ _____ %
(see table for appropriate tax rate)

VAT £/US$ _____

Total Payment £/US$ _____

* As a service to your scientific community we are able to offer those associated with institutions where a regular rate subscription is currently in place, the opportunity to subscribe at a low price. Associated personal subscriptions are sold at a price which covers our print run-on, despatch and handling costs only. Now you can receive your own copy, delivered to you personally, without waiting for your turn on the circulation list.

**PERGAMON**
*An imprint of Elsevier Science*

Elsevier Science Ltd
The Boulevard
Langford Lane
Kidlington
Oxford OX5 1GB
UK

---

Elsevier Science Ltd
The Boulevard
Langford Lane
Kidlington
Oxford OX5 1GB
UK

# The TETRAHEDRON Family

## A combined subscription to all 5 journals

**SAVE £875.00/US$1306.00**

The Tetrahedron Family Package provides a complete reference source for all new and exciting developments in the field of organic, bioorganic, bioinorganic and medicinal chemistry. This combined subscription comprises:

- *Bioorganic & Medicinal Chemistry*
- *Bioorganic & Medicinal Chemistry Letters*
- *Tetrahedron*
- *Tetrahedron: Asymmetry*
- *Tetrahedron Letters*

Those libraries which take the Tetrahedron Family Package will see an immediate benefit and saving. Further details are available from your nearest Elsevier Science office.

1995: (148 issues)
Subscription price: **£7755.00 (US$11555.00)**
(00876)

Sterling prices quoted apply worldwide, except in The America, US dollar prices apply in The Americas only.

Please send me more information on **the TETRAHEDRON Family Package (00876)**

Name_____ Position_____

Address _____

_____

Post/Zip Code _____ Country_____

**Return to:** Elsevier Science Ltd, The Boulevard, Langford Lane, Kidlington, Oxford OX5 1GB, UK
Telephone: +44 0865 843479/843781

**or** Elsevier Science Inc., 660 White Plains Road, Tarrytown, NY 10591-5133, USA
Telephone: +1-914-524-9200

CO5A16

*Printed in Great Britain by Nuffield Press Ltd.*